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Abstract 
Protein prenylation is an important post-translational modification that occurs in all eukaryotes; 
defects in the prenylation machinery can lead to toxicity or pathogenesis. Prenylation is the 
modification of a protein with a farnesyl or geranylgeranyl isoprenoid, and it facilitates protein-
membrane and protein-protein interactions. Proteins of the Ras superfamily of small GTPases are 
almost all prenylated and of these the Rab family of proteins forms the largest group. Rab proteins 
are geranylgeranylated with up to two geranylgeranyl groups by the enzyme Rab 
geranylgeranyltransferase (RGGT). Prenylation of Rabs allows them to locate to the correct 
intracellular membranes and carry out their roles in vesicle trafficking. 
Traditional methods for probing prenylation involve the use of tritiated geranylgeranyl 
pyrophosphate which is hazardous, has lengthy detection times, and is insufficiently sensitive. The 
work described in this thesis developed systems for labelling Rabs and other geranylgeranylated 
proteins using a technique known as tagging-by-substrate, enabling rapid analysis of defective Rab 
prenylation in cells and tissues. An azide analogue of the geranylgeranyl pyrophosphate substrate of 
RGGT (AzGGpp) was applied for in vitro prenylation of Rabs by recombinant enzyme. Alternatively, 
geranylgeranylated proteins (including Rabs) were labelled with AzGG via metabolic labelling of live 
cells with AzGGOH. Once Rabs were tagged with an azide moiety they could be labelled via a 
bioorthogonal ligation reaction with a trifunctional alkyne probe. The probe contained a fluorophore 
for in-gel fluorescence analysis and a biotin affinity label for affinity purification of labelled proteins. 
The conditions for protein tagging, labelling, affinity purification and LC-MS/MS analysis were 
optimised significantly during this work. Affinity purified proteins were identified and in some cases 
quantified using LC-MS/MS techniques, with iTRAQ labelling for quantification. Rab prenylation was 
probed in cell culture, in cells treated with the drug Mevastatin and in tissue from mouse models 
with defects in the prenylation machinery. 
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  Introduction Chapter 1
 Ras superfamily of proteins  1.1
The Ras superfamily of proteins are small GTPases that act as molecular switches by cycling between 
the GDP-bound inactive and the GTP-bound active form; in its active form the GTPase can interact 
with diverse effector proteins, which stimulates a range of cellular processes (Figure 1). Five families 
of proteins comprise the Ras superfamily: the Ras, Rho, Rab, Sar1/Arf, and Ran families. The proteins 
within these families are related structurally as well as functionally; for example, proteins in the Ras 
family regulate gene expression, whilst  Rho family members regulate both cytoskeletal 
reorganisation and gene expression and the Rab and Sar1/Arf family proteins regulate intracellular 
vesicle trafficking.1  
 
Figure 1: The Ras superfamily molecular switch. The GDP-bound RasGTPase, delivered to its intracellular membrane,  
becomes active and GTP-bound through the action of a GEF (guanine nucleotide exchange factor). Once GTP-bound, the Ras 
protein can recruit downstream effectors leading to cellular events. Once the effectors have been recruited and the Ras 
protein has carried out its role, the GTPase hydrolyses GDP to GTP, assisted by a GAP (GTPase activating protein). The 
inactive Ras protein will then be cycled back to the cytosol by a GDI (GDP dissociation inhibitor) protein. Figure adapted 
from Takai et al.
1
 
GAPs (GTPase activating protein) and GEFs (Guanine nucleotide exchange factor) help regulate the 
cycling of the GTPase between active and inactive forms by assisting with GTP hydrolysis and 
nucleotide exchange respectively; without them the rates of these processes are intrinsically slow.1 
Furthermore, in order to carry out their function correctly, the majority of Ras superfamily proteins 
require post-translational lipidation; Ras, Rho and Rab proteins are prenylated with either farnesyl or 
geranylgeranyl groups at C-terminal cysteine residues, whilst Arf proteins are N-terminally 
myristoylated. Ras proteins are also often reversibly palmitoylated and palmitoylation is often found 
GAP
GDP GTP
Ras
superfamily 
protein
GDP GTP
Ras
superfamily 
protein
GEF
Effector
Downstream signal
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combined with other lipid modifications.2, 3 Protein lipidation is discussed if greater detail below in 
section 1.2.1. 
1.1.1 Rab proteins 
Rab proteins were first discovered in yeast in 1983 by Gallwitz et al. and over 60 human Rabs have 
been identified to date 4-7 with many of these conserved from yeast to humans. In some cases a 
murine Rab protein is able to functionally compensate its yeast counterpart, demonstrating that the 
function of Rabs is conserved between organisms.8 Rab proteins constitute the largest family of 
proteins in the Ras superfamily (Figure 2).9   
61
36
20
1
27
9
Rab
Ras
Rho
Ran
Arf
Other
 
Figure 2: Pie chart showing the numbers of proteins that comprise the different families within the human Ras 
superfamily of proteins. Information was obtained from the review by Cox and Der and the graph created using Microsoft 
Excel.
9
 
Like all Ras superfamily proteins, Rab proteins act as molecular switches and cycle between an 
inactive GDP-bound form and an active GTP-bound form, where the protein can bind effector 
molecules and perform its biological function (as in  Figure 1).  Rab proteins are intrinsically soluble, 
but to function correctly they must associate with membranes.10 This is made possible by the post-
translational geranylgeranylation of Rabs at one or (more often) two C-terminal cysteine residues, 
allowing them to associate with membranes reversibly and thus to carry out their roles as regulators 
of membrane traffic.  
Rabs are involved in almost all eukaryotic membrane trafficking processes through their interactions 
with various cellular components, such as SNAREs (soluble N-ethylmaleimide sensitive factor 
16 
 
attachment protein receptors).7 SNAREs are proteins found on vesicles or target membranes that 
interact with each other to cause vesicle docking and fusion.7 Rabs regulate the budding, motility 
and fusion of vesicles as well as the transport of other compartments such as endosomes, lysosomes 
and melanosomes;7, 11  these roles are described in further detail below (section 1.1.1.4). 
1.1.1.1 The structure of Rab family proteins 
The structures of Rab proteins are similar to other members of the Ras superfamily; they contain a 
conserved fold, consisting of a six-stranded β-sheet (five parallel strands and one anti-parallel 
strand) flanked by five α-helices.12 Sequence analyses of Rab proteins revealed five conserved motifs 
termed RabF (Rab family) regions that distinguish Rabs from other members of the Ras superfamily 
(Figure 3).  Phylogenetic analysis (using the neighbour joining algorithm) revealed clusters of related 
Rab proteins with overlapping functions that have been classed as subfamilies.  These subfamilies 
typically share 75-90% sequence homology and are characterised by motifs conserved between 
subfamilies termed RabSF (Rab subfamily).13 
 
Figure 3: Rab7 structure. RabSF regions are depicted in purple, RabF regions depicted in green and conserved nucleotide 
binding regions in pink. The image was created in PyMol (pdb accession code 1VG0). 
13-15
 
As Rabs cycle between the active GTP-bound and inactive GDP-bound form they adopt different 
structural conformations depending upon which nucleotide is bound. These changes in structure 
primarily occur in two regions termed Switch I and Switch II, first revealed by Stroupe and Brunger 
through crystallographic analysis of the yeast Rab Sec4 bound to a GDP or GTP analogue.12, 16 The 
protein structure tends to be more disordered in the Switch regions when the Rab is GDP-bound and 
becomes more rigid on binding GTP; both Switch regions contact the γ-phosphate group of GTP.17 
Superimpositions of the structures of active (GTP-bound) Rabs show large structural variations in the 
17 
 
Switch regions and the α3/β5 loop (the loop connecting α-helix 3 with β-sheet 5) that lies adjacent 
to the Switch II region, with little conformational change elsewhere in the structure (Figure 4). These 
structural differences explain how different Rab proteins recruit specific effectors to regulate their 
individual pathways.12, 17, 18 The RabSF regions are also important for effector recruitment, for 
example Rabphillin3A is an effector for Rab3A and the crystal structure of these proteins in complex 
showed that interactions between the two involved three out of four RabSF regions.19, 20 
 
Figure 4: A comparison of the structures of GDP and GTP-bound Rabs illustrating how the structure of the Switch regions 
becomes more rigid on GTP binding. A) Rab3 as a representative Rab, functional regions are coloured as indicated in the 
image text. B) Comparison of inactive GDP-bound Rab structures after superposition with Rab3. Switch regions are either 
poorly ordered or only adopt ordered conformations as a result of crystal packing. C) Comparison of active GppNHp-bound 
Rab (GppNHp is a non-hydrolysable analogue of GTP) structures after superposition with Rab3. Switch regions adopt stable 
active conformations but there are large conformational differences in the Switch II regions between Rabs. Figure from 
Lambright et al.
17
 
The C-terminus of Rabs is most divergent within Rab families, it is termed the hypervariable domain 
and contains the prenylation motif; in order to function correctly Rab proteins must be prenylated at 
this motif. This hypervariable domain has been proposed to be involved in targeting Rabs to specific 
18 
 
membranes, for example, replacement of the Rab5 hypervariable domain with that of Rab7 by 
Chavrier et al. caused targeting of the protein to late endosomes normally marked by Rab7.21  
1.1.1.2 Rab subcellular location and function  
Rab proteins are exquisitely localised to their particular intracellular compartment and are often 
utilised as molecular markers for these compartments. Many Rabs are ubiquitously expressed in all 
cell and tissue types; such as Rab1, which regulates Endoplasmic Reticulum (ER) to Golgi transport; 
and Rab5, which regulates early endosome dynamics. Other Rabs are cell-type and tissue specific; 
for example Rab3a is expressed only in cell types capable of regulated secretion and is found 
associated with secretory granules and synaptic vesicles.22  
Rabs have a variety of functions within the cell (Figure 5) and some of these are discussed later in 
this chapter. For further information, tables containing details of the localisation, functions, effectors 
and known diseases that Rabs are implicated in can be found in the reviews by Stenmark (2009) and 
Hutagalung and Novick (2011).7, 19  
19 
 
 
Figure 5: A diagram illustrating the locations of Rab proteins within an epithelial cell. Figure from the review by 
Stenmark. 
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1.1.1.3 The Rab cycle model 
Rab proteins not only cycle between active and inactive forms, depending on the nucleotide bound, 
but they also cycle between being cytosolic and membrane-bound; this is known as the Rab cycle. 
Rab proteins are synthesised in the cytoplasm and are post-translationally prenylated with GGpp by 
a complex of Rab escort protein (REP) and Rab geranylgeranyl transferase (RGGT).  RGGT dissociates 
from the complex after Rab prenylation and REP escorts the Rab protein to its appropriate 
membrane in a process that is poorly understood. There are several theories for how Rabs are 
delivered to their target membranes which include nucleotide exchange by GEFs (Guanine 
20 
 
nucleotide exchange factors, GTP-bound Rabs bind less tightly to REP and GDI than GDP-bound 
Rabs) and interactions with GDFs (GDI displacement factors) as well as specific protein targeting 
factors.23  Once in the membrane, GEFs catalyse the exchange of GDP for GTP; the high 
concentration of GTP in the cell (~1 mM) means it binds to the Rab as soon as GDP is released.7 GTP-
bound, active Rabs can interact with a plethora of different effector proteins, such as kinases, 
phosphatases, molecular motors and tethering factors, allowing Rabs to perform a diverse range of 
functions.7 Rabs are inactivated when GTP is hydrolysed to GDP by the intrinsic GTPase activity of 
the Rab in a process which is further catalysed by GTPase-activating proteins (GAPs), of which there 
are 38 known.1, 7, 18 The GDP-bound Rab protein can then be extracted from the membrane into the 
cytosol by Rab GDP dissociation inhibitor (RabGDI). RabGDI may then mediate the association of the 
Rab protein with another membrane, allowing the commencement of a new cycle of Rab activation 
(Figure 6). The Rabs remain prenylated (prenylation is irreversible) and hence are more hydrophobic 
than when first synthesised and require a chaperone protein such as RabGDI or REP in order to 
remain soluble in the cytosol. The roles of REP and RabGDI are discussed in section 1.2.5. 
 
 
 
21 
 
 
Figure 6: The Rab cycle. Cartoon illustrating how Rab proteins are associated with vesicular transport between intracellular 
membranes. Left pathway: Newly synthesised Rab is delivered to the membrane by REP following geranylgeranylation by 
RGGT. Right pathway: Step 1 Rab proteins are transferred to a membrane during vesicle formation, from the cytoplasmic 
pool where they are found bound to GDI in their GDP-bound form; a GDI displacement factor (GDF) causes GDI to dissociate 
from the Rab. Steps 2 and 3 Rabs are activated to their GTP-bound form by a GEF (Guanine-nucleotide exchange factor) and 
then can recruit tethering and SNARE protein effectors. These direct the vesicle to the target membrane. Step 4 Rab-GTP is 
converted to the GDP-bound form by a GAP (GTPase activating protein) and the effector dissociates from Rab-GDP. Step 5 
Rab-GDP, in response to recruitment of GDI to the membrane is returned to the cytoplasm. Adapted from 
24
 and 
25
. 
1.1.1.4 The role of Rabs in vesicular transport 
The traffic of vast arrays of factors into and out of cells and between membrane-bound organelles is 
essential for cell survival; the transport of cargo is very complex and is tightly regulated at all stages 
by the cell. Rab GTPases are vitally important at all steps of vesicle trafficking (formation, transport, 
tethering and fusion) and the topic has been extensively reviewed; in particular by Stenmark in 2009 
and Hutagalung and Novick in 2011.7, 19 Specific Rabs associate to both organelles and transport 
vesicles and it is their function as molecular switches (Figure 1) that enables them to recruit various 
effectors and so regulate vesicular transport.19 Figure 5 illustrates the subcellular locations of the 
Rab proteins involved in membrane trafficking, whilst Figure 7 illustrates their roles in vesicle 
transport. One example of a Rab involved in vesicle movement is that of Rab27A, which has a role in 
melanosome transport in melanocytes. Active Rab27A recruits its effector melanophilin, binding it to 
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myosin Va, which causes anchoring of the melanosomes to the actin cytoskeleton at the cell 
periphery and hence transport (Figure 7c).19, 26 A further example of a Rab involved in vesicle 
trafficking is that of Rab5, which promotes vesicle uncoating through interactions with its GEF, 
GAPVD1 (GTPase-activating protein and VPS9 domain-containing protein 1).7, 27 Together they 
promote dephosphorylation of the µ2 subunit of the protein AP2, which is the cargo adaptor protein 
complex of the clathrin coat on endocytic vesicles. Rab5 and GAPVD1 also increase the turnover of 
phosphatidylinositol-4,5-bisphosphate a phosphoinositide that stabilises the interaction of AP2 with 
the plasma membrane. Rab5 and GAPVD1 thus act to destabilise the interaction of AP2 with the 
plasma membrane, and this leads to vesicle uncoating (Figure 7b).7, 27  
 
Figure 7: Rab functions in vesicle trafficking. a) An active GTP-bound Rab can cause a sorting adaptor to sort a receptor 
into a budding vesicle. b) The phosphoinositide (PI) composition of a transport vesicle can be altered by recruiting PI kinases 
or phosphatases, which causes vesicle uncoating through dissociation of PI-binding coat proteins.c) Rabs can recruit motor 
adaptors or bind to motors to facilitate vesicle transport). d) Rabs recruit rod-shaped tethering factors to help vesicle 
tethering to the acceptor membrane. Figure from the review by Stenmark.
7
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1.1.1.5 Rab effectors and downstream processes 
There are a number of known Rab effectors and interaction with various effectors is the mechanism 
by which Rabs regulate specific intracellular pathways.19 In general, effector proteins interact 
preferentially with Rabs in the GTP-bound, active form, although the effector protrudin has been 
shown to interact with GDP-bound Rab11 and coronin3 interacts with GDP-Rab27A.28, 29 Rab 
effectors may help stabilise the interaction of Rabs with their target membrane as well as helping to 
target them to their specific membrane. Effectors can also bind to more than one Rab 
simultaneously, helping with membrane interactions in vesicle tethering; for example, rabenosyn5 
has binding sites for both Rab5 and Rab4.7 A table containing known Rab effectors can be found in 
the 2011 review by Hutagalung and Novick.19 
 Protein prenylation 1.2
1.2.1 Protein Lipidation 
Protein lipidation is an important post-translational and co-translational modification of proteins in 
the cell; the covalent attachment of hydrophobic lipid groups can modify protein structure and allow 
the proteins to carry out their correct functions.30 Lipidation allows the control of protein 
interactions with both membranes and other proteins, enabling signal transduction, vesicular 
transport and protein trafficking.31 Thus the study of lipid modifications is important for the 
elucidation of disease mechanisms and for protein function studies. For example, if cell signalling 
goes awry this can lead to uncontrolled cell growth and hence to cancer, whilst if proteins are not 
localised to their correct cellular compartment other serious diseases may arise as cellular trafficking 
then cannot occur correctly (discussed further in section 1.2.7).32  
Common lipids that proteins are modified with include: isoprenoid groups (farnesyl (15-carbon) or 
geranylgeranyl (20-carbon)), fatty acids (myristic acid (14-carbon) or palmitic acid (16-carbon)), 
cholesterol, and glycosylphosphatidylinositol anchors (lipid structures are shown in Figure 8).30, 31 
Protein lipid transferases carry out protein lipidation and the lipid modification can either be 
reversible or irreversible. Protein prenylation, carried out by protein prenyltransferases and required 
for protein signalling and membrane attachment, is described below in section 1.2.2, whilst protein 
acylation is described later in this section. Chemical techniques for investigating protein lipidation 
are described in further detail in section 1.3. Reviews in the area of protein lipidation include those 
by Hang et al. and by Resh.30, 31  
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Figure 8: Examples of protein lipidations. The green bars represent the protein amino acid chain. AAX represents the amino 
acids at the end of a CAAX prenylation motif. Adapted from a figure in the review by Hang et al.
30
 
Acyltransferases catalyse the transfer of fatty acid-CoAs to proteins. N-myristoyltransferases 
catalyse the transfer of myristic acid to N-terminal glycine of their protein substrates, which is an 
irreversible process and results in a stable amide bond between the fatty acid and the protein. 
N-myristoylation occurs irreversibly at the glycine residue of the consensus sequence GXXX[S/T]. 
Proteins may be myristoylated either co-translationally or post-translationally. Palmitoylation can 
occur at protein cysteine residues (S-palmitoylation) and DHHC-protein acyltransferases (with a 
conserved Asp-His-His-Cys or DHHC motif) catalyse the transfer of palmitic acid to intracellular 
proteins whilst secreted proteins such as Hedgehog are palmitoylated at N-terminal cysteine 
residues by palmitoyl acyltransferases of the MBOAT (membrane bound O-acyl transferase) family.33 
Unlike myristoylation and prenylation, palmitoylation at cysteine residues is a reversible process, 
modulated by stimulation of cells, and there is no known consensus sequence for this protein 
modification.30 The thioester bond between the palmitoyl group and the cysteine can be readily 
broken by protein thioesterases. Palmitoylation also often stabilises membrane targeting of N-
myristoylated and prenylated proteins. For example, the Src family kinases are myristoylated and 
palmitoylated whilst H-Ras and N-Ras proteins are both farnesylated as well as palmitoylated; in all 
these cases inhibiting palmitoylation results in reduced membrane binding and a decrease in 
signaling.31 The cycling between palmitoylation and depalmitoylation of lipid-modified proteins 
Cholesterylation
GPI anchor
Farnesylation Geranylgeranylation
Myristoylation
S-Palmitoylation N-Palmitoylation
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allows them to signal from multiple subcellular locations as their membrane association is thus also 
reversible.33 For further details on protein acylation see the reviews by Resh, Magee and Seabra, and 
Nadolski and Linder.33 34, 35 
1.2.2 Protein Prenylation 
Protein (S)-prenylation is the covalent attachment of either a farnesyl or geranylgeranyl isoprenoid 
group to C-terminal cysteine residues of a protein via a thio-ether linkage; it occurs in all eukaryotic 
cells and is a critical process. It allows the spatial and temporal control of proteins through their 
attachment to intracellular membranes and is estimated to occur for approximately 0.5% of 
intracellular proteins, with geranylgeranylation thought to be the most common form of 
prenylation.30, 32, 36 Prenylation has been widely studied as Ras proteins, one of the most common 
oncoproteins in human tumours, are prenylated, as are many signalling proteins (e.g. heterotrimeric 
G proteins).37 As many small GTPases of the Ras superfamily are prenylated, the study of prenylation 
could help elucidate disease mechanisms, probe the function of prenylation in the cell, identify drug 
targets and assess the efficacy of drugs on prenylated targets. 
The C-terminal prenylation of proteins was first reported in the late 1970s with the discovery of a 
farnesylated cysteine on a mating factor of the yeast Rhodosporidium toruloides.32 Prenylation of 
mammalian proteins was discovered a few years later, in 1984, during studies on the effects of a 
statin called Compactin (also known as Mevastatin).32, 38 The process of prenylation is catalysed by 
enzymes known as protein prenyltransferases, which are described in the following section (1.2.3). A 
comprehensive history of protein prenylation is given in the review by Benetka.32 
Prenyl groups are secondary metabolites that are synthesised in the cell via the mevalonic acid 
pathway, which also leads to cholesterol synthesis. The pathway begins with acetyl-CoA forming 
mevalonic acid via condensation and reduction steps. The mevalonic acid is then phosphorylated 
twice and decarboxylated to form isopentenyl pyrophosphate, which is used to build the different 
isoprenoids (Figure 9).  
26 
 
 
Figure 9: The mevalonic acid pathway showing an overview of isoprenoid biosynthesis. IDI1: isopentenyl pyrophosphate: 
dimethylallyl diphosphate isomerase. 
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1.2.3 Protein Prenyltransferases 
Proteins are prenylated with farnesyl or geranylgeranyl groups by enzymes known as 
prenyltransferases. There are three known examples of prenyltransferases: 
geranylgeranyltransferase type I (GGT-I), farnesyltransferase (FT) and Rab geranylgeranyltransferase 
(RGGT); all three of these enzymes are heterodimers with an α- and a β-subunit.40 Bioinformatic 
analysis predicts that there are a large number of protein substrates for these enzymes and small 
GTPases of the Ras superfamily make up the largest group; indeed, of the Ras superfamily, only the 
Arf and Ran proteins are not prenylated. Other prenylated proteins include γ-subunits of 
heterotrimeric G proteins, centromeric proteins and nuclear lamins.41  
GGT-I and FT, termed CAAX prenyltransferases, generally prenylate proteins with the C-terminal 
amino acid motif CAAX, where C is a cysteine residue, A is an aliphatic residue and X is any amino 
acid. However, since the discovery of this motif it has been noted that there is more flexibility than 
first thought for the identity of the A amino acids and there is not a strict requirement for them to 
be aliphatic (discussed below in section 1.2.3.2).32  
1.2.3.1 The structures of the protein prenyltransferases 
High resolution crystal structures are reported for all three of the prenyltransferases. All are 
metalloenzymes, binding Zn2+ ions in their actives sites and also requiring Mg2+.32, 42, 43 The Zn2+ ion is 
required for catalytic activity and indeed studies involving different metal ions in place of zinc were 
able to affect both binding and transfer of the prenyl substrate. It is thought that the Mg2+ is 
required to help activate the pyrophosphate as a leaving group and so catalyse the reaction.32 
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GGT-I and FT share a common α-subunit (48 kDa) which is primarily α-helical in structure and any 
shifts in structure between the α-subunits are due to the differences in the homologous β-subunits 
(42 and 46 kDa respectively) which are also α-helical in structure and both form an α-α barrel (Figure 
10).44-46 RGGT has a larger α-subunit than GGT-1/FT (60 kDa); its structure has been resolved to less 
than 2Å and revealed four distinct structural domains.47, 48 The RGGT α-subunit is composed of three 
domains: a helical domain (as in GGT-1/FT), an Ig-like domain, and a leucine-rich repeat (LRR) 
domain. The functions of the extra domains in the RGGT α-subunit are unknown especially as they 
are absent in the yeast homolog of RGGT and a mutant form of the enzyme that lacks the Ig-like and 
LRR domains can retain catalytic activity.41, 49, 50 As in GGT-1 and FT, the β-subunit of RGGT consists of 
an α-α barrel with a central cavity lined with hydrophobic residues that bind the GGpp substrate. 
The β-subunit (38 kDa) has a positively-charged area near the opening of the cavity which in the 
corresponding area in FT has been shown to bind to the diphosphate group of farnesyl 
pyrophosphate.  
 
 Figure 10: A comparison of the structures of the 3 protein prenyltransferases. The α-subunits are shown in green and the 
β-subunits in cyan; the catalytic zinc ion is shown as an orange sphere and the prenyl group (Fpp or GGpp) in red and with a 
stick representation, REP-1 is shown in yellow. Structures of FT (PDB code 1FPP),  GGT-1(PDB code 1N4S) and  RGGT in 
complex with REP-1 (PDB code 1LTX). Images were created using PyMol. 
Fig2
FT GGT-1
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RGGT differs further from the other prenyltransferases as it requires the presence of an accessory 
protein, termed Rab escort protein (REP-1 or REP-2), in order for it to recognise and prenylate Rabs; 
FT and GGT-1 do not require accessory proteins to recognise their substrates.40, 47 Also, unlike the 
CAAX prenyltransferases, RGGT can attach up to two geranylgeranyl groups to Rabs (Figure 11); the 
sequence motifs for Rab prenylation at the C-terminus are XXXCC, XCCXX, XXCXC, CCXXX, XXCCX and 
XCXXX, where X is any amino acid residue and C is cysteine.6, 13, 51, 52 Those Rabs with only one C-
terminal cysteine residue tend to have motifs that are not suitable for prenylation by the CAAX 
protein prenyltransferases, for example Rab13 has the motif CSLG, which is unlikely to be a substrate 
for FT or GGT-1.52 However, some Rab proteins such as Rab8, which has the prenylation motif CVLL, 
can be geranylgeranylated by both RGGT and GGT-1 in vitro.53 RGGT also requires the complete Rab 
protein as a substrate in order for prenylation to occur, whereas FT and GGT-1 are able to prenylate 
short peptide sequences containing prenylation motifs.22, 54-56 Table 1 offers a summary of the 
similarities and differences between the protein prenyltransferases. 
 
Figure 11: An illustration of how Rab proteins are prenylated at their C-terminus by RGGT and REP. Cys is cysteine and X is 
any amino acid residue.  
Comparison of Prenyltransferases 
 RGGT GGT-1 FT 
Size of α-subunit (kDa) 60 48 48 
Size of β-subunit (kDa) 38 42 46 
Prenyl substrate GGpp GGpp Fpp 
Metal ion requirement Zn
2+
 Zn
2+
 Zn
2+
, Mg
2+
 
Accessory protein REP - - 
Accepts peptide substrate? No Yes Yes 
Number of cysteines in prenylation motif 1 or 2 1 1 
Table 1: A comparison of the protein prenyltransferases 
1.2.3.2 Mechanism of protein prenylation by the prenyltransferases GGT-1 and FT 
The CAAX prenyltransferases have similar mechanisms for prenylation and this is discussed here; the 
mechanism for prenylation by RGGT differs substantially and is described in greater detail in section 
Rab
Rab(GG)2
RGGT
GGpp
REP
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1.2.4.1. 57, 58 Desnoyers and Seabra demonstrated that the stoichiometry of the interaction between 
RGGT and GGpp is 1:1;59 they also demonstrated that FT and GGT-1 exhibit this stoichiometry of 
prenyl substrate binding and thus postulated that all protein prenyltransferases contain only a single 
prenyl binding site. The isoprenoid pyrophosphate binds in a hydrophobic cavity in the β-subunit in a 
similar manner in all the prenyltransferases and it is in protein substrate binding where the most 
obvious differences between the CAAX prenyltransferases and RGGT lie.41 The crystal structures of 
prenyltransferases bound to their lipid substrates show that the hydrophobic cavity is formed by the 
α-α barrel structure of the β-subunit. The isoprenoid forms hydrophobic interactions with aromatic 
residues in the active site and the pyrophosphate group is held in place by the hydrogen-bonding 
network at the opening of the cavity. All three prenyltransferases can bind both Fpp and GGpp; 
however, FT can only transfer Fpp to its protein substrate in vivo. This is reported to be due to the 
larger size of GGpp, preventing isoprene unit rotation as required for catalysis; even though the 
pyrophosphate group can bind in the correct position.41, 60 RGGT autoinhibits by coordination of 
histidine residue His2 of the α-subunit to the catalytic zinc ion in the enzyme active site.47, 61 RGGT is 
a slower enzyme than FT ad GGT-1 and thus the autoinhibition may be of physiological significance 
and Wu et al. postulate that an (as yet) unidentified activation factor may be required for RGGT to 
exhibit maximum activity.61 
FT and GGT-1 both recognise their protein substrates based on the sequence at the substrate C-
terminus; hence both will prenylate peptides containing the correct C-terminal sequence as well as 
their complete protein substrates. As mentioned, it is the CAAX sequence that is important for 
protein substrate recognition with these enzymes and the sequence binds in the hydrophobic cavity 
of the active site, next to the prenyl substrate. The CAAX sequence forms the majority of the binding 
surface between the peptide/protein substrate and the enzyme-prenyl complex;41, 62, 63 the binding 
site of the isoprenoid and CAAX sequence in FT and GGT-1 is illustrated in Figure 12.  According to 
structural studies performed by Reid et al. the first ‘A’ residue is solvent exposed and so can be any 
amino acid, whilst the second ‘A’ residue must be aliphatic or aromatic (although not tryptophan) 
because its side chain interacts with a hydrophobic site on the enzyme.63 Furthermore, FT has a 
preference for isoleucine or valine at the second ‘A’ residue, whilst GGT-1 prefers isoleucine or 
leucine here, although both enzymes will accept a selection of other amino acids at this position.63 
However, it is the ‘X’ amino acid that is the primary determinant of which enzyme will act on the 
protein substrate. FT has a less hydrophobic binding site for the ‘X’ residue than GGT-1; FT 
preferentially accepts peptides with serine, methionine, glutamine, alanine or phenylalanine at this 
position but GGT-1 only accepts hydrophobic residues and prefers leucine or phenylalanine.63 
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Figure 12: Binding of the isoprenoid and CAAX peptide in the active site of FT (blue) and GGT-1 (red), showing interactions 
with key residues and metal ions. Adapted from a figure in Nguyen et al. 
64
  
The reaction mechanism model for prenylation by FT and GGT-1 is reportedly characterised by an 
associative electrophilic alkylation mechanism and ordered substrate binding, although several 
mechanisms have been proposed.41, 64 From structural studies, for FT it is believed that initially Fpp 
binds in the hydrophobic funnel of the active site before subsequent CAAX peptide association. The 
reactive thiol of the cysteine residue is coordinated by the Zn2+ ion, lowering the pKa of the thiol and 
activating it for nucleophilic attack on the isoprenoid pyrophosphate (Figure 13).65-67 Structures of 
GGT-1 and FT in complex with both isoprenoid and peptide substrate before and after prenylation 
show little change in the conformation of the peptide backbone; it is believed that it is the 
isoprenoid substrate that rotates (at the third isoprene unit for Fpp and the fourth for GGpp) to 
move the C1 carbon closer to the cysteine thiol of the CAAX sequence.
65, 67 Following the release of 
the pyrophosphate group a thioether bond forms irreversibly between the CAAX cysteine and the 
isoprenoid. Catalysis by FT requires Mg2+, whilst GGT-1 can catalyse prenylation independently of 
Mg2+ presence. This is due to a lysine side chain (K311β) with a positive charge in GGT-1 in place of 
the glutamic acid side chain (D352β) that is present in FT (Figure 12).  It is the positive charge of the 
coordinated Mg2+ in FT that stabilises the developing negative charge of the Fpp diphosphate group; 
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in GGT-1 K311β can take this role without the requirement for Mg2+.42, 68, 69 Product release is 
stimulated by Fpp/GGpp or a CAAX peptide binding competitively to the enzyme.65, 67, 70 
 
Figure 13: The proposed mechanism for protein prenylation in the FT active site. Adapted from figures in 
64
 and 
71
 
1.2.4 RGGT and REP 
1.2.4.1 Mechanism of Rab prenylation by RGGT and REP 
The ability of Rab proteins to bind membranes and localise within a cell depends upon the post-
translational modification (PTM) of their C-terminal cysteine residues with (up to) two 
geranylgeranyl (GG) groups (Figure 11).22 There are two proposed mechanisms for Rab protein 
delivery to RGGT for prenylation, based on biochemical assays. The classical mechanism involves the 
Rab protein first associating with REP 72 in an interaction involving ionic bonds and no interaction 
with the C-terminal prenylation motif.22 RGGT then recognises this REP-Rab complex, binds it and 
attaches (one or) two GG groups to the Rab protein, without REP dissociation from the complex.73, 74 
Once one GG moiety has been transferred, the complex remains associated until the second one is 
attached to the Rab (depending on the prenylation motif). The REP:Rab:(2)GG complex dissociates 
once a new GGpp molecule binds. The REP is then proposed to deliver the Rab to its target 
membrane. An alternative pathway was proposed by Thomä et al.;75 in this case RGGT first binds to 
REP in the presence of GGpp before binding the Rab and following the rest of the pathway, as 
described above. It was also demonstrated that the concentration of GGpp affects the affinity of 
RGGT for the Rab:REP complex.74 This suggested that the pathway adopted may depend upon the 
concentration of GGpp available. Baron and Seabra demonstrated that the alternative mechanism is 
likely to be the predominant pathway in vivo by using both in vitro and cell-based assays. This study 
also found that GGpp binding to RGGT promotes the formation of a REP:RGGT complex, which is 
then recognised by unprenylated GDP-bound Rab.76 However, subsequently Alexandrov et al. used 
computational, biochemical and crystallisation studies on Rab7 mutants with RGGT and REP to 
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suggest a mechanism for Rab prenylation which again involved the formation of a preformed 
Rab:REP complex that binds to RGGT; both mechanisms are illustrated in Figure 14.43 
 
Figure 14: An illustration of the two proposed mechanisms for Rab prenylation by REP/RGGT. Classical (orange): Rab 
binds to REP via the Rab binding platform (RBP), the CIM of the Rab then binds to the CBR of REP and the complex can then 
bind to RGGT via the REP binding platform. Alternative (purple): RGGT forms a complex with a REP and subsequent GGpp 
binding to RGGT leads to association with a GDP-bound Rab protein. 1. The first prenylation step then occurs, where GGpp 
is transferred to a C-terminal cysteine of the Rab. 2. The REP-RGGT complex remains tightly bound to the Rab so that the 
Rab does not leave until the 2nd prenylation step has occurred. 3. On binding another GGpp to RGGT the REP-Rab complex 
dissociates and the REP delivers the Rab to its target membrane. 4. Once the REP has delivered the Rab to the membrane it 
dissociates and returns to the cytosol. Partly based on figures from 
14.
and 
43
. 
Structural and biochemical studies into RGGT mediated prenylation have revealed important binding 
regions on the proteins involved.64 From the crystal structure of the Rab:REP complex two binding 
interfaces were found: between the Rab binding platform (RBP) of REP and the Switch II region of 
the Rab and between the C-terminal binding region (CBR) of REP and the C-terminal CBR interacting 
motif (CIM) of Rab.15, 77 Pylypenko et al. used biochemical studies to demonstrate that there are two 
REP-1 residues (F279 and R290) critical for interaction with the RGGT α-subunit. To date there is no 
structure of the ternary (RGGT:REP:Rab:GGpp) complex, although Wu et al. used computational and 
biophysical studies to model the complex and suggested that weak associations form between RGGT 
and the Rab C-terminus; this presents the cysteine of the prenylation motif to the RGGT active site.43 
For doubly prenylated Rabs it is the cysteine towards the N-terminal end of the prenylation motif 
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that is prenylated first, as demonstrated by Baron et al.78 Once the Rab is prenylated, the isoprenoid 
moieties move from the hydrophobic funnel in the RGGT active site (where they are during 
prenylation) and into the lipid binding site of REP-1, which consists of five helices. This causes F279 
and R290 of REP-1 to shift as the lipid-binding cavity is enlarged by the isoprenoids and the affinity of 
REP-1 for RGGT subsequently decreases. The Rab(GG):REP complex is then released and the REP can 
deliver the prenylated Rab to its target membrane.43, 64 
1.2.5 REP and RabGDI 
1.2.5.1 Structure and function of REP and RabGDI 
As discussed in relation to the Rab cycle, Rab GDP dissociation inhibitor (RabGDI) binds to prenylated 
GDP-bound (inactive) Rabs and recycles them from the membrane to the cytosol.79 This provides a 
cytosolic reservoir of RabGDP:GDI complex that can be used to deliver Rabs to newly formed vesicles 
in response to cellular signalling events. After delivering the Rab to the membrane, RabGDI 
dissociates and returns to the cytosol; the Rab remains membrane bound and is activated to the 
GTP-bound form by a RabGEF (see Figure 6).80  
Sasaki et al. originally isolated RabGDI from bovine brain as a protein that inhibited the dissociation 
of GDP from Rab3a.81 In yeast there is only one isoform of GDI (GDI1/Sec19) and it is essential for 
yeast survival but in humans two isoforms are expressed, GDIα and GDIβ.82-84 The two human GDI 
isoforms have 85% homology but their separate functions remain unclear and both interact with the 
majority of Rab proteins in vitro. In vivo the GDI isoform that a Rab associates with generally 
depends on the expression levels of the isoforms i.e. if there is more GDIα in a cell then there will 
tend to be more Rab associated with that than with GDIβ. It has been found that GDIβ is generally 
abundant in all cell types, whilst GDIα is expressed much more highly in the brain.82 Like REP, the 
structure of RabGDI is tightly packed and composed of two domains; the larger forms a protein-
protein binding interface with the catalytic domain of the Rab protein, whilst the smaller domain 
binds the isoprenoid moieties (Figure 15).85, 86 Unlike REP, RabGDI does not bind unprenylated Rabs 
and thus cannot present Rabs to RGGT for prenylation, whilst Pylypenko et al. reported that REP is 
unable to remove prenylated Rabs from membranes when RabGDI can.87 However, in vitro assays 
carried out by Baron and Seabra suggest REP is able to extract prenylated Rabs from membranes.76 
Comparative structural and functional analyses carried out by Pylypenko et al. established that the 
Rab binding site of REP is more extensive than that of RabGDI and thus it is able to bind 
unprenylated Rabs with nanomolar affinity whilst RabGDI requires the Rabs to be prenylated in 
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order for stable complex formation to occur.87 Furthermore, RabGDI is unable to interact with RGGT 
and so cannot assist in Rab prenylation; the structure of RGGT:REP suggests that this is due to both 
the absence of a phenylalanine residue in RabGDI that is conserved in REP and is critical for binding 
of RGGT (REP F279), and the presence in only RabGDI of another phenylalanine residue on the 
adjacent helix (GDI F138).88  
 
Figure 15: Rab7:REP-1 and Ypt1:RabGDI structures. Left: REP-1 is shown in yellow, GGpp in Red, RabSF regions in purple, 
RabF regions in Green and conserved nucleotide binding region in pink. The image was created in PyMol (pdb accession 
code 1VG0). Right: Structure of the Ypt1GG:RabGDI complex. Ribbon representation of RabGDI (orange) bound to Ypt1 
(teal); domain I (bright orange), domain II (light orange), Rab-binding platform (dark blue), C-terminus-binding region (CBR) 
(raspberry) and MEL (green).The Switch I and II regions of Ypt1 are highlighted in dark orange and yellow, respectively. The 
isoprenoid moiety (red) is displayed in ball-and-stick representation. The GDP (grey) and Mg
2+ 
(magenta) ion are shown in 
the nucleotide-binding pocket. 
13-15, 86
 The image was created in PyMol (pdb accession code 1UKV). 
REP and RabGDI both interact preferentially with GDP-bound Rabs.81, 89 The crystal structure of yeast 
RabGDI in complex with the yeast RabYpt1 gave insights into how RabGDI is able to distinguish 
between GDP- and GTP-bound Rabs;86 the structure of REP-1 in complex with Rab7 has been 
published by Alexandrov et al. (Figure 15) as has the structure of REP-1 in complex with RGGT.15 The 
binding of RabGDI to Rab proteins involves several residues in the Rab Switch I and II regions, which 
are highly conserved between Rabs. When GTP is bound the conformation of these regions results in 
a poor fit with the Rab-binding regions in RabGDI. However, when Rab-GDP is bound to RabGDI the 
Switch regions become more rigid and a closed conformation is formed, possibly explaining the GDP 
dissociation inhibition properties of RabGDI. Rab GDI was discovered initially to stabilise the inactive 
Rab-GDP form (there are very few effectors that interact with GDP-bound Rabs)7 but its most 
Rab7:REP-1 Ypt1:RabGDI 
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important role is to cycle Rabs between the cytosol and their target membranes.79 REP and RabGDI 
interact with Rabs in a conserved manner via a Rab-binding platform; for REP there is also a smaller 
interface at the C-terminal binding region (CBR) which is hydrophobic and interacts with the 
hydrophobic CBR interacting motif (CIM) of the Rabs.15, 43 RabGDI also has a region implicated in 
interaction with the membrane, termed the mobile effector loop (MEL) (see Figure 15).  
1.2.5.2 REP-1 vs. REP-2 
There are two isoforms of Rab escort protein: REP-1 and REP-2. REP-1 was first discovered by Seabra 
et al. as a co-factor of the enzyme RGGT and cDNA cloning identified it as the Choroideremia CHM 
gene product.56, 72, 90 REP-2 was discovered later by Cremers et al. as encoded by the Choroideremia-
like gene CHML. This was discovered from the observation that there was still RGGT activity in the 
lymphoblasts of CHM patients and lead to the hypothesis that REP-2 can only partially compensate 
for the loss of REP-1 in CHM patients, meaning a subset of Rabs is left unprenylated.91, 92 CHM 
(Rep-1) is an X-linked gene (Xq21.1) of 15 exons leading to a protein of 653 amino acids 93 whilst REP-
2 is encoded by just a single exon linked to chromosome 1q42-ter and contains three additional 
amino acid residues as compared to REP-1.91, 92  REP-1 has been reported to display a more tissue 
specific expression pattern than REP-2 and the isoforms may have different substrate specificities, 
which could explain the fact that the disease Choroideremia (explained in detail below, section 
1.2.7.2) only affects the eyes of patients.77, 91 Both the REP isoforms are ubiquitously expressed but 
REP-1 is reportedly overexpressed in the eye.24  
In 2003 Larijani et al. postulated that a difference in affinity between REP-1:Rab27A and 
REP-2:Rab27A with RGGT could help explain the fact that Rab27A was identified as being strongly 
affected in Choroideremia; they also found Rab3 family members were less well prenylated with 
REP-2 than with REP-1.94 Furthermore, since REP binds preferentially to GDP-bound Rabs, the 
intrinsic GTPase activity of a Rab could also affect the efficiency of its prenylation and thus, in the 
case where there is no REP-1, Rabs with lower GTPase activity would not be prenylated as efficiently 
as other Rabs with higher GTPase activity.94 The different roles of the REP isoforms have not yet 
been discovered and nor has REP-2 been implicated in disease so far.95 
1.2.6 Post-prenylation modifications  
Many proteins with the C-terminal amino acid sequence CAAX are modified further following 
prenylation. The C-terminal AAX residues may be cleaved by proteases such as Rce1p and Zmpste24 
and, following cleavage by Rce1p, methylation at the prenylated cysteine residue  is catalysed by 
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isoprenylcysteine carboxylmethyltransferases (Icmt) (Figure 16).31, 37 This post-prenylation 
methylation is implicated in the cellular localisation of proteins, as well as other processes such as 
membrane attachment and interactions with other proteins, as the methyl group further increases 
the hydrophobicity of the prenylated cysteine.37 Carboxylmethylation of Ras proteins is implicated in 
Ras-induced oncogenesis and thus Icmt inhibitors have been synthesised, for example cysmethynil.37, 
96 With regard to Rab proteins, those with a CAAX or CXC prenylation motif can undergo methylation 
of the C-terminal prenylcysteine whereas Rabs with a XXXCC or XCCXX prenylation motif are not 
suitable substrates for methylation, for example Rab8 and Rab13 are methylated after prenylation 
whilst Rab5A and Rab11A are not.37, 97, 98  
 
Figure 16: Post-prenylation methylation of farnesylated CAAX proteins.Icmt - isoprenylcysteine 
carboxylmethyltransferase, SAM – S-adenosylmethionine 
Palmitoylation is a reversible process that is often important for protein binding and localisation to 
membranes. Prenylated proteins may also be palmitoylated, for example Ras proteins, which are 
farnesylated, can also be palmitoylated.37 Davis et al. showed that a wide range of proteins, 
including some Rabs, are palmitoylated.99 They found that Rab40C was palmitoylated; however, the 
role of palmitoylation of Rab proteins remains unclear.99 More recently, Cravatt et al. used a palmitic 
acid analogue and SILAC labelling to profile cellular palmitoylation quantitatively.100 
1.2.7 Rab Prenylation and Disease 
Defective prenylation of Rabs has been shown to result in their mistargeting; for example, mutant 
mono-prenylated mammalian Rab5 and Rab27 cannot localise to the correct subcellular 
compartment and so do not function. These proteins appear to be prenylated by the same REP-
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RGGT machinery as wild-type Rabs but are subsequently mistargeted to the ER.52 Mutations in the 
enzymatic machinery that prenylates Rabs can thus lead to a number of diseases, as detailed below. 
Mutations of Rab proteins also cause disease, unsurprisingly given their key role in vesicle trafficking; 
the role of Rab proteins in inherited and acquired disorders is extensively discussed by Mitra et al.101 
Indeed, mutations affecting any part of the Rab cycle can lead to disease because of the vital role 
that Rabs play in cellular trafficking.19 
1.2.7.1 Hermansky-Pudlak syndrome and gunmetal mutations 
Mutation of RGGT in the gunmetal (gm) mouse102 leads to a disease similar to the rare, autosomal 
recessive human disease Hermansky-Pudlak syndrome. This disease affects melanosomes, 
lysosomes and platelet dense granules and patients present symptoms of partial albinism, prolonged 
bleeding times and platelet dysfunction.103, 104 The gm mutation does not affect REP expression but 
there is a ~75% reduction in RGGT α-subunit expression and hence a reduction in Rab prenylation. 
The gm mutation in mice was identified as a G to A substitution in a splice-acceptor site of the gene 
encoding the mouse RGGT α-subunit, resulting in an exon skipping error that reduces RGGT activity 
4-fold.102 All tissues show a reduction in RGGT activity but the phenotypes caused by defects in Rab 
prenylation are found to be tissue specific, occurring in platelets and melanocytes.102, 105, 106 Swank 
et al. postulated that the reason for this was that there is a higher concentration of Rabs in platelets 
and melanocytes.105 Another possible explanation could be that there is a subset of Rabs in these 
tissues that have lower affinity for RGGT-REP and are thus more affected when the concentration of 
enzyme is limiting.102  
1.2.7.2 Choroideremia 
Choroideremia (CHM) is a rare, hereditary, X-linked recessive retinal degenerative disease that leads 
to the degeneration of the choroid, the retinal pigment epithelium (RPE) and the photoreceptors of 
the eye (Figure 17). The choroid is a network of blood vessels located between the retina and the 
sclera; it provides oxygen and nutrients to both the RPE and the retina's photoreceptor cells. The 
RPE, directly beneath the retina, supports the function of photoreceptor cells which convert light 
into the electrical impulses that transfer messages to the brain. In CHM the choroid and the RPE 
deteriorate initially and, eventually, photoreceptor cells also degenerate, leading to loss of vision. To 
date there is no effective treatment or cure for the disease. However, recently gene therapy clinical 
trials commenced to treat CHM patients by replacing REP-1 using viral vectors containing REP-1 
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cDNA; following work by the Seabra group at Imperial College London and the MacLaren group at 
the University of Oxford. 
 
Figure 17: Diagram of the human eye.
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 and images showing the fundus of a patient with Choroideremia (left) and that 
of a normal eye (right).
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 There is extensive chorioretinal degeneration in the Choroideremia eye (middle) compared to a 
normal eye (right). 
CHM has an incidence of approximately 1 in 50,000 and normally affects men as the CHM gene is 
found only on the X chromosome.109 The disease begins in youth with night blindness, followed by 
loss of peripheral vision and depth perception. Total blindness occurs by middle age as the choroid 
and RPE atrophy, starting peripherally and spreading centrally (Figure 17).11 Heterozygous female 
carriers of the mutant gene are usually asymptomatic and have no visual impairment. However, they 
do show characteristic pigment changes in the midperiphery fundus (the fundus of the eye is the 
interior surface, opposite the lens, and incorporates the retina, optic disc, macula, posterior pole, 
Bruch's membrane and the choroid), which resembles the fine mottling seen in the early stages of 
the disease in males; there are also areas of chorioretinal degeneration.11, 24 
Mutations of the CHM gene, which encodes REP-1, cause CHM.110, 111 There are many different 
mutations of REP-1 reported and the vast majority of mutations result in an absence of the REP-1 
gene product.112-114 Mutations include: gross deletions; small deletions of a few base pairs that 
disrupt the open reading frame; and splice-site, nonsense (a point mutation where a nucleotide is 
changed and results in a stop codon), missense (point mutations where the nucleotide change 
results in the codon for a different amino acid) and frameshift mutations. Rab27A has been shown to 
be selectively unprenylated in CHM lymphoblasts and Rab27A is highly expressed in the RPE and 
choroid of rat eyes, which are the layers that degenerate in CHM.115 Rab27A is involved in the 
transport of melanosomes in dermal melanocytes and thus CHM could be caused by defects in 
melanosome transport in the choroid and RPE.116, 117 However, Rab27A is also highly expressed in a 
number of other tissues, such as the spleen, that remain unaffected in patients with CHM.115, 118, 119 
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Furthermore, human loss-of-function mutations in the RAB27A gene result in Griscelli syndrome 
type II and the lack of eye defects in these patients suggests that Rab27A cannot be solely 
responsible for the phenotype of CHM.120 In spite of this, Rab27a may still be involved, along with 
other hypoprenylated Rabs, in causing CHM.103 
Knock-out mouse models of CHM are not possible because knock-out of REP-1 is embryonically 
lethal in mice.121 To study CHM, Tolmachova et al. developed mouse models with conditional knock-
outs of the REP-1 gene both in a ubiquitous and a tissue-specific manner.109, 122 A mouse model of 
CHM is highly useful as it allows the cause of the disease to be identified, as well as allowing the 
testing of different potential treatments.112 The conditional knock-out of REP-1 in the RPE and 
photoreceptors, allowed Tolmachova et al. to probe the progression of CHM.122 They found that 
when REP-1 was knocked out in both those cell layers then the rate of degeneration of the 
photoreceptors was increased compared to REP-1 knockout in the photoreceptors or RPE alone, 
implying that diseased RPE has an impact on the rate of photoreceptor degeneration. Their findings 
in this research supported their earlier work which suggested that both the RPE and the 
photoreceptors are primary sites of CHM disease. In the case of REP-1 knockouts in individual layers, 
with REP-1 knockout in the RPE, the RPE slowly degenerated whilst the photoreceptors remained 
normal and vice versa for the photoreceptor-specific knockout.122 Recently Tolmachova et al. 
published further work describing a lentiviral technique for ocular gene therapy.123 They used the 
conditional knockout mouse models of CHM, both in vivo and in vitro, to rescue the prenylation 
defect caused by REP-1 knock-out using a lentiviral vector containing CHM cDNA; they transfected 
human CHM patient fibroblasts, CHM mouse RPE cell culture and performed subretinal injections of 
the lentivirus into CHM and wild type mice and found that the lentiviral CHM cDNA transgene 
rescued the prenylation defect in the CHM mouse RPE. They used this work to evaluate whether the 
lentiviral system would be suitable for gene therapy to treat Choroideremia; as mentioned above, 
there is currently a clinical trial in progress linked to this work. 
1.2.7.3 Drugs that affect protein prenylation 
1.2.7.3.1 Prenyltransferase inhibitors 
Since prenylated Ras proteins were first implicated in cancer, effective prenyltranferase inhibitors 
(PTIs) have been sought. A number of FT inhibitors (FTIs) have been created that compete with 
either the lipid binding or the CAAX substrate or both.124, 125 There are even three inhibitors 
(tipifarnib, lonafarnib, and BMS214662) in clinical trials as anti-cancer drugs.64 FTIs are not always 
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successful at inhibiting prenylation as in some cases GGT-1 will prenylate the substrate in the 
absence of FT.64, 126 Thus there are also a number of GGT-1Is that have been designed to treat 
tumours in vivo and they also inhibit Rho signalling, which leads to cell cycle arrest and apoptosis.127 
Some of these FTIs and GGT-1Is were also found to inhibit RGGT, for example the compounds BMS1-
4 (Bristol-Myers Squibb) were thought to act as FTIs but were later shown to induce apoptosis by 
inhibiting RGGT.128 Waldmann et al. have used BMS3 to develop more selective RGGT inhibitors that 
target the tunnel that is specific to RGGT and is adjacent to the GGpp binding site.129 
Bisphosphonates inhibit isopentenyl diphosphate (IPP) isomerase and FPP synthase, essential 
enzymes in the mevalonic acid pathway, which are required for the synthesis of Fpp and GGpp.53 
Inhibitors of RGGT that are phosphonocarboxylate analogues of bisphosphonates have been 
designed to treat osteoporosis, a bone metabolism disorder, and other resorptive bone diseases.130, 
131  Bisphosphonates are used clinically to prevent osteoclast-mediated bone resorption and work by 
inhibiting Fpp and GGpp synthesis, whilst phosphonocarboxylates inhibit just RGGT.132 
Phosphonocarboxylate analogues of bisphosphonates were found by Baron et al. to inhibit the 
second prenylation step of RGGT prenylation.78 Recently Waldmann et al. reported the natural 
product psoromic acid and its analogues as new RGGT specific inhibitors.61 
1.2.7.3.2 Statins 
Statins are a class of drug used clinically to reduce cholesterol levels;133 they stop cholesterol 
biosynthesis by inhibiting the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase 
in the mevalonic acid pathway (Figure 9 and Figure 19).134 Inhibition of HMG-CoA reductase results 
in the inhibition of isoprenoid synthesis including GGpp (Figure 19); this causes an accumulation of 
unprenylated proteins in the cytosol because without hydrophobic prenyl groups the proteins are no 
longer sufficiently hydrophobic to associate with their target membranes. Mevastatin (Figure 18) or 
other statin treatment of cells as a means to investigate prenylated proteins is described in several 
studies.135, 136 For example the prenylation ‘block and release’ methodology used by Seabra et al. to 
investigate the membrane targeting mechanisms of Rabs.136 
 
Figure 18: The structure of Mevastatin 
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Figure 19: How statins affect protein prenylation. The mevalonic acid pathway is shown to the left and protein prenylation on the right. Statins work by inhibiting the enzyme HMG-CoA 
reductase (top left), leading to a decrease in biosynthesis of all metabolites in the downstream steps of the mevalonic acid pathway; this includes the isoprenoids Fpp and GGpp. PTM  of small 
GTPases of the Ras superfamily with these isoprenoids is essential for their correct function. Inhibition of HMG-CoA reductase by statins stops protein prenylation and thus association of these 
proteins with intracellular membranes, resulting in a cytosolic pool of unprenylated proteins. Adapted from a figure by Greenwood et al. 
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 Chemical proteomics 1.3
Proteomics is the study of all of the proteins that are produced from a complete genome; it is the 
study of their structure, function, mechanism and interactions. Chemical proteomics is the use of 
chemical probes to study proteins and is a multidisciplinary field that involves synthetic organic 
chemistry, mass spectrometry, cell biology and biochemistry.138 The number of chemical probes 
available is ever-expanding and they are particularly useful in the case of investigating protein PTMs 
as these are not genetically encoded into the protein and are thus difficult to probe by traditional 
biochemical methods.139 
1.3.1 Bioorthogonal Ligation 
One important and emerging proteomics technique is bioorthogonal ligation chemistry, which 
enables biomolecules to be labelled without the need for direct genetic encoding of the label.139 The 
term bioorthogonal means that the chemistry of the reaction used to probe a biological process, by 
attaching labels to proteins, is orthogonal to the chemistry found in a cell and so in principle does 
not result in non-specific labelling.140 The bioorthogonal functional group, or ‘tag’, is incorporated 
into the target biomolecule, for example a protein, by means of metabolic pathways, enzymatic 
activity, or direct encoding by expanded codon usage.141 A probe or label is then attached to the tag 
by means of a highly selective chemical reaction; azides142, 143, alkynes144 and aldehydes145, 146 have 
proven to be the most versatile tags. Carrying out the protein labelling in two steps enables minimal 
interference of the tag with the process that attaches it to the protein and also permits multiple 
alternate labels from one tag. The tag must be small and biologically inert both in terms of reactivity 
and so that it does not disrupt any biological function. The application of chemical biology to protein 
lipidation has been reviewed recently by Charron et al.,30 whilst a recent review by Sletten and 
Bertozzi gives a comprehensive overview of bioorthogonal ligation.147 Further reviews of the area of 
bioorthogonal organic chemistry by van Swieten et al.148 and Prescher and Bertozzi 139 are also 
relevant.  
There have been three reactions reported for probing azide-tagged biomolecules (Figure 20): the 
copper(I) catalysed Huisgen [3+2] cycloaddition reaction,  the Staudinger-Bertozzi ligation reaction 
and strain-promoted cycloaddition.140, 149 The copper(I) catalysed [3+2] Huisgen cyclisation reaction 
is described in further detail below (section 1.3.1.1) and is commonly known as a ‘click reaction’. A 
variation of this, strain-promoted cycloaddition, is most useful in cases where labelling with a probe 
is desired in vivo rather than in vitro, since the Cu(I) catalyst used in click chemistry is cytotoxic. The 
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Staudinger-Bertozzi ligation reaction involves the use of a phosphine to react specifically with the 
azide. Again the advantage is that it is non-toxic but the disadvantage is its relatively slow reaction 
kinetics, which necessitates the use of fairly high concentrations of phosphine reagent (~250 µM).147  
 
Figure 20: Generic bioorthogonal reactions. (i) Staudinger-Bertozzi ligation reaction, (ii) Copper-catalysed Huisgen 
cyclisation reaction, (iii) Strain-promoted cycloaddition reaction. 
1.3.1.1 The click reaction 
A ‘click’ reaction, a term first coined by Sharpless in 2001, is the most common reaction used for 
bioorthogonal ligation.150 According to Sharpless, idealised click reactions are modular (i.e. made up 
of small units that can be joined together by heteroatom links), stereospecific, wide in scope, very 
high-yielding and involve simple experimental procedures. Click reactions must also make use of 
readily available starting materials and reagents and be environmentally friendly by only generating 
inoffensive by-products. Reaction conditions should be simple, as should product isolation and the 
product should be stable under physiological conditions.150 The archetypal click reaction is the 
copper-catalysed Huisgen cyclisation,151 which is the formation of a 1,2,3-triazole by a 1,3-dipolar 
cycloaddition between an azide and an alkyne; it is also often called a Cu-catalysed azide-alkyne 
cycloaddition (CuAAC) reaction.152 The original reaction conditions for a Huisgen cyclisation reaction 
involved heating the reagents to yield a 1:1 mixture of the 1,4- and 1,5-substituted triazoles (Figure 
21A). However, when the reaction is catalysed by copper(I) salts it yields only the 4-substituted 
regioisomer and requires no protecting groups and no purification step, making it an almost perfect 
click reaction, as first described by Sharpless et al. and Meldal et al. in 2001.142, 153, 154  
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Figure 21: Catalysed and uncatalysed Huisgen cyclisation reactions. A: General uncatalysed Huisgen reaction. B: The 
mechanism of the general copper(I)-catalysed Huisgen 1,3 dipolar cyclisation reaction.
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The accepted, stepwise mechanism for the azide-alkyne click reaction involves the initial formation 
of a π-complex between the alkyne and the copper, which reduces the pKa of the alkyne, enabling 
deprotonation under aqueous or mildly basic conditions. The copper(I) acetylide then becomes a 
copper(I) adduct, upon attack by the organic azide, and intramolecular cyclisation occurs, to give a 
copper-containing 1,2,3-triazole. The final reprotonation step yields the final triazole product and 
regenerates the copper(I) catalyst (Figure 21B).142, 156, 157 The source of the copper(I) is generally the 
reduction of copper(II)sulfate by sodium ascorbate, as in work by Sharpless,153 but other sources 
have also been used.155 Advantages of this reaction compared to the two mentioned above are that 
the azide and alkyne reagents used are particularly easy to synthesise and have good tolerance to a 
variety of functional groups and reaction conditions; the reaction kinetics are also faster than the 
Staudinger ligation. Click reactions have been reviewed extensively by Moses and Moorhouse.158 
Click chemistry is an especially useful technique for studying PTMs that are not directly genetically 
encoded. To probe PTMs, analogues of enzyme substrates can be synthesised so that they contain 
azide or alkyne functionality; the enzyme targets are then tagged as part of the normal process of 
PTM with a moiety that can react bioorthogonally. Bioorthogonal probes subsequently label the 
tagged proteins with, for example, biotin or a fluorescent moiety via the click reaction. CuAAC is 
A
B
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widely used in the area of chemical proteomics as it allows the analysis of multiple targets that are 
all post-translationally modified in the same manner, whereas previous biological techniques were 
more limited.147  
The bioorthogonality of the click reaction means that it has a wide number of applications; tagging-
by-substrate is described below. Another application of CuAAC is activity-based protein profiling 
(ABPP), reviewed by Raghavan and Hang.159 ABPP uses enzyme inhibitors with attached tags to 
investigate the activities and expression levels of specific protein families. ABPP can also be used to 
explore the interactions of small molecules with proteins in order to further drug development and 
target discovery.159 The click and Staudinger-Bertozzi ligation reactions are useful for this technique 
because attaching a large tag, such as biotin, to an inhibitor used as a probe can affect its specificity 
and thus its utility for investigations in living cells. The click reaction is bioorthogonal and only 
requires a very small modification of the probe (with an azide or alkyne moiety), meaning the ability 
of the probe to bind to the enzyme is maintained.159  
1.3.2 Tagging-by-substrate 
Tagging-by-substrate (TbS) is a proteomics technique developed by Zhao et al. in 2004.160 They first 
used TbS to detect and identify farnesylated proteins, which have a low-to-medium abundance in 
cells, making them difficult to identify by routine proteomic methods. They succeeded in 
synthesising azido-analogues of Fpp (AzFpp) and farnesol (AzFOH). These analogues acted as 
substrates for FT when fed to cells in culture and tagged proteins normally modified with the natural 
FT substrate, Fpp.160 Proteins post-translationally modified by AzFpp were labelled via the 
Staudinger-Bertozzi ligation reaction, using a biotinylated phosphine capture reagent (bPPCR). This 
allowed the subsequent identification of labelled proteins by proteomics techniques, such as 
Western blotting and LC-MS/MS mass spectrometry (see Figure 22 for an overview of TbS and 
section 1.4 for a discussion of mass spectrometry for proteomics).  
 
46 
 
 
Figure 22: A cartoon illustrating the tagging-by-substrate methodology first described by Zhao et al.
160
 
The advantages of the azide functional group (-N3) are: it is small and thus causes minimal structural 
changes, making it easily accepted by cellular post-translational modification machinery; it is not 
found in any known naturally produced molecules; it is only slowly reduced to an amine by thiols 
under physiological conditions;160 and it is almost inert under the biological conditions employed by 
the TbS technique. Furthermore, despite inorganic azides being toxic, organic azides are tolerated 
for the time course of an experiment. The advantage of these substrates over 3H labelling (see 
section 1.3.3.1) is the shorter detection times and the absence of hazardous radiation as well as the 
affinity labels that can be attached to the azide tag via CuAAC, allowing affinity purification and 
enrichment of the proteins of interest.30, 161 
Further examples of the TbS technique being successfully applied come from Hang et al. and Cravatt 
et al., where protein palmitoylation was investigated using azide- and alkyne-tagged fatty acid 
analogues.162, 163 The TbS technique has also facilitated identification of proteins that have 
undergone other forms of PTM. For example, as mentioned above, Bertozzi et al. have used this 
technique to investigate proteins that have undergone post-translational glycosylation149, 164, as have 
Zhao et al.165, 166, whilst Tate et al., Berthiaume et al. and Hang et al. have used it to investigate post-
translational N-myristoylation of proteins.167-169 Zhao et al. have also filed a patent for the synthesis 
of azido-GGpp, although without providing details of its synthesis or potential applications.170 
Invitrogen have filed a similar patent and market AzGGOH as part of a Click-iT® kit for metabolic 
labelling of geranylgeranylated proteins in cells and subsequent probing via click chemistry. 
Examples of some other lipid substrates with azide (or alkyne) tags are described in reviews by Hang 
et al. and more recently by Hannoush.30, 171  
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1.3.2.1 Affinity purification techniques 
Affinity purification of proteins is a widely used technique in biology for enriching and separating 
labelled proteins from unlabelled proteins; in this study azido-geranylgeranylated proteins are 
labelled with biotin to facilitate affinity purification. Biotin is also known as vitamin H and has an 
extremely high affinity for the protein avidin and the bacterial equivalent streptavidin (from 
Streptomyces avidinii).
172 Avidin is a tetrameric glycoprotein, whilst streptavidin lacks the 
glycosylation of avidin so it exhibits less non-specific binding. Another form of avidin without 
glycosylation is NeutrAvidin™, which is commercially available from Thermo Scientific and 
Invitrogen. NeutrAvidin also lacks the Arg-Tyr-Asp motif of streptavidin that binds to cell surface 
proteins, and therefore it exhibits further reduced non-specific binding.173 All of these proteins are 
available covalently linked to beads composed of e.g. agarose. All three of these proteins possess 
four Biotin-binding sites and an affinity for Biotin with a Kd of 10
-15 M; a comparison of the proteins is 
shown in Table 2. 
Comparison of biotin-binding proteins 
 Avidin Streptavidin NeutrAvidin™ 
Molecular weight of tetramer (kDa) 67 53 60 
Isoelectric point (pI) 10 6.8-7.5 6.3 
Non-specific binding High Low Lowest 
Table 2: A comparison of Biotin-binding proteins based on information from Thermo Scientific.
174
 
1.3.3 Methods used to detect protein prenylation 
1.3.3.1 Radiolabelling to detect Rab prenylation 
Seabra et al. used 3H radiolabelling to measure RGGT activity and hence to investigate Rab 
prenylation.115 The incorporation of [3H]GGpp into Rab proteins was measured in order to determine 
the activity of RGGT and this method was subsequently used to detect unprenylated Rabs present in 
CHM lymphoblasts. When REP-1 is mutated and therefore not functioning correctly, its preferential 
Rab targets are not prenylated in vivo; addition of functional RGGT, REP-1 and [3H]GGpp to the cell 
lysate allows prenylation of the available unprenylated Rabs and labels them with 3H. The aliquots 
containing newly radiolabelled, prenylated Rabs were subjected to SDS-PAGE and then 
autoradiography. The method allows visualisation of whether Rabs have been prenylated and thus 
whether the cellular prenylation machinery is functioning correctly. The proteins that were 
prenylated were digested with proteases and the [3H]GG radiolabelled peptide was isolated and 
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sequenced. The method led to identification of Rab27A as a target of REP-1. The significant 
disadvantages of this technique are the hazardous nature of working with radiation and its expense 
and, furthermore, the length of time it takes to probe radioactively-labelled proteins in a gel (up to 
several weeks). 
1.3.3.2 Chemical methods to detect protein prenylation 
Protein prenylation is an important PTM and various methods of studying it in vitro and in vivo using 
chemical techniques have been developed.30, 147 Initially the increase in hydrophobicity of prenylated 
CAAX peptides or the release of the pyrophosphate group allowed investigation of the mechanism of 
prenylation and the efficacy of prenylation inhibitors.175-177 However, these methods are limited to in 
vitro assays and do not transfer well to in vivo systems.41 The traditional method for probing the 
protein substrates of prenyltransferases is to use tritiated analogues of Fpp and GGpp (as described 
in the previous section) but apart from the lengthy exposure times needed to see protein labelling, 
radioactive labelling is also hazardous and costly. However, for the past decade work on prenylation 
has involved the synthesis of various probes that are functionalised analogues of the isoprenoids; 
these crucially have shorter detection times and greater sensitivity compared to radioactive 
labelling.171 
This section concentrates on protein prenylation but protein lipidation is widely probed using 
chemical biology and for a detailed review of the topic see the recent paper by Linder and Hang.2 
Alexandrov et al. used expressed protein ligation to establish the binding of Rab7 to REP (Figure 
15).178 Chemoenzymatic methods for investigating prenylation, as well as acylation, have also been 
developed. Fluorescent FT, GGT-1 and RGGT substrates were developed by Alexandrov et al., which 
allowed non-radioactive prenylation assays to find selective FT and RGGT inhibitors and also 
investigate the mechanism of RGGT prenylation.48, 179 Fukada et al. used a photoactivateable farnesyl 
group to investigate the interacting targets of the farnesyl group that modifies the transducin γ-
Subunit.180 There are also bioinformatics techniques available to predict proteins that are lipidated, 
for example Prenbase; however, experimental validation is still required.30 The azido-farnesyl 
labelling used by Zhao et al. is described in section 1.3.2. 
Alexandrov et al. used a biotinylated geranyl pyrophosphate (BGPP, Figure 23) to probe RGGT 
prenylation and as a substrate for FT and GGT-1 mutants (it does not act as a substrate for the native 
proteins).135, 181 This biotinylated GGpp analogue allowed affinity purification of Rabs extracted from 
COS7 cells and a significant number of Rabs were identified by mass spectrometry (MS), although 
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the published results did not provide details of any background proteins identified or the quantity of 
cell lysate required to generate the results.135 These types of probe have also been applied to 
proteomics studies of fatty-acylation; again, proteins were affinity purified using biotin labels 
attached to the proteins of interest and the enriched samples analysed by mass spectrometry.160, 163, 
169 
 
Figure 23: Examples of isoprenoid probes developed by various groups to probe prenylation.
41, 182
 
Tamanoi et al. used the recently available AzGG Click-iT™ kit from Invitrogen (AzGGOH, Figure 23) to 
metabolically tag geranylgeranylated proteins with an azide group and then CuAAC to label these 
azido-proteins with a fluorescent probe (see Figure 24 for an overview of metabolic labelling). They 
used this probe to identify proteins of interest by looking for fluorescent spots in 2D gel 
electrophoresis, followed by analysis of these spots by MS to identify geranylgeranylated proteins.183 
Hang et al. recently reported a series of alkynyl and azido farnesol analogues to use for metabolic 
labelling and subsequent bioorthogonal ligation.182 They demonstrated that the probe Alk-FOH was 
indeed labelling prenylated proteins in different cell types (Ras, RhoA and Rab7), although not 
specifically as Rab and Rho proteins are geranylgeranylated. Metabolic labelling is also commonly 
used to probe other forms of lipidation, such as myristoylation and palmitoylation.162, 167, 184 
Spielmann et al. also used metabolic labelling to probe protein prenylation. However, instead of a 
bioorthogonal labelling approach they used anilinogeraniol (AGOH, Figure 23) an unnatural analogue 
of farnesol against which they raised a specific antibody.141, 185  
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Figure 24: An illustration of how metabolic labelling can be used to purify and identify proteins of interest by using 
synthetic analogues of enzyme substrates with an azide or alkyne tag. Once proteins have been post-translationally 
modified with the azide or alkyne tag by the cellular enzymatic machinery the cells are lysed. Tagged proteins are then 
labelled with biotin and/or fluorophore moieties by means of a bioorthogonal reaction with an alkyne or azide probe 
(depending on the nature of the tag on the proteins). Labelled proteins may be visualised by in-gel fluorescence or Western 
blot and/or subjected to affinity purification with (for example) streptavidin agarose beads, using the biotin affinity tag to 
enrich the labelled proteins. The proteins may then be identified by LC-MS/MS proteomics analysis. 
 Mass spectrometry-based proteomics 1.4
Mass spectrometry is an important and widely used technique for identifying proteins from a 
sample, quantifying their relative levels and for probing PTMs. Mass spectrometry is an analytical 
technique that measures the mass-to-charge (m/z) ratio of charged particles; from this the mass of 
the particles can be determined, which leads to the elucidation of their chemical structure. The 
machinery and software for analysing samples is constantly evolving and improving and an overview 
of the different aspects of mass spectrometry is given here.  
1.4.1 Mass spectrometry and how it works 
There are a number of different types of mass spectrometer available and the kind used depends 
upon the sample and the information that is required. All mass spectrometers contain the same 
basic components as illustrated in Figure 25; this consists of an ion source to ionise samples into the 
gas phase (electrospray ionisation (ESI) or matrix-assisted laser desorption/ionisation (MALDI)), a 
mass analyser(s) to measure the m/z ratio (quadrupole (Q), ion trap (IT), time-of-flight (ToF), Fourier 
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transform ion cyclotron resonance (FT-ICR) and orbitrap (OT)) and a detector to measure the 
number of ions at each m/z (most commonly an electron multiplier is used), time-of-flight mass 
spectrometers also require a digitiser. The sample is loaded onto the machine either by online 
coupling to an HPLC (in the case of ESI machines) or offline by spotting the fractions from LC 
separation of the sample onto a MALDI plate, which is then loaded on the MALDI mass 
spectrometer.
186  
 
Figure 25: A generalised mass spectrometer. Adapted from a figure in the lecture of Dr J Vizcaino, EBI, Cambridge. 
1.4.1.1 Mass spectrometer ion sources 
Mass spectrometric analysis is carried out on ionised samples in the gas phase; the two most 
common methods are ESI and MALDI.186-188 These techniques are soft ionisation techniques 
developed in the 1980s and they allowed mass spectrometry to be used in a wide range of 
applications as they avoid excessive fragmentation of the sample on ionisation and transfer to the 
gas phase, whereas before these methods MS was limited to thermally stable molecules.189 
In ESI the liquid sample is dispersed through a heated needle into a fine aerosol by electrospray 
(Figure 26). The voltage applied causes the sample to disperse into highly charged droplets from 
which the liquid evaporates, leaving charged gas-phase analyte particles, which then pass into a 
vacuum.190 ESI can ionise samples in solution, hence ESI mass spectrometers are commonly coupled 
to liquid chromatography systems (LC-MS). MALDI works by ionising and sublimating dry samples 
that are in a crystalline matrix, using laser pulses (Figure 26). Both techniques are sensitive, although 
ESI is more commonly used for complex samples as it can be coupled online to an LC device. MALDI 
is less sensitive to contamination of samples with, for example, salts or traces of detergent.189, 190 
MALDI typically produces singly charged ions whilst ESI generates multiply charged ions (2+, 3+ and 
4+). 
sample ion source mass analyser(s) detector digitiser
Generalised mass spectrometer
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Figure 26: Commonly used mass spectrometer ion sources. Figure adapted from 
191
 and the lecture of Dr J Vizcaino, EBI, 
Cambridge. 
1.4.1.2 Mass spectrometer mass analysers 
There are a number of different mass analysers available and it depends upon the purpose of the 
proteomics investigation as to which is chosen. The four main varieties are quadrupole (Q), ion trap 
(IT), time-of-flight (ToF), Fourier transform ion cyclotron resonance (FT-ICR) and orbitrap (OT) and 
the purpose of the analyser is to resolve the ions in a sample according to their m/z ratios. These 
analysers can be stand alone or operate in tandem depending on the function required.186 
Quadrupole analysers consist of four parallel metal rods with each opposing rod pair connected 
electrically and a radio frequency (RF) voltage applied across the pairs, a direct current voltage is 
superimposed on the RF voltage and the ions travel down the quadrupole that is formed between 
the rods (Figure 27). The Q analysers separate ions because only certain ions with the correct m/z 
will have stable enough trajectories at a given ratio of voltages to reach the detector, other ions will 
collide with the rods. Thus an ion with a particular m/z can be selected or a range of m/z-values 
scanned by continuous variation of the applied voltage.192 
 
Figure 27: Illustrations of the layout of common mass spectrometer mass analysers. Adapted from figures in 
193
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ToF analysers work by measuring the time taken for an ion to travel through a tube of known length 
under vacuum and calculating the m/z ratio from this.189 Ions are accelerated with equal energies 
and will travel along the tube with different velocities that are inversely proportional to their 
masses.192 ToF analysers can be coupled to both ES and MALDI ion sources and often operate in 
tandem with other analysers e.g. Q-Q-ToF.189 
IT analysers are very popular due to their high sensitivity for analysing peptides when they are 
coupled to a nanospray source;192 they are also affordable and quick.192 Ion traps work by trapping 
ions in an oscillating electrical field; they achieve mass separation by tuning the field to eject only 
ions of a specific mass.194 IT analysers consist of a ring electrode with a cap electrode either side and 
ion-trapping and analysing takes place in the cavity these electrodes form (Figure 27).192 Adjusting 
the RF voltage applied to the ring causes ions to be ejected depending on their m/z ratio as their 
trajectories destabilise successively; the ions will reach the detector sequentially depending on their 
m/z. IT analysers are limited by their resolving capabilities and capacity for ion-trapping.194 Linear 
ion-trap (LIT) analysers give improved resolution by employing a quadrupole between 4 rods as the 
ion trap. This allows improved resolution by having the option of a slow-scanning function; the 
resolution is inversely proportional to the speed of scanning of the applied RF voltage.
189, 192, 195 
FT-ICR is another form of ion-trapping technology; the ion is trapped in a cell of four electrodes in a 
strong magnetic field (Figure 27).196 The ion is essentially trapped in a cyclotron, which is a form of 
particle accelerator. In the trap the ions oscillate with a so-called cyclotron frequency that is 
inversely proportional to their m/z ratio; the cyclotron frequency is dependent upon the strength of 
the magnetic field.192 Many ions are detected simultaneously, hence a Fourier transformation is 
needed to extract the frequencies of individual ions and hence m/z ratio. This analyser gives high 
mass accuracy and resolving power and measurements are possible in the low-sub ppm range.189 
The high resolution gives high data quality and better detection rates than lower resolution 
analysers but FT-ICR suffers from a relatively slow rate of acquisition.189 
Orbitrap mass analysers are the most recent type invented and they separate ions using an 
oscillating electrical field.197, 198 They have similar mass accuracy and resolution to FT-ICR but do not 
require an expensive superconducting magnet and are more robust and easier to maintain.189 
Resolution in mass spectrometry is defined as the width of a peak at half its height divided by its 
mass (i.e. dimensionless) and this increased from a few hundred with IT analysers to 150,000 with 
new Orbitrap analysers in just a decade.190, 199 In Orbitraps the ions are in static electrostatic fields 
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and they orbit around a central electrode, oscillating in an axial direction (Figure 27). As with FT-ICR 
a Fourier transformation is required to obtain the m/z ratios of the ions.199 Thermo Scientific coupled 
a linear ion-trap to an Orbitrap which is marketed as an LTQ-Orbitrap; this gives the excellent 
resolution and mass accuracy of an Orbitrap coupled with the speed and sensitivity of a LIT.199 
1.4.1.3 Detector 
The most common type of detector used is an electron multiplier; as with the analyser, the detector 
must be under vacuum.192 The detector monitors the ion current, amplifies it and reports it to the 
data system, it is measuring the number of ions at each m/z ratio.186 
1.4.1.4 MS/MS 
A single mass analyser can determine the mass of a peptide by using its m/z ratio; this may be 
enough information when only a single protein of known mass is being studied. The process is 
known as peptide mass fingerprinting (PMF) and uses only a single MS mode. However, in a mixture 
of peptides from a sample containing a number of different proteins it is necessary to try and 
discover the identity of a peptide and not just its mass. This is achieved by fragmenting the peptide 
ion along its backbone within the mass spectrometer; the most commonly used method of 
fragmentation is collision-induced dissociation (CID) although ETD (electron transfer dissociation) is 
another fragmentation method that is likely to increase in use in the future.200 In ETD, one of the 
mass analysers is used to measure the mass of the parent ion whilst another measures the masses of 
the fragments.190  
In CID, collision of the peptide ion with an inert gas (e.g. N2 or He) at low pressure causes 
fragmentation of the ion into b ions and y ions (Figure 28).190 The spectrum generated from 
fragmentation is known as the tandem mass spectrum (MS/MS spectrum) and it shows m/z peaks, 
the difference between the peaks corresponds to the mass of an amino acid. The collisions cause 
slow heating of the samples and so loss of labile PTMs and neutral H2O and NH3, as well as internal 
fragmentation, can also occur; this makes identification of larger peptides (more than 15 amino 
acids) difficult.201 
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Figure 28: Peptide fragmentations. Adapted from a figure in 
202
 
ECD (electron capture dissociation) and ETD are orthogonal alternatives to CID fragmentation. In 
ECD an electron beam is fired at the cloud of trapped ions; when an analyte ion captures an electron 
it forms an unstable radical ion which fragments into z and c ions (Figure 28).200 ECD is generally 
confined to use In FT-ICR machines. Electrons are again transferred in ETD but in this case it is anions 
(normally fluoranthene ions) that transfer the electrons to the analyte ions and create radical ions 
that subsequently fragment. The advantage of ETD over ECD is that it can be performed in 
quadrupole ion traps, resulting in lower cost and higher sensitivity. Neither ETD nor ECD can be 
performed on singly charged ions as by definition they result in a reduction in charge of the analyte 
ion, thus they work best on highly charged ions. This means that ECD and ETD are less widely 
applicable than CID but because CID is not as efficient at fragmenting highly charged ions they can 
generate complementary data.200, 203, 204 
Examples of tandem mass spectrometers include the triple quadrupole, Q-trap, QqToF, LTQ-Orbitrap 
and Q-FT-ICR.200 A triple quadrupole consists of three sequential quadrupole mass analysers; the first 
is used to measure the mass of the parent ion, the second as a fragmentation chamber and the third 
to measure the fragments. In a Q-trap the setup is the same as with a triple quadrupole but the final 
quadrupole is replaced with a quadrupole ion trap. This gives improved sensitivity, particularly for 
fragmentation analysis.200 LTQ-Orbitraps couple a linear quadrupole ion trap with an orbitrap mass 
analyser. The quadrupole ion trap can be used to measure the m/z and also to fragment the ions but 
suffers from low resolution and poor mass accuracy, which causes difficulties when searching 
databases to identify proteins. Thus coupling to an orbitrap allows the opportunity to measure ions 
at high resolution and mass accuracy. The ions are isolated and manipulated in the quadrupole ion 
trap and, typically for database searching strategies, the masses of the parent ions are measured in 
the orbitrap whilst fragment mass measurement takes place in the quadrupole ion trap. This is 
NH2 C
H
C COOHN
H
R1 R2
C
H
C N
H
C
H
C N
H
C
H
R3 R4
x3 y3 z3 x2 y2 z2 x1 y1 z1
a1 b1 c1 a2 b2 c2 a3 b3 c3
O O O
56 
 
because for these strategies it is the mass of the parent ion where the highest accuracy is 
required.200, 205 
1.4.1.5 Databases 
To obtain protein identification from MS and MS/MS data it is possible to use de novo methods to 
calculate each peptide fragment from the MS/MS spectrum and equate that to the mass of the 
parent peptide ion in the MS data; putting together the data from several peptides will then lead to 
protein identification. However, for more than one protein (and there are often thousands identified 
in shotgun proteomics, see section 1.4.2) this becomes prohibitively time-consuming, so proteomics 
database programmes that use algorithms to search through protein databases and assign peptides 
to proteins are most commonly used. The most popular search algorithms are Mascot 206 (Matrix 
Science), SEQUEST 207 (Scripps, Thermo Fisher Scientific), OMSSA 208 (NCBI) and X!Tandem 209 (The 
Global Proteome Machine Organization); the latter two are open source and hence freely available. 
The mass, charge, ion frequency and intensity data from the mass spectrometer are submitted to 
these search engines and they match it either to in silico fragmented peptide spectra or to a peptide 
database that contains all experimentally-identified peptides and proteins.210 
Mascot and SEQUEST are the most commonly utilised search algorithms and they operate on 
different principles: SEQUEST uses a cross-correlative approach and MASCOT a probability-based 
approach.211 Mascot scores the match of observed and predicted spectra and a significant match 
typically has a score of 70 or more. 206 The SEQUEST algorithm scores the alignment between 
observed and predicted spectra by using empirical and correlation measurements.207 
The search engines can search a number of publically available protein databases (DBs), including: 
EMBL Nucleotide DB (European Molecular Biology Laboratory),212 NCBI non-redundant DB (National 
Center for Biotechnology Information, compiles protein sequences from GenBank translations,213 the 
Protein Data Bank (PDB), UniProtKB/Swiss-Prot, PIR and PRF)214, 215, Ensembl (Sanger Institute and 
EBI),216 UniProt Knowledgebase (Universal Protein Resource),217 Swiss-Prot (Swiss Institute of 
Bioinformatics).218 The larger and better annotated the database, the more likelihood there is of 
identifying target proteins of interest. However, the larger the database, the greater the risk of false 
positives and the longer it takes to search the database. 
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1.4.2 Top-down and bottom-up proteomics strategies 
There are different proteomics strategies employed depending upon the data required from the 
experiment. Overall the strategies are commonly referred to as top-down or bottom-up approaches 
(Figure 29).201 In a bottom-up approach the presence of a protein in a sample is inferred from the 
presence of peptides obtained from proteolytic digestion of samples, whereas in a top-down 
approach whole protein samples are loaded onto the mass spectrometer. 
 
Figure 29: An illustration of coomon proteomics strategies – bottom-up and top-down. Adapted from a figure in 
201
. 
In top-down approaches the whole protein is ionised and analysed in the gas-phase and the mass of 
the protein ion measured at high resolution, the protein is then fragmented within the machine; 
usually FT-ICR is used.201, 219 This approach should allow the whole sequence of a protein to be 
analysed, including any PTMs or isoforms of the protein.201 The top-down approach gives very 
complex spectra so is not suitable for complex mixtures of proteins, which is where the bottom-up 
approach comes in. 
Bottom-up-approaches either involve fractionation of samples before digestion into peptides and 
identification by peptide mass fingerprinting (PMF) and possible further fractionation of peptides by 
LC and identification by MS/MS or they involve no pre-fractionation of samples and samples are 
digested directly before multidimensional fractionation and MS/MS analysis. The latter is what is 
more commonly known as shotgun proteomics.201 The proteomics research in this thesis uses a 
bottom-up proteomics approach. 
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1.4.2.1 Sample digestion methods 
Commonly, proteins in proteomics samples are separated initially by 1D or 2D gel electrophoresis or 
by affinity purification techniques. In bottom-up proteomics the samples are then digested using an 
enzyme, most commonly trypsin. Trypsin is a serine protease that cleaves proteins into peptides 
after lysine or arginine residues. This allows for the sequence of the peptides to be predicted as the 
cleavage sites are known. Trypsin has the following advantages: a) it is a robust and stable enzyme, 
b) it works over a range of pH and temperature values, c) it is quite specific and consistent in its 
cleavage, d) it produces peptides of suitable molecular weights for MS, e) it is inexpensive and easily 
available and f) the generated peptides have good ionization properties due to the basic residue at 
the C-terminus. Furthermore ions created by trypsin autolysis may be used for MS calibration.193 
1.4.2.2 Sample fractionation methods 
Peptides are generally fractionated using high performance liquid chromatography (HPLC) before 
they are loaded onto the mass spectrometer. They are commonly separated using either reverse 
phase or strong cation exchange chromatography depending on whether separation by 
hydrophobicity or charge, respectively, is required.199 For MudPIT (multidimensional protein 
identification technology) proteomics both kinds of column are coupled together to give 
multidimensional separation of peptides.220 
1.4.2.3 Quantification methods in proteomics 
Often it is not just the presence of a protein in a sample that is of interest but also how its 
expression varies between samples e.g. a wild type and a diseased state or its absolute abundance in 
a sample; this is where quantitative proteomics is invaluable. There are a number of different 
quantitative methods commonly used; for relative quantification these may be label-free or involve 
metabolic, chemical or enzymatic sample labelling, whilst absolute quantification involves the use of 
labelled synthetic peptides or proteins spiked into the sample.199 Label-free methods include 
spectral counting, which relates the frequency with which a peptide is identified by the mass 
spectrometer to the abundance of the protein from which it came in the sample.  Spectral counting 
is only possible where samples have been treated equally and is also not suitable for quantifying low 
abundance proteins as these will generate relatively few peptides.210 An example of a metabolic 
labelling method is SILAC (stable isotope labelling with amino acids in cell culture) where cell 
cultures are grown in media containing either light 12C or heavy 13C labelled arginine and lysine; the 
modified amino acids are incorporated into proteins through the metabolic cycle. The mass shifts 
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between isotopic pairs (multitudes of six mass units) allow their detection and the differences in ion 
intensity can be used to quantify the differences in protein level between samples. However, SILAC 
is mainly used with cells in culture and is not generally applicable to tissue samples or body fluids, 
although there is a SILAC mouse available in the Mann group.221-224 
Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) is a technique for quantifying relative 
differences in abundance of peptides (and hence proteins) between samples. Samples for 
comparison (for 4-plex iTRAQ there are four samples) are labelled with different iTRAQ tags. Each 
iTRAQ tag is chemically identical and has the same overall mass; however, each tag differs in the 
distribution of heavy carbon and nitrogen isotopes within it, with the important result that labelled 
peptides all have the same mass-to-charge ratio in the mass spectrum. When fragmented in MS/MS 
to allow peptide identification, different iTRAQ tags will fragment differently, giving rise to reporter 
ions of specific masses for each sample. This allows calculation of the abundance of labelled 
peptides in one sample relative to the other samples pooled with it and analysed by MS/MS 
simultaneously.225 A schematic description of how iTRAQ labelling works is shown in Figure 30. 
 
Figure 30: An overview of how iTRAQ works. A. The isobaric tag. B. The composition of the 4-plex isobaric tags. C. iTRAQ-
labelling of samples for relative quantification. Based on figures in 
226
 and 
227
. 
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1.4.3 Proteomics of Rab proteins 
Several studies have used mass spectrometry-based proteomics to investigate Rab proteins and 
other members of the Ras superfamily. Jahn et al. used mass spectrometry to identify proteins found 
in synaptic vesicles and Western and dot blots to quantify them.228 They also established which 
proteins were more highly expressed in purified synaptic vesicles compared to other cellular 
fractions. The same group quantified the Rab proteins found in synaptic vesicles using iTRAQ 
quantification.229  
Alexandrov et al. carried out work that is of interest to this project because of the chemical 
proteomics techniques used.135 They synthesised a biotinylated GGpp analogue (BGPP, Figure 23) 
that could act as a substrate for wild type RGGT and mutant FT and GGT-1 (the active sites of FT and 
GGT-1 had to be modified in order to accept BGPP as a substrate and transfer it to peptides). 
Recombinant RGGT and REP-1 was used, along with BGPP, to prenylate Compactin-treated COS7 cell 
lysate before MudPIT technology was used to quantify and identify the Rab proteins. Compactin is a 
statin and so inhibits protein prenylation. The sample was spiked with N15-labelled Rab22 to allow 
absolute quantification of the Rabs found in the sample.  
 Previous research 1.5
1.5.1 Synthesis of AzGGpp 
Initial work on this project, as part of an MRes degree before the PhD commenced, resulted in the 
successful synthesis of an azide-tagged GGpp analogue (AzGGpp, Figure 31 and Appendix C). This 
was developed to act as a substrate for RGGT and thus tag Rabs with an azide moiety, enabling the 
use of a bioorthogonal click reaction to label the proteins and allow their visualisation and 
purification by the TbS technique.230 The allylic azide interconverts rapidly between two 
regioisomers via a 1,3 sigmatropic rearrangement (Figure 31B); the isomers are in equilibrium and 
the interconversion does not seem to affect the labelling of proteins, it does, however, make 
assignment of NMR spectra of the compound difficult.231 
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Figure 31: A: Synthesis of AzGGpp.  a: Ac2O, DMAP, DCM, 0 °C–RT, under N2 atmosphere, 78% yield. b: Catalytic polymer 
bound SeBr, NCS, DCM, RT, under N2 atmosphere, 61% yield. c: NaN3, DMSO, O/N, RT, 36% yield. d: K2CO3, MeOH, RT, 100% 
yield. e: NCS, DMS, DCM, -40–0 °C, under N2 atmosphere, 33% yield. f: (Bu4N)3HP2O7, CH3CN, 3.5 hours, under N2 
atmosphere. g: DOWEX 50W X8 , NH4CO3, 38% yield.
232
 B: 1,3 sigmatropic rearrangement of allylic azides.
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1.5.2 Prenylation, capture and affinity purification of recombinant Rab proteins 
During the MRes, following its synthesis (synthetic method is reproduced in Appendix C), AzGGpp 
was verified as a substrate for RGGT and recombinant Rabs were used to develop a TbS system of in 
vitro prenylation and click capture, using an alkyne-Biotin capture reagent (Figure 32C). A phosphine 
reagent (for the Staudinger-Bertozzi reaction) and a cyclooctyne reagent (for a copper-free click 
reaction) were compared to the biotin-alkyne click reagent but labelling was not found to be as 
specific as with the copper-catalysed click reaction. Gel electrophoresis and Western blotting with 
NeutrAvidin™-HRP allowed visualisation of Biotin-labelled Rab proteins (Figure 32A). The biotin 
affinity tag also permitted  affinity purification of labelled proteins using NeutrAvidin™ agarose 
beads (Figure 32B).230 This finding, along with some of the research presented in this thesis was 
published in 2010 (A. F. Berry et al., Rapid Multilabel Detection of Geranylgeranylated Proteins by 
Using Bioorthogonal Ligation Chemistry, ChemBioChem, 2010, 11, 771-773).232 
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Figure 32: Figures taken from 
230
 to illustrate previous research carried out on the project. A: NeutrAvidin-HRP blot 
showing the prenylation and capture of several recombinant Rabs. B: Affinity purification of prenylated and captured Rab1a 
using NeutrAvidin™ agarose beads and visualised by NeutrAvidin™-HRP blot. C: Structure of the alkyne-biotin capture 
reagent. 
 Project aims and objectives 1.6
The global aim of this project was to develop a robust system for the labelling and identification of 
geranylgeranylated proteins, in particular Rab proteins, using chemical proteomics techniques. 
Developing a robust system for labelling geranylgeranylated proteins has the potential to yield novel 
information on a variety of interesting questions, such as what the differences between REP-1 and 
REP-2 Rab substrates are. A number of drugs affect protein prenylation and this labelling system has 
the potential to be used to both establish their cellular effects and to assess their efficacy. There is 
also the potential to characterise the ‘prenylome’ further by identifying new prenylated proteins. 
Furthermore the technique could be used to probe disease mechanism, especially of Choroideremia. 
A starting methodology for Rab protein labelling had already been developed in previous work and 
an azido-analogue of GGpp (AzGGpp) synthesised.  Previous research had focussed on labelling 
recombinant Rabs in vitro and, following on from this work, the aims for the PhD project were: 
 To determine whether a newly synthesised trifunctional capture reagent (with a fluorophore 
label) can allow in-gel visualisation, as well as affinity purification, of labelled proteins. This 
Rab1a Rab38 Rab18 Rab6 GST-
Rab11 
Rab27a 
GGpp + - + - + - + - + - + -
AzGGpp - + - + - + - + - + - +
30 -
40 -
20 -
A
B Rab1a Supernatant Beads
GGpp + - + - + -
AzGGpp - + - + - +
30 -
20 - Alkyne-Biotin capture reagent
M
W
(D
a
) 
 
1
0
3
M
W
(D
a
) 
 
1
0
3
C
63 
 
would reduce the time needed for assessing whether previously unprenylated Rab proteins 
had been azide-tagged and then labelled via a click reaction but still allow for their affinity 
purification and hence separation from a protein mixture to facilitate their identification. 
 To develop and optimise conditions for labelling unprenylated Rab proteins from cell lysate, 
using the statin Mevastatin to first create a pool of unprenylated Rabs in the cytosol. 
Previous work had focussed on the labelling of recombinant Rab proteins in proof-of-
concept studies. In order to develop the technique samples with a large pool of 
unprenylated cellular Rabs (and other prenylated proteins) were required and statins 
provide a route to inhibit the synthesis of prenylpyrophosphates and thus result in 
unprenylated proteins. 
 To further develop the labelling conditions to label those Rabs affected in mouse disease 
models of prenylation deficiency; specifically gunmetal and CHM mice. These models have 
unprenylated Rab proteins due to the defects in the cellular prenylation machinery. 
Developing the labelling technique to more complex systems could help to probe 
mechanisms of disease by identifying those Rab proteins affected. 
 To use the developed technique to label unprenylated Rabs in cell lines derived from CHM 
mice and optimise conditions for quantification of the Rab proteins affected between 
diseased and undiseased states. Using cell lines from disease models can provide a simpler 
method to obtain large quantities of cell lysate for experiment and also allow development 
of metabolic labelling techniques for the comparison of proteins prenylated in diseased and 
undiseased states. 
 To use mass spectrometry to both identify and quantify labelled proteins from the various 
systems used and determine whether a specific subset of Rabs is affected by a lack of the 
REP-1 protein or whether all Rabs show reduced prenylation. Comparisons will be made 
using cell culture and tissue from CHM and gunmetal mice.  
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 Development and optimisation of the labelling, Chapter 2
detection and identification of unprenylated Rab 
proteins from HEK293A cells 
 Aims and objectives of Chapter 2 2.1
Protein prenylation is an important post-translational modification and researchers require novel 
techniques to probe prenylated proteins. AzGGpp was developed to act as a GGpp analogue and 
label geranylgeranylated proteins, and this chapter shows how the tagging-by-substrate strategy 
previously used to label recombinant Rabs with AzGGpp was expanded to label cell lysate from 
HEK293A cells treated with the statin Mevastatin. The optimisation of protein labelling will be 
demonstrated and the usefulness of a trifunctional alkyne capture reagent over the bifunctional Yn-
Biotin will be described. The application of the optimised protein labelling protocol to mass 
spectrometry-based proteomics and the subsequent identification of unprenylated Rabs found in 
the cytosol of HEK293A cells treated with Mevastatin is also demonstrated. 
Rab prenylation must be carried out in the presence of one of the two isoforms of REP and research 
described in this chapter demonstrates that both isoforms can label Rabs in vitro with AzGGpp, 
tagging them with an azide moiety. Attempts at generating cells with a knockdown of REP-1 and 
REP-2 proteins using siRNA are also described. 
AzGGpp is additionally demonstrated in this chapter to be a prenyl substrate for the 
prenyltransferase GGT-1 in its wild type form, expanding the scope of the proteins that can be 
probed using the AzGGpp technique and offering improvements over techniques developed by other 
researchers. An overview of the technique used in this chapter to label Rabs is shown in Figure 33. 
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Figure 33: An overview of the bioorthogonal ligation of unprenylated Rab proteins from cell lysate. A: Click reaction of 
labelled proteins with alkyne capture reagent TAMRA-Yn-Biotin II; B:  Bioorthogonal ligation for proteins in cell lysate. 
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 Developing a cell model for prenylation deficiency 2.2
Previously, recombinant Rabs were used to demonstrate that AzGGpp is a substrate for the 
prenyltransferase RGGT. At the time of commencing work for this thesis there was no suitable cell 
line available as a model for prenylation deficiency that would allow optimisation of labelling in cell 
lysate. Hence it was desirable to design a system that allowed further development and optimisation 
of the simultaneous labelling of as many unprenylated proteins as possible, against a cell lysate 
background.  
As described in Chapter 1, protein prenylation is an important PTM and developing tools to study it 
can have wide-reaching uses. For example, a method to label prenylated proteins could allow the 
study of the effects of various drugs that affect prenylation on cells. One important class of drugs 
suitable for such study are the statins, which are used to clinically to lower cholesterol levels, but 
also affect prenylation by inhibiting biosynthesis of isoprenoids (described in Chapter 1, section 
1.2.4.1.2). A further class of drug of interest are the prenyltransferase inhibitors, which are 
important for treating cancer and osteoporosis (described in Chapter 1 section 1.2.4.1.1).  
2.2.1 Mevastatin treatment of HEK293A cells as a system for optimising the labelling of 
unprenylated proteins against a cell lysate background 
Mevastatin treatment of HEK293A cells was chosen as a straightforward method to create a pool of 
unprenylated proteins that could be used to optimise Rab protein labelling from lysates, and also to 
explore the effect of statins on Rab prenylation. Mevastatin (also known as Compactin) is a statin 
and was discovered in 1976 by two groups independently of each other.233, 234 Mevastatin is cheap 
and readily available and had been used previously by the Seabra group to treat cells to create a 
pool of unprenylated proteins. The effects of statins on protein prenylation are described in Chapter 
1 section 1.2.4.1.2. HEK293A cells are a commonly-used cell line, originally derived from human 
embryonic kidney cells, that can be grown easily and in large quantities. Treatment of cells with 
Mevastatin causes synthesis of GGpp to stop so unprenylated proteins accumulate in the cytosol as 
illustrated in Figure 19.  
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2.2.2 Testing the effect of a cell lysate background on in vitro prenylation and capture of 
recombinant Rab proteins 
To establish conditions for Mevastatin treatment that would cause the maximum amount of 
cytosolic accumulation of unprenylated proteins, HEK293A cells transfected with EGFP-Rab5 were 
treated for 17 hours with increasing concentrations of Mevastatin (Figure 34). After treatment with 
Mevastatin the cells were harvested, washed once with PBS and pelleted. The cell pellets were 
resuspended in lysis buffer (50 mM HEPES pH 7.2, 10 mM NaCl, 1 x Roche EDTA-free protease 
inhibitor cocktail, 1 mM DTT, and 5 mM MgCl2) and cells were lysed by passing 25 times through a 
25-Guage needle. Cell debris was removed from the lysates by centrifugation at 800 × g for 
5 minutes at 4 °C to give the post nuclear supernatant (PNS). The PNS was subjected to 
ultracentrifugation at 100,000 × g for one hour at 4 °C to achieve subcellular fractionation of the 
lysates; the resultant supernatant is the cytosolic fraction of the cells (S100) and the pellet is the 
membrane fraction (P100). Calnexin is a membrane protein and will fractionate to the P100 upon 
subcellular fractionation and is used as a control for assessing subcellular fractionation by Western 
blot.  
 
Figure 34: Mevastatin-treatment of HEK293A cells results in unprenylated Rab5. Anti-Calnexin (top panel, Stressgen SPA-
860 rabbit polyclonal antibody specific for calnexin) and anti-Rab5 Western blots (middle panel shows EGFP Rab5 and 
bottom panel shows endogenous Rab5; both are detected with antibody specific to human Rab5 (mouse monoclonal 
antibody, BD Transduction labs #R60020)). The distribution of EGFP-Rab5, Rab5 and calnexin proteins between total (T, 
post nuclear supernatant), P100 (P, membrane fraction) and S100 (S, cytosolic fraction) fractions of cell lysate is shown on 
the blots. HEK293A cells were treated for 17 hours with Mevastatin at a concentration 1, 2, 3, 5 and 10 µM as indicated 
before being lysed and the lysate subjected to SDS PAGE and Western blotting.  
Unprenylated Rabs cannot associate with their target intracellular membrane and so will accumulate 
in the cytosol (Figure 19). Mevastatin treatment causes an accumulation of unprenylated Rabs that 
should appear in the S100 fraction, whilst Rabs should progressively disappear from the P100 
fraction as the concentration of Mevastatin used to treat the cells increases. For the experiment 
shown in Figure 34 an antibody specific to human Rab5 was used (BD Transduction labs #R60020) 
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and the figure shows both EGFP-Rab5 and endogenous Rab5 accumulating in the S100 with 
increasing concentration of Mevastatin used to treat the cells. Cells treated with Mevastatin 
detached from the tissue culture dish more easily than untreated cells. 10 µM Mevastatin gave 
complete transfer of EGFP-Rab5 to the S100 and almost complete transfer of endogenous Rab5; so 
10 µM Mevastatin concentration was selected for all further Mevastatin treatment of HEK293A cells.  
The first step in moving from labelling recombinant Rabs to labelling Rabs in cell lysate was to verify 
that cell lysate did not significantly affect the azide-tagging and subsequent bioorthogonal ligation of 
recombinant Rabs; to indicate whether cellular components could interfere with either the 
prenylation or click capture reactions. Rab1a was established as a good substrate for in vitro 
prenylation with AzGGpp in previous work, as described in Chapter 1 section 1.5.2.230 Thus Rab1a 
was selected for prenylation and capture against a background of HEK293A S100. Subcellular 
fractionation of cell lysate reduces chemical complexity by removing the membrane fraction from 
the cytosolic fraction, and may reduce background labelling due to the presence of fewer proteins 
for any non-specific reactions. It should be noted that the recombinant proteins are not from the 
same species (rat RGGT, human REP-1 and canine His-Rab1a); however, prenyltransferases and Rab 
proteins from different mammalian species show a very high degree of homology (see Appendix B 
for sequence alignments). Thus, despite the enzyme being from a different species to its substrate it 
can still effectively prenylate it with AzGGpp; as demonstrated in previous work, shown in Figure 
32.135, 179, 230, 232 
Rab1a was prenylated in vitro with AzGGpp (or GGpp as a control) and then labelled with Biotin via a 
click capture reaction with the Yn-Biotin capture reagent (Figure 32), using conditions established in 
previous work.230 Briefly, 1 µM recombinant RGGT, 1 µM recombinant REP-1 and 20 µM AzGGpp in 
prenylation reaction buffer were added to 2 µM Rab1a to give a final reaction volume of 20 µl. The 
prenylation reaction mix was incubated for 40 minutes at 37 °C to allow sufficient time for the Rab 
to be tagged with AzGG. Click reaction components were added to the prenylation reaction mixture 
sequentially and in the following order, with mixing after each step to give a final volume of 50 µl: 
1. 10 µM alkyne (from a 125 μM stock in 50 mM Tris pH 8.8 and 0.4% SDS) 
2. 1 mM CuSO4 (from a 40 mM stock in dH2O) 
3. 10 mM sodium ascorbate (from a freshly made 500 mM stock in dH2O) 
4. 5 mM BCS (from a 50 mM stock in dH2O); with a gap of two minutes left between the 
addition of the ascorbate and the BCS in order to allow the Cu(II) to be reduced to Cu(I) 
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The click reaction was allowed to proceed for 20 minutes at room temperature with constant 
agitation of the solution. After this time, SDS sample loading buffer was added and the samples 
boiled for 5 minutes and run on a 12% Bis-Tris polyacrylamide gel with MES (2-(N-
morpholino)ethanesulfonic acid) SDS running buffer. Proteins were transferred to a membrane and 
the membrane probed with NeutrAvidin™-HRP which has a high affinity for biotin and so detects 
proteins labelled with the Yn-Biotin reagent. Protein labelling was visualised by chemiluminescence, 
using chemiluminescence reagents that react with the HRP (horseradish peroxidase)-tag on the 
NeutrAvidin™ that will only be bound to biotin-labelled proteins. 
To test if the S100 fraction of HEK293A cells treated with Mevastatin would affect prenylation of a 
recombinant Rab, 15 µg total protein of S100 (the S100 was at a concentration of 7-10 mg/ml) were 
added to either the prenylation (p) or click capture (c) stage of the protein labelling. The amount of 
S100 used did not affect the labelling of Rab1a, as visualised by NeutrAvidin™-HRP Western blot; 
protein samples were labelled using the conditions detailed above (Figure 35). However, some 
background labelling could be seen where lysate was present as might be expected under non-
optimised conditions. There are relatively intense bands seen in samples prenylated with AzGGpp at 
approximately 45 kDa. Rab1a is approximately 22 kDa in size so the higher molecular weight bands 
are likely to represent labelled Rab1a that has dimerised (despite the reducing agent present in the 
loading buffer) and so runs at a higher molecular weight on the gel.  
 
Figure 35: Cytosolic cell lysate does not affect the in vitro prenylation and capture of recombinant Rabs. NeutrAvidin™-
HRP blot showing prenylation and capture of Rab1A, with and without a background of HEK293A S100 and with a GGpp 
control in each case. Lanes 1 and 2 show prenylation and capture with no S100 added; in lanes 3 and 4, 15 µg S100 was 
added in the prenylation (p) stage; and in lanes 5 and 6, 15 µg S100 was added at the capture (c) stage of the bioorthogonal 
ligation. Prenylation and capture conditions and reagent and protein concentrations were as described in the main text. 
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2.2.3 Testing different alkyne capture reagents 
As described in Chapter 1 section 1.5.2, previous work on this project focussed on using a Biotin-
alkyne bifunctional capture reagent (Yn-Biotin) to label azide-tagged Rab proteins with Biotin via a 
click reaction. The Biotin label then allowed visualisation of the tagged Rabs by NeutrAvidin™-HRP 
Western blot (for example in Figure 35). The label gave much more rapid information on in vitro 
prenylation than with [3H]GGpp labelling, which has exposure times that last up to weeks,30 and also 
permitted affinity purification of the Rabs. 230, 232 
Using a capture reagent with a fluorophore label, in addition to biotin, allows use of a fluorescence 
imager to visualise labelled proteins directly in-gel (following gel electrophoresis), without the need 
for transfer of proteins to a membrane. Western blotting is still possible after gel imaging and allows 
the membrane to be probed for specific proteins of interest. A trifunctional capture reagent 
(TAMRA-Yn-Biotin I, synthesised by Dr W. Heal, Imperial College) was an excellent candidate for 
progressing with the project; it was successfully shown to label recombinant Rab1a (Figure 36). 
A fluorescein-alkyne capture reagent (Yn-Fluor, synthesised by Dr W. Heal, Imperial College) was also 
available for testing and successfully labelled Rab1a (Figure 36).  More than one fluorophore label is 
useful for work where it is desirable to compare labelling in more than one system simultaneously. 
TAMRA-Yn-Biotin I was chosen for all initial experiments and in 232 as it allowed affinity purification 
as well as in-gel visualisation of proteins and thus was more useful for work towards the goal of 
proteomics analysis of labelled Rabs, which would require an affinity purification step. 
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Figure 36: Recombinant Rabs can be labelled with a fluorescent probe. A: Structures of trifunctional capture reagent 
TAMRA-Yn-Biotin I with the TAMRA fluorescent group shown in pink and the biotin affinity tag shown in blue and structure 
of bifunctional fluorescein-alkyne capture reagent Yn-Fluor with the fluorescein moiety shown in green. B: In-gel 
fluorescence image showing Rab1A prenylation and capture with either TAMRA-YN-Biotin I (red) or Yn-Fluor (green), using 
prenylation and capture conditions as described in section 2.2.2 C: Comparison of in-gel fluorescence (left) with 
NeutrAvidin™-HRP Western blot (right) of Rab1A prenylated with either GGpp (control) or AzGGpp and captured with the 
trifunctional capture reagent TAMRA-Yn-Biotin I, ), using prenylation and capture conditions as described in section 2.2.2. 
For later experiments, the trifunctional reagent TAMRA-Yn-Biotin II (synthesised by M. Wright, 
Imperial College) superseded TAMRA-Yn-Biotin I because it is easier to synthesise in bulk and, by 
using the same reagents, sharing of protocols between all members of the Tate group using click 
chemistry techniques became possible. As can be seen in Figure 37, TAMRA-Yn-Biotin II is very 
similar in structure to TAMRA-Yn-Biotin I and gives identical results when used to label azide-tagged 
Rab1a. 
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Figure 37: Capture reagent TAMRA-Yn-Biotin II is very similar to capture reagent TAMRA-Yn-Biotin I. A: trifunctional 
capture reagent TAMRA-Yn-Biotin II, synthesised by M. Wright. B: In-gel fluorescence scan showing in vitro prenylation of 
recombinant Rab1A with either AzGGpp or a GGpp control, followed by capture with either alkyne TAMRA-Yn-Biotin I (left) 
or alkyne TAMRA-Yn-Biotin II (right), using prenylation and capture conditions as described in section 2.2.2.  
2.2.4 In vitro prenylation of Mevastatin-treated HEK293A cell lysate 
Following optimisation of the conditions for Mevastatin treatment of HEK293A cells (section 2.2.2) 
attempts were made to label unprenylated Rabs present in the S100 fraction. The different aspects 
of the in vitro prenylation and bioorthogonal ligation that were optimised are described below. It is 
important to note, however, that it is not only the reagents added to the S100 for protein labelling 
that are important but also the composition of the buffer used to lyse the cells. Cells are commonly 
lysed in buffers containing protease inhibitors to help reduce protein degradation, but commercial 
premixed inhibitor cocktails often contain ethylenediaminetetraacetic acid (EDTA), and Figure 38 
shows that omission of EDTA is important for labelling to occur. EDTA can destabilise the Cu(I) 
needed to catalyse the click reaction, thus preventing bioorthogonal ligation from occurring and so 
the Rabs remained unlabelled when EDTA was present.235 The same conditions as previously used 
successfully for labelling recombinant Rabs were used here to label 25 µg S100 and when the 
composition of the lysis buffer was EDTA-free, specific labelling could immediately be seen. This 
result was very encouraging as the specific labelling bands were seen at around 25 kDa (the 
molecular weight of Rabs) and resembled the pattern of three bands seen when labelling samples 
with [3H]GGpp.232 The bands only appeared with S100 from cells treated with Mevastatin and 
prenylated with AzGGpp and not from cells treated with DMSO and/or S100 prenylated with GGpp 
(as controls). Some background labelling at higher molecular weights, presumably of the most 
abundant cytosolic proteins, was visible (Figure 38B) rendering it desirable to optimise conditions in 
the HEK293A system before progressing to the more complex tissue samples from mouse disease 
models described in Chapter 3.  
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Figure 38: The effect of EDTA in the lysis buffer on protein labelling in Mevastatin-treated HEK293A S100. A: 
NeutrAvidin™-HRP blot showing capture of 25 µg Mevastatin-treated HEK293A S100 from cells lysed into buffer containing 
EDTA with  DMSO (- Mevastatin) and GGpp controls and capture with Yn-Biotin, using prenylation and capture conditions 
described in section 2.2.2. B: In-gel fluorescence image of capture of 25 µg Mevastatin-treated HEK293A S100 from cells 
lysed without EDTA in the lysis buffer. DMSO (- Mevastatin) and GGpp controls, capture with reagent TAMRA-Yn-Biotin I 
using prenylation and capture conditions described in section 2.2.2. 
2.2.5 Probing the sensitivity of the click capture reaction  
In vitro prenylation and alkyne capture of different amounts of recombinant Rab1a and Mevastatin-
treated HEK293A S100 samples allowed probing of the sensitivity of the capture reaction (Figure 39). 
For each quantity of S100, the in vitro prenylation reactions were performed in a reaction volume of 
40 µl with 20 µM AzGGpp and recombinant 1 µM RGGT/REP-1. The capture reactions were carried 
out in a reaction volume of 100 µl, using the conditions detailed above (10 µM alkyne (1.25 
equivalents), 1 mM CuSO4, 10 mM sodium ascorbate, 5 mM BCS).  It was possible to visualise the 
bands in the Rab molecular weight region when as little as 2.5 µg of total S100 protein was loaded 
on the gel. However, the signal was stronger at higher quantities of S100. The amount of Rab1a 
visualised went down to picograms and could most likely have still been seen by in-gel fluorescence 
at lower amounts, although this was not attempted. Thus, it was determined that the capture 
reaction is very sensitive and is appropriate for the investigation of prenylated proteins. 
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Figure 39: The effects of varying the amount of protein present in a capture reaction with reagent TAMRA-Yn-Biotin I. A: 
In-gel fluorescence scan showing the effect of varying the total amount of protein from either GGpp (control) or AzGGpp 
prenylated and DMSO- (control) or Mevastatin-treated HEK293A S100 from 2.5 µg to 20 µg, using conditions for prenylation 
and capture detailed in the main text B: In-gel fluorescence scan showing capture of different amounts of Rab1a and 
compared with capture of 12 µg Mevastatin-treated S100, using conditions for prenylation and capture described in section 
2.2.2. 
2.2.6 An overview of the protein labelling process 
Before describing the optimisation process for protein labelling in cell lysate it is useful to summarise 
the experimental methods used in sample preparation. The preparation of cell lysate is described in 
detail in section 2.2.1; the conditions used for in vitro prenylation of S100 samples are given in 
section 2.2.2, as are the conditions for the click capture reaction. For experiments involving labelling 
of S100 instead of recombinant protein, the S100 was at a concentration of 2-4 mg/ml during the 
prenylation reaction; typically 20 µg of S100 per 10 µl reaction volume or 40 µg of S100 per 20 µl 
reaction volume was used, the latter allowed for sufficient sample to run on a polyacrylamide gel 
when samples were to be affinity purified. A pictorial representation of the sample preparation and 
labelling process is shown in Figure 40.  
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Figure 40: Non-optimised protocol for sample preparation and labelling used in initial work in this study. HEK293A cells 
are treated with 10 µM Mevastatin for 17 hours when approximately 70% confluent. After Mevastatin treatment cells are 
harvested and lysed before being subjected to ultracentrifugation at 100,000 × g to give cytosolic (S100) and membrane 
(P100) fractions. In vitro prenylation is carried out on the S100 fraction for 40 minutes at 37 °C. Click reaction components 
are added sequentially to the prenylation reaction mixture and allowed to react for 20 minutes at r.t. with constant mixing 
of the sample. The protein is precipitated with ice-cold MeOH and kept overnight at -80 °C to remove any TAMRA-Yn-Biotin 
reagent and fluorescent contaminants that might interfere with the affinity purification step. Proteins are resuspended in a 
buffer containing detergent and added to NeutrAvidin™ agarose beads for affinity purification of biotin-labelled proteins for 
2 hours at r.t., with constant mixing of the sample. Labelled proteins are visualised by separating them by mass using gel 
electrophoresis before visualising the labelled protein by in-gel fluorescence using an Ettan DIGE imager (GE Healthcare). 
There are several stages in the labelling protocol where difficulties can arise which will be discussed 
briefly here. Firstly, for the in vitro prenylation reaction the conditions are those developed in 
previous work and consist of excess enzyme (RGGT and REP-1) and substrate (AzGGpp) but the time 
allowed for the reaction to occur had not been optimised and it remained possible that incubating 
the S100 for longer with the enzyme and AzGGpp would tag more of the Rab proteins in the S100 
with azide moieties. However, previous experience in the Seabra group suggested that under the 
conditions of the prenylation reaction the enzyme is unlikely to remain active for long periods of 
time due to protein degradation. Secondly, the conditions for the click capture reaction had not 
previously been optimised for labelling in cell lysate. There are a variety of reducing agents available 
and different ligands to stabilise the Cu(I) ions that act as the catalyst for the reaction. It was also 
uncertain whether 20 minutes was long enough to allow the click reaction to go to completion. 
Thirdly, it is essential to precipitate the protein before affinity purification or gel electrophoresis to 
remove any excess fluorescence that would otherwise interfere with visualisation of labelled 
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proteins by in-gel fluorescence; there are many standard protocols for protein precipitation 
available, some of these were explored to find an optimum method. Finally, after precipitation 
proteins must be resuspended, which requires detergent; the importance of using sufficient 
detergent is demonstrated below (section 2.3.4). 
 Optimisation of conditions for labelling of RGGT protein substrates in 2.3
cell lysate 
2.3.1 Optimisation of conditions for the in vitro prenylation reaction  
The first step in labelling unprenylated proteins is in vitro prenylation whereby proteins are tagged 
with an azide moiety, using recombinant enzyme with AzGGpp as the prenyl substrate; therefore 
this was the first step for optimisation. Rab proteins were tagged with azide, using AzGGpp as a 
substrate for recombinant RGGT and REP-1, for 40 minutes at 37 °C. The time allowed for in vitro  
prenylation to occur was the only part of the enzymatic reaction chosen for optimisation at this 
point as all other conditions had been adjusted in previous work to allow excess of enzyme and 
substrate to give maximum protein labelling.230 Thus, the duration of the in vitro prenylation 
reaction was varied to see if that would have an effect on the amount of protein labelling. The time 
allowed for the reaction originally was 40 minutes, which is twice as long as that used in a standard 
radiation assay.115 Alexandrov et al carried out prenylation for 4 hours at room temperature 135 so 
this reaction time was chosen as a point of comparison with the original time point of 40 minutes 
(Figure 41). There did not seem to be any significant effect of increasing the time for the prenylation 
reaction. Furthermore, one significant advantage of using bioorthogonal ligation techniques is the 
rapidity with which protein labelling results can be seen, thus the duration of prenylation was not 
altered to maintain the relatively rapid rate of sample preparation.  
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Figure 41: The effect of increasing the duration of the prenylation reaction to 4 hours from 40 minutes.  In-gel 
fluorescence scan (top) and colloidal Coomassie stain (bottom) showing in vitro prenylation of 25 µg Mevastatin-treated 
HEK293A S100 with either GGpp (control) or AzGGpp and capture with alkyne TAMRA-Yn-Biotin I. The Coomassie stain 
demonstrates equivalent protein loading in each lane.  
2.3.2 Optimisation of the conditions for the click capture reaction 
2.3.2.1 Optimisation of the concentration of the trifunctional alkyne capture reagent 
Once Rabs are azide-tagged the next step is labelling with biotin and a fluorophore via the click 
reaction. The click reaction consists of several components: the trifunctional alkyne TAMRA-Yn-
Biotin II (or TAMRA-Yn-Biotin I); copper(II) sulphate (CuSO4), as a source of copper ions; a reducing 
agent to give copper(I) ions from copper(II) ions, to catalyse the reaction; and a ligand to stabilise 
the copper in the +1 oxidation state and prevent its disproportionation. Conditions used in previous 
work230 were based on conditions optimised by other members of the Tate group. The conditions 
were not previously altered for labelling with AzGGpp as they worked adequately well with the 
recombinant Rabs used for initial research and gave little background labelling under those 
conditions. The optimisation of the click capture reaction in cell lysate, to give a more robust 
protocol with the result of a reduction in background fluorescence signal, is described here. 
Initial experiments used a 10 µM final concentration of TAMRA-Yn-Biotin I, based on conditions used 
for capture with Yn-Biotin. Protein labelling was visible using 10 µM TAMRA-Yn-Biotin I (Figure 38) 
but the signal could often be weak (not shown) rendering it necessary to try and increase the 
fluorescence signal of the TAMRA-biotin labelled Rabs. Toward this aim, the final concentration of 
TAMRA-Yn-Biotin I in a capture reaction was increased to 20, 50 and 100 µM (Figure 42). Increasing 
the concentration of alkyne significantly increased the signal obtained with in-gel fluorescence 
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imaging but it also appeared to increase the amount of background labelling. 50 µM was chosen as 
the final concentration of capture reagent to be used in subsequent capture reactions and appeared 
to give as strong a signal as 100 µM in the molecular weight region that the Rab bands appear but 
less background labelling. 50 µM was the concentration of alkyne used from this point onwards; 
including with alkyne TAMRA-Yn-Biotin II. Other members of the Tate group have also observed that 
using 50 µM capture reagent gives optimum results for the click reaction in their systems 
(unpublished observations). 
 
Figure 42: The effect of increasing the concentration of alkyne capture reagent in the click capture reaction. In-gel 
fluorescence image (top) and colloidal Coomassie stain of the same gel (bottom) showing the effect on signal of increasing 
the concentration of TAMRA-Yn-Biotin I in the click capture reaction. The Coomassie stain demonstrates equivalent protein 
loading in each lane. 12 µg S100 is loaded per lane and prenylation and capture conditions were as described in section 
2.2.2.Samples were precipitated with ice-cold MeOH and resuspended before loading and running on a 12% Bis-Tris gel with 
MES SDS running buffer. 
2.3.2.2 Selection of copper reducing agents and ligands for the click capture reaction 
The next component of the click reaction for optimisation was the copper catalyst, namely the type 
and concentration of both the reducing agent and the copper ligand required, respectively, to 
reduce Cu(II) to Cu(I) and then stabilise the +1 oxidation state. As mentioned, Cu(I) is not added 
directly to the reaction as it readily disproportionates to Cu(II) and Cu(0) and also because CuSO4 is a 
cheap and readily available source of copper ions. 1 mM CuSO4 is the concentration used by most 
researchers when using the click reaction for bioorthogonal ligation reactions; this concentration 
was maintained here since it is desirable to have an excess of copper ions available to form the 
catalyst. 
Concentration of 
TAMRA-Yn-Biotin I (µM)
10 20 50 100
30 -
20 -
M
W
(D
a)
  
1
0
3
In-gel 
fluorescence
Colloidal 
Coomassie
79 
 
2.3.2.3 Copper ligand selection 
The ligand used to stabilise Cu(I) in an aqueous environment determines the amount of catalyst 
available for the reaction by determining the stability of the Cu(I) state and hence the amount of 
protein that the alkyne probe can label. In previous work 230 the copper ligand used was BCS 
(bathocuproinedisulfonic acid). However, other groups working on bioorthogonal ligation via click 
chemistry frequently report the use of a triazole, TBTA (tris-(benzyltriazolylmethyl)amine), as the 
copper ligand.162, 163, 236, 237 Chan et al. demonstrated that in a model Huisgen [3+2] cyclisation 
reaction TBTA was the best ligand for stabilising Cu(I) compared to other available ligands tested.236 
The structures of the two copper ligands are shown in Figure 43.   
 
Figure 43: Structures of the reducing agents and copper ligands used for the bioorthogonal ligation reactions. 
The BCS ligand was used up until this point as it formed part of the protocol used previously in the 
Tate group. It was, however, found to often give high background fluorescence in this work and in 
the work of other members of the group. Furthermore, Figure 44  demonstrates that the strength of 
the signal from labelled proteins in reactions with TBTA as the copper ligand was stronger than with 
BCS, even though ascorbate was used as the reducing agent with BCS and TCEP with TBTA and in 
Figure 46 it can be seen that ascorbate gives a stronger signal than with TCEP. 
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Figure 44: A comparison of the labelling of Rabs in Mevastatin-treated HEK293A cell S100 with either BCS or TBTA as the 
copper ligand. 20 µg S100 was prenylated with AzGGpp and captured with TAMRA-Yn-Biotin I capture reagent via a click 
reaction with 100 µM of the indicated ligand to stabilise the Cu(I) oxidation state and either 10 mM ascorbate (with BCS) or 
1 mM TCEP as the reducing agent (with TBTA). Samples were precipitated with MeOH before running on a 12% Bis-Tris gel 
with MES SDS running buffer. 
BCS is reported to stabilise Cu(I) over Cu(II) because the methyl groups give steric hindrance at the 
metal binding site and so favour the tetrahedral binding of Cu(I) over the square planar preference 
of Cu(II).238 It has been suggested that it is the tetradentate binding of TBTA that allows it to stabilise 
Cu(I) so successfully; a mechanistic study of the ligand binding in copper-catalysed azide-alkyne 
cycloadditions, giving the potential coordination equilibria of ligands such as TBTA, was reported by 
Rodionov et al.152, 236 TBTA is unlikely to bind all four donor atoms to Cu(I) at once because Cu(I) 
prefers a tetrahedral geometry so the 4th binding site is more likely to be taken up by a monodentate 
donor, such as Cl-.152 TBTA has a lower reduction potential than BCS;235, 239 which could explain why 
TBTA is reported in the literature to stabilise the Cu(I) against oxidation and disproportionation more 
than BCS.236 The phenanthroline of BCS is more electron-donating than the triazoles of TBTA and so 
the Cu(I) complex with BCS is more oxidising than the one with TBTA, leading to more rapid 
oxidation of the ascorbate so it is no longer available to give copper in the +1 state.240, 241 Donnelly et 
al. reported a Cu(I) complex of TBTA that exists as an unusual dinuclear coordination complex with a 
triazole from a TBTA molecule bridging the two metal centres. However, it is suggested that the 
dinuclear complex is likely to be a precursor to the actual catalytic Cu(I) complex, which Donnelly et 
al. propose would be mononuclear.237 In their review on CuAAC, Hein and Fokin discuss that it is 
important for the metal ligand to not bind too tightly to the metal centre so as to allow the azide to 
enter the coordination sphere of the acetylide coordinated to the Cu centre. The ligand also needs to 
bind strongly enough to prevent unreactive polymeric complexes from forming. Tri-triazole ligands 
such as TBTA are thus very suitable ligands as they combine weak donors on the triazole rings with a 
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stronger central nitrogen donor. A possible structure of a reactive Cu(I) complex with TBTA is shown 
in Figure 45.237, 241 
 
Figure 45: Proposed structure of a catalytically active Cu(I) complex with TBTA, azide and acetylide ligands. Based on the 
structure proposed in the review by Hein and Fokin.
241
 
To this point, addition of click reagents to the protein sample occurred sequentially, with vortexing 
after each step, and in the order given in section 2.2.2, a method originally chosen because it 
followed an existing Tate group protocol.230 However, Hang and co-workers reported adding a 
premixed solution of click reagents to protein samples for their investigations of protein fatty 
acylation using bioorthogonal ligation chemistry.162 Therefore the effect of pre-mixing click reaction 
components instead of adding them sequentially to the protein sample was investigated. There was 
no capture with BCS following premixing of the reagents as opposed to sequential addition (not 
shown); the reason for this observation remains unclear. Since the BCS Cu(I) complex appears too 
reactive, resulting in high background fluorescence and weaker labelling compared to TBTA, 
sequential addition of reaction components was not revisited and premixed capture reagents were 
added to protein mixtures from this point onwards. Using premixing of reagents allowed further 
convergence of the protocols for click reactions used within the Tate research group and potentially 
increased the reproducibility of the results as the catalytic species was then being pre-formed, so 
intermediates could not be intercepted by lysate components prior to formation of the catalytic 
species. 
2.3.2.3.1 Reducing agent selection 
The use of sodium ascorbate as the reducing agent in the click reaction was reported by Sharpless 
and co-workers in their initial work on the Huisgen cyclisation reaction.242 Other groups, however, 
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report the use of TCEP (Tris(2-carboxyethyl)phosphine) as the reducing agent, notably the Hang and 
Cravatt groups.162, 163 Members of the Tate group routinely use TCEP as the reducing agent for click 
reactions of samples tagged by metabolic labelling of cells with an azide or alkyne probe. Both of 
these reagents reduce copper(II) in an aqueous environment so differences between them could be 
expected to be subtle. Ascorbate has the advantage of being much cheaper whilst TCEP is more 
stable in solution. The structures of both ascorbate and TCEP are shown in Figure 43. 
Ascorbate seemed to give a lower background and stronger fluorescence signal than TCEP when 
used as the reducing agent (Figure 46). However, as a result of following literature conditions, the 
concentration of ascorbate in Figure 46A was tenfold that of TCEP. When comparable 
concentrations of TCEP and ascorbate were tested, the strongest signal over background resulted 
from using 10 mM ascorbate (Figure 46B). Interestingly, no capture could be seen with 10 mM TCEP, 
presumably because either the azide was reduced before the click reaction could occur and thus no 
labelling could occur or the TCEP competes for binding the copper at this concentration.243, 244 
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Figure 46: Optimisation of click reaction conditions. A: In-gel fluorescence scan (top) and colloidal Coomassie stain to show 
protein loading (bottom) of further optimisation of premixed click conditions with DMSO controls, TBTA as the copper 
ligand and either 1 mM TCEP or 10 mM ascorbate as the reducing agent. 20 µg S100 from either Mevastatin or DMSO 
(control) treated HEK293A cell S100 was prenylated with 20 µM AzGGpp and captured with 50 µM TAMRA-Yn-Biotin I via a 
click reaction with either TCEP or ascorbate as the reducing agent. Samples were precipitated with MeOH before 
resuspending and running on a 12% Bis-Tris gel with MES SDS running buffer. B: In-gel fluorescence scan (top) and colloidal 
Coomassie stain to show protein loading (bottom) investigating the effect of different concentrations of copper reducing 
agent (either TCEP or ascorbate) with DMSO controls. Samples were prepared as described for A with different 
concentrations of reducing agent added as indicated. 
2.3.2.4 Click reaction protocol 
To summarise work on the optimisation of the click reaction to this point: particularly good capture 
was seen with the TBTA ligand; ascorbate and TBTA together show a relatively strong signal and low 
background. Furthermore, since according to work by Finn et al. ascorbate should not be added to 
the copper solution in the absence of the ligand,240 the optimised conditions for the capture reaction 
are premixed in the following order before adding to the protein sample (concentrations given are 
final, after addition to protein sample): 
1. 50 µM alkyne (from a 125 μM stock in 50 mM Tris pH 8.8 and 0.4% SDS; the original alkyne 
stock is 10 mM in DMSO) 
2. dH2O (to give the correct final concentration of reagents when added to the sample) 
3. 1 mM CuSO4 (from a 40 mM stock in dH2O) 
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4. 100 µM TBTA (from a 10 mM solution in DMSO) 
5. 10 mM sodium ascorbate (from a freshly made 500 mM stock in dH2O). Wait at least 
2 minutes after addition of ascorbate before adding to the protein sample to allow sufficient 
formation of Cu(I). 
After each addition of reaction component the solution was vortexed briefly to mix it. To obtain the 
final concentrations given above, the premixed reagents were added to the protein sample in a ratio 
of 1.5:1 by volume. The click reaction solution was then vortexed briefly again and agitated for 
20 minutes on a vortex-mixer at room temperature. Protein precipitation with ice-cold MeOH 
quenched the reaction and the optimisation of this step is described below in section 2.3.3. 
2.3.2.5 The duration of the click capture reaction 
The final aspect of the click capture reaction for optimisation was the duration of the reaction. Other 
groups using similar bioorthogonal ligation techniques report carrying out the capture reaction for 
up to 4 hours.135 It was of interest to assess whether there was any benefit, in terms of increased 
signal or reduced background labelling, to increasing the duration of the capture reaction from 
20 minutes up to 60 and 90 minutes. The 20 minute reaction time originally chosen for the click 
reaction arose originally from the protocol from the Invitrogen Click-iT™ kit. It can be seen in Figure 
47 that the signal increased significantly as the length of time allowed for the click reaction was 
increased from 20 to 60 minutes but not between 60 and 90 minutes. 60 minutes was the time 
chosen for all subsequent click reactions. 
 
Figure 47: Changing the time allowed for the click reaction. In-gel fluorescence scan (top) showing the effect of increasing 
the duration of the click capture reaction, using the conditions optimised as described in the main text above. The colloidal 
Coomassie stain is shown (bottom) to demonstrate equal loading. 90 µg Mevastatin-treated HEK293A S100 was prenylated 
with AzGGpp and then captured with TAMRA-YN-Biotin II. At the indicated time points a volume equivalent to 25 µg was 
extracted from the capture reaction and precipitated with MeOH to stop the reaction. All samples were resuspended in 
buffer containing detergent and then run on a 12% Bis-Tris polyacrylamide gel with MES SDS running buffer.  
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2.3.3 Optimisation of protein sample precipitation conditions 
In vitro prenylation and capture of recombinant Rabs involved using small volumes and very small 
quantities of protein and the fluorescence signal was very clear due to the relatively high protein 
concentration; hence samples could be run on gels directly after capture. However, for cell lysate 
assays the final volume of the captured proteins was much larger and the relative concentration of 
Rabs much lower. Precipitation of the sample enables loading of a sufficient quantity of sample onto 
a polyacrylamide gel for gel electrophoresis and, more importantly, it also removes fluorescent 
contaminants and other reaction materials, such as excess alkyne capture reagent, from the sample, 
which reduces the background fluorescence signal. The disadvantage of protein precipitation is the 
loss of protein that can occur, both from user error and because some protein may not resuspend 
following precipitation.  
Precipitation with MeOH after the click capture reaction of Rab1A showed little difference in 
fluorescence signal to Rab1A loaded straight on the SDS-PAGE gel after capture (Figure 48), 
confirming that precipitation was a suitable method for sample concentration. Samples were 
precipitated after capture in order to allow sufficient protein to be loaded onto gels for all samples 
from HEK293A cells shown in this Chapter. 
 
Figure 48: The effects of sample precipitation. A: In-gel fluorescence scan showing the effects on fluorescence signal of 
precipitation after capture of recombinant Rab1A samples. 2 µM recombinant Rab1A was prenylated with 20 µM AzGGpp 
or GGpp (control), 1 µM recombinant RGGT and REP-1 for 40 minutes. Tagged protein was captured with 10 µM Yn-
TAMRA-Biotin I capture reagent via a click reaction. Samples were either precipitated with MeOH following click capture or 
not as indicated. Samples were run on a 12% Bis Tris gel with MES SDS running buffer and imaged using an Ettan DIGE 
imager (GE Healthcare). 
To ascertain whether a further improvement in strength of the fluorescence signal was possible, 
samples were precipitated after in vitro prenylation and before the capture reaction. The Cravatt  
30 -
20 -
40 -
50 -
GGpp + - + -
AzGGpp - + - +
Precipitation - +
M
W
(D
a)
  
1
0
3
- Rab1a
86 
 
group reported precipitating or desalting metabolically-labelled cell lysate in order to remove excess 
lipid reagent that could interfere with the capture reaction used to probe protein acylation.163 
However, precipitating the samples twice frequently led to problems with sample recovery and any 
improvement in signal was not large enough to justify the possible loss of sample for the work 
described in this chapter. 
There are several different protein precipitation protocols that are commonly used to remove 
contaminants from or concentrate protein samples. The results described above resulted from 
adding eight times the sample volume of ice-cold MeOH to the sample and placing it at -80 °C 
overnight. Previously, ice-cold acetone had been used but was less effective at removing background 
fluorescence than MeOH (not shown). TCA/acetone precipitation was attempted to improve 
background with samples from mouse models but resulted in high background and poor sample 
recovery. Finally, CHCl3/MeOH precipitation gave the same or better background as with MeOH 
precipitation but is a much faster method as it does not require leaving the precipitating sample 
overnight and the protocol can be finished in less than 30 minutes (depending on the number of 
samples for precipitation). The protein pellet from CHCl3/MeOH precipitation is also more compact 
than with that from MeOH precipitation, making it easier to handle and to resuspend. The following 
protocol for protein precipitation was thus chosen: 
1. Add 4 × sample volume of MeOH, vortex 
2. Add 1 × sample volume of CHCl3, vortex 
3. Add 3 × sample volume of dH2O, vortex 
4. Centrifuge at maximum speed in a bench top centrifuge for 2 minutes 
5. Carefully remove the top, aqueous, layer from the sample (the protein pellet is now at the 
phase interface) 
6. Repeat step 1 
7. Repeat step 4 
8. Steps 6-7 may be repeated again if desired 
9. Discard the supernatant and air dry the protein pellet upside down in a laminar flow hood 
for 5 minutes 
It should be noted that it is very difficult to use this protocol if the initial sample volume is too small 
as it becomes difficult to remove the aqueous layer without disturbing the protein pellet. For 
samples where the volume following the click reaction was less than 50 µl dH2O was added to give a 
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sample volume of 50 µl before commencing the precipitation. Furthermore, very small quantities of 
protein, such as when precipitating labelled recombinant protein samples, are also difficult to handle 
because the protein pellet is too small to see at the interface so may easily be disturbed, resulting in 
loss of sample. In this case extra care should be taken or MeOH precipitation used. 
2.3.4 Conditions for the resuspension of protein samples 
The composition of sample resuspension buffer is important to ensure complete solubilisation of 
proteins for analysis by gel electrophoresis or for subsequent affinity purification. The labelling of 
proteins with the bulky capture reagent makes them more hydrophobic and thus harder to 
resuspend after sample precipitation; Figure 49 demonstrates the importance of having sufficient 
detergent in the resuspension buffer. Western blots of gels analysed initially by in-gel fluorescence 
showed a remarkable difference in the amount of protein present between samples with and 
samples without alkyne capture reagent added, despite seeing a clear fluorescence signal from 
labelled proteins. The variation was most probably due to the AzGG-TAMRA-Yn-Biotin II label 
increasing the hydrophobicity of the labelled proteins in samples with TAMRA-Yn-Biotin II added, so 
making them harder to resuspend efficiently despite the pellet appearing to be resuspended by eye. 
Alternatively, once resuspended the proteins may have aggregated in solution and so were too large 
to enter the gel.  
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Figure 49: Effect of detergent in the sample resuspension buffer on protein resuspension In-gel fluorescence scans and 
Western blots showing in vitro prenylation with AzGGpp or GGpp (control) with and without click capture with TAMRA-Yn-
Biotin II(as indicated in the figure) of Mevastatin-treated HEK293A S100, DMSO-treated (control) HEK293A S100 or 
recombinant Rab1A. 60 µg S100 and 120 ng Rab1A was prenylated and captured (with or without alkyne) and 30 µg or 
60 ng affinity purified, respectively. Samples were resuspended in a PBS buffer containing 0.6% NonidetP-40 (NP-40) and 
0.2% SDS (left 4 lanes) or 3% NonidetP-40 and 2% SDS (right 4 lanes).Samples were run on a 12% Bis-Tris gel with MES SDS 
running buffer, imaged using an Ettan DIGE imager (GE Healthcare) and Western blotted using either mouse anti-human 
Rab5 antibody  (BD Transduction labs) or mouse anti-polyhistidine antibody (Sigma Aldrich, for His-Rab1A). 
2.3.4.1 Addition of EDTA to the sample resuspension buffer 
Other researchers have noted that copper ions can have an effect on the efficiency of protein 
resuspension, affinity purification and gel electrophoresis. Following discussions with other 
members of the Tate group, EDTA was added both before protein precipitation to quench the click 
reaction and in the sample resuspension buffer; in both cases at a final concentration of 10 mM 
EDTA (from a 0.5 M stock in dH2O). Figure 50 demonstrates that addition of EDTA to samples can 
improve the fluorescence signal of labelled proteins. Thus from this point EDTA was added to all 
samples to quench the click reaction and to form part of the resuspension buffer. 
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Figure 50: Effect on fluorescence signal of addition of EDTA to samples. In-gel fluorescence scan (top) showing the effect 
of adding 10 mM EDTA (Lane 2) to 20 µg Mevastatin-treated HEK293A S100 prenylated with AzGGpp and captured with 
TAMRA-Yn-Biotin II when compared to not adding EDTA (Lane 1). EDTA was added to the sample in Lane 2 both before and 
after precipitation at a concentration of 10 mM. Colloidal Coomassie stain of the same gel is shown to demonstrate equal 
loading (bottom). 
2.3.5 Affinity purification of labelled proteins 
NeutrAvidin™ agarose beads allowed affinity purification of biotin-labelled Rabs in previous work.230, 
232 NeutrAvidin™ has a very high affinity for the biotin tag used to label the Rabs and is reported by 
the manufacturers (Thermo scientific) to give low nonspecific binding (discussed in Chapter 1 section 
1.3.2.1). However, the disadvantage of NeutrAvidin™ beads is that they are nearly colourless, 
making removal of the supernatant difficult without loss of some beads and hence sample. A 
solution was to use magnetic streptavidin coated agarose beads (Dynabeads® MyOne™ Streptavidin 
C1 beads from Invitrogen). Magnetic streptavidin beads are not only brown in colour, making them 
easy to see and thus harder to remove accidently, but can also be held to the edge of the tube by 
means of a magnetic rack, making removal of the supernatant from the beads very efficient and 
negating the need for centrifugation. For small scale work no difference could be seen between the 
two types of beads (not shown) but the ease of handling of the magnetic beads made it preferable 
to adopt them as the means of affinity purification of labelled proteins. 
Affinity purification of recombinant Rabs labelled with TAMRA-Yn-Biotin I confirmed that the biotin 
tag was compatible with affinity purification (Figure 51A). The next step was to trial affinity 
purification of TAMRA-biotin labelled Rabs from Mevastatin-treated HEK293A S100 samples, which 
was not as facile as initially expected.  
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Figure 51: Optimisation of affinity purification conditions. In-gel fluorescence images showing affinity purification of: A) 
Rab1A labelled with TAMRA-Yn-Biotin I; B) 10 µM Mevastatin or DMSO (- Mevastatin, 0.02%)-treated samples with no 
detergent added to the pull-down mixture; C) samples with either 0.3% NonidetP-40 (NP-40) or 1% CHAPS added to the pull-
down mixture, with DMSO controls.  
Early attempts at affinity purification of labelled Rabs from cell lysate samples used the same 
conditions as used for recombinant Rab protein described above. Samples were diluted ten times 
with PBS before addition to the beads, giving final concentrations of 0.06% NonidetP-40 and 0.02% 
SDS in the affinity purification buffer (prior to optimisation of protein resuspension). After 
incubation for 2 hours at room temperature with agitation of the mixture on a vortex-mixer, the 
supernatant was removed from the beads. The beads were then washed three times with 0.25% SDS 
in PBS to remove unbound proteins. Bound proteins were eluted into 1 × sample loading buffer 
(NuPage sample loading buffer, Invitrogen) by boiling the samples for 5 minutes. These affinity 
purification conditions were sufficient for recombinant Rabs; however, the amount of in-gel 
fluorescence signal seen from cell lysate protein on the beads was at best a tenth of that seen before 
affinity purification despite loading a supposedly equivalent quantity of protein on the gel (by 
volume and based on initial quantity of protein labelled, Figure 51B). This suggested that the protein 
had not properly eluted from the beads because no labelled protein was seen in the supernatant, 
Rab1a Supernatant Beads
GGpp + - + - + -
AzGGpp - + - + - +
30 -
20 -
Before pull-
down
Beads Supernatant
Mevastatin - + - + - +
Before pull-
down
Beads A         
(0.3% NP-40)
Supernatant Beads B             
(1% CHAPS)
Supernatant
Mevastatin - + - + - + - + - +
30 -
20-
30 -
20 -
A
B
C
M
W
(D
a)
  
1
0
3
M
W
(D
a)
  
1
0
3
M
W
(D
a)
  
1
0
3
91 
 
which should contain any unbound protein. After several unsuccessful attempts at purification, using 
various amounts of protein and beads, addition of more detergent to the affinity purification buffer 
finally yielded positive results (Figure 51C). It was postulated that the reason for inefficient and 
incomplete pull-down from the cell lysate samples was due to proteins aggregating and/or 
precipitating under the original conditions used. Very little detergent was present in the supernatant 
in this case and the Biotin tags may thus have been unavailable to interact with the streptavidin 
beads. The mild detergents CHAPS and NonidetP-40 (already used in the prenylation reaction buffer) 
were investigated and were found to increase the amount of pull-down to almost one hundred per 
cent (according to ImageQuantTL software (GE Healthcare), Figure 51C).  
Following optimisation of conditions for protein resuspension, the final composition of the affinity 
purification buffer (resulting from a ten times dilution of samples in resuspension buffer) were: 0.2% 
SDS (previous work also showed that concentrations of SDS above 0.25% negatively affected the 
amount of protein that could bind to the beads),230 0.3% NonidetP-40 (as in the prenylation reaction 
buffer), 1 mM DTT (to help prevent protein aggregation by reducing disulphide bridges) and 1 mM 
EDTA (as discussed above, section 2.3.4.1). Rab proteins are purified specifically when they have 
been labelled by bioorthogonal ligation as can be seen in Figure 52 with a Rab11 Western blot.232 
 
Figure 52: Rab proteins are affinity purified when tagged with TAMRA-Yn-Biotin I. In-gel fluorescence scan (top) and anti-
Rab11 (mouse anti-Rab11, BD Transduction Labs # R56320) Western blot showing labelling and affinity purification of Rabs 
prenylated with AzGGpp in 25 µg of either Mevastatin-treated or DMSO-treated (control) HEK293A S100.
232
 
The optimised protocol for labelling of unprenylated Rab proteins from HEK293A cells is illustrated in 
Figure 53. The protocol incorporates the optimised conditions for the click reaction, protein 
precipitation and affinity purification as described in the sections above. 
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Figure 53: Optimised protocol for sample preparation and labelling used in initial work in this study. HEK293A cells are 
treated with 10 µM Mevastatin for 17 hours when approximately 70% confluent. After treatment cells are harvested and 
lysed before being subjected to ultracentrifugation at 100,000 × g to give cytosolic (S100) and membrane (P100) fractions. 
In vitro prenylation is carried out on S100 for 40 minutes at 37 °C. Click reaction components are added pre-mixed to the 
prenylation reaction mixture and allowed to react for 60 minutes at r.t. with constant mixing of the sample. The protein is 
precipitated by CHCl3/ MeOH to remove any TAMRA-Yn-Biotin II and fluorescent contaminants that might interfere with the 
affinity purification step. Proteins are resuspended in a buffer containing 2% SDS and 3% NP-40 and added to magnetic 
streptavidin Dynabeads® for affinity purification of biotin-labelled proteins for 2 hours at r.t. with constant mixing of the 
sample. Labelled proteins are separated by mass using gel electrophoresis before visualising by in-gel fluorescence using an 
Ettan DIGE imager. 
 Proteomics to identify labelled proteins 2.4
One of the main aims of this work was to develop a methodology for identifying proteins that are 
unprenylated in diseases affecting the protein prenylation machinery. Mass spectrometry-based 
proteomics has been widely used in the literature for investigating various post-translational 
modifications,135, 245, 246 and can be a very sensitive technique to detect relatively small amounts of 
protein in a sample. However, with increasing protein complexity more sample is needed to ensure 
that the proteins of interest can be detected above the background of more abundant proteins, so 
labelling experiments must be scaled up. There are many different approaches to protein 
identification by mass spectrometry, and in this project many prenylated proteins needed to be 
identified from complex samples; LC-MS/MS mass spectrometry as part of a bottom-up proteomics 
strategy was chosen (see section 1.4.2 in Chapter 1).  
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The basic workflow chosen for the proteomics experiments described in this chapter is illustrated in 
Figure 54. The Biotin moiety on the TAMRA-Yn-Biotin II capture reagent allows affinity purification of 
labelled proteins, which is intended to reduce the complexity of the sample for mass spectrometric 
analysis by removing unlabelled proteins from the sample. Furthermore, because Rabs are all of a 
similar molecular weight (around 23 kDa) it was known where labelled proteins of interest would run 
on the gel, especially as the fluorescent bands of labelled proteins can be seen by in-gel fluorescence 
at this molecular weight. Thus to further reduce the amount of unlabelled protein contaminants 
from the samples, it was decided to use 1D gel electrophoresis to fractionate the sample by 
molecular weight and excise bands from the gel to include the whole area where protein labelling 
could be seen i.e. between 20 and 30 kDa. The proteins from the gel band would then be digested 
into peptides by trypsin using standard protocols. The peptides would then be concentrated and 
injected onto a liquid chromatography column to separate them prior to injection into the mass 
spectrometer; making detection of each peptide more likely as the likelihood of a particular signal 
being swamped by other more abundant peptides is reduced.  
 
Figure 54: Workflow for proteomics analysis of samples. 
The gel-based separation technique chosen for affinity purified samples was a 1D rather than a 2D 
gel because 1D gel electrophoresis is a much simpler technique to use, making the analysis faster, 
and furthermore excising labelled protein spots from a 2D gel would be difficult as the amount of 
protein per spot would be insufficient to see by Coomassie staining. Colloidal Coomassie rather than 
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silver staining was used to stain proteomics gels because it was already known where Rab proteins 
would appear and so it was not necessary to see a stained protein band to excise and furthermore 
the reagent is more compatible with mass spectrometry and the staining more facile than silver 
staining. 
2.4.1 Optimisation of sample preparation conditions for proteomics analysis of samples 
from Mevastatin-treated HEK293A cells 
Rab proteins are all of a similar molecular weight and run at a similar place on a SDS PAGE gel (see 
gels in figures above). Thus to go some way to reducing any possible background from non-specific 
binding to the streptavidin beads, gel bands were excised at the molecular weight where Rab 
proteins run on a gel. The proteins in the gel band were then extracted and digested into peptide 
fragments by trypsin and fragments were separated by LC on a reverse-phase column (75 μm i.d. x 
250 mm) containing Symmetry 100 Å C18 media (Waters, UK) at a flow rate of 0.3 µl/min for two 
hours (details of the gradient can be found in Materials and Methods) before being injected into the 
LTQ-Orbitrap Velos (Thermo Scientific) mass spectrometer on-line. The LTQ-Orbitrap Velos was set 
to use electrospray ion source in a positive ion mode and to acquire in a data dependent mode; 
dynamic exclusion was enabled to prevent repeated analysis of peptides. Proteomics samples were 
sent to Dr Andrew Bottrill at the PNACL (Protein Nucleic Acid Chemistry Laboratory) at the University 
of Leicester for trypsin digestion and LC-MS/MS analysis. 
1 mg (total protein) S100 from Mevastatin-treated and DMSO-treated HEK293A cells prenylated with 
AzGGpp, labelled and affinity purified were sent for analysis as excised polyacrylamide gel bands. 
The gels from the first set of samples are shown in Figure 55A; from Coomassie staining of the gel for 
proteomics analysis it can be seen that both samples had a lot of background protein that had bound 
non-specifically to the beads, especially at higher molecular weights. The background was also seen 
in the proteins identified by LC-MS/MS from the samples as there were a large number of non-Rab 
proteins (Table 4). 
 
 
95 
 
 
Figure 55: Gels showing samples sent for proteomic analysis. A: Proteomics experiment 1, 1 mg total S100 protein from 
Mevastatin-treated or DMSO-treated (control) HEK293A cells. Left: in-gel fluorescence scan (top) and colloidal Coomassie 
stain of the same gel (bottom) showing a 20 µg extract of samples before and after affinity purification. Right: the colloidal 
Coomassie stain of the gel of the 1 mg samples once the gel bands were excised. B: Proteomics experiment 3, 1 mg total 
S100 protein from Mevastatin-treated or DMSO-treated (control) HEK293A cells. Samples were prenylated with either 
AzGGpp or GGpp (control). Left: in-gel fluorescence scan showing a 20 µg extract of samples before and after affinity 
purification (B = beads, S = supernatant). Right shows the colloidal Coomassie stain of the gel of the 1 mg samples once the 
gel bands were excised. 
The wash protocol used to remove unbound protein is shown in Table 3; since it did not seem to be 
sufficient for removing non-specific proteins, the protocol was adapted to that used for proteomics 
experiment 3 shown in Figure 55B. Samples in the second proteomics experiment are not shown but 
were treated in a similar manner to those in proteomics experiment 3 and proteins identified are 
given in Table 4A. The adapted protocol is also shown in Table 3 and was developed to ensure 
sufficient washing to remove non-specifically bound protein. The different wash buffers used have 
different roles to try and ensure maximum removal of background protein. SDS, urea and guanidine 
are all protein denaturing agents. The streptavidin tetramers are covalently bound to the beads and 
have a very high affinity for Biotin, making any labelled protein difficult to remove from the beads. 
Thus by briefly washing the beads in solutions of SDS, urea and guanidine it is possible to remove 
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unlabelled proteins that are bound non-specifically, without disrupting the biotin-streptavidin 
interaction. 
Buffer Initial wash conditions Optimised wash conditions 
0.6% NP-40 in PBS 2 × 200 µl - 
0.2% SDS in PBS 2 × 200 µl 3 × 500 µl 
4 M guanidine in PBS 1 × 200 µl 2 × 500 µl 
4 M Urea in PBS 1 × 200 µl 2 × 500 µl 
PBS 2 × 500 µl 2 × 500 µl 
50 mM ammonium bicarbonate - 2 × 500 µl 
Table 3: Table detailing the different buffers used to wash affinity purification beads following affinity purification. 
The reduction in background made by altering the wash protocol can be seen in the difference in 
protein staining between the gels for proteomics analysis; which reflects the amount of non-specific 
binding of proteins to the beads as only Rab proteins should be labelled, and appear at around 
25 kDa. The gel for samples submitted for the first proteomics experiment (Figure 55A) shows 
substantial staining in the lane above where the bands were excised, whilst for proteomics 
experiment 3 which used the optimised wash protocol there is very little staining in the gel from 
which the bands were excised (Figure 55B). The difference in the amount of non-specifically binding 
proteins can also, more importantly, be seen in the total number of proteins detected from the gel 
band i.e. there are fewer non-Rab proteins identified with the improved wash protocol and there are 
fewer Rabs in the control samples. Those Rab proteins identified from the samples submitted for 
proteomics are shown in Table 4A and the total numbers of proteins identified are shown in Table 
4B. Eleven Rabs are identified consistently between the samples (highlighted in bold in the table) 
and of the others all apart from Rab24, Rab35, Rab3D and Rab43 are identified in two of the 
samples. Rab24, Rab3D and Rab43 are identified in the third, more optimised experiment from 
which more Rabs were identified. The improvement in background and the consistent identification 
of at least sixteen Rab proteins was very encouraging; it highlighted that the technique had the 
potential to be expanded to probe defective prenylation in other cell lines and in tissue samples.   
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Table 4A Number of unique peptides 
Mevastatin 1 Mevastatin 2 Mevastatin 3 DMSO 1 DMSO 2 
# Identified Rab Proteins Accession # AzGGpp AzGGpp AzGGpp AzGGpp AzGGpp 
1 Rab14 P61106 5 7 11 3 4 
2 Rab7a P51149 4 12 17 0 0 
3 Rab1B Q9H0U4 4 3 11 0 0 
4 Rab11B Q15907 5 9 12 2 3 
5 Rab5C P51148 9 11 8 5 7 
6 Rab2A P61019 8 7 8 0 0 
7 Rab21 Q9UL25 0 5 7 0 0 
8 Rab6A P20340 3 5 8 0 4 
9 Rab1A P62820 5 4 4 6 3 
10 Rab18 Q9NP72 7 3 8 0 0 
11 Rab3D O95716 0 0 5 0 0 
12 Rab10 P61026 8 3 3 4 2 
13 Rab5B P61020 4 4 3 0 2 
14 Rab4A P20338 4 0 5 3 0 
15 Rab43 Q86YS6 (+1) 0 0 3 0 0 
16 Rab5A P20339 2 0 3 0 0 
17 Rab9A P51151 0 2 4 0 0 
18 Rab24 Q969Q5 0 0 2 0 0 
19 Rab8A P61006 4 2 0 2 2 
20 Rab32 Q13637 2 4 0 0 0 
21 Rab35 Q15286 3 0 0 0 0 
 
Table 4B Proteomics experiment 
DMSO 1 Mevastatin 1 DMSO 2 Mevastatin 2 DMSO 3 Mevastatin 3 Mevastatin 3 
AzGGpp AzGGpp AzGGpp AzGGpp AzGGpp GGpp AzGGpp 
Total Rabs 9 18 9 16 1 0 19 
Total protein 154 158 115 149 11 16 27 
Table 4A and Table 4B: Rab proteins detected in proteomics experiments 1, 2 and 3. The Rabs were identified from trypsin 
digest of an excised gel band. The number of unique peptides detected for each Rab in the experiment is shown in Table 4A. 
The (+1) after Rab43 indicates that the peptides identified were unique to both Rab43 and its isomer Rab43-like protein. 
Samples were prepared by in vitro prenylation with either AzGGpp or GGpp (control) of 1 mg of either DMSO S100 (control) 
or Mevastatin S100 samples. The optimised conditions for prenylation, capture and affinity purification detailed above were 
used. No Rabs were detected for the GGpp control for experiment 3 and only Rab14 (with two unique peptides) in the DMSO 
control sample; these samples are not included in the table. Beads from affinity purification of samples from experiments 1 
and 2 were washed with the non-optimised wash protocol and samples in experiment 3 with optimised protocol (Table 3). 
Scaffold files containing data from experiments shown in these tables are provided in the electronic supplementary 
information (Proteomics experiments 1, 2 and 3 refer to the data shown here). 
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 Samples were run on the LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific) and analysed 
using the Mascot search engine (Matrix Science) and Scaffold (version Scaffold_3.2.0, Proteome 
Software Inc., Portland, Oregon, USA). Scaffold was used to validate protein identifications 
probabilistically derived from MS/MS sequencing results. Peptide identifications assigned by Mascot 
were accepted by Scaffold if they could be established at greater than 95.0% probability as specified 
by the Peptide Prophet algorithm. After Scaffold probabilistically validates these peptide 
identifications using PeptideProphet it derives corresponding protein probabilities using 
ProteinProphet.247-251 Protein identifications were accepted if they could be established at greater 
than 95.0% probability and contained at least 2 identified peptides. The settings chosen were 
selected to ensure as many protein hits were identified as possible whilst reducing the number of 
false-positives and false-negatives. The settings are those generally recommended by the Scaffold 
manufacturer although identification was accepted with two unique peptides identified (rather than 
three) as the identity of labelled proteins was already expected to be Rabs. 
Excision of a gel band to allow identification of proteins of a narrow molecular weight range was 
chosen as a means to reduce background signal and reduce the complexity of the sample, to allow 
identification of more proteins. However, there remained the possibility that some Rabs could be 
running as protein dimers and so would not be detected at the narrow mass range analysed and also 
that some proteins may not have eluted or eluted incompletely from the beads, under the elution 
conditions used. To ascertain whether digesting the proteins with trypsin directly from the 
streptavidin beads would yield a larger number of Rab proteins, the samples from proteomics 
experiment 3 were also digested directly from the beads. The comparison was made by prenylating 
and affinity purifying 2 mg total S100 protein and running half of the sample on a gel (i.e. 1 mg, 
Figure 55B) and retaining half for digesting the proteins bound to the beads directly. The Rabs 
identified from these two methods are shown in Table 5A whilst the total proteins identified are 
shown in Table 5B. There is a much higher background of non-specific proteins from samples 
subjected to on-bead digest, which is to be expected as in this case the whole molecular weight 
range of proteins was available for analysis. The total number of Rabs identified in the different 
digests did not differ greatly and no Rabs were identified from the control (DMSO) samples for on-
bead digest and only Rab14 (two unique peptides) was identified for the in-gel digest control. The 
number of unique peptides identified for each Rab seems to be slightly more for the in-gel digest, 
probably due to the lower background of non-specifically bound proteins, although this may not be 
significant as the samples were only analysed once; with no technical repeat. For the remainder of 
99 
 
the proteomics experiments described in this chapter, proteins were extracted from excised gel 
bands but the on-bead digest was not ruled out for further work. 
Table 5A Number of unique peptides 
Mevastatin 3 
Mevastatin 3 
Gel Beads 
# Identified Rab Proteins Accession # AzGGpp AzGGpp 
1 Rab7A P51149 17 10 
2 Rab11B Q15907 12 10 
3 Rab1B Q9H0U4 11 7 
4 Rab14 P61106 11 12 
5 Rab5C P51148 8 6 
6 Rab2A P61019 8 6 
7 Rab6A P20340 8 4 
8 Rab18 Q9NP72 8 3 
9 Rab21 Q9UL25 7 7 
10 Rab3D O95716 5 4 
11 Rab4A P20338 5 3 
12 Rab1A P62820 4 0 
13 Rab9A P51151 4 0 
14 Rab5A P20339 3 2 
15 Rab5B P61020 3 4 
16 Rab10 P61026 3 6 
17 Rab43 Q86YS6 (+1) 3 3 
18 Rab24 Q969Q5 2 0 
19 Rab27A P51159 1 2 
  
Table 5B DMSO 3 Mevastatin 3 Mevastatin 3 DMSO 3 Mevastatin 3 Mevastatin 3 
AzGGpp AzGGpp GGpp AzGGpp AzGGpp GGpp 
Gel Gel Gel Beads Beads Beads 
Total Rabs 1 19 0 0 16 0 
Total protein 11 27 16 51 71 103 
Table 5: Tables showing the Rab proteins identified from in-gel and on-bead proteolytic digests and the total number of 
Rab proteins compared to the total number of proteins identified. Samples were prepared from 2 mg total S100 protein 
from HEK293A cells treated with either Mevastatin or DMSO (control) and the S100 prenylated with either AzGGpp or GGpp 
(control). The sample of beads was split in half and half run on a polyacrylamide gel and gel bands excised at the molecular 
weight of Rab proteins for in-gel proteolytic digest and half retained for on-bead proteolytic digest. There were no Rabs 
detected in the DMSO and GGpp controls for the on-bead digest samples and there were no Rabs detected for the GGpp 
control for the gel sample and only Rab14 (two unique peptides) in the DMSO control gel sample; these experiments are not 
shown in Table 5A. The (+1) after Rab43 indicates that the peptides identified are found only in Rab43 and its isomer Rab43-
like protein. Scaffold files containing data from experiments displayed in this table are provided in the electronic 
supplementary information (Proteomics experiment 3 refers to the data shown here). 
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Further proteomics experiments with HEK293A-derived samples investigated whether more Rab 
proteins could be detected than had already been identified. Alexandrov et al. reported detection of 
42 Rab proteins from Mevastatin-treated COS-7 cells using their biotinylated GGpp analogue (BGPP, 
Figure 23) and affinity purification with magnetic streptavidin beads; the absence of some Rab 
proteins was thought to be due to their cell-type specific expression.135 The BGPP-labelled Rab 
proteins were identified using the MudPIT proteomics technique (described briefly Chapter 1 section 
1.4.2.2) and the absolute abundance of the Rabs in the cytosol was quantified by spiking in a known 
quantity of recombinant 15N-labelled Rab22A.220 The Mevastatin-treated sample was compared to a 
sample treated with the RGGT inhibitor BMS3 and no significant differences were seen in the 
amount of each Rab detected and hence the amount of unprenylated Rab labelled in each sample. 
The quantity of protein analysed by MS is not detailed, whilst the quantification of Rab abundance is 
given as pmol/ml cell lysate (1 ml cell lysate was labelled for the mass spectrometric analysis). The 
concentration of the cell lysate is not given, and there is no data on what proteins were detected in 
the control samples nor on the level of background proteins detected, nor indeed the number of 
repetitions or the criteria used to identify a protein hit. This lack of information makes it difficult to 
judge how robust the technique used was and whether it would be possible to improve the number 
of Rabs identified from the HEK293A cells used in work for this thesis.  COS-7 cells may be more 
metabolically active than HEK293A cells, so it is possible that the turnover of Rabs is faster meaning 
that more unprenylated Rabs are available in the cytosol for labelling. It is also possible that more 
Rabs were identified by Alexandrov et al. due to the extra liquid chromatography column employed 
on the peptides (as part of the MudPIT technique); which may have given enough separation to 
allow identification of lower abundance peptides that were unique to particular Rabs. However, 
from the data provided it is not possible to tell. 
To assay whether a further reduction in sample complexity could improve the number of Rab 
proteins identified from Mevastatin-treated HEK293A S100 samples, both a 2 mg total S100 protein 
sample and a 1 mg sample with the excised gel band cut into three parts to give further fractionation 
of the sample were submitted for proteomics analysis. Neither sample type showed any difference 
in the number or identity of Rabs detected (not shown but data are provided in the scaffold file 
‘Proteomics experiment 3.2’ in the electronic supplementary information). 
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2.4.2 The cellular roles of Rab proteins detected by mass spectrometry-based proteomics 
of Mevastatin-treated HEK293A-derived samples  
A total of 20 Rabs out of approximately 60 possible mammalian Rabs were detected from 
Mevastatin-treated HEK293A cells. The Rabs identified are those that are affected by the inhibition 
of HMG-CoA reductase, likely to be the majority of the Rab proteins as all Rabs require 
geranylgeranylation in order to be able to associate with their target membrane and will accumulate 
in the cytosol when unprenylated. Some Rabs will not be expressed as expression can be cell-type 
specific and it is also possible that in the 17 hours of Mevastatin treatment the turnover of some Rab 
proteins may be slower than others and so the amount available for labelling would fall below the 
detection limit. There is some evidence that expression of Rab5 and Rab7 is upregulated at the 
mRNA level following statin treatment,252 but the expression levels of other Rabs in statin-treated 
cells does not appear to have been investigated in the literature so it is not possible to say whether, 
in fact, expression levels of all Rabs increase on treatment with statins. The Rabs identified in the 
experiments described and their cellular functions are described in Table 6. From the functions of 
the Rabs identified it seems that all areas of the cell and all areas of Rab trafficking have been 
affected i.e. there is not one specific cellular trafficking pathway or family of Rabs affected, instead 
the effect is global.  
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Rab 
protein 
Accession 
Number 
Cellular location Function 
Rab1A P62820 ER, Golgi ER to Golgi and intra-Golgi trafficking 
Rab1B Q9H0U4 ER, Golgi ER to Golgi and intra-Golgi trafficking 
Rab2A P61019 ER, ER-Golgi intermediate 
compartment, Golgi 
ER to Golgi trafficking 
Rab3D O95716 Secretory vesicles, PM Regulated exocytosis 
Rab4A P20338 EE Protein recycling/transport to PM 
Rab5A P20339 PM, CCVs, EE EE fusion 
Rab5B P61020 PM, CCVs, EE EE fusion 
Rab5C P51148 PM, CCVs, EE EE fusion 
Rab6A P20340 Golgi Endosome to Golgi, intra-Golgi and 
Golgi to ER transport 
Rab7A P51149 LE, lysosomes/vacuole, 
Melanosomes, phagosomes 
LE to lysosome trafficking 
Rab8A P61006 Cell membrane, vesicles, primary cilia Exocytosis, TGN/RE to PM trafficking 
Rab9A P51151 LE Endosome to TGN trafficking 
Rab10 P61026 Golgi, basolateral sorting endosomes, 
GLUT4 vesicles 
Exocytosis, TGN/RE to PM trafficking 
Rab11B Q15907 Golgi, RE, EE TGN/RE to PM trafficking 
Rab14 P61106 Golgi, EE, GLUT4 vesicles TGN/RE to PM trafficking, apical 
membrane targeting 
Rab18 Q9NP72 Golgi, lipid droplets Lipid droplet formation 
Rab21 Q9UL25 EE Endosomal transport 
Rab24 Q969Q5 ER Autophagosome formation 
Rab27A P51159 Melanosomes Exocytosis 
Rab32 Q13637 Mitochondria, melanosomes TGN to melanosome trafficking, 
mitochondrial fission 
Rab35 Q15286 PM, endosome RE to PM trafficking, actin assembly 
Rab43 Q86YS6 ER, Golgi ER to Golgi trafficking, Shiga toxin 
transport 
Table 6: The cellular location and function of the Rab proteins identified from Mevastatin-treated HEK293A S100. EE = 
Early Endosome, PM = Plasma Membrane, LE = Late Endosome, TGN = Trans-Golgi Network, CCV = Clathrin-coated Vesicle, 
RE = Recycling Endosome, ER = Endoplasmic Reticulum. Information adapted from the review by Hutagalung and Novick.
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 Probing REP-1 vs. REP-2 prenylation in vitro 2.5
As discussed in Chapter 1 section 1.2.5.2 there are two isoforms of the REP protein essential for Rab 
prenylation. It is unclear why there are two isoforms and whether the two have different Rab 
substrates that they prenylate preferentially in vivo, although there is evidence that Rab27A and 
Rab3 proteins are preferentially prenylated by REP-1.94 The rare X-liked disease Choroideremia 
results from Null mutations of the gene encoding the REP-1 protein, meaning that patients do not 
have working REP-1 protein. The patients progressively lose their sight but do not seem to have any 
other symptoms so REP-2 must be compensating to a large extent for the lack of REP-1. It was, 
therefore, of interest to investigate whether REP-2 could also prenylate Rabs in vitro with AzGGpp 
and whether any significant differences could be seen between the Rabs labelled by the two 
isoforms, as identified using mass spectrometry based proteomics. 
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In all in vitro prenylation steps described to this point, recombinant REP-1 protein was used with 
recombinant RGGT as the enzyme catalyst. Recombinant REP-2 protein was next investigated for use 
in in vitro prenylation reactions. In vitro prenylation of 25 µg Mevastatin-treated HEK293A cell S100, 
using REP-2 at 1 µM concentration with 1 µM RGGT and 20 µM AzGGpp, was successful and 
comparable to prenylation with REP-1, as shown in Figure 56. 
 
Figure 56: Prenylation of Mevastatin-treated HEK293A S100 using REP-1 and REP-2.Top. In-gel fluorescence scan showing 
in vitro prenylation and bioorthogonal ligation of Mevastatin-treated HEK293A cell lysate S100 fractions. Samples were 
prenylated with either REP-1 or REP-2. Bottom: Colloidal Coomassie stain of fluorescence gel to demonstrate protein 
loading. 
2.5.1 Proteomics of samples prenylated using either recombinant REP-1 or recombinant 
REP-2 
Having established that AzGGpp would also label proteins when REP-2 formed part of the enzyme 
complex, the next step was to employ the proteomics techniques described above to compare the 
Rabs prenylated with REP-1 or REP-2, gaining an indication of which Rabs are preferred substrates 
for each REP in vitro. Mevastatin-treated (or DMSO control) HEK293A S100 samples prenylated with 
AzGGpp using either REP-1 or REP-2 were treated as described above and the excised gel bands 
were sent for proteomics analysis. The Rabs identified from the samples submitted and the total 
numbers of proteins identified are given in Table 7A. Table 7B gives an indication of the degree of 
background, which most probably arose from non-specific binding of proteins to the beads.  
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 Table 7A  Proteomics experiment 
   
Mevastatin 4 
Mevastatin 4 
Mevastatin 4 
   # Unique Peptides 
# Identified Rab Proteins Accession # REP-1 REP2 a REP-2 b 
1 Rab14 P61106 9 14 9 
2 Rab7A P51149 9 13 10 
3 Rab2A P61019 8 11 7 
4 Rab11A P62491 7 11 9 
5 Rab1A P62820 6 8 5 
6 Rab5C P51148 6 7 5 
7 Rab6A P20340 6 10 7 
8 Rab21 Q9UL25 6 8 5 
9 Rab5B P61020 4 5 3 
10 Rab9A P51151 4 4 0 
11 Rab4A P20338 3 4 3 
12 Rab1B Q9H0U4 2 3 2 
13 Rab3D O95716 2 4 3 
14 Rab5A P20339 2 3 2 
15 Rab10 P61026 0 6 0 
16 Rab18 Q9NP72 0 4 0 
17 Rab24 Q969Q5 0 2 2 
18 Rab27A P51159 0 2 0 
19 Rab31 Q13636 0 3 0 
20 Rab32 Q13637 0 3 0 
21 Rab35 Q15286 0 3 0 
22 Rab43 Q86YS6 (+1) 0 4 0 
 
Table 7B Experiment 
 Mevastatin 4 DMSO 4 Mevastatin 4 DMSO 4 Mevastatin 4 DMSO 4 
 REP-1 REP-1 REP2 a REP-2 a REP-2 b REP-2 b 
Total Rabs 14 0 22 0 14 0 
Total protein 26 8 34 10 21 8 
Table 7: Rab proteins identified in a proteomics experiment to compare REP-1 and REP-2 prenylation of HEK293A S100-
derived samples and the total number of Rab proteins identified compared to the total number of proteins identified for 
each sample. Samples were prepared from 1 mg total S100 protein from HEK293A cells treated with either Mevastatin or 
DMSO (control) and the S100 prenylated with AzGGpp using either recombinant REP-1 or recombinant REP-2. All samples 
were from in-gel digestion of excised gel bands. There were no Rabs in the DMSO controls so these results are not included 
in the table. The (+1) after Rab43 indicates that the peptides identified were unique to both Rab43 and its isomer Rab43-like 
protein. Scaffold files containing data from the experiment shown in this table are provided in the electronic supplementary 
information (Proteomics experiment 4 refers to the data shown in this table). 
Samples prenylated with REP-2 showed little difference to those prenylated with REP-1 in terms of 
Rabs detected; although it would have been interesting to see a difference in the identity of the 
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Rabs, it is possible that the difference would be quantitative i.e. lie in the relative amount of a Rab 
prenylated rather than the identity of the Rabs. In order to see a difference in the preferred Rab 
substrates for REP-1 and REP-2 (if any), another method is to knock out the endogenous REP-1 and 
REP-2 proteins and see which Rabs remain unprenylated in those cases. Attempts towards this are 
described below in section 2.5.2. Difficulties from using recombinant REP also arise because the 
activity of the REPs could be different and so skew the results, further increasing the need for an 
alternative method of comparison between the two REP isoforms. 
2.5.1.1 Testing the iTRAQ technique for quantitative mass spectrometry 
Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) is a technique for quantifying relative 
differences in abundance of peptides (and hence proteins) between samples; iTRAQ is explained in 
Chapter 1 (section 1.4.2.3). The iTRAQ tags are particularly useful for making comparisons between 
diseased and undiseased states in tissue from mouse models or cell lysate from different types of 
cell or cells placed under different conditions. Using iTRAQ, the relative differences between protein 
levels in different samples can be quantified from the amount of each peptide detected; the samples 
are pooled following iTRAQ labelling and run together, ideally as an equimolar mixture. In this 
project, other systems used for labelling are described in later chapters with the potential to 
generate interesting quantitative results using iTRAQ; however, the samples were more difficult to 
generate than those from HEK293A samples so HEK293A samples were chosen for initial testing of 
the technique. Furthermore, it was of interest to see if any significant quantitative differences in 
either Rab identity or Rab abundance could be seen between samples prenylated with REP-1 or REP-
2. Additionally, there was no previous experience within the Tate or Seabra groups in this technique 
so it was important to establish whether it was a viable option to quantify the relative differences in 
protein abundance between AzGG-labelled samples. 
The first iTRAQ experiment carried out for this thesis aimed firstly to establish if any difference could 
be seen quantitatively between the Rabs identified in samples prenylated by REP-1 and those 
prenylated by REP-2; the second aim of the experiment was to determine whether there was a 
detection threshold for identification and quantification of protein in each sample, i.e. was 0.5 mg 
S100 too small an amount for protein identification in iTRAQ experiments; and the third and most 
simple aim was to see the 1:2 ratio of the two REP-1 and REP-2 samples to establish reproducibility 
of the technique as used here. 1.5 mg of Mevastatin-treated HEK293A S100 was prenylated in vitro 
using either 1 µM REP-1 or 1 µM REP-2 as described above and then captured via click reaction and 
affinity purified as in previous proteomics experiments. After washing the beads, samples were split 
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into ⅓ and ⅔ to give 0.5 mg and 1 mg samples respectively to run on a gel; gel bands were excised in 
the same way as previous experiments. Figure 57 shows an in-gel fluorescence scan of a small 
quantity of the samples sent for proteomics.  
 
Figure 57: in-gel fluorescence scan of gel with ~20 µg of samples submitted for iTRAQ proteomics before and after 
affinity purification (pull-down). Top: 20 µg extracts of 1.5 mg HEK293A S100 samples prenylated with AzGGpp using 
either REP-1 or REP-2 with RGGT before and after affinity purification. E = Eluate from boiling beads, B = beads after sample 
elution, S = supernatant.  Bottom: Colloidal Coomassie staining to show protein loading. 
The Rabs identified by iTRAQ and their ratios to each other are shown in Table 8; the number of 
Rabs identified was very low compared to previous proteomics experiments. The low detection may 
have been due to insufficient sample prepared and/or loaded on the mass spectrometer. Another 
point to note is that the ratio of the 1 mg samples to the respective 0.5 mg sample is not 1:0.5 but 
instead is approximately 1:0.3, which could indicate that 0.5 mg S100 sample is at the limit of 
detection for the mass spectrometer so fewer peptides with the iTRAQ tags than expected were 
detected in the 0.5 mg samples relative to the 1 mg samples. The Rab proteins are generally more 
abundant in the REP-2 samples compared to the appropriate REP-1 sample. From this experiment it 
is impossible to say whether those identified have a higher affinity for REP-2 or whether the REP-1 
protein used was less active (it should be noted that although the REP-1 protein came from the same 
protein preparation as other experiments described in this thesis it was divided into aliquots, which 
could deteriorate if freeze-thawed too many times, for example). This is one of the difficulties of 
using in vitro prenylation to compare between REP-1 and REP-2 and it was concluded that it was not 
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the most suitable method to use to compare the substrates of the REPs (as mentioned at the start of 
this section). 
 
Ratio of Rab identified to amount of Rab identified in REP-1 0.5 mg S100 sample 
Rab proteins identified REP-1 0.5mg S100 REP-11 mg S100 REP-2 0.5mg S100 REP-2 1 mg S100 
Rab1B 1 4.07 1.83 5.44 
Rab5C 1 2.83 1.92 6.26 
Rab1A 1 4.41 1.98 7.13 
Rab25 1 5.31 2.26 7.91 
Rab7A 1 2.85 1.64 5.58 
Rab6A 1 3.44 1.71 5.45 
Table 8: Table showing Rab proteins quantified by iTRAQ of samples prenylated with either REP-1 or REP-2. Rab proteins 
identified and quantified from 0.5 mg and 1 mg of Mevastatin-treated HEK293A S100 prenylated with 20 µM AzGGpp, 1 µM 
RGGT and either 1 µM REP-1 or 1 µM REP-2 as indicated, followed by capture with Yn-TAMRA-Biotin II and affinity 
purification with magnetic streptavidin beads. Following trypsin digestion samples were labelled with iTRAQ reagents and 
pooled before LC-MS/MS analysis on an LTQ-Orbitrap and protein identification and quantification by Proteome Discoverer 
(Thermo Scientific). Quantitative values are given as a ratio to the 0.5 mg REP-1 sample. A Scaffold file containing data from 
this table and an excel file containing quantification data from Proteome discoverer are provided in the electronic 
supplementary information (Proteomics experiment 5 refers to the data in this table). 
 
Figure 58: Bar chart showing the relative quantification Rab proteins identified in iTRAQ experiment displayed in Table 8. 
Error bars represent the variability in the peptide ratios used to calculate the protein ratios in the samples. Chart created 
using Microsoft Excel. 
2.5.1.2 Further testing of the iTRAQ technique 
From the iTRAQ experiment described above it was not possible to normalise the protein 
abundances in order to control for any differences in sample preparation, which could affect the 
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number of peptides detected by the mass spectrometer, so the design of the experiment was not 
optimal. Addition of a protein standard either at the in vitro prenylation step or prior to trypsin 
digestion (to control for differences in sample handling during trypsin digestion and iTRAQ labelling) 
would allow normalisation of samples relative to the amount of the standard protein detected, 
which should be equal across all samples. It was decided to spike in a recombinant Rab38 protein as 
it was unlikely to be detected in the sample (having not been detected in any other proteomics 
experiments for this thesis and because it is not normally detected in HEK293A cells) and also to add 
a control for the steps from trypsin digestion onward by adding a known amount of BSA in a gel plug 
to the tubes containing the excised gel bands of the samples for analysis. Four separate 1 mg 
samples of S100 were prepared in the standard way using REP-1 and optimised protocols; 10 ng or 
20 ng of His-tagged recombinant Rab38 was spiked into the samples (two for each amount of Rab38) 
at the in vitro prenylation step.  
The quantification of the relative abundances of the Rabs detected is shown in Table 9 and Figure 
58. The spiked Rab38 protein was not identified during analysis of the proteomics data. The protein 
may not have been in high enough concentration either to be prenylated or detected by the mass 
spectrometer, or had perhaps degraded. Previously the Rab38 had been prenylated with AzGGpp 
and seen by in-gel-fluorescence but it seems that scaling up the amount of protein was not 
successful. However, it was still possible to normalise the proteins to the BSA standard added at the 
in-gel digest stage. For three of the samples there were no significant differences between them; 
however, one sample showed substantial variation. The whole iTRAQ sample was run at once so 
there was no opportunity for a technical repeat of the experiment at the level of LC-MS/MS analysis. 
When the samples were normalised to the amount of BSA detected, the amount of streptavidin 
detected was also equal across the samples; a streptavidin dimer from the streptavidin beads runs at 
the same molecular weight as the gel band excised, so streptavidin appears in the protein 
identification data. From the gel of the samples, protein loading appeared equal and equal amounts 
of protein were prenylated initially; however, there are a number of sample processing steps (see 
Figure 54) and variation in protein recovery could have occurred in any one of them. These results 
seemed to validate the iTRAQ technique in combination with AzGGpp prenylation to identify 
geranylgeranylated proteins, although they also emphasise that every caution needs to be taken to 
ensure that samples are treated equally throughout the preparation steps before LC-MS/MS 
analysis. 
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Accession  Protein  Coverage # Peptides Score 115/114  115/114 
Variability (%) 
116/114  116/114 
Variability (%) 
117/114  117/114 
Variability (%) 
P00761 Trypsin  26.84 5 44814.27 1.06 11.85 1.40 44.13 1.14 9.65 
P02769 Serum 
albumin 
51.4 30 21077.26 1.00 12.58 1.00 25.08 1.00 11.94 
P22629 Streptavidin  40.98 5 9738.802 1.07 12.96 1.00 43.71 1.02 12.32 
Q9H0U4 Rab1B 48.76 11 7350.602 1.48 6.97 1.84 6.29 1.21 7.03 
P62820 Rab1A 42.44 9 5624.642 1.38 17.01 1.75 10.37 1.32 5.61 
P62491 Rab11A 46.3 9 3037.072 1.25   1.12   0.99   
P61106 Rab14 16.28 4 2321.175 1.37 3.37 2.37 8.75 1.40 3.75 
Q15286 Rab35 13.93 3 2295.57 1.32 7.19 1.67 7.60 1.53 7.03 
P51148 Rab5C 23.61 5 2088.14 1.31 11.65 1.82 15.58 1.26 8.94 
P61026 Rab10 20.5 4 1897.135 1.29 8.14 2.15 12.47 1.15 8.29 
P20340 Rab6A 12.5 3 1544.131 1.40 3.08 2.31 5.45 1.40 9.61 
P61020 Rab5B 23.72 5 832.742 1.39 8.07 2.14 4.59 1.19 4.52 
P51149 Rab7A 57.49 11 541.48 1.36 12.36 1.97 31.62 1.26 17.66 
P20339 Rab5A 18.14 4 358.751 1.28   2.35   1.23   
P61019 Rab2A 18.4 4 294.4694 1.39 20.30 1.82 4.32 1.33 8.54 
P60953 cdc42 15.18 3 150.206 1.26 10.28 1.79 34.09 1.20 8.50 
Q9UL25 Rab21 8.89 2 59.19152 1.47 32.29 2.63 13.42 1.14 26.73 
Table 9: Proteins identified and quantified from Mevastatin-treated HEK293A S100 by iTRAQ labelling and subsequent quantification by proteome discoverer. Four 1 mg Mevastatin-
treated HEK293A S100 samples were prenylated with AzGGpp by recombinant REP-1 and RGGT. Samples were labelled via a click reaction with TAMRA-Yn-Biotin II capture reagent and affinity 
purified with magnetic streptavidin beads. Samples were run on a 10% Bis-Tris precast gel and gel bands were excised for each sample at the molecular weight of Rabs. Following trypsin 
digestion of the excised proteins into peptides, one of the iTRAQ reagents from 114-117 were added to the samples and the samples pooled. The combined samples were run on an LTQ-
Orbitrap Velos and proteins identified using Mascot and quantified using Proteome Discoverer software (Thermo Scientific). The samples were normalised to the known amount of BSA spiked 
into each sample at the trypsin digest step. Accession is the accession number of the protein, Coverage is the % of the protein sequence covered by the peptides detected, # peptides is the 
number of unique peptides used to calculate the protein ratios, Score is the mascot score for the protein i.e. how confident the identification is. Quantification is given as a ratio to the sample 
labelled with the 114 mass iTRAQ label and the % variability of the quantification of each ratio is also given. A Scaffold file containing data from these experiments and an excel file containing 
quantification data from Proteome discoverer are provided in the electronic supplementary information (Proteomics experiment 6 refers to the data in this table).      
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Figure 59: Graphical depiction of the ratios of the iTRAQ samples from Table 9.Shows all four samples submitted for 
iTRAQ quantification. The variability of each ratio is shown as a percentage of the ratio in the error bars. Where there is no 
% variability there were not enough unique peptides for that protein to generate data.10 ng refers to addition of 10ng 
recombinant Rab38 and 20 ng to addition of 20 ng Rab38. 
2.5.2 siRNA knockdown of endogenous protein as a method to probe protein function 
Short interfering RNA (siRNA, also called small interfering RNA or silencing RNA) is a commonly used 
tool in biology to interfere with the expression of a gene to stop the synthesis of a particular protein. 
siRNA interferes with gene expression through the RNA interference (RNAi) pathway; the general 
mechanism of siRNA action is shown in Figure 60. siRNAs are short segments of double-stranded 
RNA that are 20-25 nucleotides long;253 single-stranded siRNAs associate with RNA-induced silencing 
complexes (RISCs).254 The identities of the genes to be silenced are specified by the siRNA 
component when bound to RISC, and it recognizes target sequences by Watson-Crick base pairing; 
which means that siRNA gene silencing is readily reprogrammable and synthetic siRNAs may be used 
to silence a target gene of interest.253 There are of course caveats to using siRNA, such as possible 
off-target effects from the sequence chosen or difficulties in transfecting the siRNA into the cell. 
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Figure 60: Major steps on the biogenesis and mechanism of action of siRNAs: 1) siRNAs are incorporated into RISC and 2) 
unwinding of the dsRNAs requires ATP. Once unwound, 3) the single-stranded antisense strand of the siRNA guides RISC to 
target mRNAs with a complementary sequence and results in cleavage of the mRNA. Adapted from a figure in 
255
. 
siRNA treatment of cells is a commonly used method to knock down the expression level of a protein 
of interest and study the cellular effects. As discussed above, the difference between REP-1 and 
REP-2 prenylation poses interesting questions that the AzGGpp labelling technique has the potential 
to answer. Since no difference could be seen between Rabs identified by mass spectrometry-based 
proteomics in samples prenylated with recombinant REP-1 and those prenylated with recombinant 
REP-2, under the experimental conditions used, it was decided to use a siRNA-based approach to 
probe REP-1 and REP-2 prenylation. The overall strategy was to induce knockdown of both REP-1 
and REP-2 in HEK293A cells, maintain the knockdown for long enough to allow a pool of 
unprenylated Rabs to accumulate, and then prenylate the S100 fraction containing the unprenylated 
Rabs enzymatically, using AzGGpp. LC-MS/MS could then be used to identify the labelled proteins 
and so elucidate whether the REP isoforms have greater affinity for particular Rabs. However, the 
first step was knockdown of each REP protein; which proved a significant challenge, as discussed 
below. 
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2.5.2.1 siRNA knockdown of endogenous REP protein in HEK293A cells 
Pools of siRNA oligonucleotides (oligos) from Dharmacon (Dharmacon siGENOME SMARTpool®, 
Thermo Scientific) against REP-1 (CHM) and REP-2 (CHML) mRNA were purchased, the sequences of 
which are given in Table 10. The siGENOME SMARTpool® targets four mRNA sequences at once and 
was chosen as it should give a higher chance of knockdown than when a single siRNA sequence is 
used; the sequences were designed by Dharmacon. As a negative control a non-targeting siRNA oligo 
was used (On-target® Non-targeting siRNA #2, Thermo Scientific). Cells were transfected with each 
SMARTpool and allowed to grow for 48 hours; a further transfection was then carried out and the 
cells allowed to grow for a further two days. The cells were subsequently harvested and analysed to 
determine the degree of knockdown.  
REP-1/REP-2 siRNA SMARTpool siRNA SMARTpool Oligo Number Sequence 
REP-1 1 GCAAACAACUUACUAUGGU 
2 GAUUACCAUCCAACGUUU 
3 AGAAUGCGCUAGAAGUAAA 
4 UGUCAUAGGGAUUCGAUUU 
REP-2 1 GAAGGACACCUAUCUGGUA 
2 GCGACGAAAUGCCUGCAAA 
3 GAUGUUAGUCGUUAUGUAG 
4 UACAAUAGAUGGUCUUAAC 
Table 10: Table showing the 4 siRNA sequences in the siGENOME SMARTpool (Thermo Scientific) used to knockdown 
REP-1 and REP-2 expression in HEK293A cells 
Reverse transcription polymerase chain reaction (RT PCR) is a method to detect levels of mRNA in 
cells available to be translated into particular proteins.256 The mRNA from cell lysate is first extracted 
and then a reverse transcriptase is used to reverse transcribe the complementary DNA (cDNA) from 
the mRNA. Once the cDNA has been obtained then a normal PCR reaction is used to amplify the 
DNA, using primers specific to the DNA from the gene of interest.  Since RNAi results in mRNA 
degradation, RT PCR was chosen as the most appropriate method to assess knockdown efficacy by 
each siRNA pool.  
For RT PCR, first PCR primers specific to the REP-1 or REP-2 DNA sequence (ascertained by 
performing a Blast search) were designed and ordered from Invitrogen; the sequences for the 
forward and reverse primers are given in Table 11. Unfortunately it transpired that significant 
optimisation was required to see REP-1 or REP-2 PCR products on an agarose gel. The annealing 
temperature of the PCR reaction was varied and the buffers and MgCl2 solution needed for the PCR 
were also replaced with fresh stocks. Eventually DNA from the RT PCR could be detected, shown in 
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Figure 61. However the knockdown of either REP-1 or REP-2, using the conditions described above, 
did not appear to be successful. 
Primer Sequence 
REP1F2 ACCAGGAACTTTTGCTGTTCGGG 
REP1R2 CGAGTTAGCCTCTGGTATGGCACTG 
REP2F2 GCCAGAGGCTCCTGGAACCAATAATG 
REP2R2 TGTATGTTTCACTATTCGAACAGGCCG 
hRab5AF CATTGGGGCTGCTTTTCTAA 
hRab5AR AGGACTTGCTTGCCTCTGAA 
Table 11: Sequences for the primers ordered from Invitrogen for PCR of cDNA generated from REP-1 and REP-2 mRNA in 
cells with REP-1 or REP-2 siRNA knockdown. F = forward primer, R = reverse primer. 
 
Figure 61: Agarose gel of RT PCR to show REP-1 and REP-2 mRNA levels in HEK293A cells treated with REP-1 or REP-2 
siRNA SMART pools and Western blot of the same samples. A: PCR was carried out on cDNA generated by RT PCR of cell 
lysate of HEK293A cells treated with either REP-1 or REP-2 siRNA SMARTpools. Reverse transcriptase was omitted in 
controls to show genomic DNA was not being detected. Product size for REP-1 primers is 466, and for REP-2 primers is 536. 
hRab5A primers were used as a control for the PCR reaction, product size 217.B: Western blot of lysate from siRNA-treated 
cells used for the PCR, using antibodies specific for hREP-1 (2F1)
257
 and α-tubulin (loading control). 
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2.5.3 Testing available REP-2 antibodies for specificity 
The success, or otherwise, of REP-1 knockdown was visible by Western blot due to the availability of 
a specific antibody against human REP-1 (2F1, Figure 61). Antibody stocks were probed to see if they 
could be used to detect endogenous REP-2 specifically. Dot blots showed that one antibody was 
specific for recombinant REP-2 (Figure 62), however it could not detect endogenous REP-2 (not 
shown) so was of no use for determining the success of siRNA knockdown of REP-2.  
 
Figure 62: Dot blots to determine if any of the available antibodies were specific for REP-2 and a Western blot to 
demonstrate the specificity of one antibody. A: Dot blots comparing the various REP-2 antibodies available in the Seabra 
group. The amounts indicated of recombinant REP-1 and REP-2 were spotted onto nitrocellulose membrane and then 
incubated with the antibodies to see if they bound to the proteins. B: Western with antibody M192 showing specificity for 
recombinant REP-2 over recombinant REP-1 at the concentrations of recombinant protein indicated. 
The conditions for successful and large scale knockdown of both REP-1 and REP-2 proved elusive in 
the time frame available for this project but in the future could be revisited. However, a cell line with 
an inducible REP-1 knockout became available whilst the work described above was on-going; these 
cells were derived from the mouse model for the disease Choroideremia and hence were of 
considerable interest for this project; work on these cells is discussed in Chapter 4. 
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 AzGGpp as a substrate for GGT-1 2.6
In 2009 Alexandrov et al described a biotinylated GGpp analogue (biotinylgeranylpyrophosphate, 
BGPP, Figure 23) that could be used to identify prenylated proteins by affinity purification and mass 
spectrometric analysis following in vitro prenylation of samples with the analogue.135 As discussed, 
this work did not make use of click chemistry, instead the GGpp analogue already contained the 
Biotin moiety and thus proteins were labelled with the affinity tag directly in vitro.  The bulky Biotin 
group meant that whilst RGGT, with its larger active site, would accept the substrate (although with 
a significant reduction in affinity compared to GGpp, whilst AzGGpp appears comparable to GGpp as 
a substrate for RGGT from competition assays232), GGT-1 and FT had to be mutated in order to 
accept BGPP as a substrate and transfer geranylbiotin to proteins.135  
Recombinant GGT-1 was assayed to see if AzGGpp could act as its substrate because, like RGGT, 
GGT-1 uses GGpp as a substrate. The conditions employed for prenylation with GGT-1 were: 20 µM 
AzGGpp, 2 µM recombinant protein substrate, 1 µM GGT-1, prenylation buffer (as for RGGT) and 
10 µM ZnCl2. GGT-1 does not require REP-1 for prenylation but 10 µM ZnCl2 was added as the 
enzyme active site contains a Zn2+ ion required for enzyme activity; ZnCl2 is routinely added to GGT-1 
prenylation reaction mixtures in the literature.135 Recombinant protein substrates of GGT-1 and 
RGGT were tested for prenylation with AzGGpp by both enzymes. The recombinant proteins chosen 
were Rac1 and GST-RhoA, known substrates for GGT-140 that were readily available in the lab, and 
also Rab1A as it is a RGGT substrate that is not prenylated by GGT-1. Bioorthogonal ligation with 
TAMRA-Yn-Biotin I gave labelling of azide-tagged protein as previously described with labelled Rabs. 
GGT-1 was shown to prenylate the selected recombinant proteins in a specific manner; no capture 
was seen where GGpp was used as the GGT-1 prenyl substrate or where Rab1A was the GGT-1 
protein substrate. With RGGT prenylation a fluorescence band can only be seen where both AzGGpp 
and Rab1A were present in the sample. Thus the protein substrate specificity of wild type GGT-1 and 
RGGT is maintained with AzGGpp.232 Figure 63 demonstrates that AzGGpp is a prenyl substrate for 
both enzymes with recombinant proteins as the protein substrates.  
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Figure 63: AzGGpp is a substrate for GGT-1: In-gel fluorescence image of GGT-1/AzGGpp and RGGT/REP-1/AzGGpp labeling 
of recombinant Rac1, GST-RhoA and Rab1A.
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Following confirmation that AzGGpp was a substrate for wild type GGT-1, GGT-1 was used to 
prenylate proteins in Mevastatin-treated HEK293A S100 samples. As mentioned, some of the protein 
substrates of GGT-1 are small GTPases (like Rabs) but could be expected to show a different 
prenylation pattern on gels as GGT-1 protein substrates are of slightly lower average molecular 
weights; which proved to be the case (Figure 64). In addition, an affinity purification using magnetic 
streptavidin beads was attempted and achieved for GGT-1-prenylated Mevastatin-treated S100 
(Figure 64). Rab11 was not affinity purified following prenylation with GGT-1 as expected as it is not 
a substrate for the enzyme. The work in this section was published as part of 232. 
 
 
GGT-1 RGGT
Rac1 + - + -
GST-RhoA - + - - + -
Rab1a - + - +
GGpp + - + - + - + - + - + -
AzGGpp - + - + - + - + - + - +
30 -
20-
40 -
50 -
M
W
(D
a)
  
1
0
3
117 
 
 
Figure 64: In vitro prenylation of Mevastatin-treated HEK293A S100 by recombinant RGGT and GGT-1. A) In-gel 
visualization of azido-prenylation, capture and affinity purification of 25 µg Mevastatin- treated and untreated HEK293A 
cytosolic fractions showing prenylation with either RGGT or GGT-1. B) anti-Rab11 (mouse anti Rab 11, BD Transduction Labs 
# R56320) Western blot of gel A.
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That AzGGpp is a substrate for GGT-1 can also be seen from the proteomics experiments described 
in section 2.4.1. In addition to the Rab proteins some Rho and Rac proteins were detected and are 
shown in Table 12. It is possible that the detected GGT-1 substrate proteins have bound non-
specifically but also may have been prenylated with AzGGpp by any GGT-1 enzyme present in the 
S100.  
  # Unique peptides 
  DMSO 1 Mevastatin 1 DMSO 2 Mevastatin 2 Mevastatin 3 Mevastatin 3 
Protein  Accession Gel Gel Gel Gel Gel Beads 
RhoC P08134 4 3 1 4 0 0 
RhoA P61586 2 3 2 1 6 3 
Rac1 P63000 1 3 0 1 0 0 
Cdc42 P60953 1 2 1 2 6 3 
Rap1b P61224 0 5 0 3 0 0 
RhoG P84095 0 2 0 0 0 0 
Table 12: Table showing other geranylgeranylated Ras superfamily proteins detected in the proteomics experiments 
detailed in Table 4A.  All samples were prenylated with AzGGpp. There were no Ras superfamily proteins in the control 
(DMSO and GGpp) samples of proteomics experiment 3 and these are not displayed in the table. Scaffold files containing 
data from experiments shown in this table are provided in the electronic supplementary information (Proteomics 
experiments 1, 2 and 3 refer to the data in this table). 
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 Conclusions 2.7
The work described in this chapter focused on the development of a model system of Mevastatin-
treated HEK293A cells to develop the azide-tagging of unprenylated proteins in cell lysate and 
optimise the conditions for the click reaction of the azide tag with a TAMRA-alkyne-Biotin label. The 
suitability of a trifunctional alkyne capture reagent with both biotin and TAMRA labels over that of a 
bifunctional reagent with just a biotin moiety was also demonstrated using recombinant Rab1A.  
Conditions for Mevastatin treatment of HEK293A cells were developed and used to provide samples 
containing unprenylated Rabs. The optimisation of conditions for all stages of in vitro prenylation, 
bioorthogonal ligation and affinity purification of unprenylated proteins was demonstrated. 
Conditions for successful identification of Rab proteins from Mevastatin-treated samples by mass 
spectrometry based proteomics were developed and optimised. The technique of iTRAQ 
quantification of protein levels between samples was assayed for its applicability for protein 
identification from AzGG-tagged samples. It was possible to identify and quantify Rabs using the 
iTRAQ technique although the importance of extreme care in sample preparation was highlighted, as 
well as the need for suitable internal controls. 
Once the stages of protein labelling and identification were optimised it was possible to investigate 
prenylation of samples with both recombinant REP-1 and REP-2. No significant results were gained 
from the system used but it could prove useful for future work that builds on this project. 
Unfortunately, attempts at siRNA knockdown of endogenous REP-1 and REP-2 gene products via 
siRNA proved unsuccessful in the timeframe of this project. However the work should certainly be 
revisited as it could facilitate elucidation of REP-1 and REP-2 specific Rab substrates. 
AzGGpp was demonstrated to be a substrate for the prenyltransferase GGT-1 as well as for RGGT, an 
important result as work by other groups had resorted to mutating the enzyme active site in order 
for it to accept a GGpp substrate analogue. Both recombinant protein substrates and those from cell 
lysate could be labelled specifically with AzGGpp by GGT-1. 
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 Developing and optimising the labelling, detection Chapter 3
and identification of unprenylated Rab proteins in 
mouse disease model samples 
This chapter discusses the labelling of samples from mouse models for Choroideremia and for 
Hermansky-Pudlak syndrome (gunmetal (gm/gm) mice), both of which have prenylation 
deficiencies. Initial labelling experiments and affinity purifications used the in vitro prenylation and 
bioorthogonal ligation methodology optimised for labelling of Mevastatin-treated HEK293A cell 
samples in Chapter 2. The difficulties that arose from attempts to label unprenylated Rab proteins in 
more complex systems and the subsequent optimisation required are discussed here. Interesting 
data also arose from mass spectrometry-based proteomics and are included in this chapter. 
 A conditional knock-out mouse model for Choroideremia and the 3.1
gunmetal mouse 
Two mouse models with defects in their prenylation machinery were available for study; these were 
models for the disease Choroideremia and for Hermansky-Pudlak syndrome (the gunmetal mouse). 
The mice have reduced prenylation of Rab proteins, and in the gunmetal mouse this is because the 
activity of RGGT is reduced to 25%.102 In the Choroideremia (CHM) mouse model there is a knock-out 
of the gene encoding REP-1 so that the mouse does not express REP-1 and prenylation is then only 
carried out by REP-2, as in the human Choroideremia disease. Knock-out of the mouse REP-1 protein 
is embryonically lethal due to defective trophoblast development and vascularisation;121, 258 thus 
Seabra et al. used the Cre/loxP system to create genetically modified mice with conditional knock-
out, whereby REP-1 would be knocked out when the mice were injected with the drug Tamoxifen 
(TM).109 The gunmetal mouse is discussed in Chapter 1 (section 1.2.7.1) and the available CHM 
mouse models are briefly mentioned in Chapter 1 section 1.2.7.4 while the Cre/loxP system is 
explained in further detail below. 
In the Cre/loxP  system the target gene sequence to be deleted is flanked by loxP sites which are 
sensitive to the enzyme Cre recombinase; this enzyme catalyses DNA recombination between loxP 
sites so that when two loxP sites are in the same orientation both the target DNA sequence and a 
loxP site are excised (Figure 65). Sequences flanked by loxP sites are said to be ‘floxed’.259 Both the 
Cre and the loxP sites originally come from the P1 bacteriophage;260 for knock-out of the gene of 
interest to occur, the mice will need to express the Cre enzyme as well as having a floxed gene of 
interest.  
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Figure 65: Cre-mediated DNA recombination. Left: A DNA segment flanked by two loxP sites (white triangles) is excised by 
Cre as a covalently closed circular molecule. DNA recombination is conservative; there is no loss or gain of nucleotides 
during the reaction. Right: The loxP site is 34 bp in size and composed of two 13 bp inverted repeat elements, to which Cre 
binds, surrounding a central 8 bp core region where breaking and re-joining of DNA occurs. Adapted from a figure in the 
review by Sauer 
261
. 
In the case of the mouse model for CHM, ChmFlox/Y (male) or ChmFlox/Flox (female) mice carry the 
ChmFlox allele (that has loxP sites either side of exon 4 of the Chm/Rep-1 gene) and express Cre as a 
fusion protein with 2 copies of a TM-responsive murine estrogen receptor (Mer, the fusion protein is 
known as MerCreMer (MCM)).109, 261, 262 The CMV enhanced chicken β-actin promoter pCAGGS 
controlling the MerCreMer protein expression is ubiquitous, thus REP-1 is expected to be knocked 
out throughout the animal when it is injected with TM subcutaneously.109  The MCM protein is 
normally located in the cytoplasm due to binding of Mer to HSP90 (heat shock protein 90) but when 
TM binds to the Mer it causes translocation of the MCM protein to the nucleus, where it can then 
catalyse recombination of the DNA between the loxP sites and hence knock-out of REP-1 (Figure 66). 
Thus, injection of ChmFlox mice that express Cre (ChmFlox MCM+) with TM induces REP-1 knock-out by 
deleting exon 4, which leads to a frameshift mutation and the appearance of a premature stop 
codon.109 The Flox allele is as the wild type, but with loxP sites either side of exon 4 so the ChmFlox 
MCM+ mouse (uninjected) is a control for the ChmFlox MCM+ TM+ mouse; as is the ChmFlox mouse with 
no Cre expression. Additionally, female mice that are heterozygous-Null carriers (ChmNull/wt) have a 
knock-out of REP-1 in approximately 50% of cells. The mice used in this study were either ChmFlox 
wild type-like controls (referred to here as Flox mice), ChmNull/wt female heterozygous carriers 
(referred to here as Null/wt mice) or TM-treated ChmFlox MCM+ (referred to here as CHM mice). 
+
A B C
A C B
loxP loxP
loxP
Cre 5’ ATAACTTCGTATA ATGTATGC TATACGAAGTTAT 3’
3’ TATTGAAGCATAT TACATACG ATATGCTTCAATA 5’
34 bp loxP site
loxP
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Figure 66: Generation of mice carrying the knock-out CHM alleles. Tamoxifen treatment of the MCM
+
 Chm
Flox
 mouse 
causes Cre-mediated recombination between the loxP sites within the Chm
Flox
 allele and results in CHM mice (Chm
Flox 
MCM
+
 
TM
+
).
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Figure 67A demonstrates that the CHM mice have no REP-1 protein in the stomach and spleen after 
TM injection. The molecular weight difference between mouse REP-1 and REP-2 is greater than 
between the human proteins and thus they can be visualised by Western blot as their bands are 
distinct. Null/wt mice are female carriers of CHM so have 50% of their REP-1 protein missing, which 
results in reduced REP-1 levels by Western blot. The antibody J905 is specific to REP protein and thus 
can detect REP-1 and REP-2 levels, it can be seen that there is no difference in the levels of REP-2 
between the samples and it is only REP-1 that is affected by the TM treatment or Null/wt genotype. 
After the initial injection of the mice with TM they were assessed for the REP-1 knock-out by using 
PCR with primers specific to the ChmFlox and ChmNull (exon 4 deleted) alleles by Dr T. Tolmachova, 
Imperial College; PCR of Flox, CHM and Null/wt mice used in this thesis are shown in Figure 67B.  
Exon 4
loxP loxP
ChmFlox MCM+
loxP
ChmFlox MCM+ TM+
TM-induced
Cre recombination
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Figure 67: Western blot and PCR to show REP-1 knock-out in CHM mouse models. A: Stomach and spleen PNS from TM 
MCM
+
 Chm
Null
 (CHM) male mice which have an induced REP-1 knock-out, Chm
Null/wt
 female carrier mice which have a 50% 
knock-out of REP-1 and MCM
+
 Chm
Flox
 mice without induced REP-1 knock-out (control). 50 µg PNS was loaded on the gel, 
proteins were transferred to a PVDF membrane and blotted with J905 antibody (specific to REP protein) and anti α-tubulin 
antibody (Sigma Aldrich, loading control). Recombinant REP-1 protein (50 ng) was loaded as a control to show the position 
of REP-1 on the gel. B: Results of PCR reaction with H7/H9 primers (to show Chm
Flox
, Chm
WT
 and Chm
null
 alleles) or tail 
sections from Chm
Flox
 MCM
+
 TM
+
 (lanes 1 and 2), Chm
Flox
 (Lanes 3 and 4) and Chm
Null/wt
 mice (Lanes 5 and 6). PCR and 
separating samples on agarose gel was carried out by Dr T. Tolmachova, Imperial College. 
Mouse strain Flox N/w CHM Flox N/w CHM -
Tissue Stomach Spleen -
REP-1 50 ng - +
Lane 1 2 3 4 5 6 7
- REP-1
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ChmFlox
ChmWT
Mouse strain CHM Flox N/w
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100 bp
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1000 -
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 Labelling of unprenylated Rabs in lysate from tissue of gunmetal and 3.2
CHM mouse models 
Optimisation of the conditions for labelling the unprenylated Rab proteins in S100 from Mevastatin-
treated HEK293A cells was discussed in Chapter 2. Optimisation was required in that case because 
the conditions that were adequate for recombinant Rab proteins were not as successful when 
translated to cell lysate. The same was true for the application of cell lysate labelling conditions to 
labelling samples from CHM and gunmetal mouse models. The initial conditions for the labelling of 
unprenylated Rabs from gunmetal and CHM mouse models are described below and subsequent 
sections of this chapter describe the difficulties experienced with labelling and its optimisation. 
Samples from mouse models were prepared by thawing frozen organ tissue taken from mice that 
had been perfused with PBS and the organs snap-frozen in liquid nitrogen. A volume of lysis buffer 
three times the mass of the tissue was added to each sample e.g. stomach tissue that weighed 0.3 g 
would have 0.9 ml lysis buffer added to it. Samples were lysed by disruption with a Polytron 
homogenizer on ice and then centrifuged at 800 × g and 4 °C for 5 minutes to remove cell debris and 
yield the post nuclear supernatant (PNS). The PNS was subjected to ultracentrifugation at 
100,000 × g for one hour to give subcellular fractionation; as with HEK293A cell samples, the 
supernatant is termed the S100 and contains the cytosolic proteins, which should include 
unprenylated Rab proteins. In vitro prenylation of the S100 was carried out exactly as for HEK293A 
S100 samples, using 20 µM AzGGpp, 1 µM RGGT and 1 µM REP-1, for 40 minutes at 37 °C. The click 
capture reaction conditions used were the same as those optimised in Chapter 2: 50 µM TAMRA-Yn-
Biotin I or II, 1 mM CuSO4, 100 µM TBTA and 10 mM ascorbate premixed together to give a click 
reaction premix that was then added to the prenylation reaction mixture in a volume ratio of 1.5:1 
of click reaction premix to prenylation reaction mixture. Following capture, samples were 
precipitated using the CHCl3/MeOH method and resuspended in a buffer containing detergent to 
allow affinity purification by magnetic streptavidin beads and/or gel electrophoresis to visualise 
labelling by in-gel fluorescence. The initial workflow for labelling Rabs in mouse samples using the 
optimised conditions described in Chapter 2 is shown in Figure 68. The optimisation of HEK293A 
labelling was not entirely complete before labelling of S100 from mouse samples commenced, when 
the conditions differ from those given in Figure 68 it is indicated in the description of the 
experiment. The increased complexity of the samples from mouse model organs required extra 
optimisation of labelling, which is discussed below. 
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Figure 68: Overview of in vitro prenylation and labelling of mouse organ samples. Mouse organ e.g. stomach from mouse 
perfused with PBS has lysis buffer added to it in an Eppendorf. The cells are lysed using a Polytron homogenizer on ice and 
are subjected to ultracentrifugation at 100,000 × g to give S100 (cytosolic) and P100 (membrane) fractions. S100 fraction is 
prenylated in vitro with AzGGpp by recombinant RGGT and REP-1 for 40 minutes at 37 °C. Samples are then labelled via the 
click capture reaction by the TAMRA-Yn-Biotin II capture reagent for 1 hour at r.t. Following capture, samples are 
precipitated using the CHCl3/MeOH method and then resuspended in resuspension buffer before affinity purification using 
magnetic streptavidin beads. Following affinity purification samples are separated by molecular weight using 
polyacrylamide gel electrophoresis and visualised by in-gel fluorescence using an Ettan DIGE imager. 
Figure 69 demonstrates the initial labelling of unprenylated Rab proteins in tissue S100 from the 
CHM and the gunmetal (gm/gm) mouse compared to wild type (wt) and Flox mouse controls.232 
Strong fluorescent bands can be seen at the molecular weight of Rab proteins (around 23 kDa) in the 
lanes showing labelled S100 from gunmetal and CHM mice and not in those from samples from 
control mice, which have no prenylation deficiency and so no Rabs accumulate unprenylated in the 
cytosol. Furthermore, the labelling pattern seen from in vitro prenylation with AzGGpp and 
subsequent bioorthogonal ligation with TAMRA-Yn-Biotin I was very similar to that seen when 
samples from these mouse models were radiolabelled with 3[H]GGpp and the signal from the tritium 
detected (carried out by Dr T. Tolmachova). The samples were labelled before the majority of the 
optimisation of HEK293A sample labelling had been carried out; meaning that bioorthogonal ligation 
with the alkyne was for only 20 minutes, they were precipitated overnight at -80 °C with MeOH and 
the resuspension buffer was 0.2% SDS and 50 mM Tris.  
S100 In vitro prenylation for 
40 minutes at 37 °C
20 µM AzGGpp, 1 µM 
RGGT, 1 µM REP-1 
50 µM TAMRA-Yn-Biotin, 1 mM CuSO4, 
10 mM ascorbate, 100 µM TBTA ligand 
Click capture reaction, 
60 minutes at r.t.
1. CHCl3/MeOH precipitation
Affinity purification of 
labelled proteins
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streptavidin 
beads
Beads resuspended in 
sample loading buffer
Gel electrophoresis
2. Resuspension with 0.2% SDS/0.3% NP-
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Figure 69: Fluorescently-labelled proteins show a similar pattern of labelling to those labelled with 
3
[H]GGpp. Left: In-gel 
fluorescence detection of labelled Rabs from 50 µg gunmetal (gm) mouse lung and stomach tissue S100 and 20 µg TM-
treated Chm
Flox
 MCM
+
 (CHM) Choroideremia mouse model stomach tissue S100. C57BL/6J mice (wt) and Chm
Flox
 mice (Flox) 
were used as a Rab prenylation-competent control. Right: Lysate prenylated in vitro with 
3
[H]GGpp (carried out by Dr T 
Tolmachova, Imperial College).
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3.2.1 Affinity purification of labelled proteins from mouse S100 samples 
As with the Mevastatin-treated HEK293A cell samples described in Chapter 2, the purpose of 
labelling the unprenylated Rabs from mouse disease models was to allow enrichment of these Rabs 
by affinity purification and so facilitate their identification using LC-MS/MS. Figure 70 demonstrates 
effective affinity purification of biotin-labelled proteins from the gunmetal and CHM mouse samples 
with streptavidin beads was possible, even though the conditions used in both cases were not the 
final optimised ones described in Chapter 2. For these samples the capture reaction was left for only 
20 minutes (as opposed to the optimised 60 minutes); 100 µg S100 was subjected to in vitro 
prenylation with AzGGpp and capture with TAMRA-Yn-Biotin II followed by precipitation with 
CHCl3/MeOH, resuspension in prenylation buffer (again not optimised conditions) and affinity 
purification with magnetic streptavidin beads. There is a strong fluorescence signal above 
background at the molecular weight of Rabs for both the CHM and gunmetal stomach samples and 
not in the controls. The fluorescence signal from labelled proteins was then successfully eluted from 
the streptavidin beads following the affinity purification step and can be seen in the lane of the gels 
where the beads were run. This was very encouraging as it suggested that it could be possible to 
isolate unprenylated Rab proteins to identify them and thus obtain more information on the Rabs 
affected in Choroideremia. However, as discussed in following sections of this chapter, labelling of 
tissue samples was not always facile and optimisation of the protocols for sample labelling was 
subsequently required. 
In-gel fluorescence 3[H]GGpp
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Figure 70: In-gel fluorescence scans showing affinity purification with magnetic streptavidin beads of TAMRA-Biotin-
labelled S100 from Choroideremia and gunmetal mouse models and control mice. Left: 100 µg S100 from Chm
Flox
 (Flox) 
control mouse stomach or Chm
Flox
, MCM
+
, TM
+
 (CHM) mouse stomach was subjected to in vitro prenylation with AzGGpp, 
20 minutes capture with TAMRA-Yn-Biotin II and precipitation with MeOH, followed by affinity purification with magnetic 
streptavidin beads. Right: 100 µg S100 from either wild type or gunmetal (gm/gm) mouse stomach was subjected to in vitro 
prenylation with AzGGpp, 20 minutes capture with TAMRA-Yn-Biotin II and precipitation with MeOH,  followed by affinity 
purification with magnetic streptavidin beads. In both A and B samples were run on a 12% Bis-Tris gel with MES SDS 
running buffer and scanned with an Ettan DIGE imager. 
Typically, experiments with S100 from mouse tissue used approximately double the amount of total 
protein of S100 as used with experiments with HEK293A S100 i.e. if 25 µg labelled S100 was run in a 
gel lane for HEK293A samples then 50 µg was used for labelled S100 from mouse samples. The 
difference was chosen because the in-gel fluorescence signal from labelled proteins in cell culture 
samples was much clearer with lower fluorescence background than the mouse samples, making it 
much easier to see. Furthermore, the reduced complexity of the cell culture S100 samples compared 
to the mouse organ S100 samples means that they have fewer components, such as extracellular 
matrix, which could interfere with protein labelling. 
 Optimisation of labelling of unprenylated Rab proteins in samples 3.3
from mouse models of prenylation deficiency 
3.3.1 Problems experienced with protein labelling 
As seen above, there was some initial success with labelling Rab proteins in samples from mouse 
disease models; however, labelling was not visible on every occasion it was attempted. Frequently 
the background fluorescence signal was so high that specific labelling could not be seen by in-gel 
fluorescence; an example of labelling not working despite using the optimised conditions from 
Chapter 2 is shown in Figure 71. All of the optimised conditions from Chapter 2 were used in this 
case but there was no labelling seen despite several repeat attempts. Both stomach and spleen S100 
samples were used and, as seen above in Figure 70, labelling of stomach samples at least had 
previously been successful.  
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Figure 71: Labelling tissue-derived samples was not always successful. 50 µg S100 from the mice and tissues indicated 
were prenylated with AzGGpp followed by capture with TAMRA-Yn-Biotin II reagent, protein precipitation and resuspension 
under the conditions optimised in Chapter 2.Samples were run on a 12% Bis-Tris gel with MES SDS running buffer, imaged 
using an Ettan DIGE imager (GE Healthcare)(top) and stained with colloidal Coomassie (bottom). 
There are several potential reasons why the labelling was unsuccessful: it could be that the samples 
from mouse models degraded faster than samples from cell culture due to the presence of more 
proteases and other components of extracellular matrix so the Rabs were either not folded properly 
or had been broken down and so could not be labelled with AzGGpp during the in vitro prenylation 
step; degradation of the sample could also lead to protein aggregation so that even if the proteins 
were labelled they may not have resuspended properly after precipitation and/or could not enter 
the gel; or some component of mouse tissue lysate could either react with the capture reagent or 
itself cause a high background fluorescence signal. Hence the requirement for optimisation of the 
labelling conditions to give more consistency in the results, described in subsequent sections of this 
chapter. 
3.3.2 Testing the effects of increased amounts of protease inhibitor on the stages of 
bioorthogonal ligation and affinity purification of unprenylated Rab proteins 
One reason for the poor labelling seen with the mouse organ S100 was thought to be because the 
mouse samples were degrading faster than cell culture samples, possibly because they were likely to 
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be more proteolytically active due to their greater complexity. Therefore, it was decided to add 
protease inhibitors (EDTA-free protease inhibitor cocktail, Roche) to the prenylation and affinity 
purification steps. In order to first confirm that the in vitro prenylation and click capture steps in 
particular would not be affected by the addition of extra protease inhibitors, it was tested on the 
labelling and affinity purification of Mevastatin-treated HEK293A S100. Aliquots of 25 µg Mevastatin-
treated HEK293A S100 were prenylated and captured using the optimised protocol from Chapter 2; 
additional EDTA-free protease inhibitor was added to each step as indicated in Figure 72. Mouse 
tissue S100 samples were not used for the testing of the protease inhibitors as, at this point, 
labelling was not reliable in tissue samples and thus any inhibitory effects on protein labelling from 
the addition of protease inhibitors would have been difficult to see. 
In Figure 72  it can be seen that there were no apparent negative effects of adding extra protease 
inhibitor to the samples at any stage of the labelling process. From this information, it was decided 
to add protease inhibitor at the start of the labelling process in the in vitro prenylation step and at 
the end of the process, during the affinity purification step. During in vitro prenylation the reaction 
mix is warmed to 37 °C and is likely to be an optimum temperature for any proteases present in the 
sample, increasing the rate of protein degradation. The affinity purification step lasts for two hours 
so protease inhibitor would prevent any further degradation of the sample over this time period. 
 
Figure 72: In-gel fluorescence scan showing the effect on fluorescence signal of adding extra protease inhibitors to 
different stages of the protein-labelling and affinity purification process. 50 µg Mevastatin-treated HEK293A S100 was 
prenylated in vitro and captured using optimised conditions and half of the labelled sample (25 µg) was subjected to affinity 
purification. 25 µg DMSO-treated HEK293A S100 was also prenylated and captured (Lane 1). Protease inhibitors (cOmplete 
EDTA-free, Roche) were added to the prenylation, bioorthogonal ligation (capture) and affinity purification steps for 
Mevastatin-treated samples as indicated in the figure. The samples were run on a 12% Bis-Tris gel with MES SDS running 
buffer, imaged with an Ettan DIGE imager (GE Healthcare) and stained with colloidal Coomassie to show protein labelling. E 
= sample eluted from beads, S= supernatant, B= beads following sample elution. 
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3.3.3 Probing the effects of additional reduction and alkylation steps in the bioorthogonal 
ligation technique on background fluorescence signal   
The Overkleeft group reports using reduction and alkylation steps to prevent cross-coupling 
between cysteine residues that can lead to protein aggregation and poor results for affinity 
purification of biotin-labelled samples.263 To test whether these extra steps could improve results for 
bioorthogonal ligation and affinity purification of samples from CHM and gunmetal mice, the 
conditions were applied for both Mevastatin-treated HEK293A S100 and CHM mouse lung S100 
(Figure 73). Using Mevastatin-treated HEK293A lysate gave a positive control for Rab protein 
labelling, since tissue labelling had been unreliable to this point. Briefly, 120 µg HEK293A S100 and 
300 µg CHM mouse lung S100 were prenylated with AzGGpp using standard conditions. Samples 
were then treated in three different ways: neither reduced nor alkylated (control) and reduced and 
alkylated after either the in vitro prenylation or capture reaction step (as indicated in Figure 73).  
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Figure 73: The effects of reduction and alkylation of labelled samples before capture and before affinity purification. 
120 µg HEK293A S100 and 300 µg CHM mouse lung S100 were prenylated with AzGGpp using optimised conditions. 40 µg 
or 100 µg S100 respectively was then subjected to either no reduction and alkylation or reduction and alkylation after either 
prenylation or capture as indicated. Half of each sample was then affinity purified using magnetic streptavidin beads and 
the other half retained to run on the gel. Samples were eluted from the beads by heating to 95 °C for 5 minutes and then 
run on a 12% Bis-Tris gel, along with the before pull-down samples and the supernatant (supernatant loaded was 
approximately half the amount of eluted and before sample). Gels were imaged using an Ettan DIGE imager and the gels 
stained with colloidal Coomassie to show protein loading. 
For the reduction/alkylation steps, samples were handled as follows: CHCl3/MeOH precipitation of 
the sample (after the appropriate step, prenylation or capture, as indicated in the figure) and MeOH 
wash of the pellet; followed by rehydration of the pellet in a urea buffer of 180 µl 8 M Urea/100 mM 
ammonium bicarbonate for 15 minutes at room temperature; 10 µl 90 mM DTT was added to the 
sample in the urea buffer and incubated at 37 °C for 30 minutes; 15 µl 100 mM iodoacetamide was 
added and the samples incubated for 30 minutes in the dark at room temperature; finally, samples 
were precipitated again and resuspended using resuspension buffer. Following resuspension for the 
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final time, following either the capture step or reduction and alkylation, samples were affinity 
purified with magnetic streptavidin beads. After washing the beads five times with 0.2% SDS in PBS 
the samples were eluted into SDS sample loading buffer (NuPage sample loading buffer, Invitrogen) 
by heating for 5 minutes at 95 °C and samples were run on a 12% Bis-Tris gel for analysis by in-gel 
fluorescence. 
The extra reduction and alkylation steps did not appear to improve protein labelling consistently. 
The fluorescence signal for labelled protein in the HEK293A sample appeared stronger when 
reduction and alkylation was carried out after the prenylation step; however, for the tissue samples 
the signal was clearest with no reduction and alkylation. Additionally, carrying out reduction and 
alkylation added up to three further precipitation steps to the protocol, giving a greatly increased 
chance of protein loss; and, furthermore, the extra steps significantly increased the amount of time 
taken to label samples (by several hours). The disadvantages outweighed the benefits and 
consequently the reduction and alkylation steps were not included in the sample labelling protocol. 
3.3.4 Adding a sample precipitation step after in vitro prenylation to improve labelling of 
unprenylated Rab proteins in mouse S100 samples  
The problems with protein labelling encountered with mouse tissue S100 seemed to indicate that 
some component of the lysate was interfering with the bioorthogonal ligation or increasing the rate 
of sample degradation, leading to the addition of extra protease inhibitors to the samples. However, 
the labelling was still not optimised and still gave results such as seen in Figure 71. Thus it was 
proposed that precipitation of the sample after the in vitro prenylation step could improve protein 
labelling by removing some of those components of the S100 that may be interfering with the 
labelling reaction. In addition, Tris was removed from the click reaction buffer to probe whether the 
amine groups of the Tris were interfering to some extent with the click reaction. To assay these 
different conditions, 20 µg S100 from Mevastatin-treated HEK293A cells (control for the prenylation 
and capture reactions), 50 µg CHM mouse lung and 50 µg Flox mouse lung (control) were prenylated 
with AzGGpp in vitro and either precipitated with CHCl3/MeOH and captured (in either a PBS or 
50 mM Tris buffer) or captured directly after prenylation, without first precipitating. All samples 
were precipitated after capture, resuspended with resuspension buffer and run on a 12% Bis-Tris 
polyacrylamide gel (shown in Figure 74).  
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Figure 74: The effects of sample precipitation after prenylation and capture in Tris or PBS buffer. In-gel fluorescence scan 
and colloidal Coomassie stain of gel to show protein loading. 50 µg CHM or Flox mouse lung S100 prenylated with AzGGpp, 
samples were precipitated after prenylation or not as indicated with CHCl3/MeOH. Samples in lanes 3 and 4 were 
resuspended in 20 µl 30 mM Tris/2% SDS and samples in lanes 5-8 were resuspended in 20 µl PBS/2% SDS. The TAMRA-Yn-
Biotin II capture reagent was in from the standard  stock in lanes 1-4 and 9 (125 µM alkyne in 50 mM Tris and 0.4% SDS) in 
lanes 5 and 6 the alkyne was in a 125 µM stock in PBS/0.4% SDS and in lanes 7 and 8 the alkyne stock was 10 mM in DMSO. 
During the capture reaction all samples were in a final volume of 50 µl (1 mg/ml) and either 10 mM ascorbate or 1 mM 
TCEP was used as the reducing agent. Following the click capture reaction, samples were precipitated with CHCl3/MeOH 
and resuspended in resuspension buffer. Samples were run on a 12% Bis-Tris gel with MES SDS running buffer and imaged 
with an Ettan DIGE imager before staining with colloidal Coomassie. The labelling in lanes 3-4 and 7-8 could not be seen 
without adjusting the contrast as the labelling in the other lanes had such high background as to eclipse it otherwise. 
From Figure 74 it did not appear that changing the buffer for the click reaction from Tris to PBS 
improved the fluorescence signal so the Tris buffer was retained. With PBS in the buffer for the click 
reaction, ascorbate and TCEP as the reducing agents for the reaction were compared as previously 
described for HEK293A sample reactions with Tris in the buffer and as described in the next section 
for mouse tissue S100 capture reactions containing Tris buffer. Neither condition resulted in a good 
signal over background for the in-gel fluorescence scan. It should be noted that the conditions used 
in lanes 1,2,5,6 and 9 of the gel shown in Figure 74 resulted in a much higher background signal than 
those used in lanes 3, 4, 7 and 8 and, due to the auto-contrasting that occurs with the imaging 
software used to view in-gel fluorescence scans (ImageQuant™ TL, GE Healthcare), the contrast had 
to be adjusted in the latter lanes in order to see any signal at all. However, once the contrast had 
been adjusted, precipitating the samples after prenylation seemed to give more promising results 
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with lower fluorescence background and increased signal intensity of CHM over Flox samples (seen 
in lanes 3, 4, 7 and 8). Thus precipitating after prenylation was repeated and is discussed below. 
From the in-gel fluorescence image shown in Figure 74, precipitating the mouse S100 samples after 
prenylation seemed a promising way of improving the fluorescence signal of labelled Rab proteins 
over background noise. To further probe whether it was indeed worthwhile to add an extra step to 
the labelling protocol, lung S100 from several different mouse models was labelled by in vitro 
prenylation and click capture with a CHCl3/MeOH sample precipitation step included after either just 
the capture or after both the prenylation and capture steps. Samples precipitated after prenylation 
were resuspended in prenylation buffer with 2% SDS added and 2% SDS was added to all samples 
not precipitated after prenylation in order to give the same capture conditions for all samples. Figure 
75 illustrates the reduction in background signal achieved when tissue samples were precipitated 
after prenylation in addition to precipitation after capture. The reason for the reduced background 
may be because the precipitation step removes components of the S100 that interfere with the click 
reaction or result in increased degradation of the sample. Precipitation after prenylation seemed to 
achieve clearer labelling of samples from mice and consequently precipitation was adopted after the 
prenylation step as well as after the capture step for all future experiments with mouse S100 
samples. 
 
Figure 75: The effect of sample precipitation after capture. In-gel fluorescence scan and colloidal Coomassie stain of gel 
containing 50 µg mouse lung S100 samples (or 20 µg Mevastatin-treated HEK293A cell S100) prenylated with AzGGpp, 
precipitated or not with CHCl3/MeOH, as indicated, captured with TAMRA-Yn-Biotin II under optimised conditions, 
precipitated again after capture and resuspended in resuspension buffer. Samples were prenylated together and half was 
precipitated and half not. Flox and +/gm are negative controls whilst Mevastatin-treated HEK293A S100 was a positive 
control for labelling and capture. Samples were run on a 12% Bis-Tris gel with MES SDS running buffer, imaged on an Ettan 
DIGE imager and stained with colloidal Coomassie to show protein loading. 
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3.3.5 Further affinity purification of mouse lung samples 
Before optimisation of affinity purification conditions, elution of labelled Rabs from streptavidin 
beads was frequently inefficient with only approximately 10% of the sample appearing to elute from 
the beads when visualised by in-gel fluorescence (although it was not always unsuccessful, as seen in 
Figure 70). As with the HEK293A samples, it was suspected that protein aggregation was preventing 
the labelled proteins from entering the gel. Once the optimised conditions from Chapter 2, (i.e. 
addition of extra protease inhibitors and sample precipitation after prenylation) were added to the 
protocol for labelling of unprenylated Rabs in mouse S100 samples, it was also possible to 
demonstrate affinity purification of Rab proteins by in-gel fluorescence and Western blot. Figure 76 
shows affinity purification of samples from Flox (control), gunmetal or CHM mouse stomach S100. 
Briefly, 100 µg of the respective mouse stomach S100 was subjected to in vitro prenylation with 
AzGGpp as previously described, precipitated after prenylation and captured using optimised 
conditions. Samples were then precipitated again, using the CHCl3/MeOH protein precipitation 
protocol, and resuspended in resuspension buffer. Once resuspended, half of the samples 
(approximately 50 µg total S100 protein) were affinity purified using magnetic streptavidin beads. 
Samples were then run on a gel and the protein labelling was assessed by in-gel fluorescence and 
Western blotting for Rab27A using the specific antibody 4B12. This way it was possible to 
demonstrate that not only could affinity purification be seen by in-gel fluorescence but affinity 
purification of specific Rab proteins could also be seen. Rab27A was chosen because it has already 
been shown to be under-prenylated in CHM and gunmetal mice.115 
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Figure 76: In-gel fluorescence scan and Western blot showing affinity purification with magnetic streptavidin beads of 
TAMRA-Biotin-labelled Rabs from stomach S100 of Choroideremia mouse model and control mouse. 100 µg Flox 
(control), CHM or gm/gm mouse stomach S100 was subjected to in vitro prenylation with AzGGpp, followed by 
precipitation, resuspension and then capture with Yn-TAMRA-Biotin II; samples were then precipitated again, resuspended 
and affinity purified with magnetic streptavidin beads. Samples were run on a 12% Bis-Tris gel with MES SDS running buffer 
and imaged using an Ettan DIGE imager. Gels were subjected to Western blotting and probed with antibodies for α-tubulin 
(loading control) and Rab27A (4B12). 
3.3.6 Investigating whether changing the reducing agent for the click capture reaction 
could improve sample labelling 
In order to confirm that there was no additional improvement in protein labelling seen when using 
TCEP as the reducing agent for the click reaction instead of ascorbate, a comparison of the two was 
made, as had been done for Mevastatin-treated HEK293A S100 sample labelling. Figure 77 shows 
the comparison between TCEP and ascorbate in the click reaction for labelling of various mouse lung 
S100 samples prenylated in vitro with AzGGpp; similar results were seen for spleen S100 (not 
shown). 50 µg S100 from CHM, gunmetal (gm/gm), Flox (negative control for CHM), +/gm (negative 
control for gm/gm) mouse lung and 20 µg HEK293A (positive control for Rab labelling) were 
prenylated in vitro with AzGGpp followed by click capture at 1 mg/ml concentration of S100 (the 
conditions used with TCEP for bioorthogonal ligation of metabolically labelled samples in the 
standard protocol used by other members of the Tate group for click reactions with TCEP as the 
reducing agent) with TAMRA-Yn-Biotin II and either 10 mM ascorbate or 1 mM TCEP as the reducing 
agent for the copper catalyst. Samples were also precipitated after both prenylation and capture, as 
in the previous section. The in-gel fluorescence scan shown in Figure 77 indicates that ascorbate is 
still the more suitable reducing agent under the conditions used. 
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Figure 77: The effects on labelling in mouse samples of using TCEP or ascorbate as the reducing agent for the click 
capture reaction. 50 µg S100 from CHM, gunmetal (gm/gm), Flox (negative control for CHM), +/gm (negative control for 
gm/gm) mouse lung and 20 µg HEK293A (positive control for Rab labelling) were prenylated in vitro with AzGGpp followed 
by capture at 1 mg/ml concentration of S100 with TAMRA-Yn-Biotin II and either 10 mM ascorbate or 1 mM TCEP as the 
reducing agent for the copper catalyst. Samples were also precipitated after prenylation and capture as in the previous 
section. Samples were run on a 12% Bis-Tris gel and imaged with an Ettan DIGE imager (top) before transfer to a PVDF 
membrane and blotting with anti-α-tubulin antibody (Sigma Aldrich, loading control) and anti-Rab5 antibody (Abcam). 
In summary the current protocol for preparation and labelling of mouse tissue S100 samples is 
illustrated in Figure 78. 
 
Figure 78: Optimised protocol for preparing mouse tissue S100 and subsequent labelling of unprenylated Rab proteins 
and affinity purification. 
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 Proteomics of analysis of labelled samples of tissue lysate from mouse 3.4
models of prenylation deficiency 
3.4.1 A first attempt at proteomics of samples derived from mouse models of prenylation 
deficiency to identify Rab proteins affected in these models 
One of the aims of this thesis was to develop a system for identifying the differences in Rab 
prenylation between samples from wild type mice and mouse models of disease, particularly the 
CHM and gunmetal mice. Based on the initial work carried out on Mevastatin-treated HEK293A cells, 
bottom-up proteomics was judged to have the potential to identify Rab proteins affected by the 
prenylation deficiencies in the disease models.  
The first attempt at mass spectrometry-based proteomics of S100 from mouse tissue samples was 
with lung S100 from CHM and Flox mice that had been labelled and affinity purified. The experiment 
was carried out at the same time as the third proteomics experiment discussed in Chapter 2 
(proteomics experiment 3, section 2.4.1) and also compared the results from on-bead and in-gel 
trypsin digestion. The lung samples used were from the same mice as the stomach samples where 
Rab protein labelling was first demonstrated (Figure 70). The proteomics experiment was thus 
carried out before any of the significant optimisation of mouse S100 sample labelling described 
above had been carried out. This first proteomics experiment was to establish whether any Rabs 
could be identified from mouse tissue by using the same conditions as used for labelling and 
purifying unprenylated Rabs in Mevastatin-treated HEK293A S100.  
Figure 79 shows the gel of a small extract of the lung samples submitted for proteomics analysis; 
there is some signal over background with the CHM mouse lung S100 compared to the Flox mouse 
lung S100 and for the CHM mouse some fluorescence signal at the molecular weight of Rabs appears 
in the lane where the streptavidin beads were run. However, there is a high fluorescence 
background, which could represent sample degradation particularly as samples from these mice had 
shown more successful labelling in previous experiments under the same conditions as used here 
(Figure 70). For the proteomics experiment, 4 mg lung S100 was prenylated and captured exactly as 
in proteomics experiment 3 shown in Chapter 2 (section 2.4.1). Following affinity purification using 
magnetic streptavidin Dynabeads® (Invitrogen), the beads were split in two with half of the sample 
submitted for on-bead digest and half run on a pre-cast 1.5 mm thick NuPage 10% Bis-Tris 
polyacrylamide gel (Invitrogen) and a gel band subsequently excised around the molecular weight of 
Rabs and submitted for in-gel trypsin digestion and LC-MS/MS analysis.  
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Figure 79: First mouse model proteomics experiment. In-gel fluorescence scan showing a ~30 µg sample of the before pull-
down, beads and supernatant from the first proteomics experiment carried out on mouse samples. 4 mg S100 from CHM or 
Flox (control) mouse lung was prenylated, captured via click reaction and affinity purified using the same conditions as in 
proteomics experiment 3 (Chapter 2, section 2.4.1).  
The protein hits identified from the proteomics analysis using the Mascot and X! Tandem search 
engines and Scaffold software, as detailed in Chapter 2 (section 2.4.1), are shown in Tables 13A. The 
same settings for LC-MS/MS were used for this experiment as were used in proteomics experiment 
3, also described in Chapter 2 section 2.4.1. Detailed information on the proteomics protocols used 
is given in the Materials and Methods chapter.  
 
Table 13A 
 
Number of unique peptides 
   
Beads Gel 
# Identified Rab Proteins Accession # CHM Flox CHM Flox 
1 Rab7A P51150 0 0 7 0 
2 Rab1A P62821 0 0 5 0 
3 Rab11B P46638 0 0 4 0 
4 Rab18 P35293 0 0 3 0 
5 Rab5C P35278 0 0 3 0 
 
Table 13B Lung 
 Beads Gel 
 CHM Flox CHM Flox 
Total Rabs 0 0 5 0 
Total protein  241 163 145 107 
Tables 13A and 1B: 13A: Rabs identified from the first proteomics experiment on mouse tissue S100 (CHM and Flox 
mouse lung S100) and 13B: number of Rabs and total number of proteins. 4 mg CHM and Flox (control) lung S100 was 
prenylated and captured using optimised conditions. Following CHCl3/MeOH precipitation, samples were resuspended in 
200 µl resuspension buffer without EDTA and affinty purified in a volume of 1.5 ml by 60 µl magnetic streptavidin beads. 
Following washing the beads were split in half and half were run on a 10% Bis-Tris pre-cast gel and gel bands excised at the 
molecular weight of Rabs, and half the beads were submitted for on-bead trypsin digestion. The number of unique peptides 
identified for each Rab is given. A Scaffold file containing data from these experiments is provided in the electronic 
supplementary information (Proteomics experiment 7 refers to the data in this table). 
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There were no Rab proteins identified in the samples submitted for on-bead trypsin digest or in 
either of the control samples and, disappointingly, only five Rab proteins were identified from the 
gel slice (Tables 13A). There could be several reasons for the low level of identification; one reason is 
that the samples were slightly degraded so the Rab proteins were not folded correctly and could not 
be labelled to a sufficient extent for detection. Another reason is that the complexity of the tissue 
samples compared to samples from cell culture generates a higher background of non-specific 
proteins that adhere to the streptavidin beads. The signal from detecting peptides from the non-
specific proteins could potentially swamp the signal of peptides from Rab proteins, particularly if the 
Rabs are less abundant.  
Tables 13B demonstrates that even when sample complexity is reduced by excising a gel band, 
instead of submitting the entire sample for analysis, there is still a relatively large number of non-
Rab proteins identified compared to the number of Rab protein hits. Furthermore, twice the amount 
of mouse tissue S100 was submitted compared to the Mevastatin-treated HEK293A samples 
submitted for proteomics analysis at the same time and yet less than a third of the Rab proteins 
were identified from the tissue samples. This suggested that further optimisation of sample 
preparation was required, as described in the sections of this chapter on labelling optimisation. 
The results of the first tissue proteomics experiment were encouraging because although there were 
relatively few Rab proteins identified they were at least identified specifically in the CHM mouse 
sample, where unprenylated Rabs are expected to accumulate in the cytosol and not in the Flox 
mouse sample as the Flox mouse has functional REP-1. The few Rab proteins that were identified 
were also identified in the proteomic analysis of Mevastatin-treated HEK293A S100 samples. 
Although it was unlikely that the Rabs identified from the Mevastatin-treated cells and those 
identified from the mouse models would be exactly the same it seemed likely that further Rabs 
could be identified, especially because no Rab27A was identified in the mouse samples and it had 
already been demonstrated by Seabra et al. to be hypoprenylated in Choroideremia and can be seen 
by Western blot in lung tissue lysate. The optimisation of labelling (described in previously in section 
3.3) was carried out before any further attempts at proteomics on tissue samples were made. 
3.4.2 Identification of Rab proteins from proteomics of samples derived from mouse 
models of prenylation deficiency  
The second attempt at mass spectrometry-based proteomics of tissue samples was carried out after 
the substantial optimisation of labelling described above in section 3.3. For the second proteomics 
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attempt, S100 from lung, stomach and spleen of CHM, gunmetal and control mice for the respective 
disease models were labelled, affinity purified and submitted for LC-MS/MS analysis using optimised 
conditions (Figure 78). Briefly, 1 mg of S100 from stomach, lung and spleen of CHM, Flox (control) 
gunmetal (gm/gm) and +/gm (control) were subjected to in vitro prenylation, precipitation and 
resuspension, capture, further precipitation and resuspension and finally affinity purification of the 
samples and washing of the beads.  
On this occasion NeutrAvidin™ agarose beads were used instead of magnetic streptavidin beads, the 
guanidine wash steps were omitted and samples were submitted for on-bead trypsin digest, rather 
than excising a gel band and digesting the proteins contained within it. The reasons for changes in 
beads and wash protocol were made primarily because during preparation of samples for 
proteomics analysis as a part of this project and for other projects in the Tate group, it was noted 
that washing magnetic beads frequently posed some difficulties in the form of aggregation of the 
beads and their adherence to the sides of the microcentrifuge tubes the samples were prepared in, 
especially during the guanidine wash step. The magnetic beads also degraded during on-bead digest 
to obtain peptides for proteomic analyses. Furthermore, it was noted that very few other research 
groups who use click chemistry and affinity purification before LC-MS/MS analysis also use magnetic 
beads; with the exception of the paper from Alexandrov et al. in 2009, the majority use agarose 
beads.135 The main and significant advantage of using magnetic beads is their ease of handling 
during small scale experiments (<200 µg S100) as affinity purification then requires relatively small 
amounts of beads (<20 µl beads). NeutrAvidin™ agarose beads are difficult to see by eye, making it 
difficult to removal of the supernatant during wash steps without some accidental removal of beads 
at small scale (as discussed in Chapter 2, section 2.3.5). The guanidine wash steps were thus also 
omitted to avoid adversely affecting the beads and because work carried out by other researchers in 
the Tate group on other systems had suggested it was not an essential component.  
An on-bead trypsin digest protocol as opposed to in-gel trypsin digest was chosen for several 
reasons, despite the results of the previous on-bead digest experiment identifying no Rabs from the 
mouse lung samples. Firstly, it was felt that a more accurate comparison could be made between the 
samples to be analysed if the beads were submitted as a complete sample, as it was difficult to 
ensure that gel bands were excised at exactly the same position and that they were exactly the same 
size for each sample. Secondly, by removing the gel step of sample preparation there was a reduced 
risk of keratin contamination as the amount of sample handling was reduced; this is particularly 
important for the tissue samples as their greater complexity compared to cell culture samples 
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already gave rise to a higher protein background. Finally, by this stage the process of preparing 
samples for proteomics had been optimised considerably so that if there were Rabs to be seen then 
they would be unlikely to have their signal swamped by peptides from non-specifically bound 
proteins in the mass spectrometer. The decision to use on-bead digest was also undertaken based 
on the fact that other members of the Tate group had started to use on-bead digest for routine 
analysis of their samples, so the protocol for digesting proteins bound to beads was already in place.  
Figure 80 shows a small extract (~30 µg) of the samples submitted for proteomics analysis. Although 
there is a relatively high fluorescence background compared to that seen with samples derived from 
cells in culture, there is also a strong signal where expected at the molecular weight of Rab proteins. 
However, the in-gel fluorescence scans did not give as clear a signal for all the samples as hoped for, 
following the optimisation steps undertaken previously. Nevertheless, signal could be seen at the 
molecular weight of Rab proteins in the lanes where the beads from the affinity purification of CHM 
and gunmetal samples were run. 
Rab protein hits identified from the LC-MS/MS analysis of the samples using the Mascot and 
X! Tandem search engines and Scaffold software as before are shown in Tables 14A; where a Rab 
protein was identified in a sample, the box of the table is shaded grey and the number of unique 
peptides identified for that Rab are shown in bold. Significantly more Rab proteins were identified 
compared to the first attempt at proteomics on mouse tissue samples (section 3.4.1), confirming 
that conditions for sample preparation had indeed been optimised compared to the conditions used 
in the first experiment. Pleasingly, there were again far fewer Rab proteins identified in the control 
samples compared to the disease models (in some cases no Rabs were identified from the control 
samples) as expected because prenylation should have been unaffected in the control mice. The 
number of non-Rab protein hits was also reduced compared to the previous proteomics experiment 
(Tables 14B), giving further indication of the optimisation of sample labelling conditions. However, 
compared to the number of Rab proteins identified the number of non-specific proteins identified 
was still high and suggests that there is some scope for further optimisation. 
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Figure 80: Second mouse model proteomics experiment. In-gel fluorescence scans and colloidal Coomassie stains of gels 
containing ~30 µg extract of tissue samples submitted for proteomic analysis. 2 mg of S100 from CHM, Flox (control), 
gunmetal (gm/gm) and +/gm (control) mouse lung stomach and spleen were prenylated and captured under optimised 
conditions before affinity purification with NeutrAvidin™ agarose beads. Samples were submitted for on-bead trypsin 
digest. 30 µg extracts of before pull-down, beads (B) and supernatant (S) samples were run on 12% Bis-Tris polyacrylamide 
gels with MES SDS running buffer before scanning with and Ettan DIGE imager and staining with colloidal Coomassie.   
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 Table 14A  Number of unique peptides 
   Lung Stomach Spleen 
# Identified Rab Proteins Accession # CHM Flox gm/gm +/gm CHM Flox gm/gm +/gm CHM Flox gm/gm +/gm 
1 Rab7A P51150 12 2 11 5 11 0 9 0 9 0 7 2 
2 Rab1A P62821 7 3 10 6 14 4 9 2 7 2 10 4 
3 Rab5C P35278 7 0 7 3 7 0 4 0 3 0 4 0 
4 Rab3D P35276 6 0 8 0 7 0 4 0 0 0 0 0 
5 Rab10 P61027 5 0 4 0 5 0 3 0 4 0 5 0 
6 Rab11B P46638 5 4 7 3 7 0 6 0 5 0 7 0 
7 Rab18 P35293 5 0 0 0 7 0 3 0 8 0 4 0 
8 Rab12 P35283 4 0 0 0 0 0 0 0 0 0 0 0 
9 Rab2A P53994 3 0 7 3 6 0 5 2 3 0 5 0 
10 Rab5B P61021 3 0 4 0 5 0 3 0 2 0 2 0 
11 Rab21 P35282 3 0 6 0 5 0 3 0 5 0 6 0 
12 Rab3A P63011 2 0 2 0 2 0 0 0 0 0 0 0 
13 Rab6A P35279 2 0 5 0 7 0 0 0 8 0 5 0 
14 Rab35 Q6PHN9 2 0 3 0 0 0 3 0 3 0 3 0 
15 Rab43 Q8CG50 2 0 4 0 2 0 3 0 4 0 6 0 
16 Rab1B Q9D1G1 0 0 3 0 4 0 2 0 0 0 3 0 
17 Rab2B P59279 0 0 2 0 0 0 0 0 0 0 0 0 
18 Rab4B Q91ZR1 0 0 0 0 0 0 0 0 0 0 4 0 
19 Rab5A Q9CQD1 0 0 2 0 0 0 0 0 0 0 0 0 
20 Rab6B P61294 0 0 0 0 0 0 0 0 0 0 2 0 
21 Rab14 Q91V41 0 0 2 0 7 0 0 0 4 0 7 0 
22 Rab22A P35285 0 0 5 0 0 0 3 0 0 0 7 0 
23 Rab25 Q9WTL2 0 0 0 0 4 0 0 0 0 0 0 0 
24 Rab27A Q9ERI2 0 0 0 0 0 0 3 0 0 0 0 0 
25 Rab27B Q99P58 0 0 0 0 3 0 3 0 0 0 8 0 
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Table 14B Lung Stomach Spleen 
 CHM Flox gm/gm +/gm CHM Flox gm/gm +/gm CHM Flox gm/gm +/gm 
Total Rabs 15 3 18 5 17 1 16 2 13 1 18 2 
Total Other  76 76 78 88 116 105 103 81 58 68 81 69 
Total protein  91 79 114 93 133 104 119 83 71 69 99 71 
Tables 14A and 14B: Tables showing Rab proteins identified from CHM and gunmetal mouse tissues (top) and total Rabs identified from various mouse tissue S100 samples (bottom). 2 mg 
of S100 from CHM, Flox (control), gunmetal (gm/gm) and +/gm (control) mouse lung stomach and spleen were prenylated and captured under optimised conditions before affinity purification 
with NeutrAvidin™ agarose beads. Samples were submitted for on-bead trypsin digest. A Scaffold file containing data from these experiments is provided in the electronic supplementary 
information (Proteomics experiment 8 refers to the data in this table). 
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Eight Rab proteins were identified in both of the mouse disease models and in all three of tissue 
types (lung, stomach and spleen) analysed; these are: Rab7A, Rab1A, Rab5C, Rab10, Rab11B, Rab2A, 
Rab5B and Rab21. This may indicate that these Rabs are affected more strongly by deficiencies in 
the prenylation machinery. Alternatively, the fact that these Rabs were identified in all of the mouse 
disease model samples may suggest that they are more highly expressed than other Rabs or are 
upregulated when they are not prenylated as normal, meaning more of them are available to 
accumulate in the cytosol unprenylated. Statins cause upregulation of Ras superfamily proteins, so 
the lack of protein prenylation could cause them to be upregulated.252, 264, 265 Furthermore, Rab1A 
was also identified in all of the control samples, although with fewer unique peptides detected in 
each case, which suggests that there is a cytoplasmic pool of unprenylated Rab1A. The cellular 
location and functions of the Rabs identified from tissue samples are shown in Table 15. Those Rabs 
identified and particularly the ones which were not detected in control samples could well be 
important in causing the phenotypes of these prenylation deficiency diseases. 
Another factor to take into consideration when discussing the identity of the protein hits from the 
tissue samples is that only proteins with unique peptides detected can be identified. Additionally it is 
preferable to have at least three unique peptides detected in order to be sure of a protein hit. Since 
Rab proteins have a high degree of similarity, particularly between subfamilies, there are some 
peptides that may be from more than one Rab protein. This means that if a unique peptide is not 
detected for a particular Rab then it will not appear on the list of identified proteins, even though it 
may have been present in the sample. It is difficult to say how much of a problem this is with the 
samples described in this thesis. However, a large number of Rab proteins have been detected 
through their unique peptides and an attempt to scale up the samples, mentioned in Chapter 2, did 
not result in increased protein hits. This is one avenue for future work as it would help to validate 
the proteins detected. 
For the gunmetal mouse, Rab2B and Rab5A were identified only in the lung, Rab27A only in the 
stomach and Rab6B and Rab4B only in the spleen and none of them were detected in the CHM 
mouse samples. From the lung of the CHM mouse Rab12 was identified confidently, with 4 unique 
peptides assigned to the protein, giving 24% sequence coverage; Rab12 was not identified in any of 
the other samples. Rab25 was identified only in the stomach sample from the CHM mouse and not 
in any of the other samples submitted. It could be that these Rabs are more highly expressed in the 
tissue they were detected in than in the other tissue types and thus any effect on their prenylation 
state will be more easily detectable. It is also possible that the identified Rab proteins are present in 
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the other tissue types but the signal intensity from the peptides was too low or there were not 
enough unique peptides to identify the proteins in the other samples. However, the key comparison 
is between the disease and control organ samples and these proteins were not detected in the 
control samples and so may be implicated in the disease phenotype. Rab3D was observed in 
relatively high abundance (based on the number of unique peptides identified for the protein) in 
stomach and lung samples but not at all in the spleen samples nor in the control samples. However, 
according to the Uniprot entry for mouse Rab3D (accession number P35276) it is expressed in the 
spleen; one reason why it was not identified in this experiment could be that there were no unique 
peptides for Rab3D detected in the spleen samples, only ones that shared identity with those from 
other proteins, so that it could not be confidently identified even though it was present.  
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Rab 
Protein 
Accession 
Number 
Cellular Location Function Mouse sample(s) HEK293A 
Rab1A P62821 ER, Golgi ER to Golgi and intra-Golgi 
trafficking 
CHM: St, L, Sp;  
Flox: St, L, Sp; gm/gm: 
St, L, Sp; +/gm: St, L, Sp 
Y 
Rab1B Q9D1G1 ER, Golgi ER to Golgi and intra-Golgi 
trafficking 
CHM: St; gm/gm: St, L, 
Sp 
Y 
Rab2A P53994 ER, ER-Golgi IC, Golgi ER to Golgi trafficking CHM: St, L, Sp; gm/gm: 
St, L, Sp; +/gm: St, L 
Y 
Rab2B P59279 ER, ER-Golgi IC, Golgi ER to Golgi trafficking gm/gm: L N 
Rab3A P63011 Secretory vesicles, PM Exocytosis, 
neurotransmitter release 
CHM: St, L; gm/gm: L N 
Rab3D P35276 Secretory vesicles, PM Regulated exocytosis CHM: St, L; gm/gm: St, L Y 
Rab4B Q91ZR1 EE Protein recycling/transport 
to PM 
gm/gm: Sp N 
Rab5A Q9CQD1 PM, CCVs, EE EE fusion gm/gm: L Y 
Rab5B P61021 PM, CCVs, EE EE fusion CHM: St, L, Sp; gm/gm: 
St, L, Sp 
Y 
Rab5C P35278 PM, CCVs, EE EE fusion CHM: St, L, Sp; gm/gm: 
St, L, Sp; +/gm: L 
Y 
Rab6A P35279 Golgi Endosome to Golgi, intra-
Golgi and Golgi to ER 
transport 
CHM: St, L, Sp; gm/gm: 
L, Sp 
Y 
Rab6B P61294 Golgi Intra-Golgi transport gm/gm: Sp N 
Rab7A P51150 LE, lysosomes/vacuole, 
Melanosomes, 
phagosomes 
LE to lysosome trafficking CHM: St, L, Sp; Flox: L; 
gm/gm: St, L, Sp; +/gm: 
L, Sp 
Y 
Rab10 P61027 Golgi, basolateral sorting 
endosomes, GLUT4 
vesicles 
Exocytosis, TGN/RE to PM 
trafficking 
CHM: St, L, Sp; gm/gm: 
St, L, Sp 
Y 
Rab11B P46638 Golgi, RE, EE TGN/RE to PM trafficking CHM: St, L, Sp; Flox: L; 
gm/gm: St, L, Sp; +/gm: 
L 
Y 
Rab12 P35283 Golgi, secretory vesicles Exocytosis CHM: L 
 
N 
Rab14 Q91V41 Golgi, EE, GLUT4 vesicles TGN/RE to PM trafficking, 
apical membrane targeting 
CHM: St, Sp; gm/gm: L, 
Sp 
Y 
Rab18 P35293 Golgi, lipid droplets Lipid droplet formation CHM: St, L, Sp; gm/gm: 
St, Sp 
Y 
Rab21 P35282 EE Endosomal transport CHM: St, L, Sp; gm/gm: 
St, L, Sp 
Y 
Rab22A P35285 EE Endosomal transport, 
protein recycling to PM 
gm/gm: St, L, Sp N 
Rab25 Q9WTL2 RE RE (apical) to PM CHM: St N 
Rab27A Q9ERI2 Melanosomes Exocytosis gm/gm: St Y 
Rab27B Q99P58 Melanosomes Exocytosis CHM: St; gm/gm: St, Sp N 
Rab35 Q6PHN9 PM, endosome RE to PM trafficking, actin 
assembly 
CHM: L, Sp; gm/gm: St, 
L, Sp 
Y 
Rab43 Q8CG50 ER, Golgi ER to Golgi trafficking, 
Shiga toxin transport 
CHM: St, L, Sp; gm/gm: 
St, L, Sp 
Y 
Table 15: The cellular location and function of the Rab proteins identified from tissue samples from CHM and gunmetal 
mouse models and whether these Rabs were identified in the HEK293A samples described in Chapter 2. EE = Early 
Endosome, PM = Plasma Membrane, LE = Late Endosome, TGN = Trans-Golgi Network, CCV = Clathrin-coated Vesicle, RE = 
Recycling Endosome, ER = Endoplasmic Reticulum, Golgi IC = Golgi Intermediate compartment, St = stomach S100, Sp = 
Spleen S100, L = Lung S100.  Information adapted from the review by Hutagalung and Novick.
19
  
148 
 
 Conclusions 3.5
The research discussed in this chapter focussed on further developing the AzGGpp bioorthogonal 
labelling technique for labelling unprenylated Rab proteins so that the technique may be used to 
probe the prenylation state of Rabs in mouse disease models and in particularly the gunmetal and 
CHM mouse. Rab proteins were successfully labelled in tissue S100 samples from the CHM and 
gunmetal mouse models and no labelling was seen in samples from their respective controls; the 
labelling was judged by in-gel fluorescence and Western blot. The fluorescence signal from labelled 
proteins could also be seen by in-gel fluorescence when samples were affinity purified using 
magnetic streptavidin or NeutrAvidin™ agarose beads and the beads subsequently run on a 
polyacrylamide gel. The labelling required further optimisation from the initial protocol developed in 
work described in Chapter 2. Rab proteins were identified from tissue of the mouse disease models 
by LC-MS/MS analysis. A total of twenty-five Rabs were identified over the three tissue types from 
the two mouse disease models that were submitted for analysis.  
Initial conclusions about the effects of defects in prenylation machinery caused by either reduction 
in RGGT activity or lack or REP-1 can be drawn from the proteomics data described in this chapter. 
Eight Rabs were identified as being unprenylated in the organs investigated in both types of disease 
model: Rab7A, Rab1A, Rab5C, Rab10, Rab11B, Rab2A, Rab5B and Rab21. The fact that these Rabs 
were also identified as protein hits in Mevastatin-treated HEK293A samples submitted for 
proteomics analysis and described in Chapter 2 suggests that lack of prenylation affects these 
proteins strongly.   
Some Rab proteins were identified only in the CHM or the gunmetal mouse samples (not in both) 
and these could be Rabs that are affected by the particular defect in the prenylation machinery of 
each model. This would mean that Rab25 and Rab12 are most affected by a lack of REP-1 rather than 
a reduction in prenylation due to decreased RGGT activity. Rab12 is localised to the trans Golgi 
network (TGN) whilst Rab25 is involved in transport of recycling endosomes. It is not clear what role 
they could play in the phenotype of CHM and indeed it seems Rab25 has not been detected in the 
eye. 
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 Developing and optimising the labelling, detection Chapter 4
and identification of unprenylated Rab proteins 
from ChmFlox MCM+ cells  
This chapter describes work on cell cultures derived from the CHM mouse model described in 
Chapter 3 section 3.1. These mice are genetically engineered so that upon injection with the drug 
Tamoxifen (TM) the REP-1 gene is knocked out. Fibroblasts and bone marrow from these mice were 
grown in cell culture and treated with TM to induce REP-1 knock-out. The TM treatment and the 
subsequent labelling of the lysate from these cells and proteomics analyses to identify the 
geranylgeranylated proteins affected are described here. 
 Cell lines derived from ChmFlox MCM+ and ChmFlox mice 4.1
Fibroblasts and bone marrow cells were taken from ChmFlox MCM+ mice and from ChmFlox mice (bone 
marrow was obtained by Dr Rajesh Singh and fibroblasts by Elham Ostad-Saffari (both Imperial 
College)). As explained in Chapter 3 (section 3.1), if the cells express the Cre recombinase as a fusion 
protein with 2 copies of murine estrogen receptor (MerCreMer or MCM) then, upon treatment with 
TM, exon 4 of the REP-1 gene will be deleted, which will cause a frameshift, early stop codon 
appearance and loss of  functional   REP-1 protein  (Figure 81). The knock-out of REP-1 is still present 
when the cells are passaged i.e. a cell line with a knock-out of REP-1 is created once the ChmFlox 
MCM+ cells have been treated with TM. ChmFlox cells that do not express the Cre fusion protein will 
not undergo REP-1 knock-out upon treatment with TM. ChmFlox MCM+ cells that are not treated with 
TM still express the REP-1 protein and so can also act as a control for the REP-1 knock-out cells. 
 
Figure 81: Illustration of Cre recombination in cells from Chm
Flox
 MCM
+
 mice in culture, once the cells are dosed with TM. 
Cell lines with a REP-1 knock-out offered an opportunity to gain complimentary information to that 
obtained from the mouse model samples described in Chapter 3. Lysates from cell culture are easier 
to prepare than samples from mouse organs and it is more facile and cost effective to obtain large 
Exon 4
loxP loxP
ChmFlox MCM+ cell
loxP
ChmFlox MCM+ TM+ cell
TM-induced
Cre recombination
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amounts of lysate. Furthermore, samples from cell culture tend to give lower background 
fluorescence than samples from tissue, based on observations during work carried out for this thesis. 
Cells in culture can also be metabolically labelled, using the cellular prenylation machinery, to probe 
endogenous prenylation. In vitro prenylation with AzGGpp may still be used to identify unprenylated 
proteins as described in Chapters 2 and 3 (Metabolic labelling is described in detail in section 4.3.5). 
 Bone marrow cell culture from ChmFlox MCM+ mice  4.2
Bone marrow consists of a number of different cell types and can also be grown in culture and thus 
it was hoped that there would be less of the unwanted background signal found in the lung, stomach 
and spleen samples described in Chapter 3. This section discusses the treatment of bone marrow 
culture with TM to cause REP-1 knock-out and subsequent attempts to label the pool of 
unprenylated Rab proteins that should accumulate in the cytosol once prenylation has been 
affected. Bone marrow cells were taken from the tibia and femur of two ChmFlox MCM+ mice by Dr 
Rajesh Singh, Imperial College.  
4.2.1 REP-1 knock-out by TM treatment in bone marrow cell culture from ChmFlox MCM+ 
mice  
The first step, once the bone marrow cells were in culture, was to optimise the amount of TM 
needed to induce a conditional knock-out of REP-1 in the cells, whilst minimising cell death due to 
TM toxicity. In a 6-well plate, cells were treated for 48 hours with different concentrations of TM 
(from a 0.1 M stock in EtOH) added to the cell media or with equal amount of EtOH added as a 
negative control. The concentrations chosen for initial testing were 0, 2, 5 and 10 µM TM; TM was 
added to the cells at the same time as they were plated at a concentration of 5 × 105 cells/ml of 
media. Following TM treatment, the media was replaced and cells were either harvested 
immediately or allowed to grow for a further passage. The bone marrow culture consisted of both 
adherent cells and cells in suspension and all cell types were grown together in the same flask and 
harvested, pelleted and resuspended together. Bone marrow cells kept under the conditions given 
above will largely differentiate into mast cells after about 3 weeks (Dr Rajesh Singh, PhD thesis); 
consequently cells were grown for up to two weeks.   
Once cells were harvested, the cell pellet was prepared for PCR analysis to determine the extent of 
any knock-out of REP-1 that had occurred. To this end, 200 µl of enzyme buffer GNTK and 2 µl of the 
enzyme Proteinase K (Sigma Aldrich) were added to the pellet and incubated overnight at 55 °C. This 
enzyme digests DNAses and other unwanted proteins from a sample and allows isolation of DNA. 
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DNA from the samples was then added to a PCR mix and PCR was carried out using primers that 
could detect ChmFlox and ChmNull alleles. It is noteworthy that bone marrow cells treated with 5 µM 
TM grew very slowly and those treated with 10 µM TM appeared not to survive well, with the cell 
pellet invisible to the eye, although DNA could still be detected for cells treated at these 
concentrations. Figure 82 shows that the knock-out of the REP-1 gene was partially successful at all 
concentrations of TM added to the cells; thus 2 µM TM was selected as the concentration to 
proceed with from this point due to its lower toxicity when compared to higher TM concentrations. 
It was uncertain from these results whether the partial knock-out of REP-1 was present in all cell 
types or whether some cell types were susceptible to TM whilst others were not. For example it is 
known that the chicken β-actin promoter is not active in some cells, such as certain types of T-cells 
the precursors of which are present in bone marrow.266 
 
Figure 82: Image of PCR of TM-treated bone marrow DNA, demonstrating partial knock-out of the REP-1 gene  at the 
different TM concentrations assayed. In a 6-well plate, bone marrow cells were treated with 2, 5 and 10 µM TM or EtOH 
control for 48 hours under standard conditions.Cell pellets were digested with proteinase K and PCR carried out on the DNA 
in these samples. Positive control tamoxifen treated Chm
Flox 
fibroblast, negative control Chm
Flox 
MCM
+
 fibroblasts. H7/H9 
primers that could detect Chm
Flox
 and Chm
Null 
alleles were used in the PCR reaction. PCR products were run on a 1.5% 
agarose gel with ethidium bromide. The size of the PCR products are 860 bp (Chm
Flox
) and 330 bp (Chm
Null
). 
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When the 2 µM TM treatment of bone marrow culture was repeated on a larger scale in a 150 cm2 
tissue culture flask the knock-out of REP-1 appeared complete by PCR and also by Western blot 
(Figure 83). 
 
Figure 83: Tamoxifen treatment of Chm
Flox
 MCM
+ 
bone marrow cells causes knock-out of REP-1 by PCR and Western blot. 
A: Image of agarose gel of PCR reaction productsfrom bone marrow cells treated with 2 µM TM in a T150 tissue culture 
flask. Positive control tamoxifen treated Chm
Flox 
fibroblast, negative control Chm
Flox 
MCM
+
 fibroblasts. Primers H7/H9 that 
could detect Chm
Flox
 and Chm
Null 
alleles were used in the PCR reaction. B: Western blot using J905 antibody for REP-1 protein 
and α-tubulin antibody as a loading control. Recombinant human REP-1 (30 ng) was loaded on the gel to show where  REP-
1 appears. 30 µg bone marrow S100 from cells either treated with EtOH or 2 µM TM were loaded on the gel to demonstrate 
knock-out of REP-1. 
4.2.2 Mevastatin treatment of bone marrow cell culture 
Once REP-1 has been knocked out, Rab prenylation can still occur via REP-2; thus some Rab proteins 
are still prenylated. As discussed in section 1.2.4.1.2, Mevastatin treatment of cells stops all 
prenylation (by inhibiting HMG-CoA reductase in the mevalonic acid pathway), meaning all Rabs 
should remain unprenylated and accumulate in the cytosol. Therefore, as with the HEK293A cells 
described in Chapter 2, bone marrow cell cultures were treated with Mevastatin to try and inhibit 
prenylation and thus accumulate as many unprenylated Rabs in the cytosol as possible and act as a 
positive control for knock-out of Rab prenylation. This would enable a useful comparison between 
Rab proteins available to label in cells with complete inhibition of prenylation, partial reduction in 
prenylation (i.e. REP-1 knock-out) and wild type prenylation. Figure 84 shows by PCR that Mevastatin 
treatment did not affect the REP-1 knock-out on cells that had previously been treated with TM; as 
was expected as the knock-out of REP-1 is permanent once TM is removed from the media. As with 
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Recombinant REP-1 - +
TM + - -
Lane 1 2 3
-REP-1
-REP-2
-α-tubulin
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TM concentration (µM) 2 2 0 - -
Bone Marrow + + + - -
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1000 -
A B
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HEK293A cells, 10 µM Mevastatin was used to treat the bone marrow cells overnight before the cells 
were harvested. 
 
Figure 84: Agarose gel of PCR reaction demonstrating that Mevastatin treatment of bone marrow cells has no effect on 
REP-1 knock-out in cells that have already been treated with TM to cause the knock-out. Cell pellets were digested with 
proteinase K and a PCR reaction carried out on the DNA from the samples plus positive and negative control samples. 
Primers that could detect Chm
Flox
 and Chm
Null 
alleles were used in the PCR reaction. PCR reaction products were run on a 
1.5% agarose gel containing ethidium bromide. 
Once it had been established that REP-1 could be knocked out in the bone marrow cells, as seen by 
PCR and Western blot, attempts were made to label and visualise the unprenylated Rabs by in vitro 
prenylation with AzGGpp and subsequent capture with TAMRA-Yn-Biotin II. The same optimised 
conditions as for HEK293A cells were used on 25 µg and 50 µg bone marrow S100; unfortunately the 
capture was not successful (Figure 85) as judged by the lack of signal seen at the molecular weight of 
Rab proteins, whilst a band could be seen in Mevastatin-treated HEK293A S100 labelled at the same 
time. The reason that no labelling was seen could be because the bone marrow cells were not 
allowed to grow for long enough after TM treatment to give sufficient accumulation of unprenylated 
Rab proteins in the cytosol and furthermore if the turnover of the Rab proteins in these cells was 
slow then unprenylated Rabs would not accumulate enough to see them following Mevastatin 
100 -
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400 -
500 -
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treatment either. Alternatively, there could be some component of bone marrow cells that 
interferes with the in vitro prenylation or capture reactions or the concentration of lysate was not 
high enough to give sufficient Rabs for labelling, although it was between 3 and 5 mg/ml 
concentration, which is sufficient for labelling to be seen in other types of sample. 
 
Figure 85: In vitro prenylation with AzGGpp and biorthogonal ligation with TAMRA-Yn-Biotin II capture reagent of TM 
and Mevastatin-treated bone marrow cell S100 did not result in labelling by in-gel fluorescence. A: Top: In-gel 
fluorescence scan of 25 µg of S100 from Mevastatin-treated HEK293A cells (positive control for prenylation) or Chm
Flox
 
MCM
+
  bone marrow cells treated with TM, Mevastatin or DMSO (negative control)was prenylated with AzGGpp and 
captured with TAMRA-Yn-Biotin II using conditions optimised for labelling cell culture samples as described in Chapter 2. 
Bottom: Colloidal Coomassie stain of gel. B: Further example of prenylation and capture of 25 µg bone marrow S100 
samples 
 Due to the difficulties experienced with the bone marrow culture work with these cells was not 
continued and instead experiments proceeded with a fibroblast cell culture from the same mice, as 
described in the remainder of this chapter. With more time, using bone marrow cells could yield 
interesting information as there is more complexity in these samples compared to culture of a single 
type of cell; however, optimisation is required before work can proceed. Several bisphosphonate 
RGGT inhibitors have been designed to target RGGT in bone and hence help treat osteoporosis. 
Labelling of unprenylated proteins in bone marrow following treatment with these drugs could 
prove a useful method of assessing their efficacy, which is one reason why it would be important to 
continue with this work, given sufficient time. 
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 Fibroblast cell culture from ChmFlox MCM+ and ChmFlox mice 4.3
Fibroblast cells from ChmFlox MCM+ (and ChmFlox fibroblasts as a control) were chosen to create a 
REP-1 knock-out cell line, using TM to induce the knock-out. These cells were chosen to work on as 
knock-out of REP-1 and REP-2 in HEK293A cells (by siRNA treatment, as described in Chapter 2 
section 2.5.2.1), was proving difficult to realise. This section describes the conditions selected for TM 
treatment of the cells to achieve conditional REP-1 knock-out, labelling of cell lysate via in vitro 
prenylation and bioorthogonal ligation, affinity purification and proteomics identification of Rabs 
from these samples. Furthermore, metabolic labelling with AzGGOH to label geranylgeranylated 
proteins using the endogenous cellular prenylation machinery is also described with the subsequent 
bioorthogonal ligation, in-gel visualisation and affinity purification of these samples. Proteomics 
identification and quantification of the Rabs identified from metabolically labelled cell lysate are also 
detailed here. 
Fibroblasts were harvested from ChmFlox MCM+ and ChmFlox mice by Elham Ostad-Saffari (Elham 
Ostad-Saffari, PhD thesis, Imperial College) using the standard protocols described in the Materials 
and Methods chapter. The cells were grown in DMEM medium with 10% heat inactivated FBS, 500 
U/ml penicillin/streptomycin/ amphotericin B (Invitrogen) at 37 °C and 10% CO2. 
4.3.1 TM treatment of ChmFlox MCM+ fibroblast cell culture to knock out REP-1 expression 
The first step towards a cell line with no REP-1 expression was to establish a suitable concentration 
for TM treatment of the cells; concentrations of 5 µM and 10 µM TM were chosen initially based on 
previous experience with these cells in the Seabra group. The fibroblasts were treated with TM or 
EtOH (control) for 48 hours at 37 °C and 10% CO2 before the TM-containing media was replaced with 
fresh media; the cells were allowed to grow until confluent. Cells were plated at the same time as 
the TM was added to the media and were at an initial concentration of 2.5 × 105 cells per 10 cm 
tissue culture dish. The cells were harvested once confluent to confirm knock-out by PCR; PCR 
conditions were the same as those described above for the bone marrow samples (section 4.2.1). 
Figure 86A demonstrates that ChmFlox MCM+ fibroblast cells treated with TM showed REP-1 knock-
out by PCR but where either the cells did not express Cre (MCM-) or there was no TM added to the 
media then no knock-out was seen. The knock-out of REP-1 at 10 µM TM was also confirmed by 
REP-1 Western using the J905 antibody specific to REP protein (Figure 86B). From this point ChmFlox 
MCM+ fibroblasts will be referred to as Flox fibroblasts and ChmFlox MCM+ TM+ fibroblasts as CHM 
fibroblasts 
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Figure 86: Agarose gel of PCR reaction and Western blot demonstrating knock-out of REP-1 in ChmFlox MCM+  
friboblasts treated with TM. A:  
 
Chm
Flox
 MCM
+
 and
 
Chm
Flox
 fibroblasts were treated with 0 (EtOH), 5 and 10 µM TM for 48 
hours. Cells were harvested and lysed and the nuclear pellets digested by proteinase K and  PCR reactions carried out using 
primers H7/H9 that could identify Chm
Flox
 and Chm
Null
 alleles. PCR reaction products were run on 1.5% agarose gel 
containing ethidium bromide. B: Western blot of 50 µg PNS from Chm
Flox
 MCM
+
  fibroblasts treated with either 10 µM TM or 
EtOH (control) with recombinant human REP-1 loaded as a control to show the position of REP-1 in the gel. J905 was used 
for REP-1 Western and α-tubulin antibody to detect α-tubulin as a loading control. 
4.3.2 Mevastatin treatment of Flox and CHM fibroblasts 
Once conditions for TM treatment of cells were established, the cells were also treated with 
Mevastatin to create a positive control for accumulation of unprenylated Rabs in the cytosol. As with 
the HEK293A and bone marrow cells, fibroblasts were treated overnight with 10 µM Mevastatin 
before the cells were harvested and lysed. Figure 87A and B demonstrate, by PCR and Western blot, 
that Mevastatin treatment does not affect the REP-1 knock-out in the cells, as was expected. The 
Mevastatin treatment causes Rabs to accumulate in the cytosolic fraction (S100) which is shown in 
Figure 87C; the effect is most obvious with Rab27A. Rab27A has already been shown to be affected 
in the disease Choroideremia, as discussed in Chapter 1 section 1.2.7.4. Anti-calnexin antibody is 
used here as a control for subcellular fractionation as calnexin is a membrane-bound ER protein and 
will thus fractionate to the P100; anti-α-tubulin antibody was used as a control for protein loading. 
When REP-1 is knocked out by TM treatment, the Rab proteins should appear more in the S100 
fraction as there will then be more cytosolic, unprenylated Rabs; this is seen in lanes 1, 2, 7 and 8 of 
the Western blot in Figure 87C. The same is also true with Mevastatin treatment and because 
Mevastatin treatment affects all Rab prenylation by stopping GGpp synthesis the effect on the Rabs 
could be expected to be stronger with Mevastatin treatment of cells with no REP-1, as can be seen in 
lanes 1 and 2 of the Western blot shown in Figure 87C. 
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Figure 87: Mevastatin treatment has no  affect on REP-1 knock-out in fibroblasts where REP-1 has already  been knocked 
out by TM treatment; Mevastatin treatment coause Rab proteins to accumulate in the cytosol. A: 1.5% agarose gel 
containing ethidium bromide demonstrating REP-1 knock-out in cells that had been treated with TM even after subsequent 
mevastatin treatment. Primers that could detect Chm
Flox
 and Chm
Null 
alleles were used in the PCR reaction. B: J905 antibody 
for REP protein Western blots. 30 ng recombinant REP-1 was loaded as a control for REP-1 position on the gel. The REP-2 
ban of the antibody acts as a loading control.C: 30 µg S100 and P100 from Flox (-TM) and CHM (+TM) fibroblasts with and 
without Mevastatin treatment. Western blots probed with Rab5, Rab11 and Rab27A antibodies with α-tubulin loading 
control and clanexin as a control for subcellular fractionation. 
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Unlike with the bone marrow cells, when attempts were made to label unprenylated Rabs in S100 
from fibroblasts treated with TM and/or Mevastatin they were successful (Figure 88). 30 µg of S100 
from CHM or Flox fibroblast with or without Mevastatin treatment, were prenylated in vitro with 
AzGGpp and captured with TAMRA-Yn-Biotin II via click reaction, using the optimised conditions 
described in Chapter 2. Pleasingly, the signal from CHM fibroblast samples without Mevastatin 
treatment (Figure 88, lanes 3 and 5) was weaker than that from Mevastatin-treated Flox fibroblast 
samples (lane 1) and samples from CHM fibroblasts treated with Mevastatin (lanes 4 and 6). This is 
consistent with the REP-1 knock-out causing only a reduction in Rab prenylation and not stopping it 
entirely (as with Mevastatin treatment); hence only some Rabs will accumulate unprenylated in the 
cytosol. It should be noted that because cells were not treated with TM and Mevastatin 
simultaneously, instead Mevastatin treatment occurred at least two passages after TM treatment as 
the REP-1 knock-out is persistent. 
 
Figure 88: In-gel fluorescence scan demonstrating labelling of the pool of unprenylated Rab proteins in TM-treated and 
Mevastatin-treated Chm
Flox
 MCM
+
  fibroblasts. 30 µg S100 from Chm
Flox
 MCM
+
 cells that had been treated with TM to 
cause REP-1 knock-out and then with Mevastatin at least 2 passages later as well as untreated control samples and 
Mevastatin-treated HEK293A S100 as a positive control for labelling. 
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4.3.3 Affinity purification of labelled Rab proteins from CHM fibroblast samples 
As with labelled proteins from HEK293A cell lysate, it was also possible to demonstrate affinity 
purification of labelled proteins from fibroblast samples. Figure 89 shows that labelled proteins from 
CHM fibroblast samples (both with and without Mevastatin treatment) can be affinity purified; 80 µg 
S100 was prenylated in vitro, captured with TAMRA-YN-Biotin II and half was affinity purified using 
magnetic streptavidin beads. Cells were treated with DMSO as a control for Mevastatin treatment 
(Mevastatin was stored as a 50 mM stock in DMSO); again TM and Mevastatin treatment was not 
simultaneous, the TM notation on the in-gel fluorescence image in Figure 89 indicates that the cells 
have a REP-1 knock-out, caused by previous treatment with TM. 
 
Figure 89: Labelled proteins from Chm
Flox
 MCM
+
 cells with TM and with and without Mevastatin treatment can be 
affinity purified. Chm
Flox
 MCM
+
 fibroblasts that had either been previously treated with TM to give a REP-1 knock-out or 
had not been treated so that REP-1 was still active (control) were treated with either 10 µM  Mevastatin (Mev) or with 
DMSO. The S100 fraction from these cells was subjected to in vitro prenylation with AzGGpp, captured with TAMRA-Yn-
Biotin II reagent and  affinity purified with magnetic streptavidin beads. The samples were then run on a 12% Bis-Tris 
polyacrylamide gel with MES SDS running buffer and imaged using an Ettan DIGE imager and the Cy3 channel.E = eluant 
from beads after heating to 95 °C for 5 minutes, B = beads after sample had been eluted from them, S  = supernatant. 
4.3.4 Attempts to optimise labelling of unprenylated Rab proteins from CHM fibroblast 
samples 
Subsequently it was noted that some samples did not show labelling by in-gel fluorescence, even 
though by PCR and Western blot there was no REP-1 protein present in the samples and so Rabs 
should have accumulated in the cytosol and labelling been visible by in-gel fluorescence. Several 
attempts at optimisation were made; however, this did not consistently give improvements which 
left the possibility that the method used to lyse the cells was sometimes causing sample degradation 
and hence poor labelling; so the lysis method was changed from sonication to passing the cells 
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through a 25-guage needle as used for HEK293A and bone marrow cells. Sonication had originally 
been selected as the technique to lyse fibroblasts based on experience from other members of the 
Seabra group. However, it does not appear to be a suitable technique for producing samples that 
can consistently be labelled via in vitro prenylation and bioorthogonal ligation. Changing to lysis 
through a needle appeared to eliminate inconsistencies in sample labelling and also did not 
significantly reduce the protein concentration of the sample, indicating that the efficiency of cell lysis 
was similar with both techniques. 
4.3.5 Metabolic labelling of CHM and Flox fibroblasts and HEK293A cells 
Metabolic labelling allows a tag to be incorporated onto proteins of interest by using the 
endogenous enzymatic machinery of a cell. The technique involves a tagged analogue of the enzyme 
substrate (commonly an azide or alkyne tag is used) being fed to the cell in the cell media and this 
analogue is taken up by the cell. The endogenous enzyme then uses the lipid substrate analogue to 
post-translationally modify its protein substrates. Once proteins have been tagged then the cells are 
lysed and bioorthogonal ligation used to label the proteins of interest; in this case with biotin and a 
TAMRA fluorophore. These labelled proteins can then be visualised or affinity purified as previously 
described. Figure 90 illustrates how metabolic labelling works.  
As discussed in Chapter 1, AzGGpp was synthesised in previous work230 and a precursor to AzGGpp in 
that synthetic route is azido-geranylgeraniol (AzGGOH); a stock of AzGGOH was thus available for 
use in work for this thesis. Tamanoi et al. demonstrated in 2009 that the Click-iT® kit azide GG 
alcohol (from Invitrogen) could be used to metabolically label prenylated proteins and that some of 
these could subsequently be identified using 2D gel electrophoresis and LC-MS/MS.183 Furthermore, 
it has been known for several years that cells are able to use GGOH to prenylate proteins via a 
salvage pathway involving GGOH kinase.267, 268 Thus AzGGOH was a viable choice to probe 
prenylation in fibroblasts further and to attempt to identify those Rab proteins still prenylated in the 
case of REP-1 knock-out. 
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Figure 90: Cartoon illustrating the process of metabolically labelling geranylgeranylated proteins with an azide tag and 
their subsequent labelling with biotin and TAMRA via bioorthogonal ligation. 
4.3.5.1 Metabolic labelling in CHM and Flox fibroblasts 
In vitro prenylation and bioorthogonal ligation of S100 samples from cells with a REP-1 knock-out 
allows identification of those Rabs that are not prenylated under these conditions. However, 
information on those Rabs that are still prenylated, even though there is no REP-1, could help to 
build a more complete picture of the roles of REP-1 and REP-2 in the cell. To this end, CHM and Flox 
fibroblasts were treated with 20 µM AzGGOH (from 50 mM DMSO stock) for 24 hours in full media; 
cells were then harvested and lysed using an SDS lysis buffer (1% NP-40, 1% sodium deoxycholate, 
0.1% SDS, 50 mM Tris-HCl, 150 mM NaCl and 1 × EDTA-free protease inhibitor cocktail (Roche)) 
found to be effective by other lab members. SDS lysis buffer was added to the cells (500 µl per 15 cm 
tissue culture dish) before transfer of the lysate to an Eppendorf tube where further lysis occurred 
for fifteen minutes on ice. Centrifugation of the lysed cells at 16,000 × g yielded the PNS, which was 
used for all subsequent bioorthogonal ligations with the TAMRA-Yn-Biotin II capture reagent. Since 
protein labelling with the azide tag occurred in the cell, further fractionation to yield the S100 and 
P100 fractions was not performed to ensure that the entirety of azide-tagged protein was available 
for bioorthogonal ligation as prenylated proteins may be membrane bound or cytosolic when bound 
to RabGDI or REP as part of the Rab cycle. 
PNS samples from fibroblast cells metabolically labelled with either AzGGOH or GGOH (negative 
control) were subjected to bioorthogonal ligation with TAMRA-Yn-Biotin II. The conditions used for 
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the click reaction for metabolically-labelled samples had previously been optimised by members of 
the Tate group. The reaction was carried out as follows: 50 µg PNS was reacted at a concentration of 
1 mg/ml with a pre-mixed capture reagent solution containing 50 µM TAMRA-Yn-Biotin II, 1 mM 
CuSO4, 100 µM TBTA and 1 mM TCEP. The components of the pre-mix solution were mixed in the 
order given, with thorough mixing after each addition and left for at least 2 minutes to allow 
reduction of the Cu(II) to Cu(I) before addition to the PNS, as with the capture mix for in vitro  
prenylation samples. The capture reaction was left to proceed for one hour at room temperature 
before addition of 10 mM EDTA and sample precipitation using the CHCl3/MeOH protein 
precipitation protocol, as with HEK293A samples. Precipitated proteins were resuspended in 
resuspension buffer and run on a 12% Bis-Tris polyacrylamide gel. From the in-gel fluorescence scan 
shown in Figure 91, it can be seen that the fluorescence signal from fibroblasts with no REP-1 was 
much weaker than that from fibroblasts where REP-1 was still present; this was the case for every 
plate of each type of fibroblasts labelled. Figure 91 shows labelling in two different plates from each 
condition used; there is reduced prenylation where REP-1 has been knocked out (lanes 1 and 2) 
compared to where prenylation is at normal levels (lanes 3 and 4), as was expected. Furthermore, 
very little background fluorescence is seen, suggesting the conditions used for sample preparation 
and click capture are close to optimal.   
 
Figure 91: In-gel fluorescence scan demonstrating metabolic labelling with AzGGOH of proteins in CHM and Flox 
fibroblasts. 50 µg PNS from AzGGOH or GGOH (control) metabolically labelled CHM and Flox 
 
fibroblasts were captured 
with TAMRA-Yn-Biotin II reagent, precipitated and resuspended and run on a 12% Bis-Tris polyacrylamide gel. PNS from 2 
different plates of cells metabolically-labelled under the conditions indicated were probed separately The gel was imaged 
using an Ettan DIGE imager (GE Healthcare) and then stained with colloidal Coomassie to show equal loading. 
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4.3.5.1.1 The choice of reducing agent for the click reaction with metabolically-
labelled samples 
The protocol described above for the click capture of samples containing proteins metabolically 
labelled with an azide tag used TCEP as the copper reducing agent, rather than the ascorbate used 
for in vitro prenylation samples. As mentioned, these conditions were those already optimised for 
metabolic labelling in the Tate group. In order to confirm that the ascorbate conditions optimised for 
labelling of S100 samples prenylated in vitro were not as appropriate as TCEP in this case, both 
conditions were compared side by side, using the same quantity and concentration of PNS from 
metabolically-labelled fibroblasts (50 µg and 1 mg/ml, respectively). Figure 92 shows that the 
ascorbate conditions gave a much higher fluorescence background than TCEP conditions (the 
contrast of the image had to be adjusted separately in order to be able to see the ascorbate labelling 
above background) and also made the Coomassie stain more smeared in appearance so bands were 
difficult to make out (this has often been noted when ascorbate is used as the reducing agent but is 
particularly evident here). Thus TCEP capture conditions were judged to be the most suitable for the 
metabolically-labelled samples.  
 
Figure 92: In-gel fluorescence scan showing capture of metabolically labelled samples with  TAMRA-Yn-Biotin II capture 
reagent and either ascorbate (A) or TCEP (T) as the reducing agent for the click reaction. 50 µg PNS was captured with 
50 µM TAMRA-Yn-Biotin II capture reagent using either TCEP or ascorbate as the reducing agent for the click reaction. 
Samples were precipitated and resuspended before runnong on a 12% Bis-Tris gel and imaging using an Ettan DIGE imager. 
The gel was stained with colloidal Coomassie to show equal loading. Contrast of the ascorbate lane was adjusted because 
otherwise background wass too high to see signal from labelled proteins. 
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4.3.5.1.2 Affinity purification of metabolically-labelled and click captured proteins 
from fibroblast samples 
As with samples prenylated with AzGGpp in vitro, samples metabolically labelled with AzGGOH could 
also be affinity purified, following bioorthogonal ligation with the capture reagent. Figure 93 shows 
the results of affinity purification of 50 µg AzGGOH or GGOH (negative control) labelled PNS, 
captured with TAMRA-Yn-Biotin II and affinity purified using magnetic streptavidin beads. The 
Western blots of Rab27A and Rab5 also demonstrate that Rabs were labelled and hence could be 
affinity purified. 
 
Figure 93: In-gel fluorescence scans and Western blots demonstrating affinity purification of TAMRA-Biotin-labelled 
samples that were metabolically tagged with an azide moieety. Two separate in-gel fluorescence scans and Western blots 
of two sets of the same type of samples – CHM fibroblasts (TM-treated Chm
Flox
 MCM
+
 cells) and Flox 
 
fibroblasts 
metabolically labelled by feeding the cells with either 20 µM AzGGOH or GGOH (control). 80 µg PNS from the fibroblasts 
was captured with TAMRA-Yn-Biotin II capture reagent via a click reaction and half was affinity purified with magnetic 
streptavidin beads and eluted by heating the beads in SDS loading buffer at 95 °C for 5 minutes. Samples were run on a 12% 
Bis-Tris polyacrylamide gel with MES SDS running buffer and imaged with an Ettan DIGE imager. After scanning the gels 
they were subjected to Western blotting and probed with α-tubulin (loading control) Rab5 (Sigma) or Rab27A (4B12) 
antibodies.E = eluant  from beads after heating to 95 °C for 5 mniutes, S = supernatant from affinity purification. 
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4.3.5.2 Metabolic labelling of HEK293A cells 
Substantial work was done to identify unprenylated Rabs from the S100 of Mevastatin-treated 
HEK293A cells by using LC-MS/MS proteomics, described in Chapter 2; metabolic labelling of 
HEK293A cells using AzGGOH was attempted in order to compliment this work. Also, because the 
Rabs that are unprenylated when the cells are treated with Mevastatin had already been identified, 
it had the potential to be a useful point of comparison to those identified from the metabolically-
labelled fibroblasts. However, unlike with the fibroblasts, labelling HEK293A cells with AzGGOH did 
not prove straightforward and in the time available was not successful. Initially the same conditions 
successfully used for the labelling of fibroblasts were employed i.e. 20 µM AzGGOH was added to 
the cells in their normal full media and the cells were treated for 24 hours before they were 
harvested, lysed and azide-tagged proteins labelled with TAMRA and Biotin via the click capture 
reaction. However, as can be seen in Figure 94A, the labelling compared to the GGOH-fed control 
HEK293A cells was very low and the background fluorescence signal was unexpectedly high. The 
apparent high background is most likely due to the automatic contrasting of the ImageQuant™TL 
software used to visualise gels scanned by the Ettan DIGE imager and results from the labelling being 
very weak compared to the background. Figure 94B highlights just how weak the metabolic labelling 
in HEK293As was by comparison to labelling in Flox fibroblasts. 
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Figure 94: Metabolic labelling of HEK293A cells with AzGGOH. A: HEK293A cells were fed with 20 µM AzGGOH or GGOH 
(control), lysed and then 50 µg PNS captured via click reaction by TAMRA-Yn-Biotin II reagent. Samples were run on a 12% 
Bis-Tris polyacrylamide gel with MES SDS running buffer, imaged with an Ettan DIGE imager and stained with colloidal 
Coomassie to show protein loading. B: A comparison of Chm
Flox
 MCM
+
 fibroblasts and HEK293A cells fed with 20 µM 
AzGGOH and treated the same way as described for figure 14A. C: A comparison of HEK293A cells fed with 20 µM AzGGOH 
and either 10 µM Mevastatin or DMSO (control) simultaneously. Samples were prepared as descriped for Figure 14A.  
The metabolic labelling conditions for HEK293A cells were subsequently altered to try and improve 
the amount of labelling seen by in-gel fluorescence. The concentration of AzGGOH added to the cells 
was increased to 50 µM (not shown) and Mevastatin was added concurrently with the 20 µM 
AzGGOH in order to stop natural GGpp synthesis and try and force the prenyltransferases to use 
AzGGOH as their substrate. These conditions did not improve the labelling significantly (Figure 94C). 
It is not clear why the HEK293A cells would not take up the AzGGOH. No further attempts were 
made to optimise labelling in HEK293A cells due to time constraints. 
4.3.6 Mass spectrometry-based proteomics of CHM and Flox fibroblast samples  
The purpose of developing the two different protein labelling techniques in CHM and Flox fibroblast 
cell samples (in vitro and metabolic labelling) described above was to allow identification of proteins 
affected by a lack of REP-1 and so go some way to answering fundamental questions about the 
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differences in Rab protein substrates for REP-1 and REP-2 as well as the potential mode of action of 
the disease Choroideremia. The experiments performed to identify prenylated and labelled proteins 
by LC-MS/MS are described below. The same basic sample preparation protocols for the mass 
spectrometry experiments as were described in Chapters 2 and 3 were used here (further detailed in 
the Materials and Methods chapter). 
4.3.6.1 Proteomics of in vitro prenylation of CHM and Flox fibroblast samples 
Samples from in vitro prenylation of S100 from fibroblasts with and without REP-1 and with and 
without Mevastatin treatment allowed identification of Rab proteins that were not prenylated 
endogenously in cells lacking REP-1 and also of those Rabs affected by Mevastatin, which should be 
all of those present in the cell. The first proteomics experiment of these samples is described below, 
followed by a description of the attempt made to quantify the differences in protein levels using 
iTRAQ quantitative proteomics. 
To identify those Rab proteins that are unprenylated in fibroblasts with a REP-1 knock-out, 1 mg of 
S100 from CHM, Mevastatin-treated and untreated Flox fibroblasts were prenylated in vitro with 
AzGGpp and captured with TAMRA-Yn-Biotin II, followed by affinity purification with magnetic 
streptavidin beads. The conditions used were those optimised for labelling of Rabs from S100 
described earlier in this thesis (Chapter 2 section 2.3.5). The beads were not washed with urea or 
guanidine in this case to try and minimise the aggregation of the beads and also because work by 
other members of the Tate group that suggested these steps were not essential to reduce detection 
of background proteins non-specifically bound to the beads; the beads were submitted for on-bead 
digest.  
Figure 95 shows a 30 µg sample of the beads submitted for MS-based proteomics analysis run on a 
gel to confirm labelling and affinity purification by in-gel fluorescence. From the in-gel fluorescence 
scan of the samples it can be seen that the labelling in the sample from cells that had a REP-1 knock-
out (lane 1, DMSO treatment was used as a negative control for Mevastatin treatment) was much 
weaker than that seen in S100 from the cells that were Mevastatin treated (lane 10). Furthermore, 
Figure 95 shows that affinity purification was successful as labelled protein can be seen in the 
sample eluted from the streptavidin beads (lanes 2 and 11). The Rab5 Western blot shown in Figure 
95 indicates that protein loading was fairly consistent between samples (Mevastatin treatment may 
affect Rab5 expression levels252) and also that Rab5 was affinity purified in the Mevastatin-treated 
samples. The Rabs identified from these samples are shown in Tables 16A. Tables 16B demonstrates 
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that a very low background of non-Rab proteins was detected from the samples, indicating that the 
protocol used for preparation of the proteomics samples was close to optimal.  This was especially 
encouraging because the samples were submitted for on-bead trypsin digest to generate the 
peptides for LC-MS/MS analysis; this meant that there was a potentially greater range of proteins 
that could be identified as the protein mass range was not restricted, as it is with in-gel trypsin digest 
of protein in a band excised from a polyacrylamide gel. 
 
Figure 95: In-gel fluorescence scan and Rab5 Western blot showing 30 µg extrcted from the 1 mg samples submitted for 
proteomics analysis. As described in the text, S100 from either Chm
Flox
 MCM
+
 TM
+
 fibroblasts or Chm
Flox
 MCM
+
 fibroblasts 
treated with Mevastatin were prenylated in vitro with either 20 µM AzGGpp or 20 µM GGpp (control) and captured and 
affinity purified using optimised conditions. 30 µg was extracted from each sample from before and after affinity 
purification and run on a 12% Bis-Tris polyacrylamide gel and imaged using the Cy3 channel of an Ettan DIGE imager. The 
gel was subjected to Western blot and probed with Rab5 antibody (Sigma). 
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 Table 16A   Number of unique peptides 
    Mevastatin Tamoxifen Mevastatin 
# Identified Rab Proteins Accession # Molecular Weight AzGGpp AzGGpp GGpp 
1 Rab7A P51150 23 kDa 9 3 0 
2 Rab18 P35293 23 kDa 9 0 0 
3 Rab5C P35278 23 kDa 7 3 0 
4 Rab1A P62821 23 kDa 6 4 0 
5 Rab10 P61027 23 kDa 6 0 0 
6 Rab21 P35282 24 kDa 6 2 0 
7 Rab14 Q91V41 24 kDa 5 0 0 
8 Rab9A Q9R0M6 23 kDa 4 0 0 
9 Rab11A P62492 24 kDa 4 0 0 
10 Rab2A P53994 24 kDa 3 2 0 
11 Rab5A Q9CQD1 24 kDa 3 0 0 
12 Rab5B P61021 24 kDa 3 3 0 
13 Rab1B Q9D1G1 22 kDa 2 2 0 
14 Rab4A P56371 24 kDa 2 0 0 
15 Rab6A P35279 24 kDa 2 0 0 
16 Rab31 Q921E2 21 kDa 2 0 0 
 
Table 16B Mevastatin AzGGpp TM AzGGpp Mevastatin GGpp 
Total Rabs identified 16 7 0 
Total proteins identified 36 40 23 
Tables 16A and 16B: Rabs identified from LC-MS/MS analysis of samples prepared from in vitro prenylation of 
fibroblasts. Proteins were identified using the Mascot database (Matrix Science) and results analysed using Scaffold 3 
(Proteome Software). The numbers of unique peptides identified for each protein are displayed here. The Scaffold file 
containing the data described in this table is provided in electronic supplementary information; Proteomics Experiment 9 
refers to the data in these tables. 
Tables 16A shows that there were more Rabs identified from the Mevastatin-treated Flox fibroblast 
sample than from the CHM fibroblast sample and those Rabs that were identified from the CHM 
fibroblast sample were identified from fewer unique peptides and spectra, which could indicate a 
lower abundance of these proteins in the sample. This is consistent with there still being some 
prenylation in CHM fibroblast cells, as REP-2 is still active, so there should be a smaller pool of 
unprenylated Rabs in the cytosol available for azide-tagging, as is also indicated by the weaker 
fluorescence signal from labelled proteins in the samples with only a REP-1 knock-out as opposed to 
those treated with Mevastatin (as in Figure 95). Pleasingly, no Rab proteins were identified from the 
GGpp control samples, as was expected because there were no Rab proteins tagged with an azide 
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that could then be labelled with biotin (and TAMRA) via the click reaction to allow affinity 
purification by streptavidin beads.  
The proteomics protein hits shown in Tables 16 suggest that Rab7A, Rab5C, Rab1A, Rab21, Rab2A, 
Rab5B and Rab1B are the Rab proteins most strongly affected by the lack of REP-1 in the CHM 
fibroblasts as they accumulated unprenylated in the cytosol, allowing labelling by AzGGpp and 
subsequent bioorthogonal ligation with TAMRA-Yn-Biotin II; whilst other Rabs that were detected in 
the Mevastatin-treated samples were not detected in the REP-1 knock-out sample. Alternatively, it 
may be that there are more of these Rab proteins expressed in the cells. This would mean that when 
the prenylation level in the cells is reduced by knocking out REP-1 then there is more of these 
proteins in the cytosol available for detection than other Rabs that are less highly expressed and so 
the amount of them that accumulates due to a reduction in prenylation may be below the detection 
levels for the techniques used here. These preliminary results thus required clarification by obtaining 
quantitative data on the relative levels of the Rab proteins that could be detected in the samples. 
4.3.6.2 iTRAQ quantitative comparison of in vitro prenylation samples 
iTRAQ quantitative proteomics allows relative quantification of protein levels between samples (as 
described in Chapter 1 section 1.4.2.3 and demonstrated in Chapter 2 section 2.5.1.1). In this case 
iTRAQ was to be used to assess the quantitative difference in the amount of unprenylated Rabs 
detected between REP-1 knock-out and Mevastatin-treated fibroblasts as well as fibroblasts with a 
REP-1 knock-out treated with Mevastatin. From the in-gel fluorescence scan, it was not clear 
whether there was complete pull-down of labelled protein onto the beads and consequently this 
step was repeated and the beads pooled before sample submission. Disappointingly, after four 
months waiting for the results of this experiment, a problem with the iTRAQ labelling steps after the 
sample was submitted resulted in the loss of the combined samples and thus there was no 
possibility to obtain quantitative data during the time frame of this thesis. As it is still important to 
discover the Rab proteins that accumulate unprenylated and whether this is specific to certain Rabs 
or it is a proportion of all Rabs that is affected, it is very likely that this work will be continued in the 
near future. 
 
171 
 
 
Figure 96: 30 µg extract of in vitro prenylated fibroblasts submitted for iTRAQ quantitative proteomics analysis.  
4.3.6.3 Proteomics of metabolically-labelled samples 
Samples containing geranylgeranylated proteins metabolically-labelled by endogenous enzyme(s) 
with an azide tag can give complimentary information to those where unprenylated Rabs are azide-
tagged in vitro. To establish whether labelled proteins could be identified from metabolically-
labelled samples, 2 mg of PNS from AzGGOH-fed CHM fibroblasts and AzGGOH-fed and GGOH-fed 
Flox fibroblasts were submitted for LC-MS/MS proteomic analysis. The samples were prepared using 
the click capture and affinity purification conditions described in section 4.3.5; the magnetic 
streptavidin beads were washed in the same manner as the in vitro prenylation samples described in 
section 4.3.6.1. Once again the samples were submitted for on-bead digest; particularly in this case 
because there are geranylgeranylated proteins of higher molecular weight, such as G proteins, that 
had the potential to be used as an internal control if labelled with AzGGOH as the level of their 
prenylation should not be affected by the level of REP-1 in the cells. Samples from AzGGOH-fed 
HEK293A cells with and without Mevastatin treatment were also submitted to see if any labelled 
protein could be detected despite the poor fluorescence signal. Figure 97 shows the gel of 
approximately 30 µg of the samples submitted for proteomics analysis.   
Mevastatin - +
Tamoxifen + -
Pull-down - B S - B S - B S
Lane 1 2 3 4 5 6 7 8 9
20 -
25 -
20 -
25 -
37 -
In-gel fluorescence
Colloidal CoomassieM
W
 (
D
a)
 ×
1
0
3
172 
 
 
Figure 97: Approximately 30 µg of extract of metabolically labelled Flox and CHM fibroblasts and HEK293A samples 
submitted for proteomics analysis by LC-MS/MS.  
As expected from the poor labelling seen with these samples by in-gel fluorescence, very few 
geranylgeranylated proteins were detected from the HEK293A samples (Table 17A) although there 
was also a low background of non-specific protein that bind to the beads (Table 17B). 
 Table 17A   Number of unique peptides 
# Identified Rab Proteins Accession # Molecular Weight AzGGOH AzGGOH Mevastatin 
1 Rab10 P61026 23 kDa 2 6 
2 Rab18 Q9NP72 23 kDa 0 3 
3 Rab14 P61106 24 kDa 0 2 
4 RhoA P61586 22 kDa 6 9 
5 CDC42 P60953 21 kDa 3 0 
 
Table 17B HEK293A AzGGOH HEK293A AzGGOH Mevastatin 
Total Ras-related proteins identified 3 4 
Total proteins identified 28 37 
Table 17A and 17B: Number of geranylgeranylated Ras superfamily proteins identified from 2 mg PNS from HEK293A 
cells metabolically-labelled with AzGGOH and cells both metabolically labelled with AzGGOH and treated with 
Mevastatin simultaneously. The Scaffold file containing the data described in this table is provided in electronic 
supplementary information; Proteomics Experiment 10 refers to the data in these tables. 
In contrast, a number of Rabs were identified from the fibroblast samples (Table 18A) and again with 
a low background of non-geranylgeranylated proteins that bound non-specifically to the beads 
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(Table 18B). Pleasingly, no Ras superfamily proteins were detected in the GGOH control sample. 
With metabolic labelling the AzGGOH probe was expected to also be a substrate for the 
prenyltransferase GGT-1 (Chapter 2 demonstrated that AzGGpp is a substrate for GGT-1 in vitro). 
Four geranylgeranylated Ras superfamily proteins were also identified in the fibroblast samples 
labelled with azide, suggesting that AzGGOH can indeed be processed into a substrate for GGT-1 as 
well as RGGT. From these data it is difficult to tell which Rabs are affected by a lack of REP-1 as most 
of those detected appear in both samples. Since Rab14, Rab1B, Rab8B, Rab21 and Rab35 were not 
detected in the AzGGOH-labelled REP-1 knock-out sample it is possible that these are more 
preferentially substrates for REP-1 than REP-2. However, other Rabs may be affected in a 
quantitative way so they would still be prenylated with AzGGOH in both samples but in reality there 
is less total prenylation in the TM-treated sample. iTRAQ quantification was the next step necessary 
to try and find out what the actual differences in prenylation levels were between samples. 
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 Table 18A   Number of unique peptides 
     Tamoxifen  
# Identified Rab Proteins Accession # Molecular Weight AzGGOH AzGGOH GGOH 
1 Rab7A P51150 23 kDa 8 8 0 
2 Rab1A P62821 23 kDa 7 3 0 
3 Rab14 Q91V41 24 kDa 5 0 0 
4 Rab18 P35293 23 kDa 5 7 0 
5 Rab5C P35278 23 kDa 4 3 0 
6 Rab10 P61027 23 kDa 4 3 0 
7 Rab11A P62492 24 kDa 4 4 0 
8 Rab1B Q9D1G1 22 kDa 2 0 0 
9 Rab5A Q9CQD1 24 kDa 2 2 0 
10 Rab6A P35279 24 kDa 2 2 0 
11 Rab8B P61028 24 kDa 2 0 0 
12 Rab21 P35282 24 kDa 2 0 0 
13 Rab35 Q6PHN9 23 kDa 2 0 0 
14 Rab2A P53994 24 kDa 0 3 0 
15 Rab5B P61021 24 kDa 0 3 0 
16 Rab9A Q9R0M6 23 kDa 0 2 0 
17 Rab23 P35288 27 kDa 0 2 0 
18 RhoA Q9QUI0 22 kDa 10 7 0 
19 Rac1 P63001 21 kDa 0 3 0 
20 Rap1B Q99JI6 21 kDa 3 3 0 
21 CDC42 P60766 21 kDa 4 2 0 
 
Table 18B Fibroblast AzGGOH Fibroblast AzGGOH TM Fibroblast GGOH 
Total Ras-related proteins identified 16 16 0 
Total proteins identified 32 35 21 
Table 18A and 18B: Number of geranylgeranylated Ras superfamily proteins identified from 2 mg PNS from 
metabolically-labelled fibroblasts. Flox
 
and CHM (TM-treated) fibroblasts were metabolically-labelled with AzGGOH or 
GGOH (control). PNS from the samples was captured and affinity purified and the proteins bound to the streptavidin beads 
were digested into peptides with trypsin on-bead. The peptides were submitted for LC-MS/MS analysis. Scaffold was used to 
visualise the protein hits identified by the mascot search engine. Results are displayed as the number of unique peptides 
detected for each Ras superfamily protein. The Scaffold file containing the data described in this table is provided in 
electronic supplementary information; Proteomics Experiment 11 refers to the data in these tables. 
4.3.6.4 iTRAQ quantification of geranylgeranylated proteins identified from 
metabolically-labelled fibroblast samples 
As discussed in the previous section (4.3.6.3), quantitative comparison of metabolically-labelled 
samples with and without REP-1 was needed to further characterise the difference between REP-1 
and REP-2 substrates. To this end, metabolically AzGG-labelled Flox and CHM fibroblasts were 
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submitted for iTRAQ quantitative proteomics. 2 mg of each sample were submitted and half (1 mg) 
subjected to LC-MS/MS to identify proteins bound to the beads. Samples were prepared as for the 
previous proteomics samples, although NeutrAvidin™ agarose beads were used instead of magnetic 
streptavidin beads for the same reasons discussed in Chapter 3 (section 3.4.1). This experiment 
combined the PNS from two separately treated plates of cells and a biological repeat of each type of 
PNS was included in the iTRAQ experiment. Figure 98 shows approximately 30 µg of each sample 
submitted and from this gel it was not clear if the pull-down of labelled protein onto the beads was 
complete, thus this step (and the subsequent wash steps) was repeated and the beads combined 
before submitting the samples. 
 
Figure 98: Approximately 30 µg of metabolically-labelled fibroblast samples submitted for iTRAQ quantitative 
proteomics. 
Table 19 shows the iTRAQ quantification results for the proteins identified from the metabolically-
labelled fibroblast samples. AzGGpp can act as a substrate for GGT-1 and from the previous 
proteomics data it appears that AzGGOH can too (presumably once converted to AzGGpp by the 
cell). The results from iTRAQ samples again shows proteins that are substrates of GGT-1; namely 
RhoA, RhoC, Rap1 and CDC42. The knock-out of REP-1 in fibroblasts following TM treatment should 
result in reduced prenylation of Rab proteins and was not expected to affect the amount of 
prenylation of other geranylgeranylated small GTPases. From Table 19 it can be seen that RhoA and 
CDC42 levels do not vary significantly between cells with and without REP-1. Yeast alcohol 
dehydrogenase was added at the trypsin digestion stage (already digested to peptides) in equal 
amounts to each sample and is thus a control for  sample preparation for MS and quantitative values 
were normalised to it as well as to CDC42.  
Cell TM AzGGOH AzGGOH TM AzGGOH 2 AzGGOH 2
Pull-down - B S - B S - B S - B S
Lane 1 2 3 4 5 6 7 8 9 10 11 12
20 -
25 - In-gel fluorescence
Colloidal Coomassie
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The total number of geranylgeranylated Ras superfamily proteins identified from this experiment 
and quantified was 30 and the total number of proteins identified was 139 (47 of which were 
identified with 3 or more unique peptides), which is comparable to other proteomics experiments 
and the number of background proteins is acceptable especially because these result from four 
separately processed samples, pooled after iTRAQ labelling and run as a single iTRAQ sample. The 
data set in its entirety is provided in the electronic supplementary information as both a Scaffold file 
and a spread sheet (containing the quantitative information). The two PNS samples from CHM 
fibroblasts were labelled with iTRAQ reagents 114 and 116 whilst samples from Flox fibroblasts were 
labelled with iTRAQ reagents 115 and 117. The quantitative ratios given in Table 19 are thus for 
CHM/Flox. The variability for each of the protein ratios as a percentage (based on the variation in 
the ratios for each peptide used to calculate the protein ratio) is also given in the table.  
Table 19 shows that there was at least a 1.5-fold difference in the amount of geranylgeranylation 
detected for 5 Rab proteins (Rab2A, Rab7A, Rab5A, Rab5B and Rab5C) and, interestingly, the Ras 
superfamily protein Rap1B. Rap1B and its closely related isoform Rap1A are geranylgeranylated 
proteins and recently they have been shown to be important in RPE cell barrier function.269 In the 
disease Choroideremia (caused by a lack of REP-1) the RPE degrades along with the choroid and 
photoreceptors and leads to the blindness that characterises this disease. So it is possible that 
pathways that link Rap1 and Rab proteins are important in the pathogenesis of the disease. The 
quantitative values for each of the geranylgeranylated proteins identified were averaged to give an 
average value of CHM/Flox for each protein when normalised to either ADH1 or CDC42 and these 
results are displayed in Figure 99, with the error bars showing the standard deviation for each 
average value given. 
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 Normalised to ADH1 Normalised to CDC42 115/114 
Variability 
[%] 
117/114 
Variability 
[%] 
116/115 
Variability 
[%] 
117/116 
Variability 
[%] 
Protein 
# Unique 
peptides 
114/115 114/117 116/115 116/117 
Average 
CHM/Flox 
114/115 114/117 116/115 116/117 
Average 
CHM/Flox 
Rab1A 6 0.732 0.636 1.039 0.769 0.794 0.825 1.004 0.731 0.803 0.841 8.424 15.514 46.519 6.465 
Rab1B 4 0.699 0.619 0.857 0.765 0.735 0.788 0.977 0.603 0.798 0.792 2.813 25.774 14.898 10.297 
Rab7A 11 0.489 0.486 0.636 0.666 0.569 0.551 0.767 0.448 0.695 0.615 5.854 11.741 16.404 8.814 
Rab5A 4 0.596 0.493 0.915 0.698 0.676 0.672 0.778 0.644 0.729 0.706 17.384 17.517 21.335 7.149 
Rab5C 5 0.516 0.554 0.838 0.678 0.647 0.582 0.876 0.590 0.707 0.689 3.806 5.005 31.063 6.830 
Rab10 5 0.755 0.437 1.424 0.752 0.842 0.851 0.690 1.003 0.785 0.832 6.682 38.951 27.468 10.807 
ADH1 8 1.000 1.000 1.000 1.000 1.000 1.127 1.579 0.704 1.044 1.114 5.411 11.605 6.703 4.704 
Rab18 9 0.737 0.609 0.993 0.826 0.791 0.830 0.962 0.699 0.862 0.838 5.726 11.952 10.382 4.120 
Rab11A 7 0.684 0.570 0.865 0.774 0.723 0.771 0.900 0.609 0.808 0.772 7.873 2.372 11.850 4.072 
Rab5B 2 0.458 0.383 0.706 0.589 0.534 0.516 0.605 0.497 0.615 0.558 6.357 4.059 2.870 1.353 
Rab21 6 0.751 0.531 0.938 0.689 0.727 0.847 0.838 0.661 0.719 0.766 10.406 11.423 15.359 24.116 
Rab6A 8 0.694 0.479 0.800 0.701 0.668 0.783 0.757 0.563 0.731 0.708 5.635 28.193 32.110 6.847 
Rab35 2 0.789 0.639 0.835 0.681 0.736 0.890 1.010 0.588 0.711 0.800 27.297 1.938 17.206 11.706 
Rab8A 2 0.474 0.367 0.634 0.495 0.493 0.534 0.580 0.447 0.517 0.519     
Rac1 6 0.801 0.725 1.134 0.880 0.885 0.903 1.145 0.798 0.918 0.941 3.420 7.205 23.254 2.953 
Rap1B 4 0.340 0.328 0.575 0.560 0.451 0.384 0.518 0.405 0.584 0.473 3.055 6.545 29.820 3.971 
Rab2A 5 0.612 0.483 0.864 0.623 0.645 0.690 0.762 0.608 0.650 0.678 11.547 28.331 30.706 8.425 
CDC42 2 0.887 0.633 1.420 0.958 0.975 1.000 1.000 1.000 1.000 1.000 2.442 29.947 39.106 2.144 
Rab14 5 0.859 0.627 1.074 0.803 0.841 0.968 0.990 0.756 0.838 0.888 9.268 28.898 27.519 5.875 
RhoC 1 0.751 0.742 0.706 0.702 0.725 0.847 1.172 0.497 0.732 0.812     
GBG12 3 0.758 0.803 0.804 0.825 0.798 0.855 1.269 0.566 0.861 0.888 1.588 9.934 13.385 2.476 
Rab32 3 0.790 0.681 0.889 0.819 0.795 0.891 1.075 0.626 0.854 0.862 3.273 16.530 3.665 3.784 
RhoG 2 0.789 0.673 0.942 0.809 0.803 0.890 1.063 0.663 0.845 0.865 0.739 0.166 5.382 4.476 
Rab31 4 0.687 0.680 0.828 0.785 0.745 0.774 1.074 0.583 0.820 0.813 13.933 8.154 30.018 11.047 
Rab9A 4 0.688 0.603 0.837 0.761 0.722 0.776 0.953 0.589 0.794 0.778 10.721 9.560 5.589 3.562 
Rab4A 1 0.675 0.662 0.726 0.717 0.695 0.761 1.045 0.511 0.748 0.767     
Rab34 3 0.689 0.447 1.183 0.650 0.742 0.776 0.706 0.833 0.679 0.749 37.880 1.389 14.720 26.285 
Rab23 2 0.686 0.531 0.924 0.719 0.715 0.774 0.838 0.650 0.751 0.753 43.539 21.275 64.925 40.176 
RalA 2 0.829 0.659 1.098 0.878 0.866 0.935 1.040 0.773 0.917 0.916 10.358 10.907 3.078 2.534 
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Rap2c 1 0.686 0.877 0.515 0.663 0.685 0.774 1.385 0.362 0.691 0.803     
RhoB 1 0.726 0.720 0.905 0.904 0.814 0.819 1.138 0.637 0.943 0.884     
Table 19: Table showing iTRAQ quantification of proteins identified from metabolically AzGG-labelled fibroblast samples. CHM/Flox quantitative ratios for each iTRAQ reagent (114-117) for 
geranylgeranylated proteins identified in the sample are given as is the variability in the peptide values used to identify each protein for each iTRAQ reagent. Samples normalised in to 2 
different proteins: to the yeast alcohol dehydrogenase standard (ADH1) spiked in; to the geranylgeranylated proteins, and CDC42. The prenylation levels of these two proteins should be 
unaffected by the presence or absence of REP-1. The raw proteomics data for this experiment is given in the electronic supplementary information (Proteomics experiment 12.1). 
 
Figure 99: Bar chart showing the average of the CHM/Flox values for the iTRAQ quantification results shown in Table 19. The average for quantification normalised to ADH1 is shown in blue 
and to CDC42 in red. The error bars represent the standard deviation of the ratios for each protein shown.Calculations were performed in Microsoft Excel.  
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Technical and biological repeats of the iTRAQ experiment detailed at the start of this section were 
generated. However, as with the iTRAQ results from in vitro prenylation of fibroblasts (section 
4.3.6.2), there were technical difficulties with these samples. Fortunately, in this case the samples 
were recoverable, following an additional gel filtration step to remove salts from the labelled protein 
to allow the sample to be subjected to LC-MS/MS (see Materials and methods section 6.13.4). The 
second and third set of samples derived from metabolically-labelled fibroblasts submitted for iTRAQ 
quantitative analysis consisted of a direct repeat of the sample set described above (I.e. from the 
same combined PNS samples, each captured, affinity purified and labelled with iTRAQ reagents in 
the same manner although not at the same time as the first set) and also of the same type of sample 
(i.e. two samples from different CHM fibroblasts and two from Flox fibroblasts) from different 
metabolically labelled cells to the first two sets. Again, each of the second and third iTRAQ samples 
contained a biological repeat within them. The second and third set of iTRAQ samples from 
metabolically-labelled fibroblasts were processed in exactly the same way as the first sample set, 
however the iTRAQ reagent-labelled proteins did not bind to the ion exchange column and instead 
were found in the flow through, necessitating the extra purification step mentioned above. The 
protein hits identified from these samples are shown in Table 20 and Table 21. Due to the extra 
preparation step the number of protein hits identified from these later samples was less than in the 
first attempt. The set of protein hits derived from the same PNS samples as the first (i.e. those from 
the second set) seemed to confirm the relative levels of Rab proteins found in the first (for those 
that were detected in both). The results from the third sample set seemed more variable but this is 
likely to be due to the low number of unique peptides used to identify each protein. The protein hits 
shown in Table 20 and Table 21 are displayed as bar charts in Figure 101 and Figure 102 and the 
average quantitative ratio for each protein over the first two and all three iTRAQ experiments are 
shown in Figure 100 and Figure 103 respectively. 
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 Normalised to ADH1 Normalised to CDC42 
Average of 2 proteomics 
experiments 
Variability (%) 
Protein 
 Unique 
peptides 
114/115 114/117 116/115 116/117 114/115 114/117 116/115 116/117 
CHM/Flox 
normalised 
to ADH1 
CHM/Flox 
normalised 
to CDC42  
114/115 115/116 114/117  116/117  
Rab1A 3 0.818 0.930 0.865 1.029 0.778 0.676 0.989 0.750 0.852 0.820 17.515 14.894 12.196 13.008 
Rab1B 2 0.859 1.008 0.745 0.963 0.816 0.733 0.852 0.702 0.814 0.784 15.470 13.942 18.397 17.627 
Rab7A 9 0.594 0.697 0.582 0.730 0.564 0.507 0.665 0.532 0.610 0.591 4.863 19.207 7.965 22.054 
Rab5A 2 0.695 0.933 0.731 1.074 0.661 0.678 0.836 0.783 0.767 0.723 0.643 2.884 0.385 2.626 
Rab5C 3 0.858 0.783 0.759 0.779 0.816 0.570 0.868 0.568 0.721 0.697 15.834 9.102 4.634 4.873 
Rab10 3 0.812 1.032 0.766 1.066 0.772 0.751 0.876 0.777 0.881 0.813 16.420 4.407 21.972 9.831 
ADH1 5 1.000 1.000 1.000 1.000 0.951 0.727 1.144 0.729 1.000 1.001 6.982 6.873 6.682 12.855 
Rab18 4 1.005 1.056 0.709 0.977 0.956 0.768 0.811 0.712 0.864 0.825 5.399 43.002 18.214 30.411 
Rab11A 2 0.818 1.237 0.730 1.144 0.778 0.900 0.835 0.834 0.853 0.804 3.551 2.338 3.069 3.061 
Rab5B 1 0.633 0.785 0.545 0.740 0.602 0.571 0.624 0.540 0.605 0.571     
Rab21 4 0.706 0.914 0.676 0.867 0.671 0.665 0.773 0.633 0.759 0.726 17.577 20.009 25.797 14.228 
Rab6A 1 0.671 0.939 0.714 1.096 0.638 0.683 0.817 0.799 0.762 0.721     
Rab8A 1 0.807 0.978 0.716 0.950 0.767 0.711 0.819 0.693 0.678 0.633 11.547 14.167 3.098 0.510 
Rap1B 2 0.595 0.791 0.443 0.645 0.566 0.575 0.507 0.470 0.535 0.501 6.129 16.338 14.023 1.189 
Rab2A 3 0.734 0.863 0.619 0.795 0.698 0.628 0.708 0.580 0.699 0.665 10.956 14.523 1.373 16.117 
CDC42 4 1.052 1.375 0.874 1.371 1.000 1.000 1.000 1.000 1.071 1.000 29.481 27.925 50.745 28.451 
Rab14 4 0.962 0.974 0.854 0.945 0.915 0.709 0.977 0.689 0.887 0.855 7.841 0.477 10.072 4.220 
RhoC 1 1.437 1.225 1.130 1.015 1.366 0.891 1.292 0.740 0.963 0.942 0.733  21.628  
GBG12 1 1.050 1.240 0.760 1.141 0.998 0.902 0.869 0.832 0.923 0.894     
Rab32 1 1.010 1.168 0.941 1.193 0.960 0.850 1.077 0.870 0.936 0.900     
Rab4A 1 0.900 1.001 0.904 1.103 0.856 0.729 1.034 0.804 0.836 0.811     
Rab34 1 0.480 0.833 0.470 0.893 0.456 0.606 0.537 0.652 0.706 0.656     
RhoB 1 1.068 1.023 0.826 0.868 1.015 0.744 0.945 0.633 0.880 0.859     
Table 20: iTRAQ protein hits  identified from the second set of iTRAQ samples. CHM/Flox quantitative ratios for each iTRAQ reagent (114-117) for geranylgeranylated proteins identified in 
the sample are given as is the variability in the peptide values used to identify each protein for each iTRAQ reagent. Samples normalised in to 2 different proteins: to the yeast alcohol 
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dehydrogenase standard (ADH1) spiked in; to the geranylgeranylated proteins, and CDC42. The prenylation levels of these two proteins should be unaffected by the presence or absence of 
REP-1. The raw proteomics data for this experiment is given in the electronic supplementary information (Proteomics experiment 12.2). 
 
Figure 100: Bar chart showing the average quantification value for CHM/Flox values in both the first and second set of iTRAQ samples derived from metabolically AzGG-labelled Flox and 
CHM fibroblasts. Error bars show the standard deviation of each average value.The average of the values from normalisation to CDC42 and ADH1 in bot samples sets is given. The average of 
the CHM/CHM and Flox/Flox values (normalised to ADH1) is also given. Graph was created in Microsoft Excel. Only the geranylgeranylated proteins found in both samples are included in the 
graph.  
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Figure 101: Comparison of the average CHM/Flox values (normalised to ADH1 and normalised to CDC42) for the first and second set of iTRAQ samples from metabolically AzGG-labelled Flox 
and CHM fibroblasts (proteomics experiments 12.1 and 12.2). Error bars show the standard deviation for each average value. Only geranylgeranylated proteins found in both samples are 
shown in the chart.Chart was created in Microsoft Excel. 
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Protein 
Unique 
peptides 
Normalised to ADH1 Normalised to CDC42 
Average of 3 samples 
CHM/Flox 
Variability (%) 
Rab1A 3 114/115 114/117 116/115 116/117 114/115 114/117 116/115 116/117 
normalised 
to ADH1 
normalised 
to CDC42 
115/114 116/115 117/114 117/116 
Rab1B 1 0.925 0.925 1.348 1.302 0.877 0.844 0.736 0.635 0.943 0.804 13.600 12.667 7.793 25.474 
Rab7A 5 0.814 0.838 1.265 1.288 0.771 0.765 0.691 0.628 0.893 0.760 7.105 2.542 16.363 6.624 
ADH1 5 0.759 0.667 1.026 0.950 0.719 0.609 0.560 0.463 0.690 0.590 13.869 10.488 20.147 17.235 
Rab18 3 1.000 1.000 1.000 1.000 0.947 0.913 0.546 0.487 1.000 0.908 11.511 7.610 3.892 6.673 
Rab11A 1 0.768 0.838 1.205 1.243 0.727 0.765 0.658 0.606 0.914 0.780 13.762 2.373 4.506 1.919 
Rab21 1 0.639 0.779 1.108 1.334 0.606 0.711 0.605 0.650 0.890 0.751 25.058 7.091 6.408 11.229 
Rap1B 1 0.750 0.804 0.935 0.991 0.710 0.734 0.510 0.483 0.796 0.687 18.461 13.624 16.003 11.192 
Rab2A 1 1.678 1.545 3.377 3.074 1.589 1.410 1.844 1.498 1.163 0.863 17.854 8.544 24.030 14.584 
CDC42 2 0.610 0.627 1.061 1.078 0.578 0.572 0.580 0.525 0.747 0.632     
Rab14 1 1.056 1.095 1.832 2.051 1.000 1.000 1.000 1.000 1.217 1.000 16.099 13.792 7.914 23.102 
RhoC 3 0.944 0.991 1.191 1.235 0.894 0.904 0.650 0.602 0.955 0.824     
GBG12 2 0.825 0.994 1.668 1.954 0.782 0.908 0.910 0.952 1.096 0.924 12.221 7.771 8.967 14.376 
  1.192 1.397 1.586 1.783 1.130 1.276 0.866 0.869 1.112 0.941 9.464 3.772 0.010 5.035 
Table 21: iTRAQ protein hits from the third iTRAQ sample set. CHM/Flox quantitative ratios for each iTRAQ reagent (114-117) for geranylgeranylated proteins identified in the sample are 
given as is the variability in the peptide values used to identify each protein for each iTRAQ reagent. Samples normalised in to 2 different proteins: to the yeast alcohol dehydrogenase standard 
(ADH1) spiked in; to the geranylgeranylated proteins, and CDC42. The prenylation levels of these two proteins should be unaffected by the presence or absence of REP-1. The raw proteomics 
data for this experiment is given in the electronic supplementary information (Proteomics experiment 12.3). 
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Figure 102: Comparison of the average CHM/Flox values (normalised to ADH1 and normalised to CDC42) for the first, second and third set of iTRAQ samples from metabolically AzGG-
labelled Flox and CHM fibroblasts (proteomics experiments 12.1, 12.2 and 12.3). Error bars show the standard deviation for each average value. Only geranylgeranylated proteins found in 
both samples are shown in the chart.Chart was created in Microsoft Excel. 
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Figure 103: Bar chart showing the average quantification value forCHM/Flox values in both the first, second and third set 
of iTRAQ samples derived from metabolically AzGG-labelled Flox and CHM fibroblasts (proteomics experiments 12.1, 
12.2, and 12.3). Error bars show the standard deviation of each average value.The average of the values from 
normalisation to CDC42 and ADH1 in bot samples sets is given. The average of the CHM/CHM and Flox/Flox values 
(normalised to ADH1) is also given. Graph was created in Microsoft Excel. Only the geranylgeranylated proteins found in 
both samples are included in the graph. 
The cellular location and functions of the Rabs and Rap1B identified from the iTRAQ samples as 
showing a quantitative difference in the amount of geranylgeranylation between metabolically 
AzGG-labelled Flox and CHM fibroblasts are shown in Table 22. 
Rab 
Protein 
Accession 
Number 
Cellular Location Function 
Rab2A P53994 ER, ER-Golgi IC, Golgi ER to Golgi trafficking 
Rab5A Q9CQD1 PM, CCVs, EE EE fusion 
Rab5B P61021 PM, CCVs, EE EE fusion 
Rab5C P35278 PM, CCVs, EE EE fusion 
Rab7A P51150 
LE, lysosomes/vacuole, Melanosomes, 
phagosomes 
LE to lysosome trafficking 
Rap1B Q99JI6 PM, cytoplasm 
Cadherin-based cell adhesion, integrin activation 
and platelet aggregation 
Table 22: The cellular location and function of the Ras superfamily proteins identified by iTRAQ in CHM Flox fibroblast 
cells and shown to vary in prenylation amount depending on the presence or absence of REP-1. EE = Early Endosome, PM 
= Plasma Membrane, LE = Late Endosome, TGN = Trans-Golgi Network, CCV = Clathrin-coated Vesicle, RE = Recycling 
Endosome, ER = Endoplasmic Reticulum, Golgi IC = Golgi Intermediate compartment, St = stomach S100, Sp = Spleen S100, L 
= Lung S100.  Information adapted from the review by Hutagalung and Novick, Zhang et al. and Wittchen et al.
19, 270, 271
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 Conclusions 4.4
Bone marrow cells from ChmFlox MCM+ mice were cultured and REP-1 successfully knocked-out of 
these cells by TM treatment, as determined by PCR and Western blot. Once conditions for 
Tamoxifen treatment of the bone marrow culture were established, work began to try and label 
unprenylated Rabs in bone marrow lysate by in vitro prenylation with AzGGpp and capture with 
TAMRA-Yn-Biotin II. Unfortunately during the timeframe of this thesis it was not possible to see a 
signal from TAMRA-labelled proteins by in-gel fluorescence. Cells were also treated with Mevastatin 
to create a larger pool of unprenylated proteins with the aim of generating a stronger signal by 
increasing the number of proteins available to label; once again no labelling could be seen by in-gel 
fluorescence. The reason why no labelling could be seen in these samples was unclear but these cells 
could certainly provide some interesting information that would be complimentary to the work on 
other tissue types and the fibroblast cells if the technique could be optimised for these samples. 
Fibroblast cells were obtained from ChmFlox MCM+ and ChmFlox mice and conditions for TM treatment 
to achieve REP-1 knock-out in the ChmFlox MCM+ fibroblasts were developed. Treatment of cells with 
10 µM TM for 48 hours was determined to be optimal and knock-out of REP-1 was shown by PCR 
and Western blot. Once the REP-1 knock-out was established then samples were subjected to in 
vitro prenylation and capture reactions and labelling was visualised. Once the cells were treated with 
TM the REP-1 knock-out persisted. Cells were also treated with Mevastatin to give a reduction in 
prenylation of all Rab proteins as a point of comparison to the partial reduction in prenylation seen 
with REP-1 knock-out. Pleasingly, the fluorescence signal from AzGG-TAMRA-Biotin labelled proteins 
in the Mevastatin-treated sample was stronger than that from the REP-1 knock-out samples. This 
was expected as REP-1 knock-out reduces the level of prenylation either over all Rabs or of specific 
Rabs, whilst Mevastatin treatment inhibits prenylation of all Rabs as so gives a larger pool of 
unprenylated proteins to tag with an azide group. These samples could also be affinity purified. 
Metabolic labelling of proteins in Flox and CHM fibroblasts with AzGGOH was successfully 
demonstrated. Proteins tagged with AzGG by the endogenous prenylation machinery could be 
visualised, following bioorthogonal ligation with TAMRA-Yn-Biotin II, by in-gel fluorescence and the 
signal from CHM fibroblast samples was much weaker than that from samples where prenylation 
was at wild type levels. This was because the reduction in prenylation in CHM fibroblasts due to REP-
1 knock-out meant fewer proteins could be labelled with AzGGOH. The labelled proteins were 
affinity purified, including Rab5 and Rab27A. 
187 
 
Metabolic labelling of prenylatable proteins in HEK293A cells was not as successful as in the 
fibroblasts. Indeed the labelling of prenylated proteins with AzGGOH was so weak when visualised 
by in-gel fluorescence that it could barely be seen above background. Treatment of the HEK293A 
cells with Mevastatin concurrently with the AzGGOH treatment in order to try and force the 
prenyltransferases to use AzGGOH as their substrate did not significantly improve the strength of the 
fluorescence signal from the labelled proteins. The poor labelling was confirmed when metabolically 
labelled HEK293A samples were submitted for proteomics analysis and very few Rab proteins could 
be identified, unlike samples described in Chapter 2 that had been prenylated in vitro. 
Proteomics analysis of fibroblasts (Flox and CHM) both prenylated in vitro and metabolically-labelled 
gave encouraging results. For the in vitro prenylation samples 16 Rabs were identified from the 
Mevastatin-treated sample, which is comparable to the Mevastatin-treated HEK293A samples 
discussed in Chapter 2, and seven Rabs were identified from the CHM fibroblast sample. This implied 
that the Rabs found in the CHM fibroblast sample were those that are preferentially substrates for 
REP-1. The best way to establish whether the differences in Rab prenylation levels were quantifiable 
was to use iTRAQ quantification. S100 from cells treated with Mevastatin, TM and Mevastatin or just 
TM were labelled by in vitro prenylation with AzGGpp and bioorthogonal ligation with TAMRA-Yn-
Biotin II, affinity purified and submitted for proteomics analysis. Unfortunately, it took 4 months to 
receive the news that there had been a problem with the iTRAQ labelling and consequently these 
potentially interesting results were not available in time for this thesis.  
For metabolically-labelled samples proteomics was attempted and, following successful 
identification of Rabs from CHM and Flox fibroblasts, more samples were compared for 
quantification of the differences in the amount of prenylated Rabs present in each sample. The 
experiment consisted of submitting lysate from Flox and CHM fibroblasts metabolically-labelled with 
AzGGOH and captured with TAMRA-Yn-Biotin II via a click reaction. A 1.5 to 3-fold difference in 
protein detected was seen for some Rabs and also Rap1 (another geranylgeranylated protein that is 
a member of the Ras superfamily). These differences were very encouraging, indicating Rab proteins 
that may be specific REP-1 substrates. Preliminary work by Neki Patel in the Tate group using the 
NBD-Fpp fluorescence assay developed by Alexandrov et al.179 has also suggested that the rate of 
prenylation of Rab5A (this Rab had a higher quantitative value in CHM fibroblast samples in the 
iTRAQ experiment) may be lower than that of Rab1A (the amount of this Rab detected in the iTRAQ 
experiment did not noticeably change) with REP-2 compared to REP-1 used for the in vitro 
prenylation.  
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  Final Conclusions and Future Work Chapter 5
Work described in this thesis focused on the development of a system of labelling unprenylated Rab 
proteins and protein substrates of GGT-1, extracting them from a complex protein mixture and 
identifying them. The system chosen was that of labelling the geranylgeranyltransferase protein 
substrates with an azide tag via either in vitro prenylation using recombinant enzyme (RGGT or GGT-
1) and AzGGpp or metabolic labelling which used the endogenous prenylation machinery of cells fed 
with AzGGOH. Once proteins were azide-tagged they were labelled with biotin and/or a fluorophore 
moiety via the click reaction. The fluorophore allowed in-gel visualisation of labelled proteins, whilst 
biotin allowed labelled proteins to be affinity purified using the very strong interaction between 
biotin and streptavidin/NeutrAvidin™ agarose beads. Affinity purified proteins present in a sample 
could then be identified using LC-MS/MS based proteomics. The work described here developed 
previous work by the author where the AzGGpp/AzGGOH probes were synthesised and preliminary 
experiments demonstrated labelling of recombinant Rab proteins by in vitro prenylation and 
subsequent bioorthogonal ligation with a biotin-alkyne reagent. 
Initial work, as described in Chapter 2, focussed on developing the conditions to allow unprenylated 
geranylgeranylatable Ras superfamily proteins, particularly Rab proteins, to be labelled and 
identified. HEK293A cells treated with the drug Mevastatin provided samples with a pool of 
unprenylated proteins as Mevastatin inhibits HMG-CoA reductase in the mevalonic acid pathway 
and so inhibits synthesis of GGpp. The cytosolic (S100) fraction of Mevastatin-treated HEK293A cells 
contained the unprenylated proteins. Labelling of unprenylated Rab proteins in S100 was 
demonstrated using in vitro prenylation of samples by RGGT, REP-1 or REP-2 and AzGGpp followed 
by bioorthogonal ligation with an alkyne reagent to label the samples with biotin and a fluorophore. 
The labelling conditions used, especially for the click reaction and affinity purification steps, was 
substantially optimised to give consistently strong labelling signal over background by in-gel 
fluorescence. Rab proteins were identified from S100 samples by LC-MS/MS. Identification of 
geranylgeranylated proteins from Mevastatin-treated cells is not only important because it allowed 
the development of the labelling technique but could also prove useful for future research as there 
are several classes of drug that are important in medicine and which act by inhibiting prenylation, for 
example statins and prenyltransferase inhibitors. 
As prenylation of proteins is an important post-translational modification the ability to identify 
proteins that are affected when prenylation is deficient, as in the case of the disease Choroideremia, 
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is important for the elucidation of disease mechanisms. This thesis demonstrated that Rab proteins 
could be labelled with AzGGpp using both REP-1 and REP-2 recombinant enzymes for in vitro 
prenylation. Work on siRNA knockout of REP-1 and REP-2 in HEK293A cells was not fully developed 
for this thesis but could provide interesting information in the future particularly on any differences 
between REP1 and REP-2 Rab substrates. 
This thesis also demonstrated that AzGGpp could act as a substrate for the prenyltransferase GGT-1 
which showed that the technique is more widely applicable than solely for the study of Rab proteins. 
This also proved the technique to be useful in generating results that were closer to native 
prenylation than those results published by Alexandrov et al. describing the use of a biotinylated 
GGpp substrate that could not be used with wt GGT-1.135  
Once the labelling of unprenylated proteins from cell cytosolic fractions had been demonstrated, the 
labelling technique was developed in tissue lysate from mouse disease models that had a 
prenylation deficiency, specifically affecting the prenylation machinery for Rab proteins. The 
labelling of proteins in tissue samples was optimised, although it proved much more difficult than for 
the optimisation of labelling in cell samples, due to the high fluorescence background experienced. 
CHM and gunmetal mouse tissue samples were used both for the optimisation of labelling and for 
the subsequent identification of the Rab proteins that accumulate unprenylated in the cytosol of 
these samples. A number of Rab proteins were identified from the samples by LC-MS/MS based 
proteomics.  
Chapter 4 described the development of the AzGGpp labelling technique in bone marrow and 
fibroblasts from ChmFlox MCM+ mice. TM treatment knocked out REP-1 in these cells, as 
demonstrated by PCR. Unfortunately it was not possible to achieve labelling of unprenylated 
proteins in S100 from bone marrow culture. However, in vitro prenylation of fibroblast S100 with 
AzGGpp and subsequent click capture reactions resulted in labelled protein visible by in-gel 
fluorescence. The fibroblast cells grown in culture retained the REP-1 knock-out over all the passages 
used.  The labelling of unprenylated proteins did not require any extra optimisation compared to the 
protocol used in Chapter 2. Useful proteomics results were obtained but unfortunately quantitative 
data could not be due to sample handling issues. Metabolic labelling of unprenylated proteins with 
AzGG in fibroblasts with and without REP-1 knock-out proved possible, as demonstrated by in-gel 
fluorescence. Furthermore, a distinct difference in intensity of the fluorescent band for prenylated 
proteins could be seen between the diseased and undiseased cells. Proteomics data was obtained 
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from metabolic labelling samples, including quantitative data. This provided evidence of some Rab 
proteins that may be affected more by the lack of REP-1 and also identified a Ras superfamily protein 
Rap1 that may also be affected by a lack of REP-1. This is interesting as this protein is important for 
cell adhesion in the RPE in the eye.  
Together the results described in this thesis provide a robust technique for labelling and 
identification of unprenylated proteins that are substrates for geranylgeranyltransferases. The 
technique was expanded from recombinant proteins to cell culture and tissue samples from mouse 
disease models. The Rab proteins identified in proteomics experiments provide a useful base for 
further work into the mechanism of disease caused by a lack of REP-1, as well as low RGGT activity. 
The technique can be used to identify protein affected by drugs that cause inhibition of prenylation, 
either by inhibiting the prenyltransferases or by inhibiting GGpp synthesis, although the former was 
not explicitly tested. The AzGG labelling technique for both in vitro labelling and metabolic labelling 
of prenylatable proteins is a promising technique for helping to elucidate disease mechanism and 
drug efficacy. 
To further develop the work described in Chapter 2 it would be useful to be able to optimise the 
siRNA knock-down of REP-1 and REP-2 in HEK293A cells and obtain a specific antibody for REP-2 to 
so the knock-down of the proteins can easily be established. Once this was achieved then iTRAQ 
quantitative proteomics could be used to quantify the difference in the Rabs that accumulate 
unprenylated in the cytosol and develop a picture of the differing cellular roles of the REP isoforms. 
This would add to the evidence for whether there are preferred Rab substrates for the different REP 
isoforms. A further technique that could be used would be metabolic labelling with AzGGOH of the 
cells with the REP-1/2 knock-down to identify those Rabs that are still prenylated. Metabolic 
labelling can give a complementary picture of prenylation to in vitro prenylation with AzGGpp. 
Furthermore, it would be interesting to test the possibility that AzGGpp could act as a substrate for 
FT, although this is highly unlikely due to its size and similarity to GGpp, it would be of use to have a 
definitive answer. 
Future work on the research described in Chapter 3 will involve replicating this work and also 
expanding the number of tissue types used. In particular, eye tissue S100 would be of enormous 
interest as in human Choroideremia patients it is blindness that is the phenotype of the disease so 
identifying the Rab proteins affected in the disease would help with the elucidation of the disease 
mechanism. Currently it is not clear why it is only the eye that is affected in the disease and not any 
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other parts of the body. This work generated new information about the Rabs affected by the 
prenylation defects present in gunmetal and CHM mice and forms a promising basis for future work. 
Due to time constraints and some difficulties with the mass spectrometry service it was not possible 
to attempt to repeat the results generated in the second set of proteomics during the time-frame of 
this thesis. As mentioned in Chapter 1 there are mouse models available that have tissue-specific 
knock-out of REP-1 in the photoreceptors and the RPE of the mouse eyes, developed by Tolmachova 
et al.122. It is possible to isolate these cell types from the rest of the eye and so should be possible to 
label proteins in S100 from them. As there are so few cells in the RPE compared to the number in a 
stomach or lung from the same mouse, it is likely that a pool of cells from several mice would be 
required before enough material was obtained for a proteomics experiment (at least 0.5 mg S100 
would be required) 
Developing the AzGGpp labelling technique to label unprenylated proteins from bone marrow 
samples would provide interesting information especially as there are RGGT inhibitors available that 
treat osteoporosis by targeting RGGT in bone, this could prove a useful technique for testing the 
efficacy of the drugs. For the work in fibroblasts, quantification of proteins identified from REP-1 
knock-out vs. Mevastatin-treated fibroblasts should be repeated. Probing the proteins where the 
level of prenylation with no REP-1 is found to be significantly reduced could help to develop a 
hypothesis for the CHM phenotype. Biochemical assays of prenylation efficiency with REP-1 vs.REP-2 
and assessing whether the proteins are in fact upregulated when there is no REP-1 are initial 
methods that could be used. As techniques for culturing RPE cells are becoming more robust so 
these cells from a mouse model where REP-1 can be knocked out just in these cells would allow 
investigation of cells actually implicated in CHM and the Rabs affected (and any other proteins) 
could be identified using the proteomics techniques described in Chapter 4. 
SILAC labelling of fibroblast cells (with and without REP-1) could also further explore the roles of 
REP-1 and REP-2 in Rab prenylation. SILAC labelling is where cell cultures are grown in media 
containing either light 12C or heavy 13C labelled arginine and lysine; the modified amino acids are 
incorporated into proteins through the metabolic cycle (as mentioned in Chapter 1, section 1.4.2.3). 
This would remove the need for iTRAQ labelling for these samples and is suitable because there is a 
comparison between REP-1 knock-out and no knock-out and SILAC is only suitable for comparison 
between two states i.e. diseased and control. Work has commenced on this at the time of writing 
but no results have yet been obtained. 
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 Materials and Methods Chapter 6
 General 6.1
Sterile PBS was obtained from the media kitchen at Imperial College, except for cell culture work 
where it was purchased from Invitrogen. Reagents were obtained from Sigma Aldrich unless stated 
otherwise. Ultrapure 18.2 mΩ laboratory water was obtained from Elix® and MilliQ® Millipore water 
purification systems.  
 Buffer compositions 6.2
Buffer Components 
Prenylation buffer 50 mM sodium HEPES pH 7.2, 25 mM KCl, 5 mM MgCl2, 1 mM DTE 
(added fresh), and 0.3% Nonidet P-40 or Igepal (stored at 4 °C as a 10× 
stock without DTE) 
Lysis buffer 50 mM HEPES pH 7.2, 10 mM NaCl, EDTA-free protease inhibitors 
(Roche), 1 mM DTT, and 5 mM MgCl2 in dH2O 
Resuspension buffer  2% SDS, 3% Igepal, 10 mM DTT, 10 mM EDTA in PBS 
SDS lysis buffer 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl pH 7.4, 
150 mM NaCl, 1 × EDTA-free protease inhibitors (Roche), dH2O to give 
final concentrations 
6 × SDS loading buffer 300 mM Tris-HCl pH 6.8, 10% w/v SDS, 40% v/v glycerol, 0.002% w/v 
bromophenol blue, 0.009% v/v β-mercaptoethanol. Solution made up 
in ddH2O 
1 × MES SDS running 
buffer 
50 mM MES pH 7.2, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.3 in 
dH2O 
GNTK buffer 50 mM KCl, 1.5 mM MgCl2, 0.01% gelatine, 0.45% Igepal, 0.45% 
TWEEN-20 in ddH2O 
Sf9 cell lysis buffer 50 mM HEPES pH 7.2, 0.1 mM Igepal, 10 mM NaCl, 1 mM β-
mercaptoethanol, 1 × protease inhibitors (Roche cOmplete protease 
inhibitor cocktail) 
S200 elution buffer 20 mM HEPES pH 7.2, 0.1 mM Igepal, 0.5 M NaCl, 1 mM DTT 
RGGT dialysis buffer 20 mM HEPES pH 7.2, 0.1 mM Igepal, 10 mM NaCl, 1 mM DTT 
Table 23: Compositions of buffers used 
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 Polyacrylamide Gel Electrophoresis 6.3
6.3.1 Bis-Tris Gels 
Gels were cast in BioRad 1.0 mm glass plates in the following compositions 
Component Volume (ml) 
H2O  3 
30% v/v Acrylamide  4 
1.25 M Bis-Tris (pH 6.7)  2.9 
10% w/v APS 0.1 
TEMED  0.004 
Table 24: Composition of 10 ml resolving gel (12%) 
Component Volume (ml) 
H2O  1.453 
30% v/v Acrylamide  0.333 
1.25 M Bis-Tris (pH 6.7)  0.714 
10% w/v APS 0.0125 
TEMED  0.002 
Table 25: Composition of 2.5 ml Stacking Gel (4%) 
6.3.1.1 Electrophoresis of Bis-Tris gels  
Samples were loaded onto the gel. Molecular weight calibration was achieved using the following 
protein markers: SeeBlue pre-stained standard (Invitrogen), biotinylated protein ladder (Cell 
Signalling Technology) and Precision Plus All Blue Protein standards (Bio-Rad). Gels were run at 180 V 
in NuPAGE MES running buffer (supplied as a 20× solution), using an Bio-Rad Mini PROTEAN® Tetra 
Cell gel electrophoresis system with a Bio-Rad power supply unit. Gels were then either visualised by 
the method described in section 6.3.3 or subjected to Western blotting as described in section 6.4. 
6.3.2 SDS-PAGE gels 
1.5 mm thick gels were cast with either 10 or 15 wells depending on the number of samples to be 
run. The compositions of stacking and resolving gels are detailed below (Table 26 and Table 27). 
 
 
 
194 
 
Component volume for  7% gel (ml) volume for 10% gel (ml) 
H2O 4.96 3.96 
30% v/v Acrylamide 2.33 3.33 
1.5 M Tris pH 8.8 2.5 2.5 
10% w/v SDS 0.1 0.1 
10% w/v Ammonium persulphate (APS) 0.1 0.1 
N,N,N′,N′-Tetramethylethylenediamine 
(TEMED) 
0.006 0.006 
Table 26: Composition of 10 ml resolving gel (7% and 10%). 
Component Volume 
H2O 2.1 
30% v/v Acrylamide 0.5 
1.0 M Tris pH 6.8 0.38 
10% w/v SDS 0.03 
10% w/v APS 0.03 
TEMED 0.003 
Table 27: Composition of 3 ml stacking gel (5%) 
6.3.2.1 Electrophoresis of SDS-PAGE Gels 
Gels were run at 40 mA per gel in a Hoefer Mighty Small II system with a BioRad power supply unit. 
Molecular weight calibration was achieved using BioRad pre-stained SDS-PAGE low-range marker. 
The running buffer used consisted of 30 mM Tris, 192 mM glycine, and 0.1% SDS.  
6.3.3 Fluorescence imaging of gels 
Proteins captured with the TAMRA-Yn-Biotin reagents were visualised in-gel using the Cy3 channel 
of an Ettan DIGE imager (GE Healthcare) and the Cy2 channel to visualise the molecular weight 
marker. Gels were washed twice with dH2O before imaging. Following imaging, proteins were either 
transferred to a PVDF membrane for Western blotting or stained using Bio-Safe Coomassie stain 
(Bio-Rad). Images were analysed with ImageQuant™ TL software (GE Healthcare). 
6.3.4 Colloidal Coomassie staining of gels 
Gels were stained with colloidal Coomassie solution (Table 28) for at least 1 hour at room 
temperature (RT) with agitation before destaining for at least 3 hours with dH2O. To prepare the 
staining solution components were added in the order given in the. 
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Component Quantity Comment 
Ammonium sulphate 50 g  
85% phosphoric acid solution 59 ml  
dH2O Make solution up 
to 400 ml 
Make ammonium sulphate and phosphoric 
acid solution up to 200 ml first and stir until 
completely dissolved then make up to 400 ml 
Brilliant Blue G (50% dye 
content) 
1.2 g Add to 400 ml solution and stir for 
~15 minutes 
MeOH 100 ml Final step, stir 15 minutes 
Table 28: The composition of the colloidal Coomassie stain.  
 Western blotting 6.4
6.4.1 Protein transfer using a Semi-Dry Western blotting system 
This procedure was carried out on Bis-Tris gels used to visualise capture and pull-down of the azide-
labelled proteins. The samples were first loaded and run in a Bio-Rad Mini PROTEAN® Tetra Cell gel 
electrophoresis system, as detailed in section 6.3 above. Transfer of the proteins to a PVDF 
membrane (Millipore) was then carried out using an Invitrogen semi-dry Western blot system. The 
PVDF membrane was activated by soaking  it for 2 minutes in MeOH and equilibrated for 5 minutes 
in NuPAGE Tris-glycine transfer buffer (supplied as a 20× solution by Invitrogen) before use; the 
blotting paper (Invitrogen 2.5 mm blotting paper) was also soaked in transfer buffer before use. The 
transfer was carried out for 27 minutes at 20 V. 
6.4.2 Transfer using a Wet Western Blotting System 
This procedure was carried out on SDS-PAGE gels. The system used was a Hoefer TE series Transphor 
electrophoresis unit with a Hoefer EPS 24200 power supply unit. Transfer buffer was composed of 
the following components; 25 mM Tris, 192 mM glycine, 20% MeOH. The PVDF membrane was 
activated by soaking it for 2 minutes in MeOH and equilibrated in the transfer buffer for 5 minutes 
before use; the blotting paper was also soaked in transfer buffer before use. The proteins were then 
transferred from the gel to the PVDF membrane for 2 hours at 500 mA. 
6.4.3  Probing membranes with antibodies  
For NeutrAvidin™-HRP (Molecular Probes) immunoblotting,  the PVDF membrane was first blocked 
by incubation for 1 hour in a 5% w/v solution of bovine serum albumin (VWR) in Tris-buffered saline 
(TBS) containing 0.1% TWEEN-20 (TBST), followed by 3 × 10 minutes washes with TBST. The 
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membrane was then incubated for a further 1 hour in NeutrAvidin™-HRP in TBST (1:5000 dilution) 
before a further 3×10 minutes washes in TBST.  
PVDF membranes were blocked in 5% milk in PBS containing 0.1% TWEEN-20 (PBST) for 1 hour 
followed by 3 quick washes in PBST, before membranes were incubated in primary antibody (see 
Table 29, dilutions were made in 5% milk in PBST for all except J905 (1:500 in 1% milk in PBST)) for 1 
hour before a further 3 × 10 minute washes in PBST. Finally the membranes were incubated with the 
appropriate secondary antibody (either polyclonal goat anti-mouse immunoglobulin-HRP or 
polyclonal goat anti-rabbit immunoglobulin-HRP (both from Dako)) at 1:10,000 dilution in 5% milk in 
PBST for one hour before a final 3 washes.  
Antigen Antibody Working 
dilution 
Source 
hRab5a αRab5a (mouse monoclonal)  1:1000 Transduction Labs R610725 
Rab5 αRab5 (rabbit polyclonal) 1:1000 Abcam ab18211 
α-tubulin α-α-tubulin (mouse monoclonal) 1:2000 Sigma T9026 
Rab11A αRab11 (mouse monoclonal) 1:1000 Transduction Labs R610657 
Rab27A 4B12 (mouse monoclonal) 1:10,000 Seabra group 
hREP-1 2F1 (mouse monoclonal) 1:1000 Seabra group 
REP J905 (rabbit polyclonal)272 1:500 Seabra group 
Calnexin  αCalnexin (rabbit polyclonal)  1:5000  Stressgen SPA-860  
Table 29: Primary antibodies used for immunoblotting 
Immunoblots were visualised using chemiluminescence substrate reagent (GE Healthcare, 
Amersham™ ECL plus Western blotting detection system, as per manufacturer’s instructions) and 
exposed to Amersham Hyperfilm™ ECl (GE Healthcare). The films were developed in a Compact X4 
developer (Xograph Imaging Systems). 
 Recombinant proteins  6.5
Recombinant proteins were prepared as described previously by A Berry and Dr M Kirsten (RGGT) 
and by previous members of the Seabra group (Rab1A, REP, RhoA, Rac1 and GGT-1). 22, 140, 273 
RGGT was prepared for this thesis from 2x5ml pellets. Purification of recombinant RGGT prepared in 
Sf9 cells was based on the protocol of Armstrong et al.273 Briefly, cells obtained from 1 l Sf9 cell 
culture (prepared by Dr M Kirsten, received as two 5 ml pellet frozen at -80 °C) were resuspended in 
40 ml Sf9 cell lysis buffer (see Table 23 for buffer composition)  and lysed by sonication for 2 × 30 s at 
20 μm (Branson Sonifier 450) . The lysate was then subjected to ultracentrifugation at 100,000 × g 
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and 4 °C for 1 hour; the supernatant was retained and bound to a miniQ column (HiLoad Q-
sepharose FF (16/10), GE Healthcare, 20 ml column volume) using an FPLC (fast protein liquid 
chromatography) system for ion-exchange chromatography. Following sample injection, the already 
equilibrated column was washed with 2 column volumes (CVs) of buffer A (50 mM Tris pH 7.5, 1 mM 
DTT), followed by a linear gradient reaching 15% buffer B (50 mM Tris pH 7.5, 1 mM DTT, 1 M NaCl) 
over 1.5 CVs. Next the column was  washed with 15% buffer B for 2 CVs before a linear gradient 
reaching 60% buffer B was applied over 7 CVs. 5 ml fractions were collected during this gradient and 
analysed by SDS-PAGE followed by Coomassie staining; finally, a step to 100% buffer B was 
performed to wash the column. Suitable fractions containing RGGT were identified based on the 
Coomassie staining and were pooled and concentrated to 2 ml using a Vivaspin 50 kDa molecular 
weight cut-off (MWCO) device (GE Healthcare). The next step in RGGT purification was size exclusion 
chromatography. The sample was loaded onto a S200 (16/60) column and protein was eluted at a 
flow rate of 1 ml/min using S200 elution buffer (see Table 23 for buffer composition) with 1 ml 
fractions collected with collection starting after 40 ml elution volume. The fractions were analysed 
by SDS-PAGE and Coomassie staining. Those fractions that contained RGGT were pooled and 
dialysed against 5 l dialysis buffer (see Table 23 for buffer composition) before they were 
concentrated using a Vivaspin 50 kDa MWCO device. Protein concentration was determined using 
the BCA assay (Pierce) against a standard BSA concentration curve, following the manufacturer’s 
protocol. 
 Cell culture 6.6
6.6.1  Culture of Human Embryonic Kidney (HEK) 293A cells 
HEK293A cells (Invitrogen) were maintained and cultured as described previously.26 Briefly, HEK293A 
cells were grown in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 
10% fetal bovine serum (FBS), 100 units(U)/ml penicillin G, and 100 U/ml streptomycin in a 
humidified chamber at 37 °C and 10% CO2. Cells grown in 10 cm tissue culture dishes were passaged 
as follows once they reached 90% confluence: the medium was removed by aspiration and the cells 
were washed once with 5 ml PBS (by applying the PBS to the cell layer and immediately removing by 
aspiration) before 3 ml 2.5% trypsin-EDTA solution was administered to the cell layer. The cells were 
incubated at 37°C for 3 minutes to detach the cells, followed by inactivation of the remaining trypsin 
by resuspending the cells in complete medium. Cells were then pelleted at 300 × g for 5 minutes at 
RT. The cells were split in ratios between 1:5 and 1:10 and seeded into fresh media and grown to 
90% confluence. 
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6.6.1.1 EGFP-Rab5A transfection of HEK293A cells 
HEK 293 cells (Invitrogen) were grown in a 6-well plate to confluence before transfection; with 
plasmid DNA encoding EGFP-Rab5A (generated by Dr Molly Strom). A solution of 1.2 ml Optimem 
(Invitrogen), containing 24 µl Fugene (Roche) was incubated at RT for 5 minutes. 60 µl of a 100 ng/µl 
solution of EGFP-Rab5A plasmid (resulting in 1 µg DNA per well) was added to the solution and 
incubated for 15 minutes at RT. 214 µl of this solution and 800 µl Optimem were then added to each 
well and the plate incubated at 37 °C for 3.5-4 hours. 
 siRNA treatment of cells 6.7
Pools of siRNA oligonucleotides (oligos) from Dharmacon (Dharmacon siGENOME SMARTpool, 
Thermo Scientific) were generated against REP-1 (CHM) and REP-2 (CHML) mRNA by the company 
and the sequences are given in Table 10. As a negative control a non-targeting siRNA oligo was used 
(On-target Non-targeting siRNA #2, Thermo Scientific). HEK293A cells were transfected with the 
SMARTpools and allowed to grow for 48 hours under standard conditions (see section 6.6.1); they 
were then transfected again and allowed to grow for a further for two days. Cells were transfected 
with the siRNA oligos using 2.5 µl oligofectamine (Invitrogen) and 5 µl of 20 µM oligo stock (66 nM 
final) added to each well of a 6-well plate in 1.5 ml Optimem media (Invitrogen). The oligos and 
oligofectamine were incubated together in optimem for 20 minutes at RT before addition to the 
cells. The cells were then incubated for 4.5 hours at 10% CO2 and 37 °C before replacing the medium 
with full medium (DMEM, FBS, penicillin/streptomycin).  The cells were subsequently harvested and 
analysed for the success of the knockdown by RT-PCR (reverse transcriptase polymerase chain 
reaction, section 6.7.1) or Western blot (section 6.4). 
REP-1/REP-2 siRNA SMARTpool siRNA SMARTpool Oligo Number Sequence 
REP-1 1 GCAAACAACUUACUAUGGU 
2 GAUUACCAUCCAACGUUU 
3 AGAAUGCGCUAGAAGUAAA 
4 UGUCAUAGGGAUUCGAUUU 
REP-2 1 GAAGGACACCUAUCUGGUA 
2 GCGACGAAAUGCCUGCAAA 
3 GAUGUUAGUCGUUAUGUAG 
4 UACAAUAGAUGGUCUUAAC 
Table 30: Table showing the four siRNA sequences in the siGENOME SMARTpool (Thermo Scientific) used to knockdown 
REP-1 and REP-2 expression in HEK293A cells 
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6.7.1 RT-PCR of siRNA-treated HEK293A cells 
Following siRNA treatment of HEK293A cells, mRNA was obtained from the cells using TRIzol® 
Reagent (Invitrogen). Briefly, in a chemical fume hood: cells were lysed directly in a culture dish by 
adding 1.6 ml of TRIzol® per well of a 6-well dish and passing the cell lysate several times through a 
pipette. Phase separation was achieved by first incubating the homogenized samples for 10 minutes 
at RT (to permit the complete dissociation of nucleoprotein complexes) and then adding 0.32 ml of 
chloroform per 1 ml of TRIzol®. Tubes were vigorously shaken by hand for 15 seconds and incubated 
at RT for 2 to 3 minutes. Samples were centrifuged at a maximum of 12,000 × g for 15 minutes at 
4 °C. Following centrifugation, the mixture separated into a lower red, phenol-chloroform phase, an 
interphase, and a colourless upper aqueous phase. RNA remains exclusively in the aqueous phase; 
the volume of the aqueous phase was about 60% of the volume of TRIzol Reagent used for 
homogenization. For RNA precipitation the aqueous phase was transferred to a fresh tube and 
mixed with isopropyl alcohol (1:1 to the amount of aqueous layer). Samples were incubated 
overnight at -80 °C then centrifuged at 12,000 × g for 10 minutes at 4 °C. The RNA precipitate, often 
invisible before centrifugation, formed a gel-like pellet on the side and bottom of the tube. The 
supernatant was removed and the RNA pellet washed with 75% EtOH (1.6 ml). The sample was 
vortexed and centrifuged at 7,500 × g for 5 minutes at 4 °C. The RNA pellet was air dried briefly (5-10 
minutes) and dissolved in RNase-free water by passing several times through a pipette tip and 
incubating for 10 minutes at 55-60 °C. Isolated mRNA was stored at -80 °C. The concentration of RNA 
was measured using a NanoDrop® ND-1000 spectrophotometer. 
The reverse transcription of the mRNA to give cDNA was carried out using the First-Strand cDNA 
synthesis kit (Invitrogen) as per the manufacturer’s instructions. 2 master mixes were made up: 1 
containing reverse transcriptase enzyme and one without (volume replaced with H2O as a control, 
Table 31). The following conditions were used for the reverse transcription step: 10 minutes 
incubation at 20 °C, 30 minutes incubation at 42 °C, 5 minutes incubation at 99 °C and 5 minutes 
incubation 5 °C in a Perkin Elmer Cetus DNA Thermal Cycler.  
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Reaction component 
Concentration of 
component 
Volume (µl) 
Transcription buffer 5× 4 
DTT 0.1 M 2 
dNTPs 10 mM 1 
Random Hexamers 50 ng/µl 5 
Reverse Transcriptase 200 U/µl 0.5 
RNAsin RNase inhibitor 40 U/µl 0.5 
H2O  3 
Mix total volume  16 
RNA 250 ng 4 
Final volume  20 
Table 31: Reverse transcription reaction components. 
The cDNA was then transferred from each sample to a fresh tube and a PCR reaction was carried out 
using the reagents detailed in Table 32 (from Invitrogen) to give a master mix of reagents from which 
17 µl was added to 3 µl cDNA from each sample. The primers (given in Table 33) were designed 
manually and purchased from Invitrogen. For the REP-1 plasmid control 1 µl (10-20 ng plasmid) was 
added to 2 µl H2O and 17 µl of the PCR master mix. The PCR reaction was carried out in a Perkin 
Elmer Cetus DNA Thermal Cycler, with the cycling conditions detailed in Table 34. 
 Concentration Volume (µl) 
Taq buffer 10× 2 
MgCl2 50 mM 0.8 
dNTPs 2.5 mM 1.6 
F Primer 10 µM 1 
R Primer 10 µM 1 
Taq enzyme 20× 1 
H2O  9.6 
Mix total volume  17 
cDNA volume  3 
Final volume for PCR reaction  20 
Table 32: PCR reaction mix composition for analysis of REP-1/REP-2 knockout by siRNA treatment of HEK293A cells. Taq 
DNA polymerase and buffers were purchased from Invitrogen 
Primer Sequence 
REP1F2 ACCAGGAACTTTTGCTGTTCGGG 
REP1R2 CGAGTTAGCCTCTGGTATGGCACTG 
REP2F2 GCCAGAGGCTCCTGGAACCAATAATG 
REP2R2 TGTATGTTTCACTATTCGAACAGGCCG 
hRab5AF CATTGGGGCTGCTTTTCTAA 
hRab5AR AGGACTTGCTTGCCTCTGAA 
Table 33: Sequences of the primers used in the PCR reactions to analyse REP-1 and REP-2 knockout by siRNA treatment of 
HEK293A cells. Primers designed manually and purchased from Invitrogen. 
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Reaction Step Temperature (°C) Time (mins) Number of cycles 
1 94 5 1 
2 94 1 30 
55 1 
72 1 
3 72 10 1 
Table 34: PCR reaction cycle for analysis of REP-1/REP-2 knockout by siRNA treatment of HEK293A cells. 
Following PCR the reaction mixtures were run on a 2% agarose gel containing ethidium bromide (6 µl 
of 10 mg/ml solution in 150 ml of 2% agarose in TAE buffer) at 100 mA in TAE running buffer (40 mM 
Tris acetate, 1 mM EDTA in dH2O). 
6.7.2 Culture of fibroblasts 
Primary mouse fibroblasts were isolated from ChmFlox MCM+ and ChmFlox MCM- mice by Elham 
Ostad-Saffari (MCM = MerCreMer fusion protein, + indicates the protein is expressed and – indicates 
it is not expressed). Briefly, CHM pups were culled 2-3 days after birth from a breeding cage of a 
heterozygous ChmFlox/Y MCM+ male and ChmFlox/Flox female breeding pair. All pups from this breeding 
pair were screened by PCR analysis for the presence of the MCM promoter/Cre transgene (see 
section 6.8.3). This breeding scheme produced offspring which were homozygous for the ChmFlox 
allele and carried the Cre transgene under the control of the MCM promoter.  Fibroblasts were 
derived directly from excised skin explants. Dermal fibroblast isolation from the mouse skin requires 
isolation to be carried out prior to the development of pigment and hair follicles around day 4 after 
birth; this meant that all isolations were individually carried out on each pup. Once the PCR analysis 
was performed, fibroblasts were pooled into ChmFlox MCM+ or ChmFlox MCM- fibroblasts. Fibroblasts 
were grown in DMEM supplemented with 10% heat-inactivated FBS, 500 U/ml penicillin, 500 U/ml 
streptomycin and 25 μg/ml amphotericin B (PSA solution from Invitrogen) at 10% CO2 and 37 °C. 
Cells grown in 15 cm tissue culture dishes were passaged as follows once they reached 90% 
confluence: the medium was removed by aspiration and the cells were washed once with 5 ml PBS 
(by applying the PBS to the cell layer and immediately removing by aspiration) before 3 ml 2.5% 
trypsin-EDTA solution was administered to the cell layer. The cells were incubated at 37°C for 
4 minutes to detach the cells, followed by inactivation of the remaining trypsin by resuspending the 
cells in complete medium. Cells were then pelleted at 300 × g for 5 minutes at RT. The cells were 
split in ratios between 1:3 and 1:6 and seeded into fresh media and grown to 90% confluence. 
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6.7.3  Culture of Bone Marrow 
Bone marrow cells were taken from the tibia and femur of two ChmFlox MCM+ mice by Dr Rajesh 
Singh. Cells were flushed out using RPMI 1640 buffer (Invitrogen) using a 25-guage needle. Cells 
were filtered through a cell strainer before pelleting at 300 × g for 5 minutes at RT and resuspending 
in complete medium (RPMI 1640 (Invitrogen), 10% heat-inactivated FBS, 100 U/ml 
penicillin/streptomycin, 55 μM β-mercaptoethanol, 20 ng/ml recombinant murine interleukin 3 (IL-
3) and 20 ng/ml stem-cell factor (SCF) (Peprotech, London, UK)) at a density of 500000 cells/ml 
media. Cells were grown in a humidified chamber at 37 °C and 5% CO2. There were both adherent 
and suspension cells present in the bone marrow culture and these were all passaged at the same 
time once cells were confluent after 2-3 days. Bone marrow cell cultures were grown for no more 
than 2.5 weeks. Cells grown in 150 cm2 tissue culture flasks were passaged as follows once they 
reached 90% confluence (after approximately 3 days): the medium containing cells in suspension 
was transferred to a sterile Falcon tube and the adherent cells were washed once with 5 ml PBS (by 
applying the PBS to the cell layer and immediately removing by aspiration) before 6 ml 2.5% trypsin-
EDTA solution was administered to the cell layer. The cells were incubated at 37°C for 3 minutes to 
detach the cells, followed by inactivation of the remaining trypsin by resuspending the cells in the 
complete medium containing the cells in suspension. Cells were then pelleted at 300 × g for 
5 minutes at RT. The cells were split in ratios of 1:10 and seeded into fresh media and grown to 90% 
confluence. 
 Drug treatment of cell culture 6.8
6.8.1  Mevastatin treatment of cells 
HEK293A cells were grown to around 80% confluence and treated overnight with either Mevastatin 
(10 µM in 10 ml medium, 50 mM stock in DMSO) or DMSO (negative control, 0.02% v/v). Following 
overnight treatment, the cells were pelleted at 300 × g for 5 minutes at RT and washed with PBS 
before being lysed in lysis buffer (see section 6.9) 
6.8.2  Tamoxifen treatment of ChmFlox MCM+ fibroblast and bone marrow cells 
6.8.2.1 Bone marrow 
Cells were treated with the following concentrations of Tamoxifen (TM) in a 6-well plate 
immediately following passaging and plating at a concentration of 500000 cells/ml: 0 µM (EtOH), 
2 µM, 5 µM and 10 µM TM. Cells were grown for 48 hours at 37 °C and 5% CO2 before all cells were 
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pelleted at 300 × g for 5 minutes at RT and washed with PBS. The cell pellets were digested 
overnight at 55°C in 200 µl GNTK buffer (50 mM KCl, 1.5 mM MgCl2, 0.01% gelatine, 0.45% NonidetP-
40, 0.45% TWEEN-20 in ddH2O) with 2 µl proteinase K. Samples were boiled for 10 minutes to 
deactivate the enzyme before PCR analysis was carried out (described below in section 6.8.3). 
Subsequent TM treatment of bone marrow cell culture was carried out in a 150 cm2 tissue culture 
flask (BD Falcon) at a concentration of 2 µM TM and the rest of the conditions as described above. 
6.8.2.2 Fibroblasts 
Fibroblasts were passaged when confluent and plated at a concentration of 2.5 × 105 cells per ml 
media. TM was added at a concentration of 5 or 10 µM at the same time as cells were added to the 
tissue culture plate. Cells were grown at 10% CO2 and 37 °C for 48 hours before the media was 
removed and replaced with fresh full medium and cells either pelleted for analysis of knockout or 
grown until confluent and passaged. 
6.8.3  PCR of fibroblasts and bone marrow digests 
Primers H7 (5′-AGAGTATCTCAGCAGTAGCTCTCC) and H9 (5′-CCAGAGAACACTGAGGGTTAGAGC) 
allowed identification of ChmFlox, and ChmNull (from ChmFlox MCM+ TM+ cells) alleles. The sizes of the 
resultant PCR products were: 860 bp (ChmFlox), 780 bp (ChmWT) and 330 bp (ChmNull). PCR was carried 
out on DNA isolated from TM treated or untreated bone marrow or fibroblast cells with the 
composition of the reaction mixture indicated in Table 35. A master mix for the all the PCR reactions 
to be carried out was made up (using the reagents indicated in Table 35, Invitrogen) and 10 µl PCR 
reaction master mix was added to 2.5 µl DNA from samples to be analysed. The PCR reaction was 
carried out in a Perkin Elmer Cetus DNA Thermal Cycler, with the cycling conditions detailed in Table 
36. Following PCR the reaction mixtures were run on a 1.5% agarose gel containing ethidium 
bromide (4 µl of 10 mg/ml solution in 100 ml of 1.5% agarose in TAE buffer) at 100 mA in TAE 
running buffer (40 mM Tris acetate, 1 mM EDTA in dH2O). 
Component Volume (µl) 
Taq Buffer (10×) 1.25 
MgCl2 (50 mM) 0.25 
dNTPs (2.5 mM) 1.25 
H7/H9 primer mix 2.5 
Taq enzyme 0.125 
Table 35: PCR reaction mix composition for analysis of conditional TM-induced REP-1 knockout. Taq DNA polymerase 
and buffers were purchased from Invitrogen. 
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Reaction Step Temperature (°C) Time (s) Number of cycles 
1 94 180 1 
2 94 40 32 
62 40 
72 60 
3 72 600 1 
Table 36: PCR reaction cycle for analysis of REP-1 knockout in cells. 
 Cell lysis 6.9
Once cells were grown to confluence, either following drug treatment or not, they were harvested 
by scraping with a cell scraper into the medium they were grown in before being pelleted by 
centrifugation at 200 × g for 5 minutes at RT. The medium was removed by aspiration and the pellet 
washed with PBS and transferred to a 1.5 ml Eppendorf microcentrifuge tube. The washed cell pellet 
was resuspended in cell lysis buffer (150 µl/20 cm tissue culture dish, see Table 23 for buffer 
composition) and lysed by passing 25 times through a 25-guage needle on ice. The post nuclear 
supernatant (PNS) was obtained by centrifugation at 800 × g for 5 minutes at 4 °C. The PNS was 
transferred to a 1.5 ml centrifuge tube (Beckman Microfuge® Tube polyallomer) and subjected to 
ultracentrifugation at 100,000 × g for 1 hour at 4 °C using a TLA 55 rotor (Beckman) in a Beckmann 
Optima™ TL ultracentrifuge to give subcellular fractionation. The supernatant (S100, soluble 
fraction) was then removed from the pellet (P100, membrane fraction). The P100 was resuspended 
in resuspension buffer (Table 23) to the same volume as the S100. Protein concentrations were 
measured using a NanoDrop® ND-1000 spectrophotometer. 
 Preparation of tissue lysates from gunmetal and CHM mice 6.10
Choroideremia mouse models (ChmFlox MCM+ TM+, and Chmnull/WT) and Flox control (ChmFlox) lung, 
stomach and spleen, and gunmetal mouse (C57BL/6J-gm/gm) and heterozygous control (C57BL/6J-
+/gm) lung, stomach and spleen tissue were used. Mouse tissue was obtained from mice perfused 
with PBS and snap-frozen in liquid nitrogen by Dr T. Tolmachova.  
6.10.1 Preparation of tissue samples 
Mouse tissue samples were homogenised in lysis buffer (see Table 23) using a Polytron homogenizer 
to disrupt the samples, whilst they were kept on ice. They were centrifuged at 800 × g at 4 °C for 
5 minutes before the PNS was subjected to subcellular fractionation, as described previously for cell 
lysis (section 6.9). The S100 fractions were used for subsequent in vitro prenylation reactions 
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(section 6.11). The protein concentration of tissue S100 was measured using the BCA assay (Pierce) 
against a standard BSA concentration curve, following the manufacturer’s protocol. Samples were 
snap-frozen in liquid N2 and stored at -80 °C. 
Radiolabelling of tissue samples with 3[H]GGpp was carried out by Dr T Tolmachova as in 109. 
 Prenylation and Capture 6.11
6.11.1 In vitro prenylation with RGGT 
6.11.1.1 Recombinant Rab 
1 µM RGGT/REP-1 and 20 µM AzGGpp (2 mM stock in 7:3 MeOH:NH4OH, synthesised in previous 
work230) or GGpp (2 mM stock in 7:3 MeOH:NH4OH) were added to recombinant Rab (1 µM) in 
prenylation buffer (see Table 23).  RGGT/REP-1/DTE in prenylation buffer was added to the other 
components of the prenylation reaction as the final step to give the final desired concentrations of 
all reaction components. Samples were incubated for 40 minutes at 37 °C in a water bath.  
6.11.1.2 Cell and tissue lysate 
1 µM RGGT/REP-1 and 20 µM AzGGpp (2 mM stock in 7:3 MeOH:NH4OH, synthesised in previous 
work230) or GGpp (2 mM stock in 7:3 MeOH:NH4OH) were added to soluble fraction of the cell lysate 
(S100, 10 – 50 µg) in prenylation buffer (see Table 23). RGGT/REP-1/DTE was added to the other 
components of the prenylation reaction as the final step to give the final desired concentrations of 
all reaction components. For S100 from mouse tissue samples 1 × EDTA-free cOmplete protease 
inhibitors (Roche) were also added to the prenylation mix. Samples were incubated for 40 minutes 
at 37 °C in a water bath.  
6.11.2 In vitro prenylation with GGT-1 
The reaction was carried out in prenylation buffer (as above) but with the addition of 10 µM ZnCl2 
and 1 µM GGT-1 to the protein substrate (1 µM Rac1/GST-RhoA or 20 µg HEK293A S100 
(±Mevastatin)) in place of RGGT and REP-1. Reaction component mixtures were made up to the 
desired concentration so that prenyl substrate could be added to the protein substrate before the 
final addition of a GGT-1/ZnCl2/DTE mix to give the final desired concentrations of all reaction 
components. The mixture was incubated for 40 minutes at 37 °C. 
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6.11.3 Capture of azide-tagged proteins from cell culture lysate following in vitro 
prenylation (optimised conditions) 
Following in vitro prenylation of samples, an alkyne capture premix was added to the prenylation 
reaction and the samples agitated for 60 minutes at RT The capture mix was premixed in the 
following order, to give final concentrations as follows: 50 µM TAMRA-Yn-Biotin II (125 µM stock in 
50 mM Tris pH 8.8 and 0.4% SDS), 1 mM CuSO4 (40 mM stock in H2O), 10 mM sodium ascorbate 
(freshly prepared as a 500 mM stock in H2O), 100 µM TBTA
236 (10 mM stock in DMSO). Following 
capture, samples were precipitated with CHCl3/MeOH. Using the following protocol: 
1. Add 4 × sample volume of MeOH, vortex 
2. Add 1 × sample volume of CHCl3, vortex 
3. Add 3 × sample volume of dH2O, vortex 
4. Centrifuge at maximum speed (16,100 × g) in a bench top centrifuge for 2 minutes 
5. Carefully remove the top, aqueous, layer from the sample (the protein pellet is now at the 
phase interface) 
6. Repeat step 1 
7. Repeat step 4 
8. Steps 6-7 may be repeated again if desired 
9. Discard the supernatant and air dry the protein pellet upside down in a laminar flow hood 
for 5 minutes 
Samples were then resuspended in resuspension buffer (see Table 23) by vortexing vigorously and 
were then either run on a Bis-Tris polyacrylamide gel or subjected to affinity purification. 
6.11.4 Capture of azide-tagged proteins from mouse tissue S100 following in vitro 
prenylation (optimised conditions) 
Following in vitro prenylation of tissue samples, samples were precipitated using the CHCl3/MeOH 
precipitation method described in the previous section. Samples were resuspended in prenylation 
buffer (Table 23) before 2% SDS and an alkyne capture reaction mix was added and the samples 
agitated for 60 minutes at RT The capture mix was premixed in the following order, to give final 
concentrations as follows: 50 µM TAMRA-Yn-Biotin II (125 µM stock in 50 mM Tris pH 8.8 and 0.4% 
SDS), 1 mM CuSO4 (40 mM stock in H2O), 10 mM sodium ascorbate (freshly prepared as a 500 mM 
stock in H2O), 100 µM TBTA
236 (10 mM stock in DMSO). Following capture, samples were 
precipitated with CHCl3/MeOH as described in section 6.11.3. Samples were then resuspended in 
resuspension buffer (see Table 23) by vortexing vigorously and were then either run on a Bis-Tris 
polyacrylamide gel or subjected to affinity purification. 
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6.11.5 Reduction and alkylation of mouse lung tissue and HEK293A cell samples 
120 µg HEK293A S100 and 300 µg CHM mouse lung S100 were prenylated using the standard 
conditions (section 6.11.1). Samples were then treated in three different ways: neither reduced nor 
alkylated (control) or reduced and alkylated after either the in vitro prenylation or capture reaction 
step. For the reduction/alkylation steps, samples were handled as follows:  
1. CHCl3/MeOH precipitation of the sample and MeOH wash 
2. rehydration of the pellet in 180 µl 8 M Urea/100 mM ammonium bicarbonate for 15 minutes 
at room temperature (RT) 
3. 10 µl 90 mM DTT was added to the sample in the urea buffer and incubated at 37 °C for 
30 minutes 
4. 15 µl 100 mM iodoacetamide was added and the samples incubated for 30 minutes in the 
dark at RT 
5. Finally samples were precipitated with CHCl3/MeOH and resuspended using resuspension 
buffer 
6.11.6 Affinity purification 
Affinity purification was carried out using either NeutrAvidin™ agarose beads (Thermo Scientific) or 
Dynabeads® MyOne™ Streptavidin C1 beads (Invitrogen). Beads were washed 3 times with PBS 
before the sample was added (in resuspension buffer) and diluted 10 times with PBS. For 
NeutrAvidin™ agarose beads the samples were centrifuged at 2 000 × g and RT for 2 minutes after 
each addition of PBS to sediment the beads at the base of the tubes. For magnetic streptavidin 
beads a magnetic sample rack was used to hold the beads to the side of the tube to allow 
supernatant removal. Once added to the beads, the sample was then agitated for 2 hours at RT For 
S100 from mouse tissue samples 1 × EDTA-free cOmplete protease inhibitors (Roche) were also 
added to the affinity purification buffer. The supernatant was removed from the beads and the 
beads washed 3 times with 0.2% SDS in PBS or more extensively for proteomics as shown in Table 
37. 
Wash buffer Number of washes 
0.2% SDS in PBS 3 × 500 µl 
4 M guanidine in PBS 2 × 500 µl 
4 M Urea in PBS 2 × 500 µl 
PBS 2 × 500 µl 
50 mM ammonium bicarbonate 2 × 500 µl 
Table 37: Wash conditions for washing affinity purification beads for proteomics experiments. 
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 Metabolic labelling of fibroblast and HEK293A cells 6.12
20 µM AzGGOH or GGOH (control) were prepared in full medium (4 µl of a 50 mM stock in 
DMSO/10 ml medium) and incubated at 37 °C for 5 minutes. Once cells were at least 80% confluent, 
the old medium was aspirated away and replaced with the AzGGOH/GGOH-containing medium. Cells 
were incubated under standard conditions for 24 hours. The cell layer was washed 3 times with PBS 
and 500 µl SDS lysis buffer (see Table 23 for composition) was added to each 15 cm tissue culture 
dish (Corning, 150 mm × 25 mm tissue culture dish). The homogenised cell suspension was scraped 
into a 2 ml Eppendorf tube and allowed to lyse on ice for 15 minutes. Samples were centrifuged at 
16,100 × g for 20 minutes at 4 °C and the supernatant transferred to a fresh Eppendorf tube, 
discarding the pellet. The supernatant was then subjected to bioorthogonal ligation via the click 
capture reaction (section 6.12.1) or stored at -20 °C (short-term) or -80 °C (long-term). 
6.12.1 Click capture of metabolically labelled cell lysate 
To attach TAMRA and biotin to fibroblast or HEK293A lysate from cells labelled with AzGGOH the 
following protocol was adhered to: 
1. Adjust protein lysate to a concentration of 1 mg/ml with SDS lysis buffer 
2. Mix the components in the following order for the final concentrations shown: 
 100 µM Capture reagent  
 1 mM CuSO4, vortex 
 100 µM TBTA, vortex  
 1 mM TCEP, vortex and wait 2 min to reduce the CuSO4 
3. Add mixture to the appropriate amount of protein 
4. Incubate for 1 h at RT (agitating on vortex-mixer) 
5. Add EDTA for a final concentration of 10 mM  
6. Precipitate the protein by CHCl3/MeOH method (section 6.11.3) 
7. Resuspend precipitated protein in resuspension buffer 
 Proteomics 6.13
6.13.1 Sample Preparation 
For proteomics experiments precautions were taken to reduce keratin contamination of samples. 
Eppendorf microcentrifuge tubes were used from unopened packs, sterile Falcon tubes were used, 
and all buffers were made with reagents reserved for proteomics experiments and filtered before 
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use. Fresh sterile dH2O and sterile PBs were used for each experiment. Where possible the 
experiment was carried out in a sterile laminar flow hood.  
Samples for proteomics analysis were labelled and affinity purified, as indicated in the appropriate 
sections above, on a scale of 1-2 mg total S100 protein. Following affinity purification and washing of 
the beads as indicated in the section 6.11.6, the beads were either submitted for on-bead trypsin 
digestion or loaded onto a 1.5 mm NuPage 10% Bis-Tris pre-cast gel (Invitrogen) and run at 200 V in 
NuPage MES SDS running buffer (Invitrogen) for approximately 1 hour. Gel bands were excised in a 
sterile hood using a sterile scalpel. Gel bands were submitted for trypsin digestion covered in 50 mM 
ammonium bicarbonate in 1.5 ml Eppendorf tubes frozen at -20 °C. Beads for on-bead digest were 
submitted at 4 °C covered with 50 mM NH4CO3. 
6.13.2 In-gel trypsin digestion 
Digestion was carried out at PNACL (Protein Nucleic Acid Chemistry Laboratory), University of 
Leicester by Dr Andrew Bottrill. The protocol used was as follows: The gel band was into 1 mm2 
pieces and incubated for 5 minutes in a solution of freshly prepared 400 mM NH4HCO3:acetonitrile in 
a 1:1 ratio. The supernatant was removed and the latter step repeated. The gel pieces were washed 
with 100 µl acetonitrile to remove aqueous solutions and shrunk by washing in 100 µl acetonitrile for 
10 to 15 minutes. The pieces were air dried for 10 minutes to remove all acetonitrile before addition 
of 100 µl of 10 mM DTT in 50 mM NH4HCO3 followed by heating of the samples to 60 °C on a heating 
block for 30 minutes. Liquid was removed and a further 2 incubations in 400 mM 
NH4HCO3:acetonitrile in a 1:1 ratio were carried out before washing the pieces with 100 µl 
acetonitrile for 10 to 15 minutes. The pieces were air dried again for 10 minutes to remove all 
acetonitrile before addition of 100 µl of 10 mM DTT in 50 mM NH4HCO3 followed by heating of the 
samples to 60 °C on a heating block for 30 minutes. Trypsin solution was added (25 µl containing 
50 ng trypsin (Promega modified porcine trypsin) in 10 mM NH4HCO3) and samples incubated for 
3 hours at 37 °C. Samples were dried in a speed vac and resuspended using 20 µl of 10 fmol/µl ADH 
standard (Waters, UK) before analysis by LC-MS/MS. 
6.13.3 On-bead trypsin digestion and sample preparation for non-iTRAQ samples  
Digestion was carried out at PNACL, University of Leicester by Dr Andrew Bottrill. The protocol used 
was as follows: 
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1. Centrifuge tubes for 5 minutes at 7,000 rpm. 
2. Remove excess NH4HCO3 solution and discard. 
3. Add 50 µl of 50 mM triethylammoniun bicarbonate buffer. 
4. Add 6 µl of acetronitrile and vortex. 
5. Add 2.8 µ of DTT (100 mM in 50 mM triethylammoniun bicarbonate buffer).  
Incubate for 30 minutes at 60 oC.  Remove from heat and allow to cool. 
6. Add 5.9 µl of Iodoacetamide (100 mM in 50 mM triethylammoniun bicarbonate 
buffer).  Incubate at room temp in the dark for 30 minutes. 
7. Re-suspend 1 vial of Promega modified porcine trypsin, sequencing grade, in 100 µl 
of 50 mM NH4HCO3.     
8. Add 25 µl to each sample (5 µg of trypsin). 
9. Leave overnight at 37 oC, preferably on a shaker. 
10. Centrifuge the samples for 5 minutes at 11,000 rpm 
11. Transfer the liquid into another tube and discard the beads 
12. Speed Vac the samples to dryness. 
13. Re-suspend the sample using 20 µl of 10 fmol/µl ADH (alcohol dehydrogenase) 
standard (Waters, UK) 
14. Analyse the samples via LC MS/MS. 
 
6.13.4 On-bead trypsin digestion and sample preparation for iTRAQ samples 
The trypsin digest was performed as Stages 1-10 in section 6.13.3. The labelling procedure was then 
as follows: 
11. Vortex each sample and transfer to a MobiCol “F” spin column (MoBiTec, Germany). 
Spin down at low speed (<6000 rpm) and retain the flow through as the sample (the 
beads can be discarded). 
12. Add 20 µl of ADH standard (10 fmol/µl) to each sample. 
13. Speed Vac each sample to dryness. 
14. Reconstitute each sample using 30 µl of the Dissolution Buffer provided in the iTRAQ 
kit (Applied Biosystems). 
15. Bring each vial of iTRAQ Reagent that you require to RT 
16. Add 70 µl of EtOH to each iTRAQ Reagent vial. 
17. Vortex each vial for 1 minute to dissolve the iTRAQ Reagent, then spin at RT to bring 
the sample to the bottom of the tube. 
18. Transfer the contents of one iTRAQ Reagent vial to one sample tube. Repeat for 
additional samples. 
19. Vortex each tube to mix, then spin then spin at RT to bring the sample to the bottom 
of the tube. 
20. Incubate the tubes at RT for 1 hour. 
21. Combine the contents of each iTRAQ Reagent labelled sample into a fresh tube. 
22. Vortex to mix, then spin then spin at RT to bring the sample to the bottom of the 
tube. 
A number of components in the sample can potentially interfere with LC-MS/MS, so a cation 
exchange clean-up was performed on iTRAQ-labelled samples, using a spin column. The sample was 
diluted at least 10-fold using the Cation Exchange Buffer-Load provided as part of the iTRAQ kit and 
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vortexed to mix. An aliquot was removed to ensure that the pH is between 2.5 and 3.3 and if not 
more Cation Exchange Buffer-Load was added. 5 mg of Poly-sulfoethyl A beads (PolyLC, Columbia, 
MD, USA and distributed by Hichrom, UK) were placed into a MobiCol “F” spin column and washed 
using 500 µl of Cation Exchange Buffer-Clean. They were then vortexed, spun and the flow through 
discarded. The wash step, vortex, spin and discard were then repeated. To equilibrate the beads, 
500 µl of Cation Exchange Buffer-Load was added, and again they were vortexed, spun and the flow 
through discarded. The equilibration step was repeated twice. The sample was transferred to the 
spin column, vortexed, placed on a shaker and incubated for 30 minutes at RT (the flow through was 
retained). Again the beads were washed with 500 µl of Cation Exchange Buffer-Load, vortexed, spun 
and flow through discarded. The wash step was then repeated. To elute the sample 100 µl of 
250 mM triethylammoniun bicarbonate buffer were added, the sample vortexed, placed on a shaker 
and incubated for 30 minutes at RT Spin and retain the flow through as the sample (the beads were 
discarded). Samples were dried using a speed vac and reconstituted in 100 µl of dH2O before again 
drying in a speed vac and storing at -80 °C until required. The sample was reconstituted in 20 µl of 
4% acetonitrile / 0.1% formic acid / 0.05% trifluoroacetic acid before analysis using LC MS/MS. 
For samples in proteomics experiment 12.2 and 12.3, where an extra purification step was required 
after the iTRAQ-labelled proteins remained in the flow-through of the cation exchange step, the 
following extra steps were carried out: a) The flow through from the Cation Exchange beads was 
diluted with a large excess (10×) of 2% acetonitrile  / 0.1% formic acid / 0.05% trifluoroacetic acid; b) 
The sample was loaded onto an equilibrated Sep-Pak Lite C18 cartridge (Waters, UK; p/n 
WAT023501) using a syringe pump (Harvard Apparatus) at a flow rate of 0.2 ml/min; c) After loading, 
the cartridge was washed with 2 ml of the loading buffer at the same flow rate; d) Peptides were 
eluted with 1 ml of 80% acetonitrile  / 0.1% formic acid / 0.05% trifluoroacetic acid at the same flow 
rate; e) Samples were dried using a speed vac and stored at -80 °C until required; f) Samples were 
reconstituted in 20 µl of 4% acetonitrile / 0.1% formic acid / 0.05% trifluoroacetic acid for LC-MS/MS 
analysis. 
6.13.5 Liquid Chromatography 
The protocol for the LC step of the LC-MS/MS analysis was carried out at PNACL as follows: 
1. The lyophilized sample was reconstituted in 20 µl of sample loading buffer (0.1% formic 
acid / 0.05% trifluoroacetic acid / 4% acetonitrile). 
2. The samples were placed on the HPLC autosampler maintained at a constant 
temperature of 7 °C. 
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3. The system was checked using a standard (trypsin digest of bovine serum albumin) and 
then equilibrated and conditioned by performing two blank injections (utilizing the full 
gradient detailed below – Table 38). 
4. Once properly equilibrated and conditioned, a sample (5.0 µl) was injected at a flow rate 
of 10 µl/min onto a reverse-phase trap column (0.3 mm i.d.µ x 1 mm, i.d. = inside 
diameter), containing 5 μm C18 300 Å Acclaim PepMap media (Dionex) maintained at a 
temperature of 37 °C. 
5. After 4 minutes of washing with sample loading buffer at 10 μl/min the trap column was 
placed in-line with the capillary column (by switching a 10-port valve). Peptides were 
eluted from the trap column at a flow rate of 0.3 µl/min and through a reverse-phase 
capillary column (75 μm i.d. x 250 mm) containing Symmetry C18 100 Å media (Waters, 
UK) that was manufactured in-house using a high pressure packing device (Proxeon 
Biosystems, Denmark). 
6. The gradient used to elute the peptides was as outlined in the table below (Table 38). 
Retention Time (min) Flow Rate (µl/min) %B 
0.00 0.300 2 
4.00 0.300 2 
90.00 0.300 45 
91.00 0.300 90 
101.00 0.300 90 
102.00 0.300 4 
120.00 0.300 4 
Table 38: Gradient conditions to elute peptides from HPLC prior to MS/MS analysis.  Time = 4.00 min represents the point 
at which the 10-port valve was switched. Solvent A was 0.1% formic acid. Solvent B was 0.1% formic acid / 80% acetonitrile. 
7. A blank injection and full gradient was performed between each sample in order to 
clean, condition and equilibrate the column. 
The volume of each sample that was injected onto the HPLC column is given in Table 39 below. 
Proteomics experiment Final Sample Volume (µl) Injection Volume (µl) 
1 and 2 18 6.4 
3 - 13 20 6.4 
14 14 6.4 
Table 39: Volume of samples injected onto HPLC for LC-MS/MS analysis for each proteomics experiment 
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6.13.6 Mass Spectrometry 
MS/MS was carried out at PNACL on an LTQ-Orbitrap Velos (Thermo Scientific) as follows: 
1. The output from the capillary column was pumped directly into a SilicaTip emitter 
(20 µm internal diameter, 10 µm tip orifice, 10.5 cm length). 
2. The capillary voltage was increased until a stable spray was achieved. This occurred at 
~2.1 kV. 
3. Calibration of the Orbitrap and ion trap parts of the LTQ-Orbitrap Velos was carried out 
according to the manufactures instructions, using the electrospray ion source and 
standard calibration solution for positive ion mode. 
4. The LTQ-Orbitrap Velos mass spectrometer was set to acquire in the data dependent 
mode 
5. A 2 microscan FTMS (Fourier Transform Mass Spectrometry) scan event at 30000 
resolution was acquired over the m/z range 400-1800 Da in positive ion mode, and 
accurate calibration of the FTMS scan was achieved using a background ion lock mass for 
polydimethylcyclosiloxane (445.120025 Da). 
6. Up to 10 data-dependent HCD MS/MS (HCD = High-energy Collision Dissociation) were 
triggered from the FTMS scan and measured at 7500 resolution in the Orbitrap. The 
isolation width was 2.5 Da, normalized collision energy 45.0, activation Q 0.25, activation 
time 0.1 ms. Dynamic exclusion was enabled to prevent repeated analysis of peptides. 
6.13.7 Data analysis 
The raw data files generated by the mass spectrometer were analysed by the Mascot (Matrix 
Science) and X!Tandem search algorithms against the Uniprot protein database (human or mouse as 
appropriate). The files were then imported into Scaffold 3.1.2 (Proteome Software Inc., Portland, 
Oregon, USA) for ease of viewing and comparisons. Scaffold was used to probabilistically validate 
protein identifications derived from MS/MS sequencing results. Peptide identifications assigned by 
Mascot were accepted by Scaffold if they could be established at greater than 95.0% probability as 
specified by the Peptide Prophet algorithm. After Scaffold probabilistically validates these peptide 
identifications using PeptideProphet it derives corresponding protein probabilities using 
ProteinProphet.247-251 Protein identifications were accepted if they could be established at greater 
than 95.0% probability and contained at least 2 identified peptides. 
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6.13.8 iTRAQ Data Analysis 
The data was processed using Proteome Discoverer 2.3 (Thermo Scientific), using the following 
schema (Figure 104): 
 
Figure 104: Overview of workflow for data analysis by Proteome Discoverer 2.3 to identify and quantify proteins based 
on detected peptides (scheme from Proteome Discoverer User Manual, Thermo Scientific). 
Each point in the scheme and the parameters that they contain are expanded below: 
(0) Spectrum Files  
The input is the raw data file (.raw) generated by the mass spectrometer. 
(1) Spectrum Selector 
Parameters used to select bona fide spectra from the raw data: 
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General Settings 
Precursor selection Use MS1 Precursor 
Spectrum properties filter 
Lower RT Limit 0 
Upper RT Limit 0 
First Scan 0 
Last Scan 0 
Lowest Charge State 0 
Highest Charge State 0 
Min. Precursor Mass 350 Da 
Max. Precursor Mass 5000 Da 
Total Intensity Threshold 0 
Minimum Peak Count 1 
Scan Event Filters 
Mass Analyzer Any 
MS Order Is MS2 
Activation Type  Any 
Scan Type Is Full 
Ionisation Source Any 
Polarity Mode Any 
Peak Filters 
S/N Threshold (FT only) 1.5 
Replacements for unrecognised properties 
Unrecognised Charge Replacements Automatic 
Unrecognised Mass Analyzer Replacements FTMS 
Unrecognised MS Order Replacements MS2 
Unrecognised Activation Type Replacements HCD 
Unrecognised Polarity Replacements + 
Table 40: The parameters used by Proteome Discoverer to identify bona fide spectra from raw MS data. 
(2) Reporter Ions Quantifier  
Parameters used to determine the values for the reporter ions and carry out quantitation: 
Quantification Method 
Quantification Method iTRAQ 4plex 
Peak Integration 
Integration Window Tolerance 20 ppm 
Integration Method Most Confidant Centroid 
Scan Event Filters 
Mass Analyzer FTMS 
MS Order MS2 
Activation Type HCD 
Table 41: Parameters used by Proteome Discoverer to determine values for reporter ions and carry out quantitation 
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(3) Mascot 
Parameters used to perform the database searching: 
Input Data 
Protein Database Uniprot Mouse 
Enzyme Name Trypsin/P 
Maximum Missed Cleavages 3 
Instrument ESI-TRAP 
Taxonomy All entries 
Tolerances 
Precursor Mass Tolerance 5 ppm 
Fragment Mass Tolerance 0.02 Da 
Use Average Precursor Mass False 
Dynamic Modifications 
1. Dynamic Modification Oxidation (M) 
2. Dynamic Modification iTRAQ4plex (Y) 
Static Modification 
1. Static Modification Carbamidomethyl (C) 
2. Static Modification iTRAQ4plex (K) 
3. Static Modification iTRAQ4plex (N-term) 
Table 42: Parameters used by Proteome Discoverer to perform the database searching. 
(4) Peptide Validator  
Statistical parameters used to determine the false-positive rate: 
Decoy Database Search 
Search Against Decoy Database True 
Target FDR (Strict) 0.01 
Target FDR (Relaxed) 0.05 
Table 43: Statistical parameters used by Proteome Discoverer to determine the rate of discovery of false-positives. 
For ease of viewing and making comparisons, the data was imported into Scaffold 3.1.2 (Proteome 
Software). 
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Appendix A Electronic Supplementary Files – Extra 
Information 
 
Proteomics Experiment File type(s) Description 
1 Scaffold HEK293A treated with Mevastatin or DMSO, in vitro 
prenylation with AzGGpp 
Non-optimised bead wash conditions 
2 Scaffold HEK293A treated with Mevastatin or DMSO, in vitro 
prenylation with AzGGpp 
Non-optimised bead wash conditions 
3 Scaffold HEK293A treated with Mevastatin or DMSO, in vitro 
prenylation with AzGGpp or GGpp 
Optimised bead wash conditions 
3.2 Scaffold HEK293A treated with Mevastatin or DMSO, in vitro 
prenylation with AzGGpp or GGpp 
Optimised bead wash conditions. Sample UL00823-
AB-07 consisted of 2 mg S100 prenylated and 
samples UL00823-AB-08 to UL00823-AB-10 were 3 
slices of the excised gel band split into 3 parts 
4 Scaffold HEK293A cells treated with Mevastatin or DMSO 
and prenylated with AzGGpp using either REP-1 or 
REP-2 with RGGT 
PNACL Sample Identifier 
in Scaffold file 
Sample Name in 
thesis 
UL00823-AB-01 Mevastatin REP-1 
UL00823-AB-02 DMSO REP-1 
UL00823-AB-03 Mevastatin REP-2 a 
UL00823-AB-04 DMSO REP-2 a 
UL00823-AB-05 Mevastatin REP-2 b 
UL00823-AB-06 DMSO REP-2 b 
 
5 Scaffold and Excel iTRAQ quantification of HEK293A cells treated with 
Mevastatin (1 mg or 0.5 mg S100) and prenylation 
with AzGGpp using either REP-1 or REP-2 with 
RGGT. 
6 Scaffold and Excel iTRAQ quantification of Mevastatin-treated 
HEK293A samples prenylated with AzGGpp using 
REP-1 
7 Scaffold Lung S100 samples from CHM and Flox mice, 
prenylated with AzGGpp 
8 Scaffold Lung, stomach and spleen S100 samples from CHM 
and Flox mice, prenylated with AzGGpp 
9 Scaffold CHM and Flox fibroblasts with and without 
Mevastatin treatment, in vitro prenylation with 
AzGGpp 
10 Scaffold HEK293A metabolic labelling with AzGGOH, with 
and without Mevastatin treatment 
235 
 
11 Scaffold CHM and Flox fibroblasts metabolically labelled 
with AzGGOH or GGOH 
12.1, 12.2, 12.3 Scaffold and Excel iTRAQ quantification. CHM and Flox fibroblasts 
metabolically labelled with AzGGOH. 3 Repeats. 
A=12.1, B=12.2, C=12.3 
114 = CHM, 115 = Flox, 116 = CHM (repeat), 117 = 
Flox (repeat) 
Table 44: Information on the contents of the electronic supplementary information. 
Website address to download the Scaffold viewer to open proteomics data files: 
http://www.proteomesoftware.com/Proteome_software_prod_Scaffold.html 
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Appendix B Protein sequence alignments 
 
Figure 105: Protein sequence alignment of human, rat and mouse REP-1 proteins sequences (UniProt identifiers P24386, 
P37727 and Q9QXG2 respectively). Alignment was carried out using the align tool on the uniprot.org website which uses the 
clustalo program to align protein sequences. Amino acid similarity is shaded in grey. For this alignment amino acid identity 
was calculated as 77.5 % between the sequences. 
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Figure 106: Protein sequence alignment of human, rat and mouse RGGTα subunit protein sequences (UniProt identifiers 
Q92696, Q08602 and Q9JHK4 respectively). Alignment was carried out using the align tool on the uniprot.org website which 
uses the clustalo program to align protein sequences. Amino acid similarity is shaded in grey. For this alignment the amino 
acid identity was calculated as 89 % between the sequences. 
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Figure 107: Protein sequence alignment of rat, mouse and human RGGTβ subunit protein sequences (UniProt identifiers 
Q08603, P53612 and P53611 respectively). Alignment was carried out using the align tool on the uniprot.org website which 
uses the clustalo program to align protein sequences. Amino acid similarity is shaded in grey. For this alignment the amino 
acid identity was calculated as 93% between the sequences. 
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Figure 108: Protein sequence alignment of mouse and human REP-2 protein sequences (UniProt identifiers Q9QZD5 and 
P26374 respectively). Alignment was carried out using the align tool on the uniprot.org website which uses the clustalo 
program to align protein sequences. Amino acid similarity is shaded in grey. For this alignment the amino acid identity was 
calculated as 75 % between the sequences. 
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Figure 109: Protein sequence alignment of human, mouse and dog Rab1A protein sequences (UniProt identifiers P62820, 
P62821 and P62822 respectively). Alignment was carried out using the align tool on the uniprot.org website which uses the 
clustalo program to align protein sequences. Amino acid similarity is shaded in grey. For this alignment the amino acid 
identity was calculated as 100 % between the sequences. 
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Appendix C Synthesis of AzGGpp 
The synthesis of AzGGpp is reproduced here from the author’s MRes thesis.230 In brief, commercially 
available geranylgeraniol 1 was protected as acetyl ether 2. This was then chlorinated following the 
method of Barrero et al.,274 polymer-bound selenium bromide was used as a catalyst with N-
chlorosuccinimde to regioselectively chlorinate the terminal alkene to yield 3. This allowed selective 
chlorination of the terminal alkene due to steric hindrance from the polymer bound to the selenium 
bromide and also due to the polymer-bound selenium bromide being used in only catalytic amounts. 
This gave a good yield and the reaction was much more successful than that achieved when 
attempting to use t-BuOOH and SeO2 to give allylic alcohols prior to a Mitsonobu-type reaction to 
yield the azide as in Zhao et al.,160 which gave extremely poor yields due to substantial oxidation of 
the other C=C double bonds as well as further oxidation of the terminal alcohol to the terminal 
aldehyde. Subsequent nucleophilic substitution of the chloride by the azide ion, on addition of 
sodium azide, gave 4. The acetyl protecting group was removed to reveal azido geranylgeraniol 5, 
which was subsequently converted to the chloride 6 by the Cory-Kim oxidation reaction, using N-
chlorosuccinimide and dimethylsulfoxide. Nucleophilic substitution of the chloride ion then yielded 
the tris(tetra N-butylammonium) pyrophosphate 7, which was immediately converted to the 
ammonium form 8 by an ion-exchange column and subsequently purified by preparative RP-HPLC. 
NMR (1H, 13C and COSY) and ESI positive MS were used to confirm the structures of compounds 1-6, 
ESI negative MS also confirmed the structure of 8. 
 
Figure 110: Synthesis of AzGGpp. a: Ac2O, DMAP, DCM, 0 °C–RT, under N2 atmosphere, 78% yield. b: Catalytic polymer 
bound SeBr, NCS, DCM, RT, under N2 atmosphere, 61% yield. c: NaN3, DMSO, O/N, RT, 36% yield. d: K2CO3, MeOH, RT, 100% 
yield. e: NCS, DMS, DCM, -40–0 °C, under N2 atmosphere, 33% yield. f: (Bu4N)3HP2O7, CH3CN, 3.5 hrs, under N2 atmosphere. 
g: DOWEX 50W X8 , NH4CO3, 38% yield. Figure reproduced from Alexandra Berry MRes thesis.
230
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Method for AzGGpp synthesis (reproduced from MRes thesis) 
(2) (2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl acetate 
1.68 g (13.8 mmol) DMAP (4-(dimethylamino)pyridine)  was dissolved in 20 ml anhydrous 
dichloromethane (DCM) with stirring under a nitrogen atmosphere at 0 °C. 2 g (6.9 mmol) of 
geranylgeraniol was added followed by 1.3 ml (13.8 mmol) Ac2O dropwise. Stirring was continued at 
0 °C for 1 hour. The mixture was washed with 2× 100 ml H2O and 1× 60 ml brine. The organic layer 
was dried over MgSO4 and the solvent was removed under reduced pressure. The product was 
purified by silica column chromatography in 1.5:1 hexane:Et2O to afford 2 as a colourless oil (78%). 
1H NMR (CDCl3) H/ppm 5.36 (1H, t, J=5.9 Hz, CHCH2OAc), 5.12 (3H, br  m, C=CHCH2), 4.61 (2H, d, J = 
7.1 Hz, CHCH2OAc), 2.20–1.93 (12H, m, CH2CH2), 2.07 (3H, s, COCH3),  1.72 (3H, s, CH3), 1.70 (3H, s, 
CH3), 1.62 (9H, s, CH3); 
13C NMR (CDCl3C/ppm 142.5, 135, 131, 124.4, 124.2, 123.6, 118.3, 61.4, 
39.7, 39.6, 26.8, 26.7, 26.2, 25.7, 21.1, 17.7, 16.5, 16.0; ESI HRMS found 333.2813 (C22H36O2 [M + 
H]+), expected 333.2794. 
(3) (2E,6E,10E)-14-chloro-3,7,11,15-tetramethylhexadeca-2,6,10,15-tetraenyl acetate 
285 mg (0.24 mmol) polymer bound selenium bromide was dissolved, with stirring, in 6 ml 
anhydrous DCM under nitrogen. 727 mg (1.97 mmol) geranylgeranyl acetate was dissolved in a 
further 6 ml anhydrous DCM. Stirring was continued and 289 mg (2.2 mmol) N-chlorosuccinimide 
(NCS) was added. The mixture was stirred at room temperature overnight. Solvent was removed 
under reduced pressure and the residue dissolved in 25 ml Et2O, filtered through cotton wool to 
remove the polymer-bound SeBr and then washed with 3× 25 ml H2O and 2× 25 ml brine. The 
solvent was removed under reduced pressure and the crude product purified by silica column 
chromatography in CHCl3 to afford 3 as a yellow oil (61%). 
1H NMR (CDCl3) H/ppm 5.37 (1H, t, J = 
5.9 Hz, CHCH2OAc), 5.15 (2H, br m, C=CHCH2), 5.02 (1H, s), 4.92 (1H, s),  4.61 (2H, d, J =  7.1 Hz, 
CHCH2OAc), 4.37 (1H, t, J = 7.2 Hz, CH(Cl)CH2CH2), 2.20-1.93 (17H, m, CH2CH2), 2.07 (3H, s, COCH3),  
1.82 (3H, s, CH3), 1.72 (3H, s, CH3), 1.62 (6H, s, CH3); 
13C NMR (CDCl3C/ppm 141.5, 121.4, 118.2, 
114.1, 61.4, 39.6, 38.1, 37.6, 36.5, 36.1, 34.7, 26.3. m/z (ESI MS) found 368 ([M + H]+), expected 
368. 
(4) (2E,6E,10E,14E)-16-azido-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl acetate 
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441 mg (1.2 mmol) 3 were dissolved in 12 ml DMSO at room temperature, 94 mg (1.44 mmol) NaN3 
were added and the reaction stirred for 5 hours. The reaction mixture was then dissolved in 25 ml 
DCM and washed with 12× 25 ml ddH2O to remove the DMSO. Crude product was purified by silica 
gel column chromatography in 1:10 EtOAc:hexane to afford 4 as a yellow oil (36%). 1H NMR (CDCl3) 
H/ppm 5.37 (1H, t, J = 5.9 Hz, CHCH2OAc), 5.12 (2H, br  m, C=CHCH2), 5.00 (1H, t, J = 1.5 Hz), 4.94 
(1H, s),  4.61 (2H, d, J = 7.1 Hz, CHCH2OAc), 4.14 (1H, dd, J1 = 7.2 Hz, J2 = 14.1 Hz), 3.82 (1H, dd, J1 = 
7.1 Hz, J2 = 15.2 Hz, CH(N3)CH2CH2), 3.67(1H, s), 2.20-1.93 (17H, m, CH2CH2), 2.07 (3H, s, COCH3),  
1.73 (3H, s, CH3), 1.62 (3H, s, CH3), 1.28 (6H, s, CH3); 
13C NMR (CDCl3C/ppm 126.4, 125.2, 118.2, 
67.9. m/z (ESI MS) found 346 ([M+H-N2]
+), expected 374 ([M+H]+). 
(5) (2E,6E,10E,14E)-16-azido-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-ol 
To 159 mg (0.43 mmol) 4 dissolved in 9 ml MeOH was added 177 mg (1.3 mmol) K2CO3. The mixture 
was stirred at room temperature for 1 hour until complete by TLC. The mixture was washed with 3× 
20 ml H2O and 2× 20 ml brine to afford 5 as a yellow oil (100%). 
1H NMR (CDCl3) H/ppm 5.44 (1H, t, 
J = 6.9 Hz, CHCH2OH), 5.14 (2H, br  m, C=CHCH2), 5.00 (1H, t), 4.97 (1H, s),  4.18 (2H, d, J= 7.0 Hz, 
CHCH2OH),  3.82 (1H, dd, J1 = 7.2 Hz, J2 = 16.0 Hz, CH(N3)CH2CH2), 3.67(1H, s), 2.20-1.93 (11H, m, 
CH2CH2), 1.76 (3H, s, CH3), 1.71 (3H, s, CH3), 1.63 (6H, s, CH3); 
13C NMR (CDCl3C/ppm 130.4, 125.2, 
124.6, 123.9, 123.3, 114.8, 67.9, 59.4, 53.3, 40.0, 35.9, 30.3, 26.3, 17.6, 16.1; ESI HRMS found 
304.2651 (C20H33NO, [M+H-N2]
+), expected 304.2652. 
 (6) (2E,6E,10E,14E)-1-azido-16-chloro-2,6,10,14-tetramethylhexadeca-2,6,10,14-tetraene 
To NCS (87 mg, 0.65 mmol) dissolved in 1.5 ml anhydrous DCM under N2 at -40 °C was added 
dimethyl sulphide (52 µl, 0.71 mmol) and the solution stirred for 5 minutes. The mixture was 
warmed to 0 °C for 5 minutes before cooling back to -40 °C. A solution of 5 in 1.5 ml anhydrous DCM 
was then added and the solution was gradually warmed to 0 °C for 30 minutes and stirring continued 
at 0 °C for 1.5 hours. Subsequently, the solution was stirred in a room temperature water bath for 
15 minutes before quenching with 30 ml brine. The aqueous layer was extracted with 3× 10 ml 
pentane, the combined organic layers dried over MgSO4 and solvent removed under reduced 
pressure to afford 6 as a yellow oil (33%). 1H NMR (CDCl3) H/ppm 5.47 (1H, t, J = 7.9 Hz, CHCH2OH), 
5.12 (2H, br  m, C=CHCH2), 5.01 (1H, t, J = 1.5 Hz), 4.97 (1H, s),  4.13 (2H, d, J = 8.0 Hz, CHCH2OH),  
3.82 (1H, dd, J1 = 7.2 Hz, J2 = 15.6 Hz, CH(N3)CH2CH2), 3.67(1H, s), 2.20-1.93 (10H, m, CH2CH2), 1.76 
(3H, s, CH3), 1.72 (3H, s, CH3), 1.63 (6H, s, CH3); 
13C NMR (CDCl3C/ppm 142.7, 135.4, 134.3, 
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130.3, 125.5, 124.8, 123.4, 120.4, 114.5, 67.9, 59.4, 41.3, 39.4, 35.8, 30.8, 26.1, 17.6, 16.0;  
ESI HRMS found 322.2295 ([M+H-N2]
+, C20H33NCl), expected 322.2302. 
(7) Tetrabutylammonium Pyrophosphate 
To a stirred solution of (NBu4)3HP2O7 in 1.5 ml anhydrous acetonitrile under N2 was added dropwise 
63 mg of 6 dissolved in 1.5 ml dry acetonitrile. The mixture was stirred at room temperature for 
3.5 hours. The solvent was removed under reduced pressure at 35 °C. The crude product (7) was 
used in the next step immediately. 
(8) Ammonium Pyrophosphate 
10 g DOWEX 50×8W resin was prepared by stirring in 30 ml ddH20 with 5.86 g NH4HCO3 (resin was 
stirred until CO2 ceased to evolve) and was loaded onto a 2 cm diameter column. The column was 
equilibrated with 60 ml buffer (25 mM NH4HCO3 and 2% isopropanol in H2O) and then 7 was loaded 
and allowed to enter the column before eluting it with 70 ml buffer. The first fraction collected was 
opaque yellow, this was lyophilised for 10 hours and then purified by preparative HPLC of 
10 minutes at 100% 25 mM NH4HCO3, followed by 20 minutes gradient to 100% acetonitrile and 
ending with 10 minutes 100% acetonitrile. The desired compound (8) eluted at around 25 minutes. 
Following lyophilisation 8 was obtained as a powdery white solid (38%). 1H NMR (ND4OD/D2O) 
H/ppm 5.46 (1H, t, J = 7.2 Hz, CHCH2P2O7), 5.17 (2H, br  m, C=CHCH2), 5.01 (1H, t, J = 1.3 Hz), 4.97 
(1H, s),  4.80 (1H, m), 4.47 (2H, br, m, CHCH2P2O7), 3.84 (1H, t, J = 6.89 Hz, CH(N3)CH2CH2), 3.64 (1H, 
s), 2.24-1.93 (11H, m, CH2CH2), 1.74 (3H, s, CH3), 1.70 (3H, s, CH3), 1.64 (6H, s, CH3); 
13C NMR 
(ND4OD/D2O)C/ppm 166.3, 165.7, 142.3, 141.7, 135.3, 134.1, 133.7, 129.8, 125.5, 124.8, 
124.4, 120.5, 114.5, 68.1, 62.4, 59.2, 39.8, 39.5 36.1, 30.8, 27.0, 26.8, 17.5, 16.2, 15.9, 14.4; 
31P NMR (ND4OD/D2O)P/ppm -6.02 (1P, d, J = 20.8 Hz), -9.96 (1P, d, J = 20.4 Hz);  m/z (ESI MS) 
found 490 ([M-H]-), expected 490. 
